## Cancer Statistics, 2004

Ca-A Cancer Journal for Clinicians 54, 8-29 DOI: 10.3322/canjclin.54.1.8

Citation Report

#	Article	IF	CITATIONS
1	Advances in prognostication and treatment of pediatric acute leukemia. , 0, , 345-356.		0
2	The Options for Palliation of Esophageal Adenocarcinoma. , 0, , 277-288.		1
3	Cancer: gynaecologic. , 2001, , 591-595.		0
5	Update on management of oral cancer: diagnostic and therapeutic modalities. Journal of Oral and Maxillofacial Surgery, 2003, 61, 106.	0.5	0
6	Management of Androgen-Independent Prostate Cancer. Cancer Control, 2004, 11, 364-373.	0.7	40
7	P53 Expression, Dna Ploidy and Mitotic Index as Prognostic Factors in Patients with Epithelial Ovarian Carcinoma. Tumori, 2004, 90, 600-606.	0.6	6
8	Clinical Trials and End-of-Life Decision Making. AMA Journal of Ethics, 2004, 6, 477.	0.4	0
9	Genitourinary Oncology: The Continuous Evolution of Multimodality Treatments. Cancer Control, 2004, 11, 351-351.	0.7	0
10	In vivo Recombinant Adenovirus-mediated p53 Gene Therapy in a Syngeneic Rat Model for Colorectal Cancer. Journal of Korean Medical Science, 2004, 19, 834.	1.1	12
11	An Increase in Reactive Oxygen Species by Dietary Fish Oil Coupled with the Attenuation of Antioxidant Defenses by Dietary Pectin Enhances Rat Colonocyte Apoptosis. Journal of Nutrition, 2004, 134, 3233-3238.	1.3	80
12	Nutrition and Cancers of the Breast, Endometrium, and Ovary. , 2004, , 770-782.		0
13	Men With Breast Cancer Have Better Disease-Specific Survival Than Women. Archives of Surgery, 2004, 139, 1079.	2.3	55
14	Contemporary Surgical Treatment of Advanced-Stage Melanoma. Archives of Surgery, 2004, 139, 961.	2.3	181
15	Medical treatment of epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2004, 4, 1125-1143.	1.1	5
16	Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy. Nature Reviews Urology, 2004, 1, 26-30.	1.4	12
17	Breast Cancer Screening with MRI — What Are the Data for Patients at High Risk?. New England Journal of Medicine, 2004, 351, 497-500.	13.9	103
18	Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 658-665.	0.7	32
19	Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opinion on Biological Therapy, 2004, 4, 1115-1128.	1.4	17

ATION REDO

#	Article	IF	CITATIONS
20	Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients. Cancer Research, 2004, 64, 6476-6481.	0.4	259
21	The role of α-blockers in the management of prostate cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 1279-1285.	0.9	32
22	Osmotic Blood-Brain Barrier Modification for the Treatment of Malignant Brain Tumors. Clinical Journal of Oncology Nursing, 2004, 8, 263-267.	0.3	36
23	Cyclooxygenase-2 and its role in ovulation: a 2004 account. Human Reproduction Update, 2004, 10, 373-385.	5.2	172
24	Screening for an Inherited Susceptibility to Colorectal Cancer. Genetic Testing and Molecular Biomarkers, 2004, 8, 421-430.	1.7	12
25	Toward New Horizons: The Future of Bisphosphonate Therapy. Oncologist, 2004, 9, 38-47.	1.9	46
26	The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer. Endocrine-Related Cancer, 2004, 11, 815-822.	1.6	30
27	Differential Response of Human Ovarian Cancer Cells to Induction of Apoptosis by Vitamin E Succinate and Vitamin E Analogue, α-TEA. Cancer Research, 2004, 64, 4263-4269.	0.4	67
28	Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis. Clinical Cancer Research, 2004, 10, 7276-7283.	3.2	46
29	Limitations of the Adenoma–Carcinoma Sequence in Colorectum. Clinical Cancer Research, 2004, 10, 5969-5970.	3.2	18
30	Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy: Table 1. Clinical Cancer Research, 2004, 10, 6304S-6309S.	3.2	48
31	A Quantitative Promoter Methylation Profile of Prostate Cancer. Clinical Cancer Research, 2004, 10, 8472-8478.	3.2	234
32	A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium. Clinical Cancer Research, 2004, 10, 6502-6511.	3.2	118
33	The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial. Journal of Clinical Oncology, 2004, 22, 2294-2302.	0.8	137
34	Silibinin Protects against Photocarcinogenesis via Modulation of Cell Cycle Regulators, Mitogen-Activated Protein Kinases, and Akt Signaling. Cancer Research, 2004, 64, 6349-6356.	0.4	137
35	Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer. Clinical Cancer Research, 2004, 10, 3927-3933.	3.2	54
36	AAPM/RSNA Physics Tutorial for Residents. Radiographics, 2004, 24, 1747-1760.	1.4	63
37	Design and evaluation of the clear-PEM detector for positron emission mammography. , 0, , .		12

#	Article	IF	CITATIONS
38	Preventing Cancer, Cardiovascular Disease, and Diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Diabetes Care, 2004, 27, 1812-1824.	4.3	125
39	Colorectal Adenomas. Clinical Cancer Research, 2004, 10, 3908-3918.	3.2	60
40	Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. New England Journal of Medicine, 2004, 351, 1513-1520.	13.9	3,344
41	Combined Genome-Wide Scan for Prostate Cancer Susceptibility Genes. Journal of the National Cancer Institute, 2004, 96, 1240-1247.	3.0	72
42	A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 5447-5454.	3.2	73
43	Ductal Carcinoma In Situ, Complexities and Challenges. Journal of the National Cancer Institute, 2004, 96, 906-920.	3.0	339
44	Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. Journal of Clinical Oncology, 2004, 22, 4302-4311.	0.8	285
45	Is the Gene Expression Pattern of Lung Cancer Detected by Screening With Spiral Computed Tomography Different from That of Symptom-Detected Lung Cancer?. Clinical Cancer Research, 2004, 10, 5973-5974.	3.2	7
46	Adjuvant Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: A Tale of Three Trials. Journal of the National Cancer Institute, 2004, 96, 1801-1804.	3.0	10
47	The Promise of Molecular Profiling for Cancer Identification and Treatment. Clinical Medicine and Research, 2004, 2, 147-150.	0.4	16
48	Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis. Clinical Cancer Research, 2004, 10, 7775-7784.	3.2	77
49	Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis, 2004, 26, 597-604.	1.3	53
50	The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors. Journal of Clinical Oncology, 2004, 22, 3517-3523.	0.8	82
51	Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I–Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer. Cancer Research, 2004, 64, 8715-8722.	0.4	281
52	Waiting Time in Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 291, 2757.	3.8	3
53	Symptoms of Ovarian Cancer—Where to Set the Bar?. JAMA - Journal of the American Medical Association, 2004, 291, 2755.	3.8	21
54	Papillary Thyroid Microcarcinoma Outcomes and Implications for Treatment. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3710-3712.	1.8	80
55	Fatigue and Depression in Patients With Lymphoma Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Oncology Nursing Forum, 2004, 31, 937-944.	0.5	23

#	Article	IF	CITATIONS
56	"Not Lighting Up": A Case Study of a Woman Who Quit Smoking. Oncology Nursing Forum, 2004, 31, E54-E63.	0.5	0
57	Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer. Journal of Oncology Pharmacy Practice, 2004, 10, 169-175.	0.5	О
58	A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 5425-5431.	3.2	19
59	Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer. Clinical Cancer Research, 2004, 10, 7958-7964.	3.2	17
60	Assessing Coughing and Wheezing in Lung Cancer: A Pilot Study. Oncology Nursing Forum, 2004, 31, 1095-1101.	0.5	8
61	Cultural Diversity Issues in Cancer Nursing. Oncology Nursing Forum, 2004, 31, 686-688.	0.5	1
62	A Case Study of Telephone Interpersonal Counseling for Women With Breast Cancer and Their Partners. Oncology Nursing Forum, 2004, 31, 997-1003.	0.5	39
63	Asian/Pacific Islander American Women: Age and Death Rates During Hospitalization for Breast Cancer. Oncology Nursing Forum, 2004, 31, E69-E74.	0.5	8
64	Computerized Symptom and Quality-of-Life Assessment for Patients With Cancer Part II: Acceptability and Usability. Oncology Nursing Forum, 2004, 31, E84-E89.	0.5	78
65	Phase I Trial of Weekly Docetaxel With Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate. Journal of Clinical Oncology, 2004, 22, 1909-1915.	0.8	57
66	Reanalysis of Cancer Drugs. Clinical Cancer Research, 2004, 10, 3897-3907.	3.2	26
67	A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Annals of Oncology, 2004, 15, 928-932.	0.6	41
68	Matched-Pair Analysis of Survival of Never Smokers and Ever Smokers With Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2004, 22, 3981-3988.	0.8	81
69	The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor β-Dependent Apoptosis in Breast Cancer. Cancer Research, 2004, 64, 3566-3571.	0.4	64
70	Preoperative chemoradiation approaches to locally advanced non-small-cell lung cancer: one man's pride, another man's burden?. Annals of Oncology, 2004, 15, 365-367.	0.6	6
71	Advanced Practice Nursing in Head and Neck Cancer: Implementation of Five Roles. Oncology Nursing Forum, 2004, 31, 579-583.	0.5	7
72	Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials. JAMA - Journal of the American Medical Association, 2004, 292, 2130.	3.8	274
73	Epidemiology of Renal Cell Carcinoma. Scandinavian Journal of Surgery, 2004, 93, 88-96.	1.3	153

#	Article	IF	CITATIONS
74	Disparities in Cancer Funding. Science, 2004, 305, 1401e-1402e.	6.0	3
75	The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function. Cancer Research, 2004, 64, 6344-6348.	0.4	159
76	Somatic genetics of testicular cancer in relationship to prognosis. Cancer Biology and Therapy, 2004, 3, 1159-1161.	1.5	20
77	Cancer as Metaphor. Oncologist, 2004, 9, 708-716.	1.9	99
78	Thymidylate Synthase 5â€2- and 3â€2-Untranslated Region Polymorphisms Associated with Risk and Progression of Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2004, 10, 7903-7910.	3.2	47
79	Report: Alcohol Consumption and Risk of Colon Cancer: Evidence From the National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study. Nutrition and Cancer, 2004, 50, 111-119.	0.9	37
80	Follow-Up for Patients With Colorectal Cancer After Curative-Intent Primary Treatment. Journal of Clinical Oncology, 2004, 22, 1363-1365.	0.8	25
81	Inactivation of the FHIT Gene Favors Bladder Cancer Development. Clinical Cancer Research, 2004, 10, 7607-7612.	3.2	26
82	Polymorphisms of DNA Repair Genes and Risk of Glioma. Cancer Research, 2004, 64, 5560-5563.	0.4	155
83	Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis. Clinical Cancer Research, 2004, 10, 3448-3456.	3.2	155
84	Conditional Deletion of Rb Causes Early Stage Prostate Cancer. Cancer Research, 2004, 64, 6018-6025.	0.4	98
85	The role of chemoradiotherapy in the treatment of stage III non-small-cell lung cancer. Annals of Oncology, 2004, 15, iv71-iv80.	0.6	4
86	Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 6993-7000.	3.2	74
87	Inhibition of Extracellular-signal Regulated Kinases 1/2 Is Required for Apoptosis of Human Colon Cancer Cells In vitro by Sulindac Metabolites. Cancer Research, 2004, 64, 8148-8151.	0.4	38
88	Telomereâ€based DNA damage responses: a new approach to melanoma. FASEB Journal, 2004, 18, 1373-1381.	0.2	76
89	Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis, 2004, 26, 209-217.	1.3	31
90	A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 7812-7819.	3.2	108
91	Preventing Cancer, Cardiovascular Disease, and Diabetes. Circulation, 2004, 109, 3244-3255.	1.6	395

#	Article	IF	CITATIONS
92	Therapeutic targets for antimetastatic therapy. Expert Opinion on Therapeutic Targets, 2004, 8, 527-536.	1.5	24
93	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Cancer Research, 2004, 64, 3386-3390.	0.4	167
95	A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2159-2170.	0.9	96
96	Conditionally Replication-Competent Adenoviral Vectors with Enhanced Infectivity for Use in Gene Therapy of Melanoma. Human Gene Therapy, 2004, 15, 637-647.	1.4	32
97	Recurrent Ovarian Cancer. Clinical Cancer Research, 2004, 10, 7439-7449.	3.2	137
98	Paclitaxel for non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 1771-1780.	0.9	91
99	Molecular Signatures in Biopsy Specimens of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 167-174.	2.5	105
100	Tailored Chemotherapy for Colorectal Cancer: A New Approach to Therapy. Cancer Investigation, 2004, 22, 762-773.	0.6	16
101	Male Breast Cancer. Clinical Journal of Oncology Nursing, 2004, 8, 191-192.	0.3	1
102	Managing Tissue Necrosis Associated With Oral Carcinoma. Clinical Journal of Oncology Nursing, 2004, 8, 408-409.	0.3	0
103	Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 627-637.	1.1	4
104	Cyclooxygenase-2 Expression in Prostate Cancer: An Inconsistent Therapeutic Target. UroOncology, 2004, 4, 113-118.	0.1	0
105	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology, 2004, 76, 333-337.	1.5	43
106	Combined ultrasound, optoacoustic, and elasticity imaging. , 2004, , .		45
107	Effects of Ultraviolet B Exposure on the Expression of Proliferating Cell Nuclear Antigen in Murine Skin¶. Photochemistry and Photobiology, 2004, 80, 587.	1.3	30
108	Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis, 2004, 26, 109-117.	1.3	42
109	Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis, 2004, 25, 1711-1720.	1.3	118
110	Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial. Cancer Investigation, 2004, 22, 858-865.	0.6	130

	CHATION R	EPORT	
#	Article	IF	CITATIONS
111	Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer. Oncologist, 2004, 9, 25-32.	1.9	47
112	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics, 2004, 13, 2443-2449.	1.4	291
113	Ultraviolet-B Radiation Causes an Upregulation of Survivin in Human Keratinocytes and Mouse Skin¶. Photochemistry and Photobiology, 2004, 80, 602.	1.3	25
114	Multiple Myeloma: An Overview. Clinical Journal of Oncology Nursing, 2004, 8, 401-405.	0.3	16
115	Endometrial cancer: a frequent orphan disease. Annals of Oncology, 2004, 15, 1149-1150.	0.6	1
116	Breast Care Is a Team Sport. Breast Journal, 2004, 10, 469-472.	0.4	9
117	Gallbladder cancer: lessons from a rare tumour. Nature Reviews Cancer, 2004, 4, 695-706.	12.8	394
118	Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene, 2004, 23, 6170-6174.	2.6	248
119	Prostate cancer is characterized by epigenetic silencing of 14-3-3 $\ddot{l}f$ expression. Oncogene, 2004, 23, 9034-9041.	2.6	83
120	Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. British Journal of Cancer, 2004, 91, 1380-1383.	2.9	58
121	Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. Modern Pathology, 2004, 17, 1309-1313.	2.9	76
122	Oral Cancer Knowledge and Examination Experiences Among North Carolina Adults. Journal of Public Health Dentistry, 2004, 64, 173-180.	0.5	49
123	Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery, 2004, 136, 1183-1191.	1.0	89
124	Follow-up of colorectal cancer patients after resection with curative intent—the GILDA trial. Surgical Oncology, 2004, 13, 119-124.	0.8	71
125	Gender differences in lung cancer: Have we really come a long way, baby?. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 346-351.	0.4	53
126	Focus on head and neck cancer. Cancer Cell, 2004, 5, 311-316.	7.7	336
127	Treatment of localized esophageal cancer. Seminars in Oncology, 2004, 31, 554-565.	0.8	40
128	Descriptive epidemiology and risk factors for head and neck cancer. Seminars in Oncology, 2004, 31, 726-733.	0.8	184

#	Article	IF	CITATIONS
129	Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in Oncology, 2004, 31, 809-815.	0.8	31
130	Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Seminars in Oncology, 2004, 31, 27-31.	0.8	12
131	Clinical update: Novel targets in gynecologic malignancies. Seminars in Oncology, 2004, 31, 22-26.	0.8	152
132	New treatment strategies for aggressive lymphoma. Seminars in Oncology, 2004, 31, 10-13.	0.8	9
133	Perspectives in the treatment of colorectal cancer. Seminars in Oncology, 2004, 31, 14-18.	0.8	23
134	Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Seminars in Oncology, 2004, 31, 19-24.	0.8	25
135	The importance of chemotherapy dose intensity in lung cancer. Seminars in Oncology, 2004, 31, 25-31.	0.8	14
136	Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Seminars in Oncology, 2004, 31, 17-21.	0.8	38
137	Radiotherapy-induced salivary dysfunction. Seminars in Oncology, 2004, 31, 29-36.	0.8	34
138	The role of amifostine in the treatment of carcinoma of the uterine cervix: An update of RTOG-0116 and review of future directions. Seminars in Oncology, 2004, 31, 37-41.	0.8	21
139	Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?. Seminars in Oncology, 2004, 31, 52-58.	0.8	1
140	Surgical risk-reduction in carriers of BRCA mutations: Where do we go from here?. Gynecologic Oncology, 2004, 93, 277-279.	0.6	20
141	Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecologic Oncology, 2004, 94, 267-276.	0.6	33
142	In vivo adenovirus-mediated gene transduction into mouse endometrial glands: a novel tool to model endometrial cancer in the mouse. Gynecologic Oncology, 2004, 94, 713-718.	0.6	17
143	High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecologic Oncology, 2004, 95, 120-126.	0.6	83
144	Predictors of final histology in patients with endometrial cancer. Cynecologic Oncology, 2004, 95, 463-468.	0.6	133
145	Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecologic Oncology, 2004, 95, 181-188.	0.6	66
146	Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecologic Oncology, 2004, 95, 588-592.	0.6	87

ARTICLE IF CITATIONS # Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian 147 0.6 21 carcinoma. Gynecologic Oncology, 2004, 95, 539-545. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?. 148 143 Gynecologic Oncology, 2004, 95, 534-538. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in 149 0.6 158 uterine corpus cancer. Gynecologic Oncology, 2004, 95, 546-551. Current Development in Hormonal Therapy of Breast Cancer. Clinical Breast Cancer, 2004, 5, S4-S5. 1.1 Nonâ€"Small-Cell Lung Cancer in Elderly Patients: Influence of Age on Vinorelbine Oral 151 1.1 20 Pharmacokinetics. Clinical Lung Cancer, 2004, 5, 237-242. Epidermal Growth Factor Receptor as a Target to Improve Treatment of Lung Cancer. Clinical Lung 1.1 Cancer, 2004, 5, 340-352. 153 Radiofrequency Ablation: Identification of the Ideal Patient. Clinical Lung Cancer, 2004, 6, 149-153. 1.1 21 Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung 154 1.1 Cancer. Clinical Lung Cancer, 2004, 6, S7-S19. Select Clinical Trials of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer with Emphasis on Phase III 155 1.1 42 Outcomes. Clinical Lung Cancer, 2004, 6, S24-S29. Predictors of Sensitivity and Resistance to Epidermal Growth Factor Receptor Inhibitors. Clinical 1.1 Lung Cancer, 2004, 6, S30-S34. Role of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of 157 3 1.1 Bronchoalveolar Carcinoma. Clinical Lung Cancer, 2004, 6, S43-S47. Minimally invasive breast surgery. Journal of the American College of Surgeons, 2004, 199, 961-975. Molecular Detection of Prostate Cancer: A Role for GSTP1 Hypermethylation. European Urology, 2004, 159 0.9 119 46,660-669. Molecular Biomarker in Prostate Cancer: The Role of CpG Island Hypermethylation. European Urology, 2004, 46, 698-708. Utilizing geriatric skills in radiation oncology. Geriatric Nursing, 2004, 25, 355-360. 161 0.9 3 Prognostic utility of a glycoprotein tumor-associated antigen (TA90) specific immune complex assay in patients with cancer. Clinical and Applied Immunology Reviews, 2004, 4, 395-410. 163 Focus on bladder cancer. Cancer Cell, 2004, 6, 111-116. 7.7 252Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl 164 2.1 sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detection and Prevention, 2004, 28, 443-452

#	Article	IF	CITATIONS
165	Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy. American Journal of Obstetrics and Gynecology, 2004, 191, 1113-1123.	0.7	55
166	Vitamin E Analog α-TEA and Celecoxib Alone and Together Reduce Human MDA-MB-435-FL-GFP Breast Cancer Burden and Metastasis in Nude Mice. Breast Cancer Research and Treatment, 2004, 87, 111-121.	1.1	50
167	Increased Cumulative Incidence of Prostate Malignancies in Colorectal Cancer Patients. International Journal of Gastrointestinal Cancer, 2004, 34, 49-54.	0.4	6
168	Synergistic Effects of Combination Therapy Employing Antisense Oligonucleotides with Traditional Chemotherapeutics in the PC-3 Prostate Cancer Model. Medical Oncology, 2004, 21, 339-348.	1.2	9
169	Cryoablation of Early-Stage Breast Cancer: Work-in-Progress Report of a Multi-Institutional Trial. Annals of Surgical Oncology, 2004, 11, 542-549.	0.7	183
170	Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance. Annals of Surgical Oncology, 2004, 11, 1030-1034.	0.7	78
171	Chairman's Reflection on the Past, Present and Future of Neurosurgical Oncology. Journal of Neuro-Oncology, 2004, 69, 19-23.	1.4	3
172	Selenium and Vitamin E Cancer Prevention Trial. Annals of the New York Academy of Sciences, 2004, 1031, 234-241.	1.8	71
173	Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbeck's Archives of Surgery, 2004, 389, 405-413.	0.8	26
175	Comprehensive therapy of pancreatic cancer by integrative traditional and western medicine. Chinese Journal of Integrative Medicine, 2004, 10, 236-237.	0.7	4
176	New hybrid stochastic-deterministic technique for fast registration of dermatological images. Medical and Biological Engineering and Computing, 2004, 42, 777-786.	1.6	6
177	Is prostate cancer like lung cancer?. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1016-1017.	0.4	1
178	Hereditary breast cancer in Jews. Familial Cancer, 2004, 3, 249-257.	0.9	57
179	Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer, 2004, 3, 259-264.	0.9	36
180	How representative are the surveillance, epidemiology, and end results (SEER) Program cancer data of the United States?. Cancer Causes and Control, 2004, 15, 1027-1034.	0.8	71
182	Breast scintigraphy today: indications and limitations. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S35-S45.	3.3	49
183	Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Current Treatment Options in Oncology, 2004, 5, 357-365.	1.3	40
184	The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Current Treatment Options in Oncology, 2004, 5, 393-403.	1.3	14

#	Article	IF	CITATIONS
185	Prevention and management of early esophageal cancer. Current Treatment Options in Oncology, 2004, 5, 405-416.	1.3	5
186	Optimizing radiation therapy and post-treatment function in the management of extremity soft tissue sarcoma. Current Treatment Options in Oncology, 2004, 5, 463-476.	1.3	21
187	Treatment options for small cell lung cancer. Current Oncology Reports, 2004, 6, 268-271.	1.8	2
188	Proteomics in cancer screening and management in gynecologic cancer. Current Oncology Reports, 2004, 6, 456-462.	1.8	5
189	Screening and early detection of skin cancer. Current Oncology Reports, 2004, 6, 491-496.	1.8	9
190	No major association between TGFBR1*6A and prostate cancer. BMC Genetics, 2004, 5, 28.	2.7	14
191	Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC Urology, 2004, 4, 11.	0.6	27
192	Positron emission tomography with18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head and Neck, 2004, 26, 890-896.	0.9	87
193	A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer, 2004, 101, 156-163.	2.0	27
194	Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer, 2004, 101, 183-188.	2.0	76
195	Establishing the multidisciplinary care of patients with cancer in the state of Delaware. Cancer, 2004, 101, 220-225.	2.0	7
196	Small cell carcinoma of the urinary bladder. Cancer, 2004, 101, 957-962.	2.0	268
197	Endoscopic ultrasound-guided fine-needle aspiration. Cancer, 2004, 102, 203-206.	2.0	23
198	Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer, 2004, 101, 1569-1574.	2.0	126
199	Leukemogenic effect of chemotherapy in patients with breast carcinoma. Cancer, 2004, 101, 1479-1481.	2.0	4
200	Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer, 2004, 101, 1632-1638.	2.0	78
201	Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer, 2004, 101, 1575-1583.	2.0	152
202	Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer, 2004, 101, 2006-2010.	2.0	135

	CITATION R	CITATION REPORT	
#	Article	IF	CITATIONS
203	The prevention of invasive breast carcinoma. Cancer, 2004, 101, 2147-2151.	2.0	8
204	Multiple primary soft tissue sarcomas. Cancer, 2004, 101, 2633-2635.	2.0	40
205	An intronic variant of theTGFBR1 gene is associated with carcinomas of the kidney and bladder. International Journal of Cancer, 2004, 112, 420-425.	2.3	42
206	Liver transplantation outcomes for early-stage hepatocellular carcinoma: Results of a multicenter study. Liver Transplantation, 2004, 10, 1343-1354.	1.3	126
207	Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: Mature results of phase II study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 111-122.	0.4	27
208	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we go. Critical Reviews in Oncology/Hematology, 2004, 50, 175-186.	2.0	9
209	Synthesis and structure–activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5285-5288.		6
210	Ganoderma lucidum Suppresses Growth of Breast Cancer Cells Through the Inhibition of Akt/NF-κB Signaling. Nutrition and Cancer, 2004, 49, 209-216.		116
211	Conditionally replicative adenovirus for gastrointestinal cancers. Expert Opinion on Biological Therapy, 2004, 4, 1241-1250.		11
212	Neoadjuvant therapy for resectable pancreatic cancer. Surgical Oncology Clinics of North America, 2004, 13, 639-661.	0.6	47
213	Quantitative Cancer Proteomics: Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) as a Tool for Prostate Cancer Research. Molecular and Cellular Proteomics, 2004, 3, 729-735.	2.5	202
214	Human Cytochromes P450 1A1 and 1B1 Catalyze Ring Oxidation but Not Nitroreduction of Environmental Pollutant Mononitropyrene Isomers in Primary Cultures of Human Breast Cells and Cultured MCF-10A and MCF-7 Cell Lines. Chemical Research in Toxicology, 2004, 17, 1077-1085.	1.7	15
215	Robotic radical cystectomy and urinary diversion in the management of bladder cancer. Urologic Clinics of North America, 2004, 31, 719-729.	0.8	109
216	ADJUNCTIVE THERAPY FOR MEN WITH HIGH RISK LOCALIZED AND LOCALLY ADVANCED PROSTATE CANCER: TARGETING DISSEMINATED TUMOR CELLS. Journal of Urology, 2004, 172, 2539-2544.	0.2	10
217	Autopsy Results After Surgery for Non-Small Cell Lung Cancer. Mayo Clinic Proceedings, 2004, 79, 1409-1414.	1.4	9
218	Vattikuti Institute prostatectomy, a technique of robotic radical prostatectomy for management of localized carcinoma of the prostate: experience of over 1100 cases. Urologic Clinics of North America, 2004, 31, 701-717.	0.8	279
219	Anal-Rectal Cytology and Anal Cancer Screening. Seminars in Colon and Rectal Surgery, 2004, 15, 196-200.	0.2	1
220	PET imaging in assessing gastrointestinal tumors. Radiologic Clinics of North America, 2004, 42, 1123-1139.	0.9	27

		CITATION R	EPORT	
#	Article		IF	Citations
221	Scientific Basis of Neoadjuvant Therapy. Seminars in Breast Disease, 2004, 7, 51-57.		0.0	5
222	Advances in Screening, Diagnosis, and Treatment of Breast Cancer. Mayo Clinic Procee 810-816.	edings, 2004, 79,	1.4	24
224	Overview of smoking and all cancers. Medical Clinics of North America, 2004, 88, 165	5-1675.	1.1	38
225	Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surgical Oncology Clinic America, 2004, 13, 605-620.	cs of North	0.6	4
226	Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strateg Gastrointestinal intergroup pancreatic cancer task force. Surgical Oncology Clinics of America, 2004, 13, 751-760.	gies from the North	0.6	10
227	Clinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 867-874.	2004, 79,	1.4	319
228	Non-Hodgkin's Lymphoma in the Microarray Era. Clinical Lymphoma and Myeloma, 200	)4, 5, 128-129.	2.1	3
229	Small Bowel Adenocarcinoma. Clinical Colorectal Cancer, 2004, 4, 249-251.		1.0	0
230	Interstitial photodynamic therapy for prostate cancer: a developing modality. Photodia Photodynamic Therapy, 2004, 1, 123-136.	ignosis and	1.3	18
231	Colorectal cancer chemoprevention—an overview of the science1 1This article was p capacity as employees of the U.S. Federal Government Gastroenterology, 2004, 126,		0.6	85
232	Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology, 20 S104-S107.	)04, 127,	0.6	103
233	Molecular pathways of pancreatic carcinogenesis. Drug Discovery Today Disease Mech 247-252.	anisms, 2004, 1,	0.8	2
234	Molecular mechanisms of head and neck cancer. Drug Discovery Today Disease Mecha 273-281.	nisms, 2004, 1,	0.8	5
235	Should Tamoxifen Be Used in Breast Cancer Prevention?. Drug Safety, 2004, 27, 979-9	89.	1.4	11
236	Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms and Thei with 5-Fluorouracil/Leucovorin Chemotherapy in Colorectal Cancer. Clinical Colorectal 2004, 3, 225-234.	r Association Cancer,	1.0	16
237	The Influence of Host Response on Colorectal Cancer Prognosis. Clinical Colorectal Ca 38-45.	ncer, 2004, 4,	1.0	37
238	Epidermal Growth Factor Receptor as a Therapeutic Target for the Treatment of Colore Clinical Colorectal Cancer, 2004, 4, 51-62.	ectal Cancer.	1.0	15
239	Development of Rationally Designed, Target-Based Agents for the Treatment of Advance Cancer. Clinical Colorectal Cancer, 2004, 4, 107-123.	ced Colorectal	1.0	4

		CITATION REPORT		
#	Article		IF	CITATIONS
240	Surgical Issues in Rectal Cancer: A 2004 Update. Clinical Colorectal Cancer, 2004, 4, 23	33-240.	1.0	16
241	An Evaluation of Bicalutamide in the Treatment of Prostate Cancer. Clinical Prostate Ca 213-219.	ancer, 2004, 2,	2.1	29
242	Screening for Prostate Cancer. Clinical Prostate Cancer, 2004, 3, 21-25.		2.1	6
243	Ethnic Variation in Localized Prostate Cancer: A Pilot Study of Preferences, Optimism, a Life Among Black and White Veterans. Clinical Prostate Cancer, 2004, 3, 31-37.	and Quality of	2.1	18
244	Thalidomide and Analogues: Current Proposed Mechanisms and Therapeutic Usage. Cli Cancer, 2004, 3, 54-61.	nical Prostate	2.1	21
245	Double Primary Cancers of the Prostate and Bladder: A Literature Review. Clinical Prost 2004, 3, 83-86.	ate Cancer,	2.1	40
246	Angiogenesis-Targeted Therapies in Prostate Cancer. Clinical Prostate Cancer, 2004, 3,	165-173.	2.1	26
247	Clinical Issues in the Management of Non–Small-Cell Lung Cancer and the Role of Pla Therapy. Clinical Lung Cancer, 2004, 5, 274-289.	atinum-Based	1.1	15
248	Pemetrexed in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Review of Clinical Lung Cancer, 2004, 5, S67-S74.	the Clinical Data.	1.1	8
249	Second-Line Chemotherapy for Non–Small-Cell Lung Cancer: Recent Data with Peme Lung Cancer, 2004, 5, S75-S79.	trexed. Clinical	1.1	13
250	Is it Time to Change Surgical Strategy for Gastric Cancer in the United States?. Annals Oncology, 2004, 11, 727-730.	of Surgical	0.7	81
251	Gene expression profiling of epithelial ovarian tumours correlated with malignant poter Molecular Cancer, 2004, 3, 27.	ntial.	7.9	41
252	Synchronously diagnosed pre-sacral neurofibroma and cutaneous spitzoid melanoma: a association?. World Journal of Surgical Oncology, 2004, 2, 31.	a fortuitous	0.8	2
253	Management of Cutaneous Melanoma. New England Journal of Medicine, 2004, 351, 9	98-1012.	13.9	735
254	Identification of high-risk pancreatic cancer-prone families. Gastroenterology Clinics of America, 2004, 33, 907-918.	North	1.0	7
255	Anal Dysplasia: Controversies in Management. Seminars in Colon and Rectal Surgery, 2	004, 15, 233-238.	0.2	0
256	A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcom Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer. Clinical Cancer I 10, 8656-8664.	es Acquired Research, 2004,	3.2	66
257	Radiation and breast cancer: a review of current evidence. Breast Cancer Research, 200	)4, 7, 21-32.	2.2	265

#	Article	IF	CITATIONS
258	RACING FOR A CURE. Journal of Urology, 2004, 172, 1773-1773.	0.2	1
259	Image-guided ablation of renal cell carcinoma. Magnetic Resonance Imaging Clinics of North America, 2004, 12, 429-447.	0.6	33
260	Hypermethylation of the CpG islands in the promoter region of the CSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?. Clinica Chimica Acta, 2004, 350, 181-188.	0.5	22
261	Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma. Cancer Treatment Reviews, 2004, 30, 473-477.	3.4	5
262	The role of ephrins and Eph receptors in cancer. Cytokine and Growth Factor Reviews, 2004, 15, 419-433.	3.2	307
263	Thyroid nodule. Disease-a-Month, 2004, 50, 486-526.	0.4	7
264	Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. European Journal of Cancer, 2004, 40, 2165-2174.	1.3	71
265	Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochemical and Biophysical Research Communications, 2004, 318, 882-892.	1.0	157
266	Human kallikrein 13 involvement in extracellular matrix degradation. Biochemical and Biophysical Research Communications, 2004, 323, 1084-1090.	1.0	57
267	Comparing breast cancer risk between lesbians and their heterosexual sisters. Women's Health Issues, 2004, 14, 60-68.	0.9	105
268	A renaissance of "biochemical genetics� SNPs, haplotypes, function, and complex diseases. Molecular Genetics and Metabolism, 2004, 83, 47-50.	0.5	14
269	Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology, 2004, 63, 1061-1065.	0.5	24
270	Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.Sborn, Jamaican, and Haitian black men: A pilot study. Urology, 2004, 64, 522-527.	0.5	6
271	Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology, 2004, 64, 1171-1176.	0.5	89
272	A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 182-187.	0.8	28
273	The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 337-343.	0.8	45
274	Delivering prostate cancer prevention messages to the public: How the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 369-376.	0.8	7
275	Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models*1. Human Pathology, 2004, 35, 798-807.	1.1	13

#	Article	IF	CITATIONS
276	The value of sentinel lymph node biopsy in elderly breast cancer patients. American Journal of Surgery, 2004, 188, 440-442.	0.9	28
277	In vitro effects of pentosan polysulfate against malignant breast cells. American Journal of Surgery, 2004, 188, 589-592.	0.9	18
278	Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. American Journal of Surgery, 2004, 188, 505-510.	0.9	23
279	Ultrahigh resolution optical biopsy with endoscopic optical coherence tomography. Optics Express, 2004, 12, 3532.	1.7	99
280	Pancreatic cancer and thromboembolic disease. Lancet Oncology, The, 2004, 5, 655-663.	5.1	229
281	Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opinion on Biological Therapy, 2004, 4, 1159-1165.	1.4	36
282	Docetaxel Improves Survival in Metastatic Androgen-Independent Prostate Cancer. Clinical Prostate Cancer, 2004, 3, 18-20.	2.1	2
283	Radiosurgical treatment of brain metastases in a community oncologic practice. Community Oncology, 2004, 1, 149-158.	0.2	1
284	Gene Expression in Prostate Cancer Cells Treated With the Dual 5 Alphaâ€Reductase Inhibitor Dutasteride. Journal of Andrology, 2004, 25, 944-953.	2.0	35
285	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004, 304, 1497-1500.	6.0	9,038
286	Nanoparticle-Aptamer Bioconjugates. Cancer Research, 2004, 64, 7668-7672.	0.4	873
287	Adjuvant therapy for stage II colon cancer: an elephant in the living room?. Annals of Oncology, 2004, 15, 1310-1318.	0.6	58
288	New treatment strategies for multiple myeloma. Seminars in Hematology, 2004, 41, 2-8.	1.8	11
289	Neoplasms of the esophagus and stomach. Seminars in Nuclear Medicine, 2004, 34, 198-208.	2.5	52
290	Positron emission tomography for prostate, bladder, and renal cancer. Seminars in Nuclear Medicine, 2004, 34, 274-292.	2.5	312
291	A Major Lung Cancer Susceptibility Locus Maps to Chromosome 6q23–25. American Journal of Human Genetics, 2004, 75, 460-474.	2.6	272
292	Interferon-Î <sup>3</sup> expression is an independent prognostic factor in ovarian cancer. American Journal of Obstetrics and Gynecology, 2004, 191, 1598-1605.	0.7	83
293	Can the genotoxicity of chemotherapy be predicted?. Lancet, The, 2004, 364, 917-918.	6.3	7

#	Article	IF	CITATIONS
294	Will mandatory folic acid fortification prevent or promote cancer?. American Journal of Clinical Nutrition, 2004, 80, 1123-1128.	2.2	275
295	An Epoxide–Furanoid Rearrangement of Spinach Neoxanthin Occurs in the Gastrointestinal Tract of Mice and In Vitro: Formation and Cytostatic Activity of Neochrome Stereoisomers. Journal of Nutrition, 2004, 134, 2237-2243.	1.3	55
296	Chirurgische Therapie des Cholangiokarzinoms. Visceral Medicine, 2004, 20, 279-285.	0.5	0
297	Vitamin E and Breast Cancer. Journal of Nutrition, 2004, 134, 3458S-3462S.	1.3	100
298	Sentinel Node Staging of Resectable Colon Cancer. Annals of Surgery, 2004, 240, 624-630.	2.1	128
299	A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 565-569.	0.6	38
300	New strategies for cervical cancer screening in adolescents. Current Opinion in Pediatrics, 2004, 16, 344-349.	1.0	15
301	The Colon Is a Pelvic Organ Too. Obstetrics and Gynecology, 2004, 104, 907-909.	1.2	0
302	Chemotherapy for Prostate Cancer. American Journal of Therapeutics, 2004, 11, 288-294.	0.5	20
303	Comparative Morbidity of Axillary Lymph Node Dissection and the Sentinel Lymph Node Technique. Annals of Surgery, 2004, 240, 1-6.	2.1	68
304	Characteristics Contributing to an Enduring Prostate Cancer Support Group in an Asian and Pacific Islander Community. Journal of Psychosocial Oncology, 2004, 22, 1-30.	0.6	14
305	Improved Prostate Cancer Imaging with SPECT/CT and MRI/MRSI. , 0, , .		0
306	Preventing Cancer, Cardiovascular Disease, and Diabetes. Stroke, 2004, 35, 1999-2010.	1.0	112
307	Lung cancer. Current Opinion in Pulmonary Medicine, 2004, 10, 239-241.	1.2	1
308	Premalignant Evolution of Lung Cancer. Chest, 2004, 125, 90S-94S.	0.4	12
309	Second-line intravesical therapy versus cystectomy for bacille Calmette-Gu??rin (BCG) failures. Current Opinion in Urology, 2004, 14, 271-275.	0.9	33
310	Pancreatic neoplasms. Current Opinion in Gastroenterology, 2004, 20, 452-458.	1.0	3
311	Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Current Opinion in Oncology, 2004, 16, 478-484.	1.1	53

#	Article	IF	Citations
312	Uncertainty Intervention for Watchful Waiting in Prostate Cancer. Cancer Nursing, 2004, 27, 339???346.	0.7	118
313	Novel therapeutics in the treatment of bladder cancer. Current Opinion in Urology, 2004, 14, 287-293.	0.9	13
314	Advances in Screening, Diagnosis, and Treatment of Breast Cancer. Mayo Clinic Proceedings, 2004, 79, 810-816.	1.4	26
315	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood, 2004, 104, 1159-1165.	0.6	134
316	Immediate Breast Reconstruction After Mastectomy Increases Wound Complications. Archives of Surgery, 2004, 139, 988.	2.3	118
317	Assessing breast cancer risk. Postgraduate Medicine, 2004, 116, 6-34.	0.9	14
318	α-TEA Plus Cisplatin Reduces Human Cisplatin-Resistant Ovarian Cancer Cell Tumor Burden and Metastasis. Experimental Biology and Medicine, 2004, 229, 1169-1176.	1.1	47
319	Gene Expression Profiling Allows Distinction between Primary and Metastatic Squamous Cell Carcinomas in the Lung. Cancer Research, 2005, 65, 3063-3071.	0.4	132
320	Retroperitoneal Sarcomas. Cancer Control, 2005, 12, 36-43.	0.7	78
321	3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 333-338.	0.0	0
322	Sindbis vectors: illuminating the path to ovarian cancer therapy. Gene Therapy, 2005, 12, 381-382.	2.3	0
323	Continuing Controversies in the Management of Thyroid Nodules. Annals of Internal Medicine, 2005, 142, 926.	2.0	218
324	Cytokine Targeted Treatments for Lung Cancer. , 2005, 126, 289-311.		0
325	Patterns of Care for Immediate and Early Delayed Breast Reconstruction following Mastectomy. Plastic and Reconstructive Surgery, 2005, 115, 1289-1296.	0.7	72
326	Phase I Study of Docetaxel, Capecitabine, and Carboplatin in Metastatic Esophagogastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 329-333.	0.6	7
327	The L84F and the I143V polymorphisms in the O6-methylguanine-DNA-methyltransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK. Pharmacogenetics and Genomics, 2005, 15, 571-578.	0.7	35
328	Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer. Annals of Surgery, 2005, 241, 295-299.	2.1	99
329	Ovarian Cancer Prevention. , 2005, , 349-362.		1

#	Article	IF	CITATIONS
330	A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 334-339.	0.6	10
331	Tumor Size Is a Determinant of Stage Distribution in T1 Non-Small Cell Lung Cancer. Chest, 2005, 128, 2304-2308.	0.4	50
332	Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anti-Cancer Drugs, 2005, 16, 159-165.	0.7	13
333	A Longitudinal Study of Symptoms and Self-care Activities in Women Treated With Primary Radiotherapy for Breast Cancer. Cancer Nursing, 2005, 28, 210???218.	0.7	86
334	The Impact of Obesity on the Incidence and Treatment of Gynecologic Cancers: A Review. Obstetrical and Gynecological Survey, 2005, 60, 683-692.	0.2	127
335	Color-Coded Automated Signal Intensity Curves for Detection and Characterization of Breast Lesions. Investigative Radiology, 2005, 40, 448-457.	3.5	31
336	Genitourinary Malignancies in Solid Organ Transplant Recipients. Transplantation, 2005, 80, 709-716.	0.5	47
337	Phase II Study of Low-Dose Docetaxel/Fluorouracil/Cisplatin in Metastatic Gastric Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 433-438.	0.6	40
338	Current Techniques for the Evaluation of Abnormal Cervical Cytology. Clinical Obstetrics and Gynecology, 2005, 48, 133-146.	0.6	6
339	Lung cancer: genetics of risk and advances in chemoprevention. Current Opinion in Pulmonary Medicine, 2005, 11, 265-271.	1.2	26
340	A Xenograft Nude Mouse Model for Perineural Invasion and Recurrence in Pancreatic Cancer. Pancreas, 2005, 31, 258-262.	0.5	45
341	Low Back Pain Resulting From Paget Disease of Bone in a Patient With Known Prostate Cancer. , 2005, 15, 384-390.		2
342	Inhibition of the Stress Response to Breast Cancer Surgery by Regional Anesthesia and Analgesia Does Not Affect Vascular Endothelial Growth Factor and Prostaglandin E2. Anesthesia and Analgesia, 2005, 100, 244-249.	1.1	123
343	Concordant Loss of MTAP and p16/CDKN2A Expression in Gastroesophageal Carcinogenesis. American Journal of Surgical Pathology, 2005, 29, 1497-1504.	2.1	47
344	Perspective on the STR Consensus Statement. Journal of Thoracic Imaging, 2005, 20, 322-323.	0.8	0
345	Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells. Annals of Surgery, 2005, 242, 224-234.	2.1	89
346	Adjuvant chemotherapy in elderly patients with breast cancer: where are we?. Current Opinion in Oncology, 2005, 17, 566-572.	1.1	13
347	Radiofrequency ablation in bone neoplasia. Current Opinion in Orthopaedics, 2005, 16, 484-488.	0.3	2

ARTICLE IF CITATIONS A Proposal for a New and More Practical Grading Scheme for Pancreatic Ductal Adenocarcinoma. 348 2.1 84 American Journal of Surgical Pathology, 2005, 29, 724-733. Advances that are changing the diagnosis and treatment of malignant bone tumors. Current Opinion 349 in Rheumatology, 2005, 17, 79-85. 350 Bladder cancer. Current Opinion in Oncology, 2005, 17, 275-280. 1.1 30 Phase I/II Trial of Gefitinib and Oxaliplatin in Patients With Advanced Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 340-344. Phase II Trial of Induction Gemcitabine/CPT-11 Followed by a Twice-Weekly Infusion of Gemcitabine and 352 Concurrent External Beam Radiation for the Treatment of Locally Advanced Pancreatic Cancer. 0.6 41 American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 345-350. Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer. Menopause, 2005, 12, 436-443. 0.8 Prolonged Response to Nilutamide in a Patient with Stage D0.5 Prostate Cancer Who Previously Failed 354 0.5 4 Androgen Deprivation Therapy. American Journal of Therapeutics, 2005, 12, 172-174. Use of Preventive Services by Medicare Fee-For-Service Beneficiaries. Medical Care, 2005, 43, 445-452. 1.1 26 The use of intensity-modulated radiation therapy in the treatment of oropharyngeal carcinoma. 356 0.8 4 Current Opinion in Otolaryngology and Head and Neck Surgery, 2005, 13, 226-232. Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer. Pancreas, 2005, 31, 119-125. The Significance of Benign Endometrial Cells in Cervicovaginal Smears. Advances in Anatomic 358 37 2.4 Pathology, 2005, 12, 274-287. Depressive Symptoms Prescreening and Postscreening Among Returning Participants in an Ovarian Cancer Early Detection Program. Cancer Nursing, 2005, 28, 325???330. Clinical application of molecular profiling in breast cancer. Future Oncology, 2005, 1, 485-496. 360 1.1 12 A Phase I/II Study of Trimetrexate and Capecitabine in Patients With Advanced Refractory Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 439-444. Cyclooxygenase-2 (COX-2) Levels Before and After Chemotherapy: A Study in Rectal Cancer. American 362 12 0.6 Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 560-564. Lung cancer screening. Current Opinion in Internal Medicine, 2005, 4, 437-442. Assessment of HER-2 Status in Pancreatic Adenocarcinoma. American Journal of Surgical Pathology, 364 2.1 54 2005, 29, 1125-1134. Recent advances in epidemiology and prevention of gastrointestinal endoscopy related infections. 1.3 44 Current Opinion in Infectious Diseases, 2005, 18, 326-330.

ARTICLE IF CITATIONS # Polymorphisms and haplotypes of serine hydroxymethyltransferase and risk of squamous cell carcinoma of the head and neck: a case–control analysis. Pharmacogenetics and Genomics, 2005, 15, 366 0.7 15 557-564. Does interstitial lung disease predispose to lung cancer?. Current Opinion in Pulmonary Medicine, 367 1.2 2005, 11, 431-437. Insulinlike Growth Factor-I???Mediated Migration and Invasion of Human Colon Carcinoma Cells 368 Requires Activation of c-Met and Urokinase Plasminogen Activator Receptor. Annals of Surgery, 2005, 2.1 54 241, 748-758. Use of an educational computer program before genetic counseling for breast cancer susceptibility: 1.1 Effects on duration and content of counseling sessions. Genetics in Medicine, 2005, 7, 221-229. Mechanisms of Human Hepatocarcinogenesis: An Overview. Handbook of Immunohistochemistry and in 370 0.0 0 Situ Hybridization of Human Carcinomas, 2005, , 153-170. The promising future of proteomics in cancer diagnosis and treatment. European Journal of Gastroenterology and Hepatology, 2005, 17, 701-703. 371 0.8 Mechanisms of Disease: polymorphisms of androgen regulatory genes in the development of prostate 372 1.4 19 cancer. Nature Reviews Urology, 2005, 2, 101-107. Cancer Caregivers Online. CIN - Computers Informatics Nursing, 2005, 23, 38-45. 0.3 44 Female Sex and Bronchioloalveolar Pathologic Subtype Predict EGFR Mutations in Non-small Cell 374 0.4 109 Lung Cancer. Chest, 2005, 128, 317-321. Pilot study prospectively evaluating the use of the measurement of preoperative sonographic 0.8 endometrial thickness in postmenopausal patients with endometrial cancer. Menopause, 2005, 12, 27-30. Spontaneous regression of peritoneal carcinomatosis from a rectal cancer. European Journal of 376 4 0.8 Gastroenterology and Hepatology, 2005, 17, 1421-1423. Understanding the Role of Gender in the Incidence of Thyroid Cancer. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0,784314 rgBT /Ove New Approaches to Drug Development in Pediatric Oncology. Cancer Journal (Sudbury, Mass), 2005, 11, 378 1.0 18 324-330. Advances in colon cancer CHEMOTHEAPY NURSING IMPLICATIONS. Home Healthcare Nurse, 2005, 23, 379 0.4 154-164. Symptom Clusters in Breast Cancer Across 3 Phases of the Disease. Cancer Nursing, 2005, 28, 219???225. 380 0.7 150 New Approaches to the Minimally Invasive Treatment of Kidney Tumors. Cancer Journal (Sudbury, Mass) Tj ETQq1 1,0,784314,gBT /C Update in Medical Oncology for Older Patients. Cancer Journal (Sudbury, Mass), 2005, 11, 506-517. 382 1.0 10 Developmental Life Stage and Couples?? Experiences With Prostate Cancer. Cancer Nursing, 2005, 28, 85???98.

	CITATION	N REPORT	
#	Article	IF	CITATIONS
384	Chemoprevention using dutasteride: the REDUCE trial. Current Opinion in Urology, 2005, 15, 29-32.	0.9	35
385	Health Beliefs of Women With and Without Breast Cancer Seeking Genetic Cancer Risk Assessment. Cancer Nursing, 2005, 28, 372-379.	0.7	24
386	Meta-Analysis: Computed Tomographic Colonography. Annals of Internal Medicine, 2005, 142, 635.	2.0	333
387	The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 2005, 106, 167-174.	0.6	172
388	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood, 2005, 106, 1042-1047.	0.6	172
389	Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood, 2005, 105, 4215-4222.	0.6	234
390	Validation of scales measuring attitudes and norms related to mammography screening in women veterans Health Psychology, 2005, 24, 555-566.	1.3	21
391	A case study of radiotherapy planning for a bilateral metal hip prosthesis prostate cancer patient. Medical Dosimetry, 2005, 30, 169-175.	0.4	30
392	Quality assurance of HDR prostate plans: Program implementation at a community hospital. Medical Dosimetry, 2005, 30, 243-248.	0.4	1
393	Cardiovascular risk assessment in cancer patients undergoing major surgery. Journal of Nuclear Cardiology, 2005, 12, 151-157.	1.4	2
394	Survival After Gastric Adenocarcinoma Resection: Eighteen-Year Experience at a Single Institution. Journal of Gastrointestinal Surgery, 2005, 9, 718-725.	0.9	121
395	Vascular Endothelial Growth Factor and Predict Adjuvant Therapy Outcomes in Resected Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2005, 9, 903-911.	0.9	27
396	Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1364-1370.	0.4	1
397	Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 104-110.	0.4	39
398	Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non–small-cell lung cancer?. International Journal of Radiation Oncology Biology Physics, 2005, 62, 70-75.	0.4	149
399	Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97–12. International Journal of Radiation Oncology Biology Physics, 2005, 62, 342-350.	0.4	93
400	An association between preoperative anemia and decreased survival in early-stage non–small-cell lung cancer patients treated with surgery alone. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1438-1443.	0.4	36
401	A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1345-1350.	0.4	138

#	Article	IF	CITATIONS
402	The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1432-1437.	0.4	14
403	A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1332-1338.	0.4	26
404	Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1379-1384.	0.4	63
405	Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. International Journal of Radiation Oncology Biology Physics, 2005, 63, 553-564.	0.4	25
406	Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 500-504.	0.4	71
407	The polymorphism and haplotypes of XRCC1 and survival of non–small-cell lung cancer after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 885-891.	0.4	50
408	Chemoprevention of prostate cancer. Critical Reviews in Oncology/Hematology, 2005, 54, 1-10.	2.0	29
409	A Comprehensive Strategy to Combat Colon Cancer Targeting the Adenomatous Polyposis Coli Tumor Suppressor Gene. Annals of the New York Academy of Sciences, 2005, 1059, 97-105.	1.8	14
410	Incidence and Clinical Significance of Lymph Node Metastasis Detected by Cytokeratin Immunohistochemical Staining in Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2005, 12, 254-259.	0.7	29
411	Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis. Annals of Surgical Oncology, 2005, 12, 616-628.	0.7	152
412	Serum Levels of Leptin, Insulin, and Lipids in Relation to Breast Cancer in China. Endocrine, 2005, 26, 019-024.	2.2	120
413	Phase I Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide plus Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Non-Hodgkin's Lymphoma. Medical Oncology, 2005, 22, 257-268.	1.2	3
414	Implications of Therapy Choice on Overall Survival in Metastatic Renal Cell Carcinoma: A Single Institution Experience. Medical Oncology, 2005, 22, 399-406.	1.2	0
415	Operative considerations in resection of hilar cholangiocarcinoma. Hpb, 2005, 7, 254-258.	0.1	43
416	Molecular Classification of Renal Tumors by Gene Expression Profiling. Journal of Molecular Diagnostics, 2005, 7, 206-218.	1.2	130
417	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:Â Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model. Journal of Medicinal Chemistry, 2005, 48, 2972-2984.	2.9	228
418	The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. American Journal of Obstetrics and Gynecology, 2005, 192, 1614-1619.	0.7	169
419	Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. American Journal of Obstetrics and Gynecology, 2005, 192, 1365-1367.	0.7	59

#	Article	IF	CITATIONS
420	The impact of obesity and age on quality of life in gynecologic surgery. American Journal of Obstetrics and Gynecology, 2005, 193, 1369-1375.	0.7	83
421	Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 2005, 193, 568-574.	0.7	28
424	Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. American Journal of Obstetrics and Gynecology, 2005, 193, 2077-2082.	0.7	51
425	Evaluation of ST13 gene expression in colorectal cancer patients. Journal of Zhejiang University: Science B, 2005, 6, 1170-1175.	1.3	7
426	The Surgical Management of Locoregional and Metastatic Colorectal Cancer Recurrences. Journal of Surgical Education, 2005, 62, 585-590.	0.7	1
427	2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 4761-4769.	3.2	210
428	Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. International Journal of Gynecological Cancer, 2005, 15, 793-798.	1.2	8
429	Bariatric surgery in the field of gynecological oncology. International Journal of Gynecological Cancer, 2005, 15, 1254-1257.	1.2	1
430	Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. International Journal of Gynecological Cancer, 2005, 15, 266-273.	1.2	30
431	Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. International Journal of Gynecological Cancer, 2005, 15, 510-516.	1.2	26
432	Future challenges in clinical and translational research for endometrial cancer. International Journal of Gynecological Cancer, 2005, 15, 398-399.	1.2	4
433	Sun Protection Policies in Miami-Dade County Public Schools: Opportunities for Skin Cancer Prevention. Pediatric Dermatology, 2005, 22, 513-519.	0.5	23
434	The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries. Journal of General Internal Medicine, 2005, 20, 38-44.	1.3	31
435	Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing. Journal of General Internal Medicine, 2005, 20, 278-282.	1.3	64
436	The Association Between Oral Health and General Health and Quality of Life in Older Male Cancer Patients. Journal of the American Geriatrics Society, 2005, 53, 1504-1509.	1.3	33
437	Period between Completion of Radiation Therapy and Prosthetic Rehabilitation in Edentulous Patients: A Retrospective Study. Journal of Prosthodontics, 2005, 14, 110-121.	1.7	7
438	Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney International, 2005, 68, 1464-1471.	2.6	11
439	Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney International. 2005. 68. 2103-2110.	2.6	100

		CITATION RE	PORT	
#	Article		IF	Citations
440	The prevalence of renal cell carcinoma diagnosed at autopsy. BJU International, 2005,	95, 31-33.	1.3	59
441	Hormonal therapy options for prostate-specific antigen-only recurrence of prostate ca previous local therapy. BJU International, 2005, 95, 285-290.	ncer after	1.3	6
442	Examining the location and cause of death within 30 days of radical prostatectomy. BJ 2005, 95, 541-544.	U International,	1.3	14
443	The influence of bladder neck mucosal eversion and early urinary extravasation on pati after radical retropubic prostatectomy: a prospective controlled trial. BJU International 757-760.	ent outcome , 2005, 95,	1.3	40
444	Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, BJU International, 2005, 95, 951-955.	MN, 1980-2000.	1.3	7
445	The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elo asymptomatic population. BJU International, 2005, 95, 977-981.	lerly	1.3	43
446	Diverse optical characteristic of the prostate and light delivery system: implications for modelling of prostatic photodynamic therapy. BJU International, 2005, 95, 1237-1244		1.3	53
447	Therapeutic approaches in metastatic renal cell carcinoma. BJU International, 2005, 95	, 1153-1161.	1.3	14
448	Increasing the number of biopsy cores improves the concordance of biopsy Gleason sc prostatectomy Gleason score. BJU International, 2005, 96, 324-327.	ore to	1.3	39
449	A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinon International, 2005, 96, 536-539.	na. BJU	1.3	17
450	Zoledronic acid is effective in preventing and delaying skeletal events in patients with metastases secondary to genitourinary cancers. BJU International, 2005, 96, 964-969.	bone	1.3	57
451	Trends in melanoma mortality in Australia: 1950-2002 and their implications for melan Australian and New Zealand Journal of Public Health, 2005, 29, 383-386.	oma control.	0.8	60
452	Update in screening of lung cancer. Respirology, 2005, 10, 558-566.		1.3	9
453	Usefulness of ultrasensitive prostate-specific antigen assay for early detection of bioch after radical prostatectomy. International Journal of Urology, 2005, 12, 1050-1054.	iemical failure	0.5	21
454	Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes me insulin: a pilot study. British Journal of Dermatology, 2005, 153, 552-557.	litus using	1.4	31
455	Childhood acute lymphoblastic leukaemia and relapse. British Journal of Haematology, 579-587.	2005, 131,	1.2	203
456	Five cardiac hormones decrease the number of human small-cell lung cancer cells. Euro of Clinical Investigation, 2005, 35, 388-398.	pean Journal	1.7	42
457	Obstacles and opportunities in translational research. Nature Medicine, 2005, 11, 705	-708.	15.2	103

#	Article	IF	Citations
458	Ovarian Cancer Metastasis: Integrating insights from disparate model organisms. Nature Reviews Cancer, 2005, 5, 355-366.	12.8	480
459	The anaemia of cancer: death by a thousand cuts. Nature Reviews Cancer, 2005, 5, 543-555.	12.8	144
460	Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Therapy, 2005, 12, 593-599.	2.2	61
461	Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia, 2005, 19, 1253-1261.	3.3	35
462	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene, 2005, 24, 732-736.	2.6	54
463	PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene, 2005, 24, 1111-1116.	2.6	82
464	Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene, 2005, 24, 2474-2482.	2.6	197
465	The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene, 2005, 24, 2568-2573.	2.6	62
466	Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene, 2005, 24, 5375-5383.	2.6	38
467	Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene, 2005, 24, 5089-5100.	2.6	57
468	Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin–epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene, 2005, 24, 7084-7093.	2.6	66
469	RET Polymorphisms and Haplotypes and Risk of Differentiated Thyroid Cancer. Laryngoscope, 2005, 115, 1035-1041.	1.1	24
470	Radiation Response Genotype and Risk of Differentiated Thyroid Cancer: A Case-Control Analysis. Laryngoscope, 2005, 115, 938-945.	1.1	41
471	Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Laboratory Investigation, 2005, 85, 532-549.	1.7	46
472	HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Modern Pathology, 2005, 18, 615-620.	2.9	45
473	Detection of asymmetric blotches (asymmetric structureless areas) in dermoscopy images of malignant melanoma using relative color. Skin Research and Technology, 2005, 11, 179-184.	0.8	68
474	Anti-Tumor Antibodies in Ovarian Cancer. American Journal of Reproductive Immunology, 2005, 54, 55-62.	1.2	35
475	The Value of Scintimammography, F-18 FDG-PET and PET-CT in Breast Cancer. Imaging Decisions (Berlin,) Tj ETQo	1 1 0.784 0.2	314 rgBT /0

#	Article	IF	CITATIONS
476	Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer. Journal of the American Academy of Nurse Practitioners, 2005, 17, 113-122.	1.4	8
477	BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genetics and Cytogenetics, 2005, 158, 119-125.	1.0	83
478	Chronic myelogenous leukemia occurring in two brothers diagnosed 26 years apart. Cancer Genetics and Cytogenetics, 2005, 160, 73-75.	1.0	5
479	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7, 469-483.	7.7	2,137
480	Behavioral associations between prostate and colon cancer screening1. Journal of the American College of Surgeons, 2005, 200, 216-223.	0.2	67
481	Complications after Preoperative Combined Modality Therapy and Radical Resection of Locally Advanced Rectal Cancer: A 14-Year Experience from a Specialty Service. Journal of the American College of Surgeons, 2005, 200, 876-882.	0.2	70
482	The Emerging Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Primary and Recurrent Rectal Cancer. Journal of the American College of Surgeons, 2005, 201, 948-956.	0.2	24
483	Esophageal cancer: Is there hope?. Journal of Surgical Education, 2005, 62, 150-155.	0.7	0
484	Update on Postoperative Colorectal Cancer Surveillance. Journal of Surgical Education, 2005, 62, 491-494.	0.7	7
485	Mutant KRAS in the initiation of pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1756, 97-101.	3.3	89
486	Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. Biochemical Pharmacology, 2005, 70, 287-299.	2.0	37
487	Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Brain Research, 2005, 1044, 197-205.	1.1	65
488	SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast, 2005, 14, 250-255.	0.9	81
489	Special issues related to breast cancer adjuvant therapy in older women. Breast, 2005, 14, 600-611.	0.9	18
490	PS-341–mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Experimental Hematology, 2005, 33, 784-795.	0.2	56
491	Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radical Biology and Medicine, 2005, 38, 50-57.	1.3	66
492	Psychosocial consequences of prostate cancer: 30 years of research. Geriatric Nursing, 2005, 26, 166-175.	0.9	68
493	Epidemiology of lung cancer. Seminars in Roentgenology, 2005, 40, 83-89.	0.2	39

#	Article	IF	CITATIONS
494	Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Seminars in Oncology, 2005, 32, 120-127.	0.8	10
495	Combined modality treatment for rectal cancer. Seminars in Oncology, 2005, 32, 103-112.	0.8	13
496	Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?. Seminars in Oncology, 2005, 32, 69-75.	0.8	22
497	Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. Seminars in Oncology, 2005, 32, 24-34.	0.8	49
498	Colorectal cancer: Looking forward. Seminars in Oncology, 2005, 32, 1-2.	0.8	0
499	The Emerging Role of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Seminars in Oncology, 2005, 32, 23-29.	0.8	23
500	Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib. Journal of Controlled Release, 2005, 104, 167-179.	4.8	16
501	Role for the double-stranded RNA-activated protein kinase PKR in Ad-TNF-α gene therapy in esophageal cancer. Surgery, 2005, 138, 261-268.	1.0	14
502	Long-term management of patients after potentially curative treatment of extremity soft tissue sarcoma: practice patterns of members of the Society of Surgical Oncology. Surgical Oncology, 2005, 14, 33-40.	0.8	10
503	Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surgical Oncology, 2005, 14, 105-113.	0.8	48
504	Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 571, 153-173.	0.4	261
505	Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncology, 2005, 41, 183-199.	0.8	74
506	The dynamics of plasma transforming growth factor beta 1 (TGF-β1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer. Oral Oncology, 2005, 41, 208-213.	0.8	10
507	Update on the Management of Oral Cancer: Diagnostic and Therapeutic Modalities. Journal of Oral and Maxillofacial Surgery, 2005, 63, 115.	0.5	0
508	Surveillance computed tomography after complete resection for non–small cell lung cancer: Results and costs. Journal of Thoracic and Cardiovascular Surgery, 2005, 129, 652-660.	0.4	28
509	The evolutionary origin of genetic instability in cancer development. Seminars in Cancer Biology, 2005, 15, 51-60.	4.3	83
510	Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology, 2005, 15, 319-326.	4.3	56
511	Management of muscle invasive bladder cancer?British approaches to organ conservation. Seminars in Radiation Oncology, 2005, 15, 19-27.	1.0	12

		CITATION REPORT		
#	Article		IF	CITATIONS
512	Molecular markers in bladder cancer. Seminars in Radiation Oncology, 2005, 15, 3-9.		1.0	21
513	The surgical management of muscle invasive bladder cancer: A contemporary review. S Radiation Oncology, 2005, 15, 10-18.	eminars in	1.0	31
514	Bringing Molecular Prognosis and Prediction to the Clinic. Clinical Breast Cancer, 2005	, 6, 61-76.	1.1	36
515	Antiangiogenesis: A Possible Treatment Option for Prostate Cancer?. Clinical Genitouri 2005, 4, 197-202.	nary Cancer,	0.9	10
516	The Prospect of Biologic Staging of Non–Small-Cell Lung Cancer. Clinical Lung Cance 217-224.	er, 2005, 6,	1.1	5
518	Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire i with metastatic colorectal cancer. BMC Cancer, 2005, 5, 116.	n patients	1.1	133
519	Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bror BMC Cancer, 2005, 5, 155.	ichial biopsies.	1.1	33
520	Female breast cancer incidence and survival in Utah according to religious preference, Cancer, 2005, 5, 49.	1985–1999. BMC	1.1	9
521	Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer, 2005, 5, 53.		1.1	48
522	Development and initial testing of a computer-based patient decision aid to promote c cancer screening for primary care practice. BMC Medical Informatics and Decision Mak	olorectal ing, 2005, 5, 36.	1.5	38
523	Pharmacy Practice, Research, Education, and Advocacy for Older Adults. Pharmacother 1396-1430.	ару, 2005, 25,	1.2	46
524	Recent Advances and Future Perspectives in the Management of Lung Cancer. Current Surgery, 2005, 42, 548-610.	Problems in	0.6	3
525	Cancer Screening. Current Problems in Surgery, 2005, 42, 620-682.		0.6	15
526	Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implica future management of epithelial carcinoma of the ovary. Gynecologic Oncology, 2005	tions for , 96, 307-313.	0.6	14
527	Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecologic Oncology, 200	15, 96, 10-18.	0.6	99
528	Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecc Oncology, 2005, 96, 531-538.	logic	0.6	64
529	Endometrial cancer: can nodal status be predicted with curettage?. Gynecologic Onco 594-600.	ogy, 2005, 96,	0.6	25
530	Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cance Oncology, 2005, 96, 902-905.	er. Gynecologic	0.6	107

#	Article	IF	CITATIONS
531	16,090: the 2004 estimated U.S. mortality from ovarian cancer. Gynecologic Oncology, 2005, 97, 301-302.	0.6	4
532	Endometroid adenocarcinoma of the uterus with cardiac metastasis. Gynecologic Oncology, 2005, 97, 256-259.	0.6	9
533	Malignant mixed mullerian tumor (MMMT) of the cervix. Gynecologic Oncology, 2005, 97, 442-445.	0.6	29
534	Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecologic Oncology, 2005, 97, 638-644.	0.6	46
535	A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: Analysis of Surveillance, Epidemiology, and End Results data. Gynecologic Oncology, 2005, 97, 550-558.	0.6	81
536	The functional assessment of cancer-vulvar: Reliability and validity. Gynecologic Oncology, 2005, 97, 568-575.	0.6	51
537	Metastatic carcinoma of the gallbladder mimicking an advanced cervical carcinoma. Gynecologic Oncology, 2005, 97, 942-945.	0.6	23
538	An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecologic Oncology, 2005, 98, 141-145.	0.6	65
539	High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology, 2005, 98, 92-98.	0.6	61
540	Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecologic Oncology, 2005, 98, 84-91.	0.6	21
541	Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecologic Oncology, 2005, 98, 24-30.	0.6	89
542	Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: An extended follow-up. Gynecologic Oncology, 2005, 98, 59-62.	0.6	12
543	Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer. Gynecologic Oncology, 2005, 99, 564-570.	0.6	57
544	Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 267-277.	0.6	324
545	A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecologic Oncology, 2005, 99, 714-719.	0.6	20
546	Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: A preliminary report. Gynecologic Oncology, 2005, 99, S187-S191.	0.6	20
547	Resource utilization for ovarian cancer patients at the end of life: How much is too much?. Gynecologic Oncology, 2005, 99, 261-266.	0.6	61
548	Gender differences in genetic damage induced by the tobacco-specific nitrosamine NNK and the influence of the Thr241Met polymorphism in theXRCC3 gene. Environmental and Molecular Mutagenesis, 2005, 46, 22-29.	0.9	17

#	Article	IF	CITATIONS
549	AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes and Cancer, 2005, 43, 249-259.	1.5	129
550	Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary adenocarcinomas in Syrian golden hamsters contain beta 2-adrenergic receptor single-nucleotide polymorphisms. Genes Chromosomes and Cancer, 2005, 44, 212-217.	1.5	9
551	Very low intensity alternating current decreases cell proliferation. Glia, 2005, 51, 65-72.	2.5	43
552	Interstitial high-dose-rate brachytherapy combined with cervical dissection on head and neck cancer. Head and Neck, 2005, 27, 1035-1041.	0.9	20
553	Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. International Journal of Cancer, 2005, 114, 806-816.	2.3	701
554	Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. International Journal of Cancer, 2005, 114, 831-835.	2.3	11
555	Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. International Journal of Cancer, 2005, 115, 484-492.	2.3	98
556	Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. International Journal of Cancer, 2005, 115, 256-262.	2.3	90
557	Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. International Journal of Cancer, 2005, 115, 734-741.	2.3	38
558	Ethnic group-related differences in CpG hypermethylation of theGSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. International Journal of Cancer, 2005, 116, 174-181.	2.3	88
559	Thyroid cancer and multiple primary tumors in the SEER cancer registries. International Journal of Cancer, 2005, 117, 281-288.	2.3	126
560	Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. International Journal of Cancer, 2005, 117, 21-31.	2.3	45
561	Expression of cytochromes P450 and glutathioneS-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogensvia acetyl-coA-, PAPS- and ATP-dependent pathways. International Journal of Cancer, 2005, 117, 8-13.	2.3	44
562	TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. International Journal of Cancer, 2005, 117, 370-375.	2.3	40
563	Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy. International Journal of Cancer, 2005, 117, 816-824.	2.3	11
564	Thalidomide for advanced hepatocellular carcinoma. Cancer, 2005, 103, 1-4.	2.0	12
565	Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer, 2005, 103, 339-348.	2.0	228
566	Receipt of colorectal testing prior to colorectal carcinoma diagnosis. Cancer, 2005, 103, 696-701.	2.0	13

ARTICLE IF CITATIONS # Screening for prostate carcinoma. Cancer, 2005, 103, 881-883. 2.0 567 1 The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian 568 carcinoma. Cancer, 2005, 103, 1397-1401. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men 569 with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer, 2005, 103, 2.0 62 2030-2034. Carcinoma core distribution in patients with palpable and nonpalpable prostate tumors. Cancer, 2005, 2.0 103, 1761-1762. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic 571 2.0 42 adenocarcinomas. Cancer, 2005, 103, 2163-2170. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer, 2005, 103, 2313-2319. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. 573 2.0 76 Cancer, 2005, 103, 2349-2354. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer, 574 2.0 88 2005, 103, 2391-2396. Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in 575 ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass 2.0 26 spectrometry. Cancer, 2005, 105, 178-183. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer, 2005, 103, 2435-2446. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer, 2005, 577 2.0 185 104, 305-313. Significance of benign endometrial cells in papanicolaou tests from women aged ≥ 40 years. Cancer, 2005, 105, 207-216. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer, 2005, 104, 579 2.0 78 388-394. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with 580 106 taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer, 2005, 104, 561-569. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer, 581 2.0 34 2005, 104, 781-787. Quality of prostate carcinoma care in a statewide public assistance program. Cancer, 2005, 104, 2.0 985-992. Genetic expression profiles and biologic pathway alterations in head and neck squamous cell 583 2.0 94 carcinoma. Cancer, 2005, 104, 1113-1128. 584 Amplification of c-erbB2 oncogene. Cancer, 2005, 104, 1391-1397.

#	Article	IF	CITATIONS
585	Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma. Cancer, 2005, 104, 1627-1632.	2.0	53
586	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer, 2005, 104, 1575-1579.	2.0	167
587	Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma. Cancer, 2005, 104, 1956-1961.	2.0	8
588	Increased incidence of melanoma in renal transplantation recipients. Cancer, 2005, 104, 1962-1967.	2.0	154
589	Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer, 2005, 104, 1918-1923.	2.0	32
590	Incidence and clinical significance of morphologically benign-appearing endometrial cells in patients age 40 years or older. Cancer, 2005, 108, 39-44.	2.0	24
591	Akt activation correlates with adverse outcome in tongue cancer. Cancer, 2005, 104, 2430-2436.	2.0	110
592	Adjuvant systemic therapy for male breast carcinoma. Cancer, 2005, 104, 2359-2364.	2.0	187
593	Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 65A, 4-14.	1.1	89
594	Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. American Journal of Hematology, 2005, 78, 212-215.	2.0	4
595	Wood dust exposure and the association with lung cancer risk. American Journal of Industrial Medicine, 2005, 47, 349-357.	1.0	68
596	Cryoablation and cryolocalization in the management of breast disease. Journal of Surgical Oncology, 2005, 90, 1-9.	0.8	32
597	Gastric cancer: New genetic developments. Journal of Surgical Oncology, 2005, 90, 114-133.	0.8	176
598	Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. Journal of Surgical Oncology, 2005, 91, 97-101.	0.8	41
599	Determinants of unresectability and outcome of patients with occult colorectal hepatic metastases. Journal of Surgical Oncology, 2005, 92, 64-69.	0.8	20
600	Molecular mechanisms of hepatic metastasis in colorectal cancer. Journal of Surgical Oncology, 2005, 92, 347-359.	0.8	65
601	Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer. Lasers in Surgery and Medicine, 2005, 36, 390-397.	1.1	79
602	Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Molecular Carcinogenesis, 2005, 43, 215-224.	1.3	75

#	ARTICLE		CITATIONS
603	Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Molecular Carcinogenesis, 2005, 44, 1-10.	1.3	60
604	Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Molecular Nutrition and Food Research, 2005, 49, 452-461.	1.5	122
605	Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin?s disease. Pediatric Radiology, 2005, 35, 169-178.	1.1	22
606	Hybrid SPECT/CT: a new era for SPECT imaging?. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 521-524.	3.3	129
607	Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunology, Immunotherapy, 2005, 54, 826-836.	2.0	65
608	90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 1200-1213.	2.0	39
609	Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology, 2005, 56, 97-104.	1.1	31
610	A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology, 2005, 56, 199-204.	1.1	13
611	Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes. Cancer Chemotherapy and Pharmacology, 2005, 56, 69-77.	1.1	3
612	IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization. Medical Dosimetry, 2005, 30, 69-75.	0.4	33
613	Laparoscopic Total Abdominal Colectomy in the Acute Setting. Journal of Gastrointestinal Surgery, 2005, 9, 881-887.	0.9	25
614	Novel Therapeutics in Colorectal Cancer. Diseases of the Colon and Rectum, 2005, 48, 1632-1650.	0.7	20
615	Crohn's Disease: Presentation and Severity Compared Between Black Patients and White Patients. Diseases of the Colon and Rectum, 2005, 48, 1404-1409.	0.7	37
617	Colonoscopy vs CT colonography to screen for colorectal neoplasia in average-risk patients. Surgical Endoscopy and Other Interventional Techniques, 2005, 19, 448-456.	1.3	5
618	Ten-year trend in the national volume of bile duct injuries requiring operative repair. Surgical Endoscopy and Other Interventional Techniques, 2005, 19, 967-973.	1.3	101
619	Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 442-450.	1.4	130
620	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 483-488.	1.4	102
621	Complex segregation analysis reveals a multigene model for lung cancer. Human Genetics, 2005, 116, 121-127.	1.8	36

		CITATION REF	PORT	
#	Article		IF	CITATIONS
622	Ovarian tissue cryopreservation: benefits and risks. Cell and Tissue Research, 2005, 322, 1	25-132.	1.5	61
624	Practice Parameters for the Management of Rectal Cancer (Revised). Diseases of the Colo Rectum, 2005, 48, 411-423.	n and	0.7	199
626	Détection du cancer colorectal et des lésions prémalignes par chromoscopie et eno grossissante. Acta Endoscopica, 2005, 35, 581-596.	loscopie à optique	0.0	1
627	Tumeurs intestinales, quelle stratégie proposer?. Acta Endoscopica, 2005, 35, 157-169.		0.0	0
628	BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or functional p53. Journal of Biomedical Science, 2005, 12, 999-1011.	without	2.6	19
629	Management of malignant colonic obstruction. Current Treatment Options in Gastroenter 2005, 8, 231-237.	ology,	0.3	13
630	Chemotherapy of metastatic colorectal cancer. Current Treatment Options in Gastroenter 2005, 8, 239-247.	ology,	0.3	9
631	Treatment of familial pancreatic cancer and its precursors. Current Treatment Options in Gastroenterology, 2005, 8, 365-375.		0.3	14
632	Treatment of metastatic malignant melanoma. Current Treatment Options in Oncology, 2	005, 6, 185-193.	1.3	156
633	Treatment of myeloma in patients not eligible for transplantation. Current Treatment Opt Oncology, 2005, 6, 241-253.	ons in	1.3	9
634	Melanoma of the head and neck. Current Treatment Options in Oncology, 2005, 6, 19-30		1.3	11
635	Overview of the management of differentiated thyroid cancer. Current Treatment Options Oncology, 2005, 6, 47-57.	in	1.3	44
636	Combined modality therapy for limited-disease small cell lung cancer. Current Treatment ( Oncology, 2005, 6, 69-74.	)ptions in	1.3	8
637	Antimetabolites in the management of non-small cell lung cancer. Current Treatment Opt Oncology, 2005, 6, 83-93.	ons in	1.3	2
638	Utilizing prognostic and predictive factors in breast cancer. Current Treatment Options in 2005, 6, 147-159.	Oncology,	1.3	55
639	Chemotherapy in patients with resectable liver metastases from colorectal cancer. Curren Colorectal Cancer Reports, 2005, 1, 34-40.		1.0	1
640	Risk factors for pancreatic adenocarcinoma: Are we ready for screening and surveillance?. Gastroenterology Reports, 2005, 7, 122-127.	Current	1.1	10
641	Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical Current Oncology Reports, 2005, 7, 419-434.	cancer.	1.8	69

		CITATION R	EPORT	
#	Article		IF	CITATIONS
642	Adjuvant chemotherapy for primary breast cancer. Current Oncology Reports, 2005, 7	, 18-22.	1.8	2
643	Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agen Oncology Reports, 2005, 7, 116-122.	ts. Current	1.8	6
644	Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung Current Oncology Reports, 2005, 7, 255-259.	cancer.	1.8	33
645	Adjuvant therapy for colon cancer. Current Oncology Reports, 2005, 7, 181-185.		1.8	10
646	Chemotherapy for advanced pancreatic cancer: Past, present, and future. Current Onc 2005, 7, 186-195.	ology Reports,	1.8	17
647	Angiogenesis and prostate cancer: Important laboratory and clinical findings. Current ( Reports, 2005, 7, 215-219.	Dncology	1.8	15
648	Surveillance following radical or partial nephrectomy for renal cell carcinoma. Current I Reports, 2005, 6, 7-18.	Jrology	1.0	108
649	Chemotherapies and immunotherapies for metastatic kidney cancer. Current Urology 35-42.	Reports, 2005, 6,	1.0	6
650	Laparoscopic radical cystectomy with continent urinary diversion. Current Urology Rep 109-117.	oorts, 2005, 6,	1.0	8
651	Laparoscopic radical cystectomy and urinary diversion. Current Urology Reports, 2005	, 6, 118-121.	1.0	13
652	Hypercalcemia in Breast Cancer: An Echo of Bone Mobilization During Lactation?. Journ Gland Biology and Neoplasia, 2005, 10, 157-167.	nal of Mammary	1.0	17
653	A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophage Adenocarcinoma. Digestive Diseases and Sciences, 2005, 50, 2218-2223.	al and Gastric	1.1	51
654	Randomized phase II trial of different schedules of administration of rebeccamycin ana second line therapy in non-small cell lung cancer. Investigational New Drugs, 2005, 23	logue as , 563-567.	1.2	9
655	A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer New Drugs, 2005, 23, 583-590.	. Investigational	1.2	85
656	MLH1 and MSH2 Mutations in Colombian Families with Hereditary Nonpolyposis Color (Lynch syndrome) $\hat{a} \in \mathcal{C}$ Description of Four Novel Mutations. Familial Cancer, 2005, 4, 2		0.9	21
657	Bone marrow metastases from glioblastoma multiforme – A case report and review o Journal of Neuro-Oncology, 2005, 72, 157-161.	of the literature.	1.4	41
658	Immunologic response to cryoablation of breast cancer. Breast Cancer Research and T 90, 97-104.	reatment, 2005,	1.1	161
659	Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Resear Treatment, 2005, 91, 11-18.	rch and	1.1	37

#	Article	IF	CITATIONS
660	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatment, 2005, 92, 151-156.	1.1	47
661	Colorectal cancer screening in average risk individuals. Cancer Causes and Control, 2005, 16, 171-188.	0.8	39
662	Hormone replacement therapy is not associated with an increased risk of leukemia (United States). Cancer Causes and Control, 2005, 16, 483-488.	0.8	9
663	Anthropometrics, Physical Activity, Related Medical Conditions, and the Risk of Non-Hodgkin Lymphoma. Cancer Causes and Control, 2005, 16, 1203-1214.	0.8	69
664	Kinetics of Marked Development of Lung Metastasis of Rat Prostatic Carcinomas Transplanted in Syngeneic Rats. Clinical and Experimental Metastasis, 2005, 22, 309-318.	1.7	2
665	Modification of an in vivo Lung Metastasis Model of Hepatocellular Carcinoma by Low Dose N-nitrosomorpholine and Diethylnitrosamine. Clinical and Experimental Metastasis, 2005, 22, 441-447.	1.7	18
666	Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. Clinical and Experimental Metastasis, 2005, 22, 47-59.	1.7	182
667	Metastatic Progression of Pancreatic Cancer: Changes in Antioxidant Enzymes and Cell Growth. Clinical and Experimental Metastasis, 2005, 22, 523-532.	1.7	66
668	Persistent demographic differences in colorectal cancer screening utilization despite Medicare reimbursement. BMC Gastroenterology, 2005, 5, 10.	0.8	59
669	Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell International, 2005, 5, 3.	1.8	24
670	Quality of life and diet intervention in individuals at risk for recurrence of colorectal adenomas. Psycho-Oncology, 2005, 14, 85-93.	1.0	15
671	Benefits from an uncertainty management intervention for African-American and Caucasian older long-term breast cancer survivors. Psycho-Oncology, 2005, 14, 962-978.	1.0	191
672	A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate, 2005, 62, 115-122.	1.2	61
673	Establishment and characterization of a human primary prostate carcinoma cell line, HH870. Prostate, 2005, 63, 91-103.	1.2	7
674	Bi-directional interactions of prostate cancer cells and bone marrow endothelial cells in three-dimensional culture. Prostate, 2005, 64, 75-82.	1.2	28
675	Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. Prostate, 2005, 64, 60-66.	1.2	4
676	Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer. Prostate, 2005, 64, 265-271.	1.2	7
677	Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate, 2005, 64, 293-302.	1.2	72

#	Article	IF	CITATIONS
678	Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate, 2005, 65, 203-215.	1.2	34
679	Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics, 2005, 5, 3183-3192.	1.3	44
680	Radioprotectors and Chemoprotectors in the Management of Lung Cancer. , 2005, , 123-134.		0
681	The Extent of Lymphadenectomy at the Time of Radical Cystectomy for Bladder Cancer and its Impact on Prognosis and Survival. Scientific World Journal, The, 2005, 5, 891-901.	0.8	2
682	Tamoxifen Inhibition of Estrogen Receptor-α–Negative Mouse Mammary Tumorigenesis. Cancer Research, 2005, 65, 3493-3496.	0.4	33
683	Colorectal Cancer Prevention. , 2005, , 203-222.		1
684	Skin Cancer Prevention. , 2005, , 161-201.		1
685	Strategies that Promote Health in Cities. , 2005, , 539-559.		0
686	Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. American Journal of Health-System Pharmacy, 2005, 62, 266-273.	0.5	15
687	Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2005, 31, 437-444.	0.7	2
688	Preliminary Evaluation of Prostate Cancer Metastatic Risk Biomarkers. International Journal of Biological Markers, 2005, 20, 141-145.	0.7	14
689	Development of a Patient Registry to Evaluate Hospital Admissions Related to Chemotherapy Toxicity in a Community Cancer Center. Journal of Oncology Practice, 2005, 1, 15-19.	2.5	19
690	Cancer Patient Survival Improvement Is Correlated With the Opening of a Community Cancer Center: Comparisons With Intramural and Extramural Benchmarks. Journal of Oncology Practice, 2005, 1, 84-92.	2.5	21
691	Effect of Race on Long-Term Survival of Breast Cancer Patients: Transinstitutional Analysis from an Inner City Hospital and University Medical Center. American Surgeon, 2005, 71, 164-170.	0.4	9
692	Increasing Mammography Screening Through Inpatient Education. Journal of Cancer Education, 2005, 20, 247-250.	0.6	25
694	False Negative Bone Scintigraphy in a Patient with Primary Breast Cancer: A Possible Transient Phenomenon of Bisphosphonate (Alendronate) Treatment. Tumori, 2005, 91, 77-80.	0.6	10
695	Concurrent 5-Fluorouracil, Mitomycin C and Radiation, with or without Brachytherapy, in Recurrent Endometrial Cancer: A Scoring System to Predict Clinical Response and Outcome. Tumori, 2005, 91, 215-220.	0.6	11
696	Breast Cancer Prevention. , 2005, , 255-276.		5

#	Article	IF	CITATIONS
697	Introduction to Cancer Prevention. , 2005, , 1-10.		2
698	Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis. Journal of Biomedicine and Biotechnology, 2005, 2005, 287-290.	3.0	19
699	Prediction of pathological stage in prostate cancer through the percentage of involved fragments upon biopsy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2005, 31, 445-451.	0.7	3
700	Narrative Review: Screening for Colorectal Cancer in Patients with a First-Degree Relative with Colonic Neoplasia. Annals of Internal Medicine, 2005, 143, 190.	2.0	13
701	Detection of Circulating CEA-IgM Complexes in Early Stage Colorectal Cancer. International Journal of Biological Markers, 2005, 20, 204-208.	0.7	34
702	Prostate biopsy: is age important for determining the pathological features in prostate cancer?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2005, 31, 331-337.	0.7	5
703	Does Screening for Barrett's Esophagus and Adenocarcinoma of the Esophagus Prolong Survival?. Journal of Clinical Oncology, 2005, 23, 4478-4482.	0.8	36
704	Randomized Comparison of Group Versus Individual Genetic Education and Counseling for Familial Breast and/or Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 3455-3464.	0.8	71
705	Prostate cancer and consistency of reporting sexual histories in men over age 50. Prostate Cancer and Prostatic Diseases, 2005, 8, 243-247.	2.0	1
706	Patient-Specific Vaccine Therapy for Non-Hodgkin Lymphoma. Clinical Journal of Oncology Nursing, 2005, 9, 85-90.	0.3	4
707	Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate. Carcinogenesis, 2005, 26, 845-854.	1.3	118
708	Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01. Journal of Clinical Oncology, 2005, 23, 8322-8330.	0.8	57
709	Phenotypic Heterogeneity in Multiple Myeloma Families. Journal of Clinical Oncology, 2005, 23, 685-693.	0.8	52
710	Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met– and Insulin-like Growth Factor-I Receptor–Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice. Cancer Research, 2005, 65, 7775-7781.	0.4	132
711	Loss of Heterozygosity Patterns Provide Fingerprints for Genetic Heterogeneity in Multistep Cancer Progression of Tobacco Smoke–Induced Non–Small Cell Lung Cancer. Cancer Research, 2005, 65, 1664-1669.	0.4	59
712	Recognition of Prostate and Breast Tumor Cells by Helper T Lymphocytes Specific for a Prostate and Breast Tumor-Associated Antigen, TARP. Clinical Cancer Research, 2005, 11, 3869-3878.	3.2	32
713	Lung cancer screening: panacea or pipe dream?. Annals of Oncology, 2005, 16, ii215-ii219.	0.6	17
714	Sunlight and Reduced Risk of Cancer: Is The Real Story Vitamin D?. Journal of the National Cancer Institute, 2005, 97, 161-163.	3.0	60

#	Article	IF	CITATIONS
715	Urinary tobaccoâ€specific nitrosamines and 4â€aminobiphenyl hemoglobin adducts measured in smokers of either regular or light cigarettes. Nicotine and Tobacco Research, 2005, 7, 729-738.	1.4	38
716	Retinoid receptors in ovarian cancer: expression and prognosis. Annals of Oncology, 2005, 16, 1477-1487.	0.6	20
717	Chemokine Receptor CXCR4 Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival. Journal of Clinical Oncology, 2005, 23, 2744-2753.	0.8	348
718	Identification of a Novel Synthetic Thiazolidin Compound Capable of Inducing c-Jun NH2-Terminal Kinase–Dependent Apoptosis in Human Colon Cancer Cells. Cancer Research, 2005, 65, 6380-6387.	0.4	42
719	Misregulated Wnt/β-Catenin Signaling Leads to Ovarian Granulosa Cell Tumor Development. Cancer Research, 2005, 65, 9206-9215.	0.4	152
720	Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 69-74.	2.0	45
721	Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells. Journal of Biological Chemistry, 2005, 280, 11583-11589.	1.6	71
722	Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?. Acta Oncolųgica, 2005, 44, 255-264.	0.8	23
723	Molecular Determinants of Cetuximab Efficacy. Journal of Clinical Oncology, 2005, 23, 3536-3544.	0.8	229
724	Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 140-151.	2.0	11
725	Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR–Chk1/2–Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 2005, 26, 1978-1987.	1.3	139
726	Functional Imaging in Lung Cancer. Journal of Clinical Oncology, 2005, 23, 3203-3211.	0.8	32
727	Endometrial Cancer and Tamoxifen. Clinical Journal of Oncology Nursing, 2005, 9, 247-249.	0.3	9
728	Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nature Reviews Urology, 2005, 2, 32-37.	1.4	12
729	Colorectal Cancer Screening in HIV-Infected Patients 50 Years of Age and Older: Missed Opportunities for Prevention. American Journal of Gastroenterology, 2005, 100, 1805-1812.	0.2	81
730	30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity. Journal of the National Cancer Institute, 2005, 97, 1525-1532.	3.0	172
731	Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research, 2005, 65, 8406-8413.	0.4	27
732	Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2005, 11, 8570-8576.	3.2	184

#	Article	IF	CITATIONS
733	Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer. Endocrine Reviews, 2005, 26, 361-379.	8.9	149
734	Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Review of Molecular Diagnostics, 2005, 5, 701-713.	1.5	60
735	Fertility-Sparing Surgery for Malignancies in Women. Journal of the National Cancer Institute Monographs, 2005, 2005, 43-47.	0.9	89
736	Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib. Clinical Cancer Research, 2005, 11, 2089-2096.	3.2	118
737	The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11005-11010.	3.3	192
738	A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. Oncologist, 2005, 10, 392-398.	1.9	47
739	Dietary Feeding of Silibinin Prevents Early Biomarkers of UVB Radiation-Induced Carcinogenesis in SKH-1 Hairless Mouse Epidermis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1344-1349.	1.1	60
740	Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis, 2005, 27, 1-22.	1.3	130
741	Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer. Clinical Cancer Research, 2005, 11, 1408-1415.	3.2	88
742	Emerging Role of Rexinoids in Nonâ€&mall Cell Lung Cancer: Focus on Bexarotene. Oncologist, 2005, 10, 22-33.	1.9	59
743	Targeted Virus Replication Plus Immunotherapy Eradicates Primary and Distant Pancreatic Tumors in Nude Mice. Cancer Research, 2005, 65, 9056-9063.	0.4	50
744	Non-Hodgkin's lymphoma in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2005, 64, 1507-1509.	0.5	113
745	Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited. Journal of Clinical Oncology, 2005, 23, 7460-7466.	0.8	34
746	Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene Expression Profiles. Clinical Cancer Research, 2005, 11, 2252-2257.	3.2	32
747	Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy. Cancer Research, 2005, 65, 6450-6458.	0.4	153
748	Does a History of Childhood Sexual Abuse Affect Sexual Outcomes in Breast Cancer Survivors?. Journal of Clinical Oncology, 2005, 23, 1261-1269.	0.8	15
749	Limitations of Screening for Lung Cancer with Low-Dose Spiral Computed Tomography. Clinical Cancer Research, 2005, 11, 4988s-4992s.	3.2	74
750	Comparisons of thresholds for carcinogenicity on linear and logarithmic dosage scales. Human and Experimental Toxicology, 2005, 24, 325-332.	1.1	20

#	Article	IF	CITATIONS
751	Progress in the Adjuvant Treatment of Colon Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 2758.	3.8	26
752	Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncology, 2005, 1, 161-167.	1.1	33
753	Silencing of poloâ€like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB Journal, 2005, 19, 1-14.	0.2	116
754	Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors. Clinical Cancer Research, 2005, 11, 4923-4933.	3.2	76
755	Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With 1311-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results. Journal of Clinical Oncology, 2005, 23, 6763-6770.	0.8	126
756	Risk Factors for Young Premenopausal Women With Endometrial Cancer. Obstetrics and Gynecology, 2005, 105, 575-580.	1.2	277
757	New Developments in Lung Cancer Screening. Journal of Clinical Oncology, 2005, 23, 3198-3202.	0.8	15
758	Mortality From Lung Cancer and Tobacco Smoking in Ohio (U.S.): Will Increasing Smoking Prevalence Reverse Current Decreases in Mortality?. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1182-1187.	1.1	12
759	A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research, 2005, 11, 3369-3376.	3.2	195
760	Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6550-6557.	3.2	174
761	Medical and Pediatric Oncology, Not Adult and Pediatric Oncology. Journal of Clinical Oncology, 2005, 23, 4003-4005.	0.8	14
762	Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer. Cancer Research, 2005, 65, 7081-7085.	0.4	125
763	Relations of Gestational Length and Timing and Type of Incomplete Pregnancy to Ovarian Cancer Risk. American Journal of Epidemiology, 2005, 161, 452-461.	1.6	18
764	Breast Cancer Treatment Guidelines in Older Women. Journal of Clinical Oncology, 2005, 23, 783-791.	0.8	219
765	Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 2918-2925.	0.8	430
766	Evaluation of Epothilone B Analog in Advanced Soft Tissue Sarcoma: A Phase II Study of the Phase II Consortium. Journal of Clinical Oncology, 2005, 23, 3069-3073.	0.8	30
767	Study of Paclitaxel, Etoposide, and Cisplatin Chemotherapy Combined With Twice-Daily Thoracic Radiotherapy for Patients With Limited-Stage Small-Cell Lung Cancer: A Radiation Therapy Oncology Group 9609 Phase II Study. Journal of Clinical Oncology, 2005, 23, 4991-4998.	0.8	62
768	Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research, 2005, 11, 5856-5862.	3.2	246

#	Article	IF	CITATIONS
769	Future of Early Detection of Lung Cancer: The Role of Mouse Models. Clinical Cancer Research, 2005, 11, 4999s-5003s.	3.2	20
770	Intrapulmonary IFN-β Gene Therapy Using an Adenoviral Vector Is Highly Effective in a Murine Orthotopic Model of Bronchogenic Adenocarcinoma of the Lung. Cancer Research, 2005, 65, 8379-8387.	0.4	45
771	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. Clinical Cancer Research, 2005, 11, 8105-8108.	3.2	125
772	Broad-Spectrum G Protein–Coupled Receptor Antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: A Dual Inhibitor of Growth and Angiogenesis in Pancreatic Cancer. Cancer Research, 2005, 65, 2738-2745.	0.4	95
773	Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 700-706.	0.6	32
774	Enhancement of Drug Delivery in Tumors by Using Interaction of Nanoparticles with Ultrasound Radiation. Technology in Cancer Research and Treatment, 2005, 4, 217-226.	0.8	87
775	Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model. Clinical Cancer Research, 2005, 11, 5984-5992.	3.2	167
776	Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. Clinical Cancer Research, 2005, 11, 3296-3302.	3.2	61
777	Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non–Small Cell Lung Cancers. Clinical Cancer Research, 2005, 11, 8235-8242.	3.2	68
778	Epigenetic Modulation of Retinoic Acid Receptor β2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. Clinical Cancer Research, 2005, 11, 3535-3542.	3.2	76
779	Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocrine-Related Cancer, 2005, 12, 839-850.	1.6	88
780	In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor. Clinical Cancer Research, 2005, 11, 7508-7515.	3.2	152
781	The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Molecular Cancer Therapeutics, 2005, 4, 824-834.	1.9	42
782	Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 596-604.	1.1	75
783	Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2178-2182.	1.1	29
784	Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial. Clinical Cancer Research, 2005, 11, 4437-4443.	3.2	58
785	Controversies in the Therapy of Early Stage Breast Cancer. Oncologist, 2005, 10, 766-779.	1.9	16
786	A Review of the Diagnosis and Management of Male Breast Cancer. Oncologist, 2005, 10, 471-479.	1.9	268

#	Article	IF	CITATIONS
787	Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation. Cancer Research, 2005, 65, 4716-4727.	0.4	51
788	Immunohistochemical Detection of the $\hat{l}^2$ 4 Integrin Subunit in Pancreatic Adenocarcinoma. Journal of Histochemistry and Cytochemistry, 2005, 53, 799-801.	1.3	22
789	Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. Journal of Clinical Oncology, 2005, 23, 5943-5949.	0.8	118
790	Human Malignant Melanomas Express Receptors for Luteinizing Hormone Releasing Hormone Allowing Targeted Therapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogue. Cancer Research, 2005, 65, 5857-5863.	0.4	40
791	CT Colonography: Where Have We Been and Where Are We Going?. Radiology, 2005, 237, 819-833.	3.6	84
792	Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis, 2005, 26, 1404-1413.	1.3	64
793	Lung Cancer in Women. Journal of Clinical Oncology, 2005, 23, 3212-3218.	0.8	137
794	Dyadic interdependence on affect and quality-of-life trajectories among women with breast cancer and their partners. Journal of Social and Personal Relationships, 2005, 22, 673-689.	1.4	69
795	Imaging of the Patient with Non–Small Cell Lung Cancer. Radiology, 2005, 237, 803-818.	3.6	47
796	Adjuvant Therapy in Stage II Colon Cancer: Current Approaches. Oncologist, 2005, 10, 325-331.	1.9	37
797	Multitarget FISH and LOH Analyses at Chromosome 3p in Non–Small Cell Lung Cancer and Adjacent Bronchial Epithelium. American Journal of Clinical Pathology, 2005, 123, 752-761.	0.4	21
798	High Risk of Brain Metastases in Surgically Staged IIIA Non–Small-Cell Lung Cancer Patients Treated With Surgery, Chemotherapy, and Radiation. Journal of Clinical Oncology, 2005, 23, 1530-1537.	0.8	168
799	Alzheimer disease and cancer. Neurology, 2005, 64, 895-898.	1.5	195
800	An Overview of Lung Cancer Genomics and Proteomics. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 169-176.	1.4	149
801	Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting. Annals of Pharmacotherapy, 2005, 39, 77-85.	0.9	58
802	Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 8321-8325.	3.2	129
803	Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 306-318.	1.1	54
804	Breast Lesion Detection and Characterization at Contrast-enhanced MR Mammography: Gadobenate Dimeglumine versus Gadopentetate Dimeglumine. Radiology, 2005, 237, 45-56.	3.6	80

#	Article	IF	CITATIONS
805	Postmastectomy Radiation and Mortality in Women With T1-2 Node-Positive Breast Cancer. Journal of Clinical Oncology, 2005, 23, 1409-1419.	0.8	40
806	Cell Death by Autoschizis in TRAMP Prostate Carcinoma Cells as a Result of Treatment by Ascorbate: Menadione Combination. Ultrastructural Pathology, 2005, 29, 221-235.	0.4	23
807	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute, 2005, 97, 94-102.	3.0	309
808	Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2005, 11, 3353-3362.	3.2	357
809	Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma. Journal of Clinical Oncology, 2005, 23, 2038-2048.	0.8	292
810	Bisphosphonates in breast cancer. Annals of Oncology, 2005, 16, 687-695.	0.6	115
811	Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis, 2005, 27, 162-169.	1.3	197
812	Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy. Clinical Cancer Research, 2005, 11, 2149-2155.	3.2	139
813	Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research, 2005, 11, 8384-8390.	3.2	35
814	Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer. Cancer Research, 2005, 65, 4218-4227.	0.4	272
815	Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nature Reviews Urology, 2005, 2, 136-142.	1.4	40
816	Development of Peptide Antagonists for the Androgen Receptor Using Combinatorial Peptide Phage Display. Molecular Endocrinology, 2005, 19, 2478-2490.	3.7	66
817	ProstaScint (Capromab Pendetide) Imaging Using Hybrid Gamma Camera–CT Technology. American Journal of Roentgenology, 2005, 184, 676-680.	1.0	35
818	Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. Future Oncology, 2005, 1, 19-22.	1.1	13
819	Preoperative Evaluation and Oncologic Principles of Colon Cancer Surgery. Clinics in Colon and Rectal Surgery, 2005, 18, 163-173.	0.5	18
820	Pulmonary Nodule Detection with Low-Dose CT of the Lung: Agreement Among Radiologists. American Journal of Roentgenology, 2005, 185, 973-978.	1.0	77
821	Docetaxel in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy, 2005, 5, 13-24.	1.1	7
822	Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ: British Medical Journal, 2005, 330, 769-773.	2.4	42

#	Article	IF	CITATIONS
823	Computer-aided detection (CAD) for CT colonography: a tool to address a growing need. British Journal of Radiology, 2005, 78, S57-S62.	1.0	65
824	Quantitative Assessment of Colorectal Cancer Perfusion Using MDCT: Inter- and Intraobserver Agreement. American Journal of Roentgenology, 2005, 185, 225-231.	1.0	68
825	The Role of Proteomics in the Diagnosis and Treatment of Ovarian Cancer. Women's Health, 2005, 1, 365-374.	0.7	2
826	Optimization of multi-slice helical respiration-correlated CT: the effects of table speed and rotation time. Physics in Medicine and Biology, 2005, 50, 5717-5729.	1.6	12
827	Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci. Clinical Cancer Research, 2005, 11, 4097-4106.	3.2	135
828	Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 4037-4043.	3.2	198
829	CT Colonography with Intravenous Contrast Material: Varied Appearances of Colorectal Carcinoma. Radiographics, 2005, 25, 1321-1334.	1.4	22
830	New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Expert Review of Anticancer Therapy, 2005, 5, 53-62.	1.1	5
831	Monoclonal antibody therapy of ovarian cancer. Expert Review of Anticancer Therapy, 2005, 5, 87-96.	1.1	15
832	Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Review of Clinical Immunology, 2005, 1, 47-62.	1.3	32
833	MR Imaging Follow-up after Percutaneous Radiofrequency Ablation of Renal Cell Carcinoma: Findings in 18 Patients during First 6 Months. Radiology, 2005, 235, 1065-1071.	3.6	119
834	Multidisciplinary treatment of synchronous primary rectal and prostate cancers. Nature Clinical Practice Oncology, 2005, 2, 271-274.	4.3	15
835	Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biology and Therapy, 2005, 4, 548-554.	1.5	132
836	Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton. Endocrinology, 2005, 146, 1727-1736.	1.4	174
837	Mechanisms of Disease: prostate cancer—a model for cancer chemoprevention in clinical practice. Nature Clinical Practice Oncology, 2005, 2, 255-261.	4.3	16
838	Green Tea Polyphenols Modulate Secretion of Urokinase Plasminogen Activator (uPA) and Inhibit Invasive Behavior of Breast Cancer Cells. Nutrition and Cancer, 2005, 52, 66-73.	0.9	70
839	Matching and reconstruction of brachytherapy seeds using the Hungarian algorithm (MARSHAL). Medical Physics, 2005, 32, 3475-3492.	1.6	56
840	Artificial Neural Network Analysis of DNA Microarray-based Prostate Cancer Recurrence. , 2005, , .		14

#	Article	IF	CITATIONS
841	Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid. Clinical Cancer Research, 2005, 11, 8312-8320.	3.2	93
842	Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility. Clinical Chemistry, 2005, 51, 102-112.	1.5	336
843	Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 2005, 26, 1170-1181.	1.3	330
844	Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clinical Medicine and Research, 2005, 3, 157-165.	0.4	44
845	Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer. Clinical Cancer Research, 2005, 11, 6422-6430.	3.2	349
846	Scintimammography for the detection of breast cancer. Expert Review of Medical Devices, 2005, 2, 191-196.	1.4	9
847	Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression. Cancer Research, 2005, 65, 9369-9376.	0.4	258
849	Quantitative Detection of Promoter Hypermethylation in Multiple Genes in the Serum of Patients with Colorectal Cancer. American Journal of Gastroenterology, 2005, 100, 2274-2279.	0.2	134
850	Positive Predictive Value of Fecal Occult Blood Testing in Persons Taking Warfarin. American Journal of Gastroenterology, 2005, 100, 1586-1592.	0.2	32
851	A Novel Educational Strategy to Enhance Internal Medicine Residents' Familial Colorectal Cancer Knowledge and Risk Assessment Skills. American Journal of Gastroenterology, 2005, 100, 677-684.	0.2	35
852	Barrett's Esophagus-Is It Bad for Your Health?. American Journal of Gastroenterology, 2005, 100, 2622-2623.	0.2	9
853	Solid tumor risks after high doses of ionizing radiation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13040-13045.	3.3	163
854	Review of current treatment practices for carcinoma of the head and neck. Expert Opinion on Pharmacotherapy, 2005, 6, 1143-1155.	0.9	14
855	Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis. British Journal of Cancer, 2005, 92, 1729-1736.	2.9	25
856	HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. British Journal of Cancer, 2005, 92, 2233-2239.	2.9	75
857	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2005, 97, 339-346.	3.0	2,194
858	The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9890-9895.	3.3	85
859	Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5524-5529.	3.3	602

	Сітатіс	CITATION REPORT	
# 860	ARTICLE CIL-102 Interacts with Microtubule Polymerization and Causes Mitotic Arrest following Apoptosis in the Human Prostate Cancer PC-3 Cell Line*. Journal of Biological Chemistry, 2005, 280, 2771-2779.	lF 1.6	CITATIONS
861	In Vivo Biodistribution of Dendrimers and Dendrimer Nanocomposites — Implications for Cancer Imaging and Therapy. Technology in Cancer Research and Treatment, 2005, 4, 603-613.	0.8	79
862	Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry. Clinical Chemistry, 2005, 51, 2229-2235.	1.5	166
863	Interruption of Homologous Desensitization in Cyclic Guanosine 3′,5′-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins. Cancer Research, 2005, 65, 11129-11135.	0.4	33
864	Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer. Cancer Research, 2005, 65, 11581-11587.	0.4	44
865	Cancer Prevention: Strong Science and Real Medicine. Journal of Clinical Oncology, 2005, 23, 249-253.	0.8	31
866	Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo. Clinical Cancer Research, 2005, 11, 3889-3896.	3.2	38
867	Promoter Methylation of DAL-1/4.1B Predicts Poor Prognosis in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 2954-2961.	3.2	76
868	Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model. Cancer Research, 2005, 65, 10371-10380.	0.4	96
869	Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database. Journal of Clinical Oncology, 2005, 23, 7114-7124.	0.8	505
870	Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 8033-8040.	0.8	439
871	Differences in Survival by Histologic Type of Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1766-1773.	1.1	253
872	Improving Accrual of Older Persons to Cancer Treatment Trials: A Randomized Trial Comparing an Educational Intervention With Standard Information: CALGB 360001. Journal of Clinical Oncology, 2005, 23, 2201-2207.	0.8	114
873	Effect of Combination Therapy with a Novel Bisphosphonate, Minodronate (YM529), and Docetaxel on a Model of Bone Metastasis by Human Transitional Cell Carcinoma. Clinical Cancer Research, 2005, 11, 6669-6677.	3.2	19
874	Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas. Clinical Cancer Research, 2005, 11, 5347-5355.	3.2	61
875	Microcomputed tomography colonography for polyp detection in an in vivo mouse tumor model. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3419-3422.	3.3	39
876	Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6657-6668.	3.2	39
877	Reduced FEZ1/LZTS1 Expression and Outcome Prediction in Lung Cancer. Cancer Research, 2005, 65, 1207-1212.	0.4	33

		CITATION REPO	ORT	
#	Article	1	IF	CITATIONS
878	Sun exposure and risk of melanoma. Archives of Disease in Childhood, 2005, 91, 131-138.	:	1.0	204
879	Interaction between epidermal growth factor receptor– and cyclooxygenase 2–mediat and its implications for the chemoprevention of head and neck cancer. Molecular Cancer Therapeutics, 2005, 4, 1448-1455.		1.9	79
880	Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Trea 10 Years. Oncologist, 2005, 10, 842-848.	ted for up to	1.9	82
881	Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic med Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mole Therapeutics, 2005, 4, 1747-1754.	icinal plant cular Cancer	1.9	85
882	8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinas extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in n myeloma. Molecular Cancer Therapeutics, 2005, 4, 569-577.		1.9	29
883	Increased Retinoic Acid Receptor-Â4 Correlates In vivo with Reduced Retinoic Acid Recepto Esophageal Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2 826-829.	r-Â2 in 005, 14,	1.1	24
884	Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chem Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radio for Patients With Unresectable Stage IIIA and B Non–Small-Cell Lung Cancer. Journal of O Oncology, 2005, 23, 3760-3767.	otherapy	0.8	151
885	Down-regulation of Integrin $\hat{l}$ ±2 Surface Expression by Mutant Epidermal Growth Factor Re (EGFRvIII) Induces Aberrant Cell Spreading and Focal Adhesion Formation. Cancer Research 9280-9286.	ceptor , 2005, 65,	0.4	50
886	Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial ( Cancer Research, 2005, 65, 3735-3744.	Cancer.	0.4	117
887	Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cyste Journal of Clinical Oncology, 2005, 23, 6533-6539.		0.8	283
888	Perspectives in the treatment of gastric cancer. Nature Clinical Practice Oncology, 2005, 2	, 98-107.	4.3	159
889	Surgical Therapy for Metastatic Disease to the Liver. Annual Review of Medicine, 2005, 56,	139-156.	5.0	119
890	Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmaco 2005, 6, 2667-2679.	therapy,	0.9	7
891	Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in C Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial. Journal of the National Ca Institute, 2005, 97, 560-566.	Ptimally ncer	3.0	434
892	Prognostic value of serum markers for prostate cancer. Scandinavian Journal of Urology an Nephrology, 2005, 39, 64-81.	d	1.4	63
893	RET Proto-Oncogene: A Review and Update of Genotype–Phenotype Correlations in Here Medullary Thyroid Cancer and Associated Endocrine Tumors. Thyroid, 2005, 15, 531-544.	ditary	2.4	269
894	3D TRUS Image Segmentation in Prostate Brachytherapy. , 2005, 2005, 7170-3.			1
895	Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nucl cytoplasmic and secreted forms. Endocrine-Related Cancer, 2005, 12, 875-889.	ear,	1.6	50

#ARTICLEIFCITATIONS896Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an<br/>soos, 12, 631-643.1.6128897Women's Decision-Making Roles Regarding Contralateral Prophylactic Mastectomy. Journal of the<br/>kaltional Cancer Institute Monographs, 2005, 556.0.0.956898Epidemiology and statistical methods in prediction of patient outcome. Scandinavian Journal of<br/>krolegy and Nephrology, 2005, 59, 94-110.1.48899Joint modelling of recurrence and progression of adenomas: a latent variable approach. Statistical<br/>wordenling, 2005, 5, 201-215.0.58

**CITATION REPORT** 

900 Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin,) Tj ETQq0 0 0,rgBT /Overlock 10 Tf

901	Cardiovascular Risk in Testicular Cancer Survivors Treated With Chemotherapy: Incidence, Significance, and Practice Implications. Oncology Nursing Forum, 2005, 32, 1005-1012.	0.5	4
902	Strengths and Limitations of Breast Cancer Risk Assessment. Oncology Nursing Forum, 2005, 32, 605-616.	0.5	7
903	Cancer in Older Adults. Oncology Nursing Forum, 2005, 32, 913-917.	0.5	0
904	Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer. Journal of Clinical Oncology, 2005, 23, 1819-1825.	0.8	109
905	Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 4888-4896.	0.8	201
906	Clinicopathologic Behavior of Gastric Adenocarcinoma in Hispanic Patients: Analysis of a Single Institution's Experience Over 15 Years. Journal of Clinical Oncology, 2005, 23, 3094-3103.	0.8	63
907	Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer. Journal of Clinical Oncology, 2005, 23, 6019-6026.	0.8	247
908	Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 5929-5937.	0.8	66
909	Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic Pancreatitis. American Journal of Clinical Pathology, 2005, 124, 838-845.	0.4	197
910	CD4+CD25+ Regulatory Lymphocytes Induce Regression of Intestinal Tumors in ApcMin/+ Mice. Cancer Research, 2005, 65, 3998-4004.	0.4	194
911	Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis. Cancer Research, 2005, 65, 7214-7222.	0.4	77
912	The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer. Cancer Research, 2005, 65, 8118-8124.	0.4	130
913	Polymorphisms of Methionine Synthase and Methionine Synthase Reductase and Risk of Squamous Cell Carcinoma of the Head and Neck: a Case-Control Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1188-1193.	1.1	61

#	Article	IF	CITATIONS
914	Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 892-899.	1.1	34
915	A Modified Host Cell Reactivation Assay to Measure DNA Repair Capacity for Removing 4-Aminobiphenyl Adducts: A Pilot Study of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1832-1836.	1.1	23
916	Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues. Clinical Cancer Research, 2005, 11, 5549-5557.	3.2	36
917	Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research, 2005, 11, 8637-8643.	3.2	127
918	Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 5057s-5062s.	3.2	41
919	CA9 Expression as a Prognostic Factor in Renal Clear Cell Carcinoma. Urologia Internationalis, 2005, 74, 68-73.	0.6	16
920	Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax, 2005, 60, 570-575.	2.7	257
921	Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab. Oncologist, 2005, 10, 282-291.	1.9	39
922	Adjuvant Radiotherapy in Endometrial Carcinoma. Oncologist, 2005, 10, 623-631.	1.9	21
923	Longâ€Term Enteral Nutrition Facilitates Optimization of Body Weight. Journal of Parenteral and Enteral Nutrition, 2005, 29, 198-203.	1.3	21
924	Modern Treatment of Lung Cancer. Journal of Clinical Oncology, 2005, 23, 7740-7742.	0.8	0
925	Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth. Cancer Research, 2005, 65, 2287-2295.	0.4	155
926	Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 2005, 16, 90-96.	0.6	108
927	Bexarotene and Erlotinib for Aerodigestive Tract Cancer. Journal of Clinical Oncology, 2005, 23, 8757-8764.	0.8	62
928	From cystic pulmonary airway malformation, to bronchioloalveolar carcinoma and adenocarcinoma of the lung. European Respiratory Journal, 2005, 26, 1181-1187.	3.1	92
929	β1A Integrin Expression Is Required for Type 1 Insulin-Like Growth Factor Receptor Mitogenic and Transforming Activities and Localization to Focal Contacts. Cancer Research, 2005, 65, 6692-6700.	0.4	69
930	Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 2785-2808.	3.2	582
931	Small-interfering RNA–induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Molecular Cancer Therapeutics, 2005, 4, 505-515.	1.9	161

#	Article	IF	CITATIONS
932	Optical Detection of Tumors In Vivo by Visible Light Tissue Oximetry. Technology in Cancer Research and Treatment, 2005, 4, 227-234.	0.8	17
933	An Ovarian Cancer Diagnosis-Seeking Process: Unraveling the Diagnostic Delay Problem. Oncology Nursing Forum, 2005, 32, 1036-1042.	0.5	14
934	Information Needs of Wives of Men Following Prostatectomy. Oncology Nursing Forum, 2005, 32, 557-563.	0.5	16
935	Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. Journal of Clinical Oncology, 2005, 23, 2781-2788.	0.8	185
936	Expression Analysis of PMP22/Gas3 in Premalignant and Malignant Pancreatic Lesions. Journal of Histochemistry and Cytochemistry, 2005, 53, 885-893.	1.3	18
937	HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). Journal of Carcinogenesis, 2005, 4, 8.	2.5	8
938	p300 Regulates Androgen Receptor–Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6. Cancer Research, 2005, 65, 5965-5973.	0.4	93
939	High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor. Journal of Clinical Oncology, 2005, 23, 9138-9145.	0.8	61
940	Prevention of Hormone-Related Cancers: Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 368-377.	0.8	48
941	Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. Carcinogenesis, 2005, 26, 1109-1116.	1.3	18
942	F-18 FDG pet in detecting renal cell carcinoma. Acta Radiologica, 2005, 46, 895-899.	0.5	46
943	Transcending Breast Cancer. Journal of Holistic Nursing, 2005, 23, 264-283.	0.6	74
944	Impact on Late Toxicity of using Transabdominal Ultrasound for Prostate Cancer Patients Treated with Intensity Modulated Radiotherapy. Technology in Cancer Research and Treatment, 2005, 4, 115-120.	0.8	4
945	The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence. Journal of the National Cancer Institute, 2005, 97, 142-146.	3.0	1,173
946	Study Design Issues and Early Stage Non-Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 5030s-5032s.	3.2	4
947	Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Therapy, 2005, 12, 1198-1205.	2.3	72
948	Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 850-856.	0.8	121
949	Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes. Cancer Research, 2005, 65, 9080-9088.	0.4	108

#	Article	IF	CITATIONS
950	Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. International Immunology, 2005, 17, 1315-1325.	1.8	13
951	Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 1870-1876.	3.2	28
952	Bronchioloalveolar Carcinoma and Adenocarcinoma of the Lung. Journal of Bronchology, 2005, 12, 174-180.	0.2	2
953	Postoperative Survival and the Number of Lymph Nodes Sampled During Resection of Node-Negative Non-Small Cell Lung Cancer. Chest, 2005, 128, 1545-1550.	0.4	247
954	The More, the Better. Chest, 2005, 127, 1092-1094.	0.4	0
955	The Use of Zoledronic Acid in Patients with Bone Metastases from Prostate Carcinoma: Effect on Analgesic Response and Bone Metabolism Biomarkers. Journal of Chemotherapy, 2005, 17, 555-559.	0.7	25
956	Integrating Survival and Quality of Life Data in Clinical Trials of Lung Disease. Chest, 2005, 127, 1094-1096.	0.4	2
957	Lung Cancer in Women. Chest, 2005, 128, 370-381.	0.4	155
958	Clinical and Dermoscopic Changes in Common Melanocytic Nevi in School Children: The Framingham School Nevus Study. Dermatology, 2005, 211, 234-239.	0.9	18
959	Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer Patients. Oncology, 2005, 69, 27-34.	0.9	24
960	An Examination of Characteristics of Lung and Colon Cancer Patients Participating in a Web-Based Decision Support Program. Oncology, 2005, 69, 311-316.	0.9	8
961	Prediction of Pancreatic Cancer by Serum Biomarkers Using Surface-Enhanced Laser Desorption/Ionization-Based Decision Tree Classification. Oncology, 2005, 68, 79-86.	0.9	85
962	Prognostic Value of Multimarker Analysis in Stage III Colorectal Cancer: One Step Forward Towards an Individualized Therapy Decision. Oncology Research and Treatment, 2005, 28, 399-403.	0.8	6
963	A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma. Oncology, 2005, 69, 130-134.	0.9	12
964	Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer. Oncology Research and Treatment, 2005, 28, 573-578.	0.8	10
965	Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma. Oncology, 2005, 69, 363-371.	0.9	53
966	Differentiation of Androgen-Independent Prostate Cancer PC-3 Cells Is Associated with Increased Nuclear Factor-IºB Activity. Cancer Research, 2005, 65, 11588-11596.	0.4	23
967	Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 7897-7903.	0.8	330

	CITATION RE	EPORT	
#	Article	IF	Citations
968	False-positive mammograms—can the USA learn from Europe?. Lancet, The, 2005, 365, 7-8.	6.3	29
969	Colorectal cancer. Lancet, The, 2005, 365, 153-165.	6.3	1,030
970	Cutaneous melanoma. Lancet, The, 2005, 365, 687-701.	6.3	511
971	Small-cell lung cancer. Lancet, The, 2005, 366, 1385-1396.	6.3	509
973	EUS features of recurrent transitional cell bladder cancer metastatic to the GI tract. Gastrointestinal Endoscopy, 2005, 61, 314-316.	0.5	17
974	Anatomy-based inverse planning dose optimization in HDR prostate implant: A toxicity study. Radiotherapy and Oncology, 2005, 75, 318-324.	0.3	26
975	Mechanisms of gelsolin-dependent and -independent EGF-stimulated cell motility in a human lung epithelial cell line. Experimental Cell Research, 2005, 307, 153-163.	1.2	17
976	Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer, 2005, 50, S3-S8.	0.9	18
977	The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. American Journal of Human Genetics, 2005, 77, 1034-1043.	2.6	197
978	Psychiatric Sequelae Following Breast Cancer Chemotherapy: A Pilot Study Using Claims Data. Psychosomatics, 2005, 46, 517-522.	2.5	6
979	Screening of patients at average risk for colon cancer. Medical Clinics of North America, 2005, 89, 43-59.	1.1	7
980	Endoscopic Palliation of Pancreaticobiliary Malignancies. Gastrointestinal Endoscopy Clinics of North America, 2005, 15, 513-531.	0.6	11
981	Contemporary Management of the Urethra in Patients After Radical Cystectomy for Bladder Cancer. Urologic Clinics of North America, 2005, 32, 199-206.	0.8	18
982	Prevention and therapy of colorectal cancer. Medical Clinics of North America, 2005, 89, 85-110.	1.1	6
983	A MULTICENTER CLINICAL TRIAL ON THE USE OF (–5, –7) PRO PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2005, 174, 2150-2153.	0.2	41
984	A Review of Prognostic Pathologic Features and Algorithms for Patients Treated Surgically for Renal Cell Carcinoma. Clinics in Laboratory Medicine, 2005, 25, 433-464.	0.7	73
985	Correlation of Polyp Number and Family History of Colon Cancer With Germline Mutations. Clinical Gastroenterology and Hepatology, 2005, 3, 1022-1028.	2.4	59
986	Lung Cancer Screening. New England Journal of Medicine, 2005, 352, 2714-2720.	13.9	265

ARTICLE IF CITATIONS MR-Guided Interventions for Prostate Cancer. Magnetic Resonance Imaging Clinics of North America, 987 0.6 28 2005, 13, 491-504. Mechanisms of Sarcomagenesis. Hematology/Oncology Clinics of North America, 2005, 19, 427-449. 19 A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH 989 0.2 480 CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2005, 173, 48-51. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITION PRESERVES ERECTILE FUNCTION IN RATS 990 0.2 AFTER CAVERNOUS NERVE INJURY. Journal of Urology, 2005, 174, 2054-2059. COMPARISON OF PRESENTATION AND OUTCOME FOR PATIENTS 18 TO 40 AND 60 TO 70 YEARS OLD WITH 991 0.2 80 SOLID RENAL MASSES. Journal of Urology, 2005, 173, 1893-1896. Melanoma Treatment Update. Dermatologic Clinics, 2005, 23, 323-333. 1.0 POTASSIUM-TITANYL-PHOSPHATE LASER LAPAROSCOPIC PARTIAL NEPHRECTOMY WITHOUT HILAR CLAMPING 993 0.2 60 IN THE SURVIVAL CALF MODEL. Journal of Urology, 2005, 174, 1110-1114. Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune 004 0.5 response to vaccinations. Pancreatology, 2005, 5, 67-74. Screening and Surveillance of Colorectal Cancer. Gastrointestinal Endoscopy Clinics of North 995 0.6 11 America, 2005, 15, 533-547. Sequential Molecular and Cellular Events during Neoplastic Progression: A Mouse Syngeneic Ovarian 996 2.3 Cancer Model. Neoplasia, 2005, 7, 944-956. Oromandibular Reconstruction After Cancer Resection. Clinics in Plastic Surgery, 2005, 32, 361-375. 997 0.7 22 Postoperative Surveillance after Transanal Excision of Rectal Neoplasms. Seminars in Colon and 998 Rectal Surgery, 2005, 16, 30-35. How Can a Massive Training Artificial Neural Network (MTANN) Be Trained With a Small Number of 999 Cases in the Distinction Between Nodules and Vessels in Thoracic CT?1. Academic Radiology, 2005, 12, 1.3 52 1333-1341. MANAGEMENT OF ISOLATED RENAL FOSSA RECURRENCE FOLLOWING RADICAL NEPHRECTOMY. Journal of 1000 0.2 66 Urology, 2005, 174, 473-477. URINARY FISTULAS FOLLOWING EXTERNAL RADIATION OR PERMANENT BRACHYTHERAPY FOR THE 1001 0.2 145 TREATMENT OF PROSTATE CANCER. Journal of Urology, 2005, 173, 1953-1957. HIGHER THAN EXPECTED ASSOCIATION OF CLINICAL PROSTATE AND BLADDER CANCERS. Journal of Urology, 2005, 173, 1526-1529. The Role of Lymphadenectomy in High-grade Invasive Bladder Cancer. Urologic Clinics of North 1003 0.8 75 America, 2005, 32, 187-197. 1004 Clear Cell Renal Cell Carcinoma. Clinics in Laboratory Medicine, 2005, 25, 305-316.

#	Article	IF	CITATIONS
1005	Adjuvant Chemotherapy of Lung Cancer: Methodologic Issues and Therapeutic Advances. Hematology/Oncology Clinics of North America, 2005, 19, 263-281.	0.9	38
1006	Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings, 2005, 80, 1517-1527.	1.4	117
1007	62 Anatomical distribution of small cell lung cancer: Effects of lobeand gender on brain metastasis and survival. Lung Cancer, 2005, 49, S394-S395.	0.9	1
1008	The emerging role of virtual colonoscopy. Medical Clinics of North America, 2005, 89, 111-138.	1.1	5
1010	Endoscopic Ultrasound for Luminal Malignancies. Gastrointestinal Endoscopy Clinics of North America, 2005, 15, 399-429.	0.6	4
1011	Surveillance of patients at high risk for colorectal cancer. Medical Clinics of North America, 2005, 89, 61-84.	1.1	12
1012	LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. Journal of Urology, 2005, 174, 2129-2133.	0.2	182
1013	From Colonic Polyps to Colon Cancer: Pathophysiology, Clinical Presentation, and Diagnosis. Clinics in Laboratory Medicine, 2005, 25, 135-177.	0.7	30
1014	Targeting and Palliating Malignant Ascites: An Overview of an Upcoming Clinical Trial from the North Central Cancer Treatment Group. Supportive Cancer Therapy, 2005, 3, 59-62.	0.3	4
1015	Computerized Texture Analysis of Mammographic Parenchymal Patterns of Digitized Mammograms1. Academic Radiology, 2005, 12, 863-873.	1.3	103
1016	Automated seed placement for colon segmentation in computed tomography colonography1. Academic Radiology, 2005, 12, 182-190.	1.3	26
1017	Abdominoperineal Resection for Rectal Cancer: Historic Perspective and Current Issues. Surgical Oncology Clinics of North America, 2005, 14, 569-586.	0.6	28
1018	Clinical Applications for Targeted Therapy in Bladder Cancer. Urologic Clinics of North America, 2005, 32, 239-246.	0.8	10
1019	Array-Based Comparative Genomic Hybridization Identifies Localized DNA Amplifications and Homozygous Deletions in Pancreatic Cancer. Neoplasia, 2005, 7, 556-IN16.	2.3	180
1020	Colorectal Cancer "Methylator Phenotype": Fact or Artifact?. Neoplasia, 2005, 7, 331-335.	2.3	63
1021	Nanomolecular Histopathology for Renal Tumor Classification. , 2005, 2006, 723-6.		1
1022	Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 791-808.	1.5	36
1023	Effects of Active and Passive Smoking on Antioxidant Enzymes and Antioxidant Micronutrients. Biotechnology and Biotechnological Equipment, 2005, 19, 117-123.	0.5	8

#	Article	IF	CITATIONS
1024	Derivatized Cellulose Combined with MALDI-TOF MS:Â A New Tool for Serum Protein Profiling. Journal of Proteome Research, 2005, 4, 2320-2326.	1.8	45
1025	Extending the Frontiers of Surgical Therapy for Hepatic Colorectal Metastases: Is There a Limit?. Journal of Clinical Oncology, 2005, 23, 8490-8499.	0.8	255
1026	The Problem of Post-Breast Cancer Lymphedema: Impact and Measurement Issues. Cancer Investigation, 2005, 23, 76-83.	0.6	190
1027	Second-generation kinase inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 975-993.	1.5	55
1028	Biliary tract cancers: current concepts and controversies. Expert Opinion on Pharmacotherapy, 2005, 6, 211-223.	0.9	27
1029	How Do Tangible Supports Impact the Breast Cancer Experience?. Social Work in Health Care, 2005, 41, 17-32.	0.8	23
1030	Prostate Cancer and the Will Rogers Phenomenon. Journal of the National Cancer Institute, 2005, 97, 1248-1253.	3.0	369
1031	Mouse models for human lung cancer. Genes and Development, 2005, 19, 643-664.	2.7	260
1032	A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer. Cancer Investigation, 2005, 23, 511-519.	0.6	2
1033	New Developments in the Staging of Melanoma. Cancer Investigation, 2005, 23, 561-567.	0.6	8
1034	Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches. Leukemia and Lymphoma, 2005, 46, 973-992.	0.6	11
1035	State of the Art in Therapy for Non-Small Cell Lung Cancer. Cancer Investigation, 2005, 23, 427-442.	0.6	65
1036	LUNG TUMOR LOCATION AND LYMPHOCYTE INFILTRATION IN MICE ARE GENETICALLY DETERMINED. Experimental Lung Research, 2005, 31, 513-525.	0.5	5
1037	Applying Proteomics in Clinical Trials. Molecular Diagnosis and Therapy, 2005, 5, 141-148.	3.3	19
1038	Quality of Life and Meaning of Illness of Women With Lung Cancer. Oncology Nursing Forum, 2005, 32, E9-E19.	0.5	75
1039	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 1938-1942.	0.2	592
1040	Antiestrogens, Aromatase Inhibitors, and Apoptosis in Breast Cancer. Vitamins and Hormones, 2005, 71, 201-237.	0.7	75
1041	Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Annals of Oncology, 2005, 16, 780-785.	0.6	79

		15	0
#	ARTICLE Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic	IF	CITATIONS
1042	Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen. Clinical Cancer Research, 2005, 11, 6414-6421.	3.2	200
1043	Improvement of SVM Algorithm for Microarray Analysis Using Intelligent Parameter Selection. , 2005, 2005, 4838-41.		8
1044	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Cancer Research, 2005, 65, 2162-2169.	0.4	484
1045	Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development. Journal of Clinical Oncology, 2005, 23, 346-356.	0.8	162
1046	lmaging of Melanoma Using64Cuâ^' and86Yâ^'DOTAâ^'ReCCMSH(Arg11), a Cyclized Peptide Analogue of α-MSH. Journal of Medicinal Chemistry, 2005, 48, 2985-2992.	2.9	124
1047	Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer. Cancer Research, 2005, 65, 1479-1488.	0.4	530
1048	Prostate Cancer: Three-dimensional Sonoelastography for in Vitro Detection. Radiology, 2005, 237, 981-985.	3.6	72
1049	Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-GueÌrin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood, 2005, 106, 3474-3482.	0.6	112
1050	Autoantibody Signatures in Prostate Cancer. New England Journal of Medicine, 2005, 353, 1224-1235.	13.9	581
1051	An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 582, 71-78.	0.9	37
1052	Patterns of Internet use and impact on patients with melanoma. Journal of the American Academy of Dermatology, 2005, 52, 779-785.	0.6	67
1053	Metastatic melanoma. Journal of the American Academy of Dermatology, 2005, 53, 314-317.	0.6	4
1054	B-RAF and melanocytic neoplasia. Journal of the American Academy of Dermatology, 2005, 53, 108-114.	0.6	61
1055	Photodynamic therapy of high grade glioma – long term survival. Journal of Clinical Neuroscience, 2005, 12, 389-398.	0.8	199
1056	Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo: Preliminary results. Journal of Surgical Research, 2005, 124, 85-91.	0.8	68
1057	Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRα, and PDGFRβ in ovarian cancers. Human Pathology, 2005, 36, 242-249.	1.1	65
1058	Correlation of presenting symptoms and patient characteristics with endometrial cancer prognosis in Japanese women. International Journal of Gynecology and Obstetrics, 2005, 91, 151-156.	1.0	14
1059	Proteomic patterns: their potential for disease diagnosis. Molecular and Cellular Endocrinology, 2005, 230, 95-106.	1.6	175

#	Article	IF	CITATIONS
1060	Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 215-223.	1.8	111
1061	Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-β1 from prostate cancer cells. Biochemical and Biophysical Research Communications, 2005, 330, 46-52.	1.0	150
1062	Ultraviolet B exposure activates Stat3 signaling via phosphorylation at tyrosine705 in skin of SKH1 hairless mouse: A target for the management of skin cancer?. Biochemical and Biophysical Research Communications, 2005, 333, 241-246.	1.0	26
1063	Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochemical and Biophysical Research Communications, 2005, 334, 223-230.	1.0	79
1064	1′-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL. Biochemical and Biophysical Research Communications, 2005, 338, 1702-1710.	1.0	19
1065	Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clinica Chimica Acta, 2005, 357, 180-183.	0.5	37
1066	Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clinica Chimica Acta, 2005, 361, 104-111.	0.5	137
1067	Oral cancer: leukoplakia and squamous cell carcinoma. Dental Clinics of North America, 2005, 49, 143-165.	0.8	38
1068	Pancreatic intra-epithelial neoplasia: current clinicopathological and molecular considerations. Current Diagnostic Pathology, 2005, 11, 80-94.	0.4	1
1069	Surgical Management of Cutaneous Melanoma of the Head and Neck. Oral and Maxillofacial Surgery Clinics of North America, 2005, 17, 191-204.	0.4	2
1070	Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treatment Reviews, 2005, 31, 423-438.	3.4	117
1071	Molecular markers in laryngeal squamous cell carcinoma: Towards an integrated clinicobiological approach. European Journal of Cancer, 2005, 41, 683-693.	1.3	131
1072	Hormonal therapy of endometrial cancer. European Journal of Cancer, 2005, 41, 673-675.	1.3	63
1073	Screening for prostate cancer. European Journal of Cancer, 2005, 41, 825-833.	1.3	71
1074	Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. European Journal of Cancer, 2005, 41, 2112-2119.	1.3	27
1075	Vaginal oestrogen therapy after breast cancer: Is it safe?. European Journal of Cancer, 2005, 41, 2673-2681.	1.3	79
1076	Systematic approach to the analysis of cross-sectional imaging for surveillance of recurrent colorectal cancer. European Journal of Radiology, 2005, 53, 387-396.	1.2	2
1077	Quality control issues in the management of colon cancer patients. European Journal of Surgical Oncology, 2005, 31, 616-629.	0.5	6

# 1078	ARTICLE Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. International Journal of Biochemistry and Cell Biology, 2005, 37, 707-714.	IF 1.2	Citations 35
1079	Nucleotide-excision repair and prostate cancer risk. Cancer Letters, 2005, 220, 125-135.	3.2	39
1080	Human tissue kallikrein gene family: applications in cancer. Cancer Letters, 2005, 224, 1-22.	3.2	128
1081	Protective effects of black tea extract on testosterone induced oxidative damage in prostate. Cancer Letters, 2005, 227, 125-132.	3.2	49
1082	Potential of faecal RNA in diagnosing colorectal cancer. Cancer Letters, 2005, 226, 55-63.	3.2	12
1083	Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Letters, 2005, 226, 123-131.	3.2	16
1084	Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Letters, 2005, 579, 6681-6687.	1.3	30
1085	Secretin Receptors in Normal and Diseased Human Pancreas. American Journal of Pathology, 2005, 167, 959-968.	1.9	38
1086	Skin self-examination practices in a convenience sample of US university students. Preventive Medicine, 2005, 40, 268-273.	1.6	34
1087	Increasing colorectal cancer screening among individuals in the carpentry trade: test of risk communication interventions. Preventive Medicine, 2005, 40, 489-501.	1.6	45
1088	Sun protective behaviors and sunburn experiences in parents of youth ages 11 to 18. Preventive Medicine, 2005, 41, 108-117.	1.6	19
1089	Test–retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS). Preventive Medicine, 2005, 41, 303-311.	1.6	26
1090	Creating a Novel Structure for Nursing Research in a Cooperative Clinical Trials Group: The Children's Oncology Group Experience. Seminars in Oncology Nursing, 2005, 21, 79-88.	0.7	17
1091	Complementary and Alternative Medicine in Pediatric Oncology. Seminars in Oncology Nursing, 2005, 21, 107-114.	0.7	20
1092	The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology, 2005, 65, 76-82.	0.5	71
1093	Analysis of acute toxicity with use of transabdominal ultrasonography for prostate positioning during intensity-modulated radiotherapy. Urology, 2005, 65, 504-508.	0.5	10
1094	Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology, 2005, 65, 750-754.	0.5	18
1095	Observed effect of age and body mass index on total and complexed PSA: Analysis from a national screening program. Urology, 2005, 65, 708-712.	0.5	86

#	Article	IF	CITATIONS
1096	Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology, 2005, 65, 1019-1023.	0.5	13
1097	Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology, 2005, 65, 1131-1136.	0.5	31
1098	Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. Urology, 2005, 66, 65-68.	0.5	30
1099	Hormone-refractory prostate cancer: Issues, approaches, and recommendations. Urology, 2005, 65, 1-2.	0.5	2
1100	National cooperative group trials. Urology, 2005, 65, 23-29.	0.5	54
1101	Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology, 2005, 66, 461-466.	0.5	53
1102	Testicular cancer patterns in Asian-American males: An opportunity for public health education to impact outcomes. Urology, 2005, 66, 606-609.	0.5	15
1103	Testicular cancer patterns in African-American men. Urology, 2005, 66, 602-605.	0.5	46
1104	A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: A new method for noninvasive lymph node evaluation. Urology, 2005, 66, 1066-1071.	0.5	100
1105	Five-alpha-reductase expression in benign and malignant urothelium: Correlation with disease characteristics and outcome. Urology, 2005, 66, 1134-1139.	0.5	8
1106	Biological considerations in the assessment of urothelial cancer: A retrospective. Urology, 2005, 66, 66-75.	0.5	17
1107	Medical care cost of patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 155-162.	0.8	13
1108	Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancerâ~†. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 246-253.	0.8	64
1109	Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 328-332.	0.8	4
1110	Comparisons of prostate cancer mortality rates with dietary practices in the United States. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 390-398.	0.8	18
1111	Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancerâ~†. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 407-412.	0.8	19
1112	Current clinical trials in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 289-292.	0.8	8
1113	Survival outcomes for second primary head and neck cancer: A matched analysis. Otolaryngology - Head and Neck Surgery, 2005, 132, 63-68.	1.1	30

#	Article	IF	Citations
1114	Introduction to Skin Cancer. Oral and Maxillofacial Surgery Clinics of North America, 2005, 17, 133-142.	0.4	1
1115	A Retrospective Analysis of Locally Advanced Esophageal Cancer Patients Treated With Neoadjuvant Chemoradiation Therapy Followed by Surgery or Surgery Alone. Annals of Thoracic Surgery, 2005, 79, 1116-1121.	0.7	39
1116	Outcomes of Tracheobronchial Stents in Patients With Malignant Airway Disease. Annals of Thoracic Surgery, 2005, 80, 434-438.	0.7	108
1117	Patient perceptions of stool-based DNA testing for colorectal cancer screening. American Journal of Preventive Medicine, 2005, 28, 208-214.	1.6	45
1118	Lysyl oxidase expression in bronchogenic carcinoma. American Journal of Surgery, 2005, 189, 297-301.	0.9	41
1119	An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer. American Journal of Surgery, 2005, 190, 406-411.	0.9	28
1120	The role of sentinel lymph node biopsy in the management of thin melanoma. American Journal of Surgery, 2005, 190, 196-199.	0.9	12
1121	Increased ipsilateral whole breast vascularity as measured by contrast-enhanced magnetic resonance imaging in patients with breast cancer. American Journal of Surgery, 2005, 190, 576-579.	0.9	24
1122	Comparison of Male and Female Breast Cancer Incidence Trends, Tumor Characteristics, and Survival. Annals of Epidemiology, 2005, 15, 773-780.	0.9	98
1123	Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer, 2005, 5, 2.	1.1	62
1124	Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Molecular Cancer, 2005, 4, 14.	7.9	81
1125	E-Cadherin and beta-Catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World Journal of Surgical Oncology, 2005, 3, 38.	0.8	40
1126	Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. Journal of Translational Medicine, 2005, 3, 32.	1.8	45
1127	Transforming Growth Factor Beta and Prostate Cancer. , 2005, 126, 157-173.		50
1128	MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. British Journal of Radiology, 2005, 78, S103-S111.	1.0	115
1129	Inherited Susceptibility to Colorectal Cancer. Annual Review of Medicine, 2005, 56, 539-554.	5.0	80
1130	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
1131	Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 2612-2619.	3.2	64

#	Article	IF	CITATIONS
1132	The Global Breast Cancer Burden: Variations in Epidemiology and Survival. Clinical Breast Cancer, 2005, 6, 391-401.	1.1	445
1133	Lymphatic Mapping and Sentinel Node Analysis in Colon Cancer. Clinical Colorectal Cancer, 2005, 4, 320-324.	1.0	7
1134	5-Fluorouracil–Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study. Clinical Colorectal Cancer, 2005, 4, 325-331.	1.0	39
1135	Long-Term Results of Local Excision with and Without Chemoradiation for Adenocarcinoma of the Rectum. Clinical Colorectal Cancer, 2005, 4, 332-335.	1.0	12
1136	Absence of Lower Urinary Tract Symptoms Is an Independent Predictor for Cancer at Prostate Biopsy, but Prostate-Specific Antigen Is Not: Results from a Prospective Series of 569 Patients. Clinical Prostate Cancer, 2005, 4, 50-54.	2.1	7
1137	Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 352, 2589-2597.	13.9	1,737
1138	Soft-Tissue Sarcomas in Adults. New England Journal of Medicine, 2005, 353, 701-711.	13.9	794
1139	Familial Nonmedullary Thyroid Cancer. Thyroid, 2005, 15, 588-593.	2.4	91
1141	Advances in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2005, 128, 1554-1566.	0.6	125
1142	Pancreatic Cancer: Basic and Clinical Aspects. Gastroenterology, 2005, 128, 1606-1625.	0.6	279
1143	CXCR4 Expression Increases Liver and Lung Metastasis in a Mouse Model of Pancreatic Cancer. Gastroenterology, 2005, 129, 1237-1250.	0.6	172
1144	Pancreatic Cancer: Novel Approaches to Diagnosis and Therapy. Gastroenterology, 2005, 129, 1344-1347.	0.6	11
1145	Computed Tomographic Virtual Colonoscopy Computer-Aided Polyp Detection in a Screening Population. Gastroenterology, 2005, 129, 1832-1844.	0.6	273
1146	Pulmonary Toxicity Associated With the Treatment of Non-Small Cell Lung Cancer and the Effects of Cytoprotective Strategies. Seminars in Oncology, 2005, 32, 55-59.	0.8	16
1147	Multiple myeloma: clinical features and indications for therapy. Best Practice and Research in Clinical Haematology, 2005, 18, 553-568.	0.7	59
1148	Functional Assessment of Mitral Regurgitation by Transthoracic Echocardiography Using Standardized Imaging Planes. Journal of the American College of Cardiology, 2005, 46, 302-309.	1.2	104
1149	The underutilization of EUS-guided FNA in the lymph-node staging of non-small-cell lung cancer: perceptions of chest physicians in Wisconsin. Gastrointestinal Endoscopy, 2005, 62, 517-520.	0.5	11
1150	Development of the self-efficacy for testicular self-examination scale. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 59-63.	0.3	13

#	Article	IF	Citations
1151	A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer, 2005, 47, 413-419.	0.9	7
1152	Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. Lung Cancer, 2005, 47, 385-394.	0.9	126
1153	Expression of E-cadherin and nm23 is associated with the clinicopathological factors of human non-small cell lung cancer in China. Lung Cancer, 2005, 48, 69-76.	0.9	19
1154	A report from the Society for Women's Health Research. Lung Cancer, 2005, 47, 427-433.	0.9	0
1155	High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer, 2005, 49, 187-191.	0.9	29
1156	Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer, 2005, 49, 353-361.	0.9	45
1157	The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer, 2005, 50, 9-18.	0.9	47
1158	Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. Lung Cancer, 2005, 50, 339-346.	0.9	47
1159	The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Medical Clinics of North America, 2005, 89, 1-42.	1.1	63
1160	EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 2005, 352, 786-792.	13.9	3,715
1161	Imaging of Non–Small Cell Lung Cancer. Radiologic Clinics of North America, 2005, 43, 467-480.	0.9	1
1162	Noninvasive Testing for Colorectal Cancer: A Review. American Journal of Gastroenterology, 2005, 100, 1393-1403.	0.2	129
1163	Improved prostate cancer imaging with SPECT/CT and MRI/MRSI. IEEE Transactions on Nuclear Science, 2005, 52, 1316-1320.	1.2	7
1164	Zoledronic acid: past, present and future roles in cancer treatment. Future Oncology, 2005, 1, 149-159.	1.1	15
1165	OBESITY AND CAPSULAR INCISION AT THE TIME OF OPEN RETROPUBIC RADICAL PROSTATECTOMY. Journal of Urology, 2005, 174, 1798-1801.	0.2	91
1166	Novel Therapies in Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 343-367.	0.9	4
1168	Induction of Apoptosis in Tumor-Associated Endothelial Cells and Therapy of Orthotopic Human Pancreatic Carcinoma in Nude Mice. Neoplasia, 2005, 7, 696-704.	2.3	29
1169	Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiologic Clinics of North America, 2005, 43, 1-21.	0.9	59

65

#	Article	IF	CITATIONS
1170	WATER JET ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY WITHOUT HILAR CLAMPING IN THE CALF MODEL. Journal of Urology, 2005, 174, 317-321.	0.2	55
1171	Integrin αβ3-Targeted Imaging of Lung Cancer. Neoplasia, 2005, 7, 271-279.	2.3	159
1172	[18F]FDG Uptake and PCNA, Glut-1, and Hexokinase-II Expressions in Cancers and Inflammatory Lesions of the Lung. Neoplasia, 2005, 7, 369-379.	2.3	205
1173	Limited Gastric Resection. Surgical Clinics of North America, 2005, 85, 1009-1020.	0.5	4
1174	The Role of Surgery in Stage IIIA Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 303-319.	0.9	3
1175	A Potential Decline in Life Expectancy in the United States in the 21st Century. New England Journal of Medicine, 2005, 352, 1138-1145.	13.9	2,193
1176	Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Human Molecular Genetics, 2005, 14, 997-1007.	1.4	57
1177	Pathogenesis of Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 216-223.	1.4	120
1179	Status of Newer Chemotherapeutic Strategies for the Treatment of Metastatic Gastric Cancer. American Journal of Cancer, 2005, 4, 65-70.	0.4	0
1180	Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology, 2005, 5, 259-265.	0.5	57
1181	RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY. Journal of Urology, 2005, 173, 1853-1862.	0.2	320
1182	Malignant Gliomas in 2005. JAMA - Journal of the American Medical Association, 2005, 293, 615.	3.8	65
1183	Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 353, 123-132.	13.9	5,267
1184	Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Research, 2005, 7, R1051-7.	2.2	15
1185	Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Research, 2005, 7, 64-9.	2.2	37
1186	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research, 2006, 8, R66.	2.2	123
1187	Germline polymorphisms in SIPA1are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Research, 2006, 8, R16.	2.2	99
1188	Management Strategies for Relapsed Multiple Myeloma. American Journal of Cancer, 2006, 5, 393-409.	0.4	2

#	Article	IF	CITATIONS
1189	The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors. Neoplasia, 2006, 8, 190-198.	2.3	505
1190	Akt- and CREB-Mediated Prostate Cancer Cell Proliferation Inhibition by Nexrutine, a Phellodendron amurense Extract. Neoplasia, 2006, 8, 523-533.	2.3	59
1191	Renal Cell Carcinoma With Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical) Tj ETQq0 0 ( 2006, 175, 864-869.	0 rgBT /Ov 0.2	erlock 10 Tf 116
1192	Overexpression of PIAS3 Suppresses Cell Growth, Restores the Drug Sensitivity of Human Lung Cancer Cells in Association with PI3-K/Akt Inactivation. Neoplasia, 2006, 8, 817-825.	2.3	55
1193	Surgical Treatment of Colon Cancer. Surgical Oncology Clinics of North America, 2006, 15, 109-127.	0.6	6
1194	Role of Radiation Therapy in Pediatric Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 455-470.	0.9	33
1195	Chemoprevention of squamous cell carcinoma of the oral cavity. Otolaryngologic Clinics of North America, 2006, 39, 349-363.	0.5	11
1196	Endoscopic Approaches for Palliation of Luminal Gastrointestinal Obstruction. Gastroenterology Clinics of North America, 2006, 35, 65-82.	1.0	27
1197	Vitamins C and K3 Sensitize Human Urothelial Tumors to Gemcitabine. Journal of Urology, 2006, 176, 1642-1647.	0.2	38
1198	Complementary and Alternative Medicine in Pediatric Oncology. Journal of Pediatric Oncology Nursing, 2006, 23, 244-253.	1.5	20
1199	Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006, 81, 973-988.	1.4	171
1200	Benign and Malignant Gallbladder Tumors. , 0, , 252-262.		0
1201	Cutaneous Reactions to Chemotherapy and their Management. American Journal of Clinical Dermatology, 2006, 7, 45-63.	3.3	58
1202	A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients with Advanced Adenocarcinoma of the Stomach or Esophagus. Cancer Investigation, 2006, 24, 229-234.	0.6	11
1203	A System for MRI-guided Prostate Interventions. , 0, , .		20
1204	The Clear-PEM Electronics System. IEEE Transactions on Nuclear Science, 2006, 53, 2704-2711.	1.2	20
1205	QUALITY OF LIFE IN MEN WITH LOCALIZED PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY OR RADIOTHERAPY. Archives of Andrology, 2006, 52, 129-133.	1.0	6
1206	Design and evaluation of the clear-PEM scanner for positron emission mammography. IEEE Transactions on Nuclear Science, 2006, 53, 71-77.	1.2	111

ARTICLE IF CITATIONS The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal 1207 1.0 1 antibodies. Expert Opinion on Emerging Drugs, 2006, 11, 665-683. An Open Pharmacokinetic Study of??Hexylaminolevulinate-Induced Photodiagnosis after Intravesical 1.1 Administration. Drugs in R and D, 2006, 7, 173-186. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable 1209 1.1 74 gastric cancer. Expert Review of Anticancer Therapy, 2006, 6, 931-939. 2-D DIGE Analysis of Butyrate-Treated HCT-116 Cells after Enrichment with Heparin Affinity 1.8 Chromatography. Journal of Proteome Research, 2006, 5, 1098-1106. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA 1211 1.3161 repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis, 2006, 27, 1030-1037. Inhibition of Adenoma Progression to Adenocarcinoma in a 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone–Induced Lung Tumorigenesis Model in A/J Mice by Tea Polyphenols and Caffeine. Cancer Research, 2006, 66, 11494-11501. 0.4 The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant 1213 1.0 13 mesothelioma. Seminars in Diagnostic Pathology, 2006, 23, 35-43. Future Direction of Renal Positron Emission Tomography. Seminars in Nuclear Medicine, 2006, 36, 1214 2.5 54 36-50. Nuclear Medicine Studies of the Prostate, Testes, and Bladder. Seminars in Nuclear Medicine, 2006, 36, 1215 2.5 129 51-72. The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone 2.5 Imaging with Emphasis on Prostate and Breast. Seminars in Nuclear Medicine, 2006, 36, 73-92. Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model. American Journal of 1217 1.9 186 Pathology, 2006, 168, 962-972. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of 5.1 105 cytotoxic treatment and metastases. Lancet Oncology, The, 2006, 7, 425-430. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective 1219 5.1 1,456 cohort study. Lancet Oncology, The, 2006, 7, 735-740. Pooled genome linkage scan of aggressive prostate cancer: results from the International 1220 1.8 Consortium for Prostate Cancer Genetics. Human Genetics, 2006, 120, 471-485. Hospitalizations subsequent to the diagnosis of lung cancer: a clinical and financial analysis. 1221 0.2 0 Community Oncology, 2006, 3, 200-204. Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: Clinical Experience and a "Number Needed to Treat―Analysis. European Urology Supplements, 2006, 5, 479-486. Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. 1223 0.11 European Urology Supplements, 2006, 5, 619-626. Clinical Considerations on the Perspectives in Renal Tumour Molecular Pathology. European Urology 1224 0.1 Supplements, 2006, 5, 566-572.

#	Article	IF	CITATIONS
1225	Classification and Regression Tree Analysis for the Prediction of Aggressive Prostate Cancer on Biopsy. Journal of Urology, 2006, 175, 918-922.	0.2	19
1226	Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer. Journal of Urology, 2006, 175, 1353-1358.	0.2	55
1227	Genomic Profiling of Hormone-NaÃ⁻ve Lymph Node Metastases in Patients with Prostate Cancer. Neoplasia, 2006, 8, 1083-IN35.	2.3	21
1228	Prostate Specific Antigen Remains an Independent Predictor of Cancer at Prostate Biopsy in Black American Men But Not in White Men: Results from a Consecutive Series of 914 Men. Journal of Urology, 2006, 175, 913-917.	0.2	11
1229	Skin Cancer After Transplantation: A Guide for the General Surgeon. Surgical Clinics of North America, 2006, 86, 1257-1276.	0.5	6
1230	Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.	2.4	22
1231	Prognostic Nomogram for Renal Insufficiency After Radical or Partial Nephrectomy. Journal of Urology, 2006, 176, 472-476.	0.2	85
1232	Selective Use of Selective Nonsteroidal Anti-Inflammatory Drugs in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 157-159.	2.4	24
1233	Nicotinamide Adenine Dinucleotide Staining Immediately Following Radio Frequency Ablation of Renal Tumors—Is a Positive Stain Synonymous With Ablative Failure?. Journal of Urology, 2006, 176, 1969-1972.	0.2	29
1234	Chemopreventive effect of trans -resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 2006, 27, 1038-1046.	1.3	127
1235	Cancer Specific Outcomes in Patients With PTO Disease Following Radical Cystectomy. Journal of Urology, 2006, 175, 1645-1649.	0.2	48
1236	Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model. Journal of Urology, 2006, 175, 1932-1936.	0.2	27
1237	Association of Family History of Specific Cancers With a Younger Age of Onset of Pancreatic Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2006, 4, 1143-1147.	2.4	22
1238	In Vivo Spectral Fluorescence Imaging of Submillimeter Peritoneal Cancer Implants Using a Lectin-Targeted Optical Agent. Neoplasia, 2006, 8, 607-IN2.	2.3	59
1239	Public Health Challenges in Sun Protection. Dermatologic Clinics, 2006, 24, 119-124.	1.0	43
1240	Contrast Enhanced Ultrasound for Radio Frequency Ablation of Canine Prostates: Initial Results. Journal of Urology, 2006, 176, 1654-1660.	0.2	15
1241	The Expression of Transcription Factor Activating Transcription Factor 3 in the Human Prostate and its Regulation by Androgen in Prostate Cancer. Journal of Urology, 2006, 175, 1517-1522.	0.2	64
1242	Tamoxifen Use and Impact on the Incidence of Endometrial Carcinoma: Should Tamoxifen use be discontinued?. Journal of Medical Imaging and Radiation Sciences, 2006, 37, 25-30.	0.1	0

#	Article	IF	CITATIONS
1243	Prostate Biopsy Tumor Extent but Not Location Predicts Recurrence After Radical Prostatectomy: Results From CaPSURE. Journal of Urology, 2006, 175, 125-129.	0.2	21
1244	Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific Mortality. Journal of Urology, 2006, 175, 907-912.	0.2	78
1245	Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 889-895.	1.4	100
1246	Bile Acids Induce Ectopic Expression of Intestinal Guanylyl Cyclase C Through Nuclear Factor-κB and Cdx2 in Human Esophageal Cells. Gastroenterology, 2006, 130, 1191-1206.	0.6	87
1247	Proteomic Classification of Pancreatic Adenocarcinoma Tissue Using Protein Chip Technology. Gastroenterology, 2006, 130, 1670-1678.	0.6	41
1248	Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. Gastroenterology, 2006, 131, 729-737.	0.6	195
1249	Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival. Laryngoscope, 2006, 116, 1-13.	1.1	652
1250	MR thermometry characterization of a hyperthermia ultrasound array designed using the k-space computational method. BioMedical Engineering OnLine, 2006, 5, 56.	1.3	4
1251	Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Molecular Cancer, 2006, 5, 15.	7.9	49
1252	Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Molecular Cancer, 2006, 5, 66.	7.9	36
1253	Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy. World Journal of Surgical Oncology, 2006, 4, 53.	0.8	6
1254	Uncommon sarcomas of the uterine cervix: a review of selected entities. Diagnostic Pathology, 2006, 1, 30.	0.9	66
1255	Trend in incidence of gastric adenocarcinoma by tumor location from 1969–2004: a study in one referral center in Iran. Diagnostic Pathology, 2006, 1, 5.	0.9	13
1256	Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease. Annals of Surgical Oncology, 2006, 13, 712-720.	0.7	133
1257	Spatial Learning and Memory Deficits after Whole-Brain Irradiation are Associated with Changes in NMDA Receptor Subunits in the Hippocampus. Radiation Research, 2006, 166, 892-899.	0.7	154
1258	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. Annual Review of Medicine, 2006, 57, 33-47.	5.0	317
1259	Polyp Miss Rate Determined by Tandem Colonoscopy: A Systematic Review. American Journal of Gastroenterology, 2006, 101, 343-350.	0.2	1,182
1260	Pancreatic cancer: a review of recent advances. Expert Opinion on Investigational Drugs, 2006, 15, 1395-1410.	1.9	74

#	Article	IF	CITATIONS
1261	Steamed American Ginseng Berry:Â Ginsenoside Analyses and Anticancer Activities. Journal of Agricultural and Food Chemistry, 2006, 54, 9936-9942.	2.4	163
1262	Investigation of living pancreas tumor cells by digital holographic microscopy. Journal of Biomedical Optics, 2006, 11, 034005.	1.4	324
1263	Endoscopic procedures and diagnoses are not influenced by seasonal variations. Gastrointestinal Endoscopy, 2006, 63, 267-272.	0.5	7
1264	Simultaneous fluorescence imaging of protease expression andÂvascularity during murine colonoscopy for colonic lesion characterization. Gastrointestinal Endoscopy, 2006, 64, 589-597.	0.5	52
1265	Peripheral Neuropathy in a Woman With Breast Cancer. Journal of Pain, 2006, 7, 2-10.	0.7	9
1266	Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. Journal of Clinical Oncology, 2006, 24, 5519-5527.	0.8	88
1267	Lung DNA Adducts Detected in Human Smokers Are Unrelated to Typical Polyaromatic Carcinogens. Chemical Research in Toxicology, 2006, 19, 295-299.	1.7	40
1268	Epidemiology and costs of chronic obstructive pulmonary disease. European Respiratory Journal, 2006, 27, 188-207.	3.1	606
1269	Image-processing technique for suppressing ribs in chest radiographs by means of massive training artificial neural network (MTANN). IEEE Transactions on Medical Imaging, 2006, 25, 406-416.	5.4	196
1270	In vivo Margin Assessment during Partial Mastectomy Breast Surgery Using Raman Spectroscopy. Cancer Research, 2006, 66, 3317-3322.	0.4	410
1271	The Prevalence Rate and Anatomic Location of Colorectal Adenoma and Cancer Detected by Colonoscopy in Average-Risk Individuals Aged 40-80 Years. American Journal of Gastroenterology, 2006, 101, 255-262.	0.2	177
1272	Racial Differences in Colorectal Cancer Test Use by Medicare Consumers. American Journal of Preventive Medicine, 2006, 30, 320-326.	1.6	30
1273	The postoperative surveillance of patients with colon cancer and rectal cancer. American Journal of Surgery, 2006, 192, 100-108.	0.9	41
1274	FDG-PET in radiotherapy treatment planning of advanced head and neck cancer—A prospective clinical analysis. Auris Nasus Larynx, 2006, 33, 303-309.	0.5	11
1275	Why Do Postmenopausal African-American Women Not Benefit from Overall Breast Cancer Mortality Decline?. Annals of Epidemiology, 2006, 16, 180-190.	0.9	6
1277	Prevalence of Benign Disease in Patients Undergoing Resection for Suspected Lung Cancer. Annals of Thoracic Surgery, 2006, 81, 1824-1829.	0.7	73
1278	Radiofrequency Ablation of Lung Malignancies. Annals of Thoracic Surgery, 2006, 82, 365-371.	0.7	37
1279	Stage IB Nonsmall Cell Lung Cancers: Are They All the Same?. Annals of Thoracic Surgery, 2006, 81, 1958-1962.	0.7	50

#	Article	IF	CITATIONS
1280	Nine-Year Single Center Experience With Cervical Mediastinoscopy: Complications and False Negative Rate. Annals of Thoracic Surgery, 2006, 82, 1185-1190.	0.7	185
1281	Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics, 2006, 28, 1779-1802.	1.1	473
1282	Expression of 5-oxoETE receptor in prostate cancer cells: Critical role in survival. Biochemical and Biophysical Research Communications, 2006, 339, 93-98.	1.0	50
1283	Array CGH analysis reveals chromosomal aberrations in mouse lung adenocarcinomas induced by the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochemical and Biophysical Research Communications, 2006, 341, 856-863.	1.0	25
1284	Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Letters, 2006, 232, 243-254.	3.2	50
1285	Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells. Cancer Letters, 2006, 233, 226-231.	3.2	28
1286	Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Letters, 2006, 237, 223-233.	3.2	13
1287	Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions. Cancer Letters, 2006, 239, 21-26.	3.2	9
1288	Steroid receptor expressions in endometrial cancer: Clinical significance and epidemiological implication. Cancer Letters, 2006, 239, 198-204.	3.2	47
1289	Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Letters, 2006, 241, 213-220.	3.2	43
1290	Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Letters, 2006, 241, 221-227.	3.2	122
1291	Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin. Cancer Letters, 2006, 243, 58-63.	3.2	13
1294	Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treatment Reviews, 2006, 32, 9-27.	3.4	59
1295	Irinotecan in the treatment of colorectal cancer. Cancer Treatment Reviews, 2006, 32, 491-503.	3.4	148
1296	Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine, 2006, 35, 21-28.	1.4	99
1297	Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine and Growth Factor Reviews, 2006, 17, 147-156.	3.2	65
1298	Reduced folate carrier gene G80A polymorphism is associated with an increased risk of gastroesophageal cancers in a chinese population. European Journal of Cancer, 2006, 42, 3206-3211.	1.3	29
1299	Characterization of breast lesion using double phase Tc-99m Tetrofosmin scintimammography: Comparison of visual and quantitative analyses. European Journal of Radiology, 2006, 57, 76-80.	1.2	2

			0
#	ARTICLE	IF	CITATIONS
1300	Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. European Journal of Surgical Oncology, 2006, 32, 148-152.	0.5	122
1301	Routine pelvic lymphadenectomy in apparently early stage endometrial cancer. European Journal of Surgical Oncology, 2006, 32, 450-454.	0.5	24
1302	Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. European Journal of Surgical Oncology, 2006, 32, 666-670.	0.5	48
1303	Suppression of the Malignant Phenotype in Pancreatic Cancer by Overexpression of Phospholipid Hydroperoxide Glutathione Peroxidase. Human Gene Therapy, 2006, 17, 105-116.	1.4	63
1304	Structure–function relationship of estrogen receptor α and β: Impact on human health. Molecular Aspects of Medicine, 2006, 27, 299-402.	2.7	445
1305	Male breast cancer: incompatible and incomparable. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2006, 3, 160-165.	0.3	15
1306	Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination?. Medical Hypotheses, 2006, 67, 951-956.	0.8	15
1307	Bisphenol A: Do recent studies of health effects among humans inform the long-standing debate?. Mutation Research - Reviews in Mutation Research, 2006, 613, 68-75.	2.4	10
1308	Presentation and detection of invasive melanoma in a high-risk population. Journal of the American Academy of Dermatology, 2006, 54, 783-792.	0.6	129
1309	Photodynamic therapy of cerebral glioma – A review Part II – Clinical studies. Journal of Clinical Neuroscience, 2006, 13, 709-717.	0.8	86
1310	What is the Biology and Optimal Treatment for Papillary Microcarcinoma of the Thyroid?. Journal of Surgical Research, 2006, 134, 160-162.	0.8	39
1311	Reality-based needle insertion simulation for haptic feedback in prostate brachytherapy. , 0, , .		35
1312	Neurotensin and growth of normal and neoplastic tissues. Peptides, 2006, 27, 2424-2433.	1.2	119
1313	Changes in gene expression contribute to cancer prevention by COX inhibitors. Progress in Lipid Research, 2006, 45, 1-16.	5.3	77
1314	In vitro and in vivo characterization of 177Lu-huA33. Nuclear Medicine and Biology, 2006, 33, 991-998.	0.3	21
1315	Update in the management of head and neck cancer. Update on Cancer Therapeutics, 2006, 1, 211-219.	0.9	8
1316	Cancers of the bowel and hepatobiliary tract. Update on Cancer Therapeutics, 2006, 1, 353-365.	0.9	1
1317	No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology, 2006, 67, 142-146.	0.5	12

#	Article	IF	CITATIONS
1318	Transitional cell carcinoma associated with marijuana: Case report and review of the literature. Urology, 2006, 67, 200.e5-200.e6.	0.5	22
1319	Racial disparities in resource utilization for cystectomy. Urology, 2006, 67, 288-293.	0.5	48
1320	Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: Defining the risk of initial bladder preservation. Urology, 2006, 67, 737-741.	0.5	41
1321	Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology, 2006, 67, 942-945.	0.5	33
1322	Current trends in molecular classification of adult renal tumors. Urology, 2006, 67, 873-880.	0.5	20
1323	Bone metastases are infrequent in patients with newly diagnosed prostate cancer: Analysis of their clinical and pathologic features. Urology, 2006, 68, 362-366.	0.5	16
1324	Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology, 2006, 68, 342-347.	0.5	40
1325	Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 4-12.	0.8	40
1326	Lymphadenectomy in bladder cancer: How high is "high enough�. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 349-355.	0.8	64
1327	Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 434-441.	0.8	32
1328	Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancerâ~†. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 344-348.	0.8	217
1329	Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: An orthotopic in vivo model. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 362-371.	0.8	13
1330	Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine, 2006, 24, 293-303.	1.7	52
1331	Experimental Study of the Survival of Metastatic Cancer Cells in Corneal Organ Culture. , 2006, 47, 1339.		4
1332	Self-Surveillance for Genetic Predisposition to Cancer: Behaviors and Emotions. Oncology Nursing Forum, 2006, 33, 221-231.	0.5	11
1333	Hormone Refractory Prostate Cancer (Hrpc): Present and Future Approaches of Therapy. International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	1.0	25
1334	Screening for Early Detection of Cancers II. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2006, 49, 515.	0.1	7
1335	Cytologic Detection of Urothelial Lesions. , 2006, , 1-4.		0

#	Article	IF	CITATIONS
1336	Robot-Assisted Radical Cystectomy in the Management of Bladder Cancer. Scientific World Journal, The, 2006, 6, 2560-2565.	0.8	8
1338	Current Trends in the Molecular Classification of Renal Neoplasms. Scientific World Journal, The, 2006, 6, 2505-2518.	0.8	12
1339	Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. Journal of Clinical Oncology, 2006, 24, 379-385.	0.8	68
1340	Estrogen receptors and human disease. Journal of Clinical Investigation, 2006, 116, 561-570.	3.9	1,077
1341	Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan. Journal of Managed Care Pharmacy, 2006, 12, 472-478.	2.2	32
1342	Combined Lycopene and Vitamin E Treatment Suppresses the Growth of PC-346C Human Prostate Cancer Cells in Nude Mice. Journal of Nutrition, 2006, 136, 1287-1293.	1.3	88
1343	Identification of Differentially Expressed Genes in Prostatic Epithelium in Relation to Androgen Receptor CAG Repeat Length. International Journal of Biological Markers, 2006, 21, 96-105.	0.7	7
1344	Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma. Oncology Issues, 2006, 21, 22-24.	0.0	0
1345	Surgical Management of Patients with Epithelial Ovarian Cancer. , 2006, , 69-81.		0
1346	Significance of Noninvasive Diagnosis of Prostate Cancer with Cytologic Examination of Prostatic Fluid. Journal of Nippon Medical School, 2006, 73, 129-135.	0.3	2
1347	A F240S Polymorphism of Protease-activated Receptor 2 (PAR2) is not Detected in Japanese Population with Gastro-esophageal Symptoms. Journal of Clinical Biochemistry and Nutrition, 2006, 39, 98-101.	0.6	4
1349	Dendrimer Nanocomposites for Cancer Therapy. , 2006, , 551-592.		0
1351	Drug Development for Advanced Colorectal Cancer in the United States. , 2006, , 317-335.		0
1352	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood, 2006, 107, 4039-4046.	0.6	139
1353	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 108, 3458-3464.	0.6	494
1354	Urinary Neopterin in Patients with Ovarian Cancer. Pteridines, 2006, 17, 145-153.	0.5	19
1355	Vaccination With Human Papillomavirus Type 16 E7 Peptide With CpG Oligonucleotides for Prevention of Tumor Growth in Mice. JAMA Otolaryngology, 2006, 132, 327.	1.5	15
1356	Innovations in the Radiotherapy of Non???Small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 85-92.	0.5	9

#	Article	IF	CITATIONS
1357	Palliative Ethanol Injections of Unresectable Advanced Esophageal Carcinoma Combined with Chemoradiation. American Journal of the Medical Sciences, 2006, 331, 110-112.	0.4	6
1358	Accurate Identification of HER2-Positive Patients Is Essential for Superior Outcomes With Trastuzumab Therapy. Oncology Nursing Forum, 2006, 33, 265-272.	0.5	9
1359	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 582-587.	0.5	10
1360	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 787-795.	0.5	14
1361	Innovations in the Radiotherapy of Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 85-92.	0.5	11
1362	Utilization of thek-Space Method in the Design of a Ferroelectric Hyperthermia Phased Array. Ferroelectrics, 2006, 331, 103-120.	0.3	4
1363	Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 238-244.	1.1	31
1364	Prevalence and Significance of Prominent Mucin Pools in the Esophagus Post Neoadjuvant Chemoradiotherapy for Barrett??s-Associated Adenocarcinoma. American Journal of Surgical Pathology, 2006, 30, 28-35.	2.1	36
1365	Phase II Trial of Gemcitabine Plus Irinotecan In Patients With Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 116-122.	0.6	15
1366	Usefulness of Scintimammography With Tc-99m MIBI in Clinical Practice. Clinical Nuclear Medicine, 2006, 31, 761-763.	0.7	4
1367	Immunohistochemical Analysis of Metastatic Neoplasms of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2006, 65, 935-944.	0.9	34
1368	Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer. Laboratory Medicine, 2006, 37, 429-435.	0.8	0
1369	Coxibs and Cancer Prevention. Journal of Cardiovascular Pharmacology, 2006, 47, S76-S81.	0.8	10
1370	Phase la/lb Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 434-440.	0.5	10
1371	Long-Term Outcome for Mammographically Detected Ductal Carcinoma In Situ Managed with Breast Conservation Treatment. Cancer Journal (Sudbury, Mass ), 2006, 12, 25-32.	1.0	21
1372	Coriolus versicolor (Yunzhi) extract attenuates growth of human leukemia xenografts and induces apoptosis through the mitochondrial pathway. Oncology Reports, 2006, 16, 609.	1.2	7
1373	Management of Squamous Cell Cancer of the Vulva. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 640-645.	0.3	11
1374	FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nuclear Medicine Communications, 2006, 27, 481-487.	0.5	23

#	Article	IF	CITATIONS
1375	A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non???small-cell Lung Carcinoma. Diagnostic Molecular Pathology, 2006, 15, 101-108.	2.1	31
1376	Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival. Journal of Thoracic Oncology, 2006, 1, 960-964.	0.5	17
1378	Anti-proliferative effect of peroxisome proliferator-activated receptor ?? agonists on human malignant melanoma cells in vitro. Anti-Cancer Drugs, 2006, 17, 325-332.	0.7	30
1379	Dose-dense Chemotherapy for Aggressive Non-Hodgkin Lymphoma. Cancer Nursing, 2006, 29, 198-206.	0.7	2
1380	Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 267-275.	0.6	13
1381	Fluorescence cystoscopy: is it ready for use in routine clinical practice?. Current Opinion in Urology, 2006, 16, 372-376.	0.9	17
1382	Predicting Survival After Surgical Resection for Pancreatic Ductal Adenocarcinoma. Pancreas, 2006, 32, 37-43.	0.5	101
1383	Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Melanoma Research, 2006, 16, 365-370.	0.6	14
1384	Update on erectile dysfunction in prostate cancer patients. Current Opinion in Urology, 2006, 16, 186-195.	0.9	53
1385	Optimal Management and Challenges in Treatment of Upper Facial Melanoma. Annals of Plastic Surgery, 2006, 57, 616-620.	0.5	30
1386	New developments in chemotherapy for advanced non-small cell lung cancer. Current Opinion in Internal Medicine, 2006, 5, 305-310.	1.5	15
1387	Telephone Outreach to Increase Colorectal Cancer Screening in an Urban Minority Population. American Journal of Public Health, 2006, 96, 2246-2253.	1.5	93
1388	Mammographic density measured as changes in tissue structure caused by HRT. , 2006, 6144, 141.		6
1389	Precursors of Endometrial Clear Cell Carcinoma. American Journal of Surgical Pathology, 2006, 30, 1519-1530.	2.1	71
1390	Improved Survival of Asians With Corpus Cancer Compared With Whites. Obstetrics and Gynecology, 2006, 107, 329-335.	1.2	17
1391	Conformal Radiotherapy of the Dominant Liver Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 562-567.	0.6	35
1392	Claudin-4, Mitogen-Activated Protein Kinase Kinase 4, and Stratifin Are Markers of Gastric Adenocarcinoma Precursor Lesions. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 281-287.	1.1	74
1393	Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cells. Anti-Cancer Drugs, 2006, 17, 1163-1169.	0.7	69

#	Article	IF	CITATIONS
1394	Recovery of sexual function after prostate cancer treatment. Current Opinion in Urology, 2006, 16, 444-448.	0.9	9
1395	Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer. American Journal of Surgical Pathology, 2006, 30, 1231-1236.	2.1	18
1396	Cost Analysis of Functional Restoration Surgery for Extremity Soft-Tissue Sarcoma. Plastic and Reconstructive Surgery, 2006, 117, 277-283.	0.7	20
1397	Multislice Computed Tomography in Planning Nephron-Sparing Surgery in a Prospective Study With 76 Patients. Journal of Computer Assisted Tomography, 2006, 30, 869-874.	0.5	26
1398	Controversies in Transrectal Ultrasonography and Prostate Biopsy. Ultrasound Quarterly, 2006, 22, 169-175.	0.3	18
1399	PHARMACOLOGICAL THROMBOPROPHYLAXIS IN MECHANICALLY VENTILATED CANCER PATIENTS IN THE INTENSIVE CARE UNIT: LOWER THAN EXPECTED. Chest, 2006, 130, 206S.	0.4	79
1400	MKK4 Status Predicts Survival After Resection of Gastric Adenocarcinoma. Archives of Surgery, 2006, 141, 1095.	2.3	21
1401	The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women. BMC Pulmonary Medicine, 2006, 6, 2.	0.8	14
1402	Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. Journal of Pathology, 2006, 209, 147-156.	2.1	125
1403	Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups. Psycho-Oncology, 2006, 15, 193-208.	1.0	55
1404	Expression and role of Foxa proteins in prostate cancer. Prostate, 2006, 66, 1013-1028.	1.2	121
1405	Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate, 2006, 66, 503-513.	1.2	112
1406	Integrin-dependent amplification of the G2 arrest induced by ionizing radiation. Prostate, 2006, 66, 88-96.	1.2	19
1407	CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate, 2006, 66, 32-48.	1.2	229
1408	Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate, 2006, 66, 49-56.	1.2	44
1409	Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate, 2006, 66, 180-192.	1.2	25
1410	90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate, 2006, 66, 283-293.	1.2	30
1411	A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate, 2006, 66, 305-316.	1.2	35

#	Article	IF	CITATIONS
1412	Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate, 2006, 66, 421-429.	1.2	90
1413	Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate, 2006, 66, 971-986.	1.2	31
1414	Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate, 2006, 66, 1194-1202.	1.2	25
1415	Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate, 2006, 66, 1641-1652.	1.2	26
1416	Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics, 2006, 6, 697-708.	1.3	59
1417	Classifications of ovarian cancer tissues by proteomic patterns. Proteomics, 2006, 6, 5846-5856.	1.3	41
1418	Genotoxicity of the marine toxin okadaic acid, in human Caco-2 cells and in mice gut cells. Environmental Toxicology, 2006, 21, 55-64.	2.1	71
1419	High-resolution gamma-camera for molecular breast imaging: First clinical results. Physica Medica, 2006, 21, 121-124.	0.4	4
1420	Outcome of Men Presenting with Clinical Breast Problems: The Role of Mammography and Ultrasound. Breast Journal, 2006, 12, 418-423.	0.4	47
1421	Management approaches to small renal tumours. BJU International, 2006, 97, 456-460.	1.3	24
1421 1422	Management approaches to small renal tumours. BJU International, 2006, 97, 456-460. Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale. BJU International, 2006, 97, 227-231.	1.3 1.3	24 36
	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale.		
1422	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale. BJU International, 2006, 97, 227-231. Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97,	1.3	36
1422 1423	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale. BJU International, 2006, 97, 227-231. Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97, 905-910. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of	1.3 1.3	36 2
1422 1423 1424	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale. BJU International, 2006, 97, 227-231. Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97, 905-910. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. BJU International, 2006, 98, 50-53. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients	1.3 1.3 1.3	36 2 11
1422 1423 1424 1425	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale.         BJU International, 2006, 97, 227-231.         Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97, 905-910.         Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. BJU International, 2006, 98, 50-53.         A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU International, 2006, 98, 580-585.         Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic	1.3 1.3 1.3 1.3	36 2 11 13
1422 1423 1424 1425 1426	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale.         BJU International, 2006, 97, 227-231.         Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97, 905-910.         Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. BJU International, 2006, 98, 50-53.         A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU International, 2006, 98, 580-585.         Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistance. BJU International, 2006, 98, 1059-1063.         Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome	1.3 1.3 1.3 1.3	36 2 11 13 103

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1430	Skin Cancer and Non-Hodgkin's Lymphoma: Examining the Link. Dermatologic Surgery	, 2005, 31, 76-82.	0.4	12
1431	A multicenter phase II study of the cryptophycin analog LY355703 in patients with plat ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 71-76.	inum-resistant	1.2	78
1432	Primary malignant mesodermal ovarian sarcomas. International Journal of Gynecologica 2006, 16, 106-109.	al Cancer,	1.2	5
1433	Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovaria single institution phase II study in 24 patients. International Journal of Gynecological C 60-67.	n carcinoma: a ancer, 2006, 16,	1.2	11
1434	The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ov International Journal of Gynecological Cancer, 2006, 16, 496-500.	<sup>,</sup> arian cancer.	1.2	44
1435	Stauffer's syndrome variant with cholestatic jaundice. Journal of General Internal M C11-C13.	ledicine, 2006, 21,	1.3	29
1436	Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of os cytolysis by distilled water vs. mitomycin. International Journal of Clinical Practice, 2000 1178-1180.		0.8	18
1437	Smoking risks need to be highlighted in Asia. Asia-Pacific Journal of Clinical Oncology, 2	2006, 2, 117-118.	0.7	0
1438	A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured huma leukaemia cells. British Journal of Haematology, 2006, 133, 141-151.	an myeloid	1.2	41
1439	Order of patient entry influences outcome for metastatic renal cell cancer after non-my allogeneic stem cell transplantation. British Journal of Haematology, 2006, 132, 747-7	veloablative 54.	1.2	8
1440	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple mye Journal of Haematology, 2006, 132, 698-704.	loma. British	1.2	4
1441	Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung c Science, 2006, 97, 737-745.	ancer. Cancer	1.7	62
1442	Progesterone receptor isoforms as a prognostic marker in human endometrial carcinor Science, 2006, 97, 1308-1314.	na. Cancer	1.7	36
1443	The epidemiology of pancreatic cancer in the United States: changes below the surface Pharmacology and Therapeutics, 2006, 24, 87-94.	e. Alimentary	1.9	141
1444	Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial British Journal of Cancer, 2006, 94, 569-577.	carcinoma.	2.9	71
1445	CCL19 reduces tumour burden in a model of advanced lung cancer. British Journal of C 1029-1034.	ancer, 2006, 94,	2.9	49
1446	A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented t bladder cancer in vitro and in vivo. British Journal of Cancer, 2006, 95, 1354-1361.	he growth of	2.9	29
1447	Ovarian cancer in younger vs older women: a population-based analysis. British Journal 2006, 95, 1314-1320.	of Cancer,	2.9	135

#	Article	IF	CITATIONS
1448	Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. British Journal of Cancer, 2006, 95, 1555-1561.	2.9	222
1449	An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Therapy, 2006, 13, 13-20.	2.2	37
1450	Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Therapy, 2006, 13, 845-855.	2.2	28
1451	Population-Based Prevalence of CDKN2A Mutations in Utah Melanoma Families. Journal of Investigative Dermatology, 2006, 126, 660-666.	0.3	51
1452	Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene, 2006, 25, 130-138.	2.6	165
1453	Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene, 2006, 25, 79-90.	2.6	46
1454	Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene, 2006, 25, 4122-4127.	2.6	54
1455	STI-571 (Gleevec) Potentiates the Effect of Cisplatin in Inhibiting the Proliferation of Head and Neck Squamous Cell Carcinoma In Vitro. Laryngoscope, 2006, 116, 1409-1416.	1.1	23
1456	Chemopreventive Effect of Celecoxib in Oral Precancers and Cancers. Laryngoscope, 2006, 116, 1842-1845.	1.1	24
1457	Epidermal growth factor receptor directed therapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 25-43.	2.0	46
1458	Do age and ethnicity predict breast cancer treatment received? A cross-sectional urban population based study. Critical Reviews in Oncology/Hematology, 2006, 59, 234-242.	2.0	25
1459	The inherited genetics of pancreatic cancer and prospects for secondary screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 253-283.	1.0	43
1460	The rationale for screening and surveillance of Barrett's metaplasia. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 829-842.	1.0	12
1461	Chemically modified carbon nanotubes as material enhanced laser desorption ionisation (MELDI) material in protein profiling. Analytica Chimica Acta, 2006, 561, 32-39.	2.6	55
1462	Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry, 2006, 39, 176-179.	0.8	170
1463	Diagnosis of Bone Metastasis in Men with Prostate Cancer by Measurement of Serum ICTP in Combination with Alkali Phosphatase and Prostate-specific Antigen. Clinical Oncology, 2006, 18, 480-484.	0.6	19
1464	The Preferred Treatment for Stage I Seminoma: A Survey of Canadian Radiation Oncologists. Clinical Oncology, 2006, 18, 696-699.	0.6	13
1465	Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. International Journal of Radiation Oncology Biology Physics, 2006, 65, 84-90.	0.4	38

#	Article	IF	CITATIONS
1466	A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients. International Journal of Radiation Oncology Biology Physics, 2006, 65, 266-273.	0.4	46
1467	Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1120-1128.	0.4	29
1468	Induced second cancers after prostate-cancer radiotherapy: No cause for concern?. International Journal of Radiation Oncology Biology Physics, 2006, 65, 637-639.	0.4	42
1469	Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1313-1319.	0.4	56
1470	Clinical utility of scintimammography: From the Anger-camera to new dedicated devices. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 281-285.	0.7	4
1471	High Levels of Aberrant DNA Methylation in Helicobacter pylori–Infected Gastric Mucosae and its Possible Association with Gastric Cancer Risk. Clinical Cancer Research, 2006, 12, 989-995.	3.2	581
1472	Clinical experience with docetaxel for Chinese breast cancer patients: Hematological toxicity profiles. Breast Cancer, 2006, 13, 192-196.	1.3	6
1473	Mass Spectrometry-Based Study of the Plasma Proteome in a Mouse Intestinal Tumor Model. Journal of Proteome Research, 2006, 5, 1866-1878.	1.8	35
1474	Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays. Journal of Clinical Oncology, 2006, 24, 778-789.	0.8	513
1475	A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. European Radiology, 2006, 16, 927-938.	2.3	89
1476	Three-dimensional MDCT imaging and CT esophagography for evaluation of esophageal tumors: preliminary study. European Radiology, 2006, 16, 2418-2426.	2.3	24
1477	Determination of the Minimum Temperature Required for Selective Photothermal Destruction of Cancer Cells with the Use of Immunotargeted Gold Nanoparticles. Photochemistry and Photobiology, 2006, 82, 412.	1.3	369
1478	Use of preoperative serum CAâ€125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 1501-1505.	1.3	103
1479	Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer. Annals of Surgical Oncology, 2006, 13, 291-301.	0.7	16
1480	Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence: Surgical and Survival Data. Annals of Surgical Oncology, 2006, 13, 1717-1723.	0.7	29
1481	Bypass Surgery Versus Palliative Pancreaticoduodenectomy in Patients with Advanced Ductal Adenocarcinoma of the Pancreatic Head, with an Emphasis on Quality of Life Analyses. Annals of Surgical Oncology, 2006, 13, 1403-1411.	0.7	46
1482	Coping with ovarian cancer risk: The moderating effects of perceived control on coping and adjustment. British Journal of Health Psychology, 2006, 11, 561-580.	1.9	20
1483	Jaw Complications Associated with Bisphosphonate Use in Patients with Plasma Cell Dyscrasias. Medical Oncology, 2006, 23, 51-56.	1.2	24

#	Article	IF	CITATIONS
1484	The Use of Early and Midpoint Adenoma-Carcinoma Sequence Biomarkers in Prediction of Neoplastic Progression in Patients with a History of Colorectal Neoplasia. Digestive Diseases and Sciences, 2006, 51, 2213-2219.	1.1	1
1485	Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: A pilot study. Investigational New Drugs, 2006, 24, 171-175.	1.2	8
1486	A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Investigational New Drugs, 2006, 24, 213-221.	1.2	7
1487	Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study. Investigational New Drugs, 2006, 24, 335-341.	1.2	17
1488	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Investigational New Drugs, 2006, 24, 89-94.	1.2	8
1489	Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats. Investigational New Drugs, 2006, 24, 479-488.	1.2	38
1490	Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Investigational New Drugs, 2006, 24, 521-527.	1.2	69
1491	A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Investigational New Drugs, 2006, 24, 515-520.	1.2	67
1492	Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Investigational New Drugs, 2006, 24, 509-514.	1.2	16
1493	Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD Peptide. Molecular Imaging and Biology, 2006, 8, 9-15.	1.3	36
1494	Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus. Molecular Imaging and Biology, 2006, 8, 30-35.	1.3	13
1495	In vitro and in vivo Evaluation of 1111n-labeled E. coli Heat-Stable Enterotoxin Analogs for Specific Targeting of Human Breast Cancers. Breast Cancer Research and Treatment, 2006, 98, 7-15.	1.1	7
1496	Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis. Breast Cancer Research and Treatment, 2006, 96, 279-292.	1.1	29
1497	Dietary Risk Factors for Ovarian Cancer: The Adventist Health Study (United States). Cancer Causes and Control, 2006, 17, 137-146.	0.8	49
1498	Unmet needs of cancer survivors: supportive care's new challenge. Supportive Care in Cancer, 2006, 14, 397-399.	1.0	19
1499	Chemoprevention of Colorectal Cancer. Diseases of the Colon and Rectum, 2006, 49, 113-125.	0.7	33
1500	Expectant Management of Anal Squamous Dysplasia in Patients With HIV. Diseases of the Colon and Rectum, 2006, 49, 36-40.	0.7	109
1501	Continued Survival of More Than Ten Years, Without Resection of Metastatic Disease, in Patients With Metastatic Colorectal Cancer Treated With Biomodulated Fluorouracil: Report of Two Cases. Diseases of the Colon and Rectum, 2006, 49, 407-410.	0.7	1

#	Article	IF	CITATIONS
1502	The Importance of Colonoscopy in Colorectal Surgeons' Practices: Results of a Survey. Diseases of the Colon and Rectum, 2006, 49, 1763-1767.	0.7	11
1503	Disseminated Tumor Cells in Peripheral Blood: A Novel Marker for Therapy Response in Locally Advanced Rectal Cancer Patients Undergoing Preoperative Chemoradiation. Diseases of the Colon and Rectum, 2006, 49, 1484-1491.	0.7	17
1504	Metastatic Burst Fracture Risk Assessment Based on Complex Loading of the Thoracic Spine. Annals of Biomedical Engineering, 2006, 34, 494-505.	1.3	21
1505	Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. International Journal of Colorectal Disease, 2006, 21, 221-230.	1.0	16
1506	Prediction of cervical involvement in endometrial cancer by hysteroscopy. Archives of Gynecology and Obstetrics, 2006, 275, 45-48.	0.8	5
1507	Natural history of the Nihon (Bhd gene mutant) rat, a novel model for human Birt–Hogg–Dubé syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 463-471.	1.4	29
1508	Esophageal squamous cell carcinoma with entirely intramural growth pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 862-866.	1.4	16
1509	Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 673-681.	1.4	51
1510	Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World Journal of Urology, 2006, 24, 296-304.	1.2	261
1511	Chemoprevention of bladder cancer. World Journal of Urology, 2006, 24, 445-472.	1.2	22
1511 1512	Chemoprevention of bladder cancer. World Journal of Urology, 2006, 24, 445-472. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.	1.2 2.0	22 68
	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation		
1512	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.	2.0	68
1512 1513	<ul> <li>Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.</li> <li>Early ovarian cancer: 3-D power Doppler. Abdominal Imaging, 2006, 31, 613-619.</li> <li>A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against</li> </ul>	2.0 2.0	68 13
1512 1513 1514	<ul> <li>Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.</li> <li>Early ovarian cancer: 3-D power Doppler. Abdominal Imaging, 2006, 31, 613-619.</li> <li>A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunology, Immunotherapy, 2006, 55, 1367-1373.</li> <li>Is There a Role for Palliative Gastrectomy in Patients with Stage IV Gastric Cancer?. World Journal of</li> </ul>	2.0 2.0 2.0	68 13 45
1512 1513 1514 1515	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.         Early ovarian cancer: 3-D power Doppler. Abdominal Imaging, 2006, 31, 613-619.         A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunology, Immunotherapy, 2006, 55, 1367-1373.         Is There a Role for Palliative Gastrectomy in Patients with Stage IV Gastric Cancer?. World Journal of Surgery, 2006, 30, 21-27.         Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemotherapy and	2.0 2.0 2.0 0.8	68 13 45 88
1512 1513 1514 1515 1516	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.         Early ovarian cancer: 3-D power Doppler. Abdominal Imaging, 2006, 31, 613-619.         A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunology, Immunotherapy, 2006, 55, 1367-1373.         Is There a Role for Palliative Gastrectomy in Patients with Stage IV Gastric Cancer?. World Journal of Surgery, 2006, 30, 21-27.         Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemotherapy and Pharmacology, 2006, 58, 292-305.         Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.	2.0 2.0 2.0 0.8 1.1	68 13 45 88 15

#	Article	IF	CITATIONS
1521	Needle and seed segmentation in intra-operative 3D ultrasound-guided prostate brachytherapy. Ultrasonics, 2006, 44, e331-e336.	2.1	32
1522	Molecular pathogenesis of pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 211-226.	1.0	161
1523	Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: Feasibility and tolerability in a subset of patients in a randomized trial. Critical Reviews in Oncology/Hematology, 2006, 58, 166-175.	2.0	11
1524	Does the Literature Support an Indication for Hepatic Metastasectomy Other Than for Colorectal Primary?. Journal of Gastrointestinal Surgery, 2006, 10, 99-104.	0.9	10
1525	Adjuvant therapy for stage II colorectal cancer: Who and with what?. Current Treatment Options in Gastroenterology, 2006, 9, 272-280.	0.3	6
1526	Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma. Clinical and Translational Oncology, 2006, 8, 676-680.	1.2	14
1527	Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Current Treatment Options in Oncology, 2006, 7, 355-362.	1.3	66
1528	Second- and third-line treatments in non-small cell lung cancer. Current Treatment Options in Oncology, 2006, 7, 37-49.	1.3	17
1529	Neuromodulatory drugs for the radical prostatectomy patient: Current and future applications. Current Sexual Health Reports, 2006, 3, 120-124.	0.4	0
1530	Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Current Urology Reports, 2006, 7, 16-22.	1.0	9
1531	Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease. Current Urology Reports, 2006, 7, 293-303.	1.0	2
1532	A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2006, 100, 111-115.	0.6	3
1533	Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecologic Oncology, 2006, 100, 116-127.	0.6	53
1534	The AP-2Î <sup>3</sup> transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecologic Oncology, 2006, 100, 462-468.	0.6	25
1535	Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecologic Oncology, 2006, 101, 46-54.	0.6	47
1536	Two for good measure: Six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecologic Oncology, 2006, 100, 417-421.	0.6	13
1537	A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecologic Oncology, 2006, 103, 315-320.	0.6	23
1538	Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecologic Oncology, 2006, 102, 140-144.	0.6	139

#	Article	IF	CITATIONS
1539	The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecologic Oncology, 2006, 103, 802-806.	0.6	23
1540	Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Experimental Hematology, 2006, 34, 713-720.	0.2	107
1541	A machine learning perspective on the development of clinical decision support systems utilizing mass spectra of blood samples. Journal of Biomedical Informatics, 2006, 39, 227-248.	2.5	91
1542	Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics and Cytogenetics, 2006, 169, 128-137.	1.0	151
1543	Who attends skin cancer clinics within a randomized melanoma screening program?. Cancer Detection and Prevention, 2006, 30, 44-51.	2.1	22
1544	Impact of breast cancer screening intervention on Korean-American women in Maryland. Cancer Detection and Prevention, 2006, 30, 297-305.	2.1	49
1545	A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Clinical Imaging, 2006, 30, 374.	0.8	2
1546	The Future of Oncological Urology in Europe: Are we Prepared?. European Urology, 2006, 49, 11-12.	0.9	3
1547	Gynaecological cancer surgery. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 157-172.	1.4	2
1548	Breast Cancer Staging. Seminars in Roentgenology, 2006, 41, 91-104.	0.2	18
1549	The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surgical Oncology, 2006, 15, 13-24.	0.8	32
1549 1550		0.8 2.9	32 21
	2006, 15, 13-24. New perspectives on hereditary influences in metastatic progression. Trends in Genetics, 2006, 22,		
1550	2006, 15, 13-24. New perspectives on hereditary influences in metastatic progression. Trends in Genetics, 2006, 22, 555-561. Differential gene expression identifies subgroups of renal cell carcinoma. Translational Research,	2.9	21
1550 1551	2006, 15, 13-24.         New perspectives on hereditary influences in metastatic progression. Trends in Genetics, 2006, 22, 555-561.         Differential gene expression identifies subgroups of renal cell carcinoma. Translational Research, 2006, 147, 250-267.	2.9 2.4	21 35
1550 1551 1552	<ul> <li>2006, 15, 13-24.</li> <li>New perspectives on hereditary influences in metastatic progression. Trends in Genetics, 2006, 22, 555-561.</li> <li>Differential gene expression identifies subgroups of renal cell carcinoma. Translational Research, 2006, 147, 250-267.</li> <li>M645. Journal of Oral and Maxillofacial Surgery, 2006, 64, 103.</li> <li>Selection of suitable reference genes for accurate normalization of gene expression profile studies in</li> </ul>	2.9 2.4 0.5	21 35 0
1550 1551 1552 1553	<ul> <li>2006, 15, 13-24.</li> <li>New perspectives on hereditary influences in metastatic progression. Trends in Genetics, 2006, 22, 555-561.</li> <li>Differential gene expression identifies subgroups of renal cell carcinoma. Translational Research, 2006, 147, 250-267.</li> <li>M645. Journal of Oral and Maxillofacial Surgery, 2006, 64, 103.</li> <li>Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer, 2006, 6, 200.</li> <li>Predictors of colorectal cancer screening in diverse primary care practices. BMC Health Services</li> </ul>	2.9 2.4 0.5 1.1	21 35 0 85

#	Article	IF	CITATIONS
1558	Molecular regulation of androgen action in prostate cancer. Journal of Cellular Biochemistry, 2006, 99, 333-344.	1.2	271
1559	lonizing radiation enhances adenoviral vector expressingmda-7/IL-24-mediated apoptosis in human ovarian cancer. Journal of Cellular Physiology, 2006, 208, 298-306.	2.0	43
1560	Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes and Cancer, 2006, 45, 154-163.	1.5	44
1561	Chromosome 18 suppresses tumorigenic properties of human prostate cancer cells. Genes Chromosomes and Cancer, 2006, 45, 220-230.	1.5	8
1562	Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes and Cancer, 2006, 45, 365-374.	1.5	47
1563	Amplification ofCDK4 andMDM2 in malignant melanoma. Genes Chromosomes and Cancer, 2006, 45, 447-454.	1.5	133
1564	Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer, 2006, 106, 79-86.	2.0	61
1565	Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer, 2006, 106, 693-702.	2.0	30
1566	Association between glutathione S-transferase π polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer, 2006, 106, 441-447.	2.0	55
1567	American founder mutation for Lynch syndrome. Cancer, 2006, 106, 448-452.	2.0	16
1568	Predictors of enrollment in lung cancer clinical trials. Cancer, 2006, 106, 420-425.	2.0	57
1569	Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma. Cancer, 2006, 106, 848-858.	2.0	123
1570	First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer. Cancer, 2006, 106, 1041-1046.	2.0	69
1571	Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer, 2006, 106, 1498-1506.	2.0	27
1572	Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer, 2006, 106, 1917-1924.	2.0	36
1573	Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer, 2006, 106, 2241-2246.	2.0	9
1574	Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer, 2006, 106, 2143-2147.	2.0	15
1575	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer, 2006, 106, 2617-2623.	2.0	4

#	Article	IF	CITATIONS
1576	A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer, 2006, 107, 266-274.	2.0	58
1577	Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer, 2006, 107, 371-379.	2.0	155
1578	Current status of lymph node-positive prostate cancer. Cancer, 2006, 107, 439-450.	2.0	58
1579	Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer, 2006, 107, 676-685.	2.0	76
1580	The Deep South Network for cancer control. Cancer, 2006, 107, 1971-1979.	2.0	69
1581	A comparison of the clinical utility of p16INK4a immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer, 2006, 108, 451-461.	2.0	40
1582	Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer, 2006, 107, 2604-2608.	2.0	54
1583	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer, 2006, 118, 222-229.	2.3	26
1584	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 2006, 118, 257-262.	2.3	601
1586	Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. International Journal of Cancer, 2006, 118, 2072-2081.	2.3	39
1587	GADD45α is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability. International Journal of Cancer, 2006, 118, 2405-2411.	2.3	26
1588	5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. International Journal of Cancer, 2006, 119, 522-526.	2.3	31
1589	Biomarker analysis on breast ductal lavage cells in women with and without breast cancer. International Journal of Cancer, 2006, 119, 359-364.	2.3	11
1590	Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. International Journal of Cancer, 2006, 119, 741-744.	2.3	128
1591	Dietary folate is associated withp16INK4A methylation in head and neck squamous cell carcinoma. International Journal of Cancer, 2006, 119, 1553-1557.	2.3	53
1592	Mutational analysis of theHER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. International Journal of Cancer, 2006, 119, 2586-2591.	2.3	170
1593	Urinary biomarker profiling in transitional cell carcinoma. International Journal of Cancer, 2006, 119, 2642-2650.	2.3	84
1594	Re: Rectal cancer surgery in the elderly: A multivariate analysis of outcome risk factors, by Bufalari A, Giustozzi G, Burattini MF, et al Journal of Surgical Oncology, 2006, 93, 167-168.	0.8	1

#	Article	IF	Citations
1595	p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. Journal of Surgical Oncology, 2006, 93, 241-252.	0.8	35
1596	Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Molecular Carcinogenesis, 2006, 45, 84-92.	1.3	60
1597	Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Molecular Carcinogenesis, 2006, 45, 613-626.	1.3	113
1598	Prevalence and Mortality of Acute Lung Injury and ARDS After Lung Resection. Chest, 2006, 130, 73-78.	0.4	166
1599	Chronic Cough Due to Lung Tumors. Chest, 2006, 129, 147S-153S.	0.4	62
1600	Selecting Clinically-Driven Biomarkers for Cancer Nanotechnology. , 2006, 2006, 3317-20.		5
1601	Long-term Survivorship in Lung Cancer. Chest, 2006, 129, 1088-1097.	0.4	148
1602	Primary Malignant Tumors of the Heart: Four Cardiovascular Hormones Decrease the Number and DNA Synthesis of Human Angiosarcoma Cells. Cardiology, 2006, 105, 226-233.	0.6	14
1603	Duration but not Intensity of Alcohol and Tobacco Exposure Predicts p16INK4A Homozygous Deletion in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2006, 66, 4512-4515.	0.4	19
1604	Galectin-3 Regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer. Cancer Research, 2006, 66, 3114-3119.	0.4	114
1605	Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult. Cancer Research, 2006, 66, 11998-12008.	0.4	21
1606	Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer. Clinical Cancer Research, 2006, 12, 29-33.	3.2	89
1607	Progression of Airway Dysplasia and C-Reactive Protein in Smokers at High Risk of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 535-539.	2.5	38
1608	Recurrent Ovarian Cancer: Spectrum of Imaging Findings. American Journal of Roentgenology, 2006, 187, 99-104.	1.0	13
1609	A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma. Nephrology Dialysis Transplantation, 2006, 21, 3585-3588.	0.4	12
1610	Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opinion on Investigational Drugs, 2006, 15, 317-326.	1.9	29
1611	Laparoscopic-assisted colectomy for colon cancer. Expert Review of Medical Devices, 2006, 3, 415-419.	1.4	2
1612	High-Performance Wavelet Compression for Mammography: Localization Response Operating Characteristic Evaluation. Radiology, 2006, 238, 62-73.	3.6	12

#	Article	IF	CITATIONS
1613	Proepithelin Promotes Migration and Invasion of 5637 Bladder Cancer Cells through the Activation of ERK1/2 and the Formation of a Paxillin/FAK/ERK Complex. Cancer Research, 2006, 66, 7103-7110.	0.4	136
1614	Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk. Carcinogenesis, 2006, 27, 2448-2454.	1.3	28
1615	Esophageal Cancer: Evaluation with Triple-Phase Dynamic CT—Initial Experience. Radiology, 2006, 239, 777-783.	3.6	65
1616	Retained Seminal Vesicles After Radical Prostatectomy: Frequency, MRI Characteristics, and Clinical Relevance. American Journal of Roentgenology, 2006, 186, 539-546.	1.0	54
1617	Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin- Neu oncogenic transgene. Carcinogenesis, 2006, 27, 1054-1067.	1.3	50
1618	Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β-catenin levels and outcome in patients with epithelial ovarian cancer. Annals of Oncology, 2006, 17, 1797-1802.	0.6	10
1619	Classification of Breast Lesions with Multimodality Computer-aided Diagnosis: Observer Study Results on an Independent Clinical Data Set. Radiology, 2006, 240, 357-368.	3.6	98
1620	Capecitabine for the Oral Treatment of Metastatic Breast Cancer. Women's Health, 2006, 2, 805-817.	0.7	0
1621	Dermoscopy Improves Accuracy of Primary Care Physicians to Triage Lesions Suggestive of Skin Cancer. Journal of Clinical Oncology, 2006, 24, 1877-1882.	0.8	227
1623	A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Annals of Oncology, 2006, 17, 226-231.	0.6	22
1624	Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?. Prostate Cancer and Prostatic Diseases, 2006, 9, 14-18.	2.0	26
1625	Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. Molecular Cancer Research, 2006, 4, 1-8.	1.5	85
1626	Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1179-1183.	1.1	11
1627	Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 2006, 28, 713-723.	1.3	123
1628	Quantitative Analysis and Effect of Attenuation Correction on Lymph Node Staging of Non-Small Cell Lung Cancer on SPECT and CT. American Journal of Roentgenology, 2006, 186, 1450-1457.	1.0	16
1629	Quantitative expression profile of PSCR in prostate cancer. Prostate Cancer and Prostatic Diseases, 2006, 9, 56-61.	2.0	51
1630	Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Molecular Cancer Therapeutics, 2006, 5, 1754-1763.	1.9	14
1631	Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncológica, 2006, 45, 717-727.	0.8	27

#	Article	IF	CITATIONS
1632	Decreased expression of the human stem cell marker, Rex-1 (zfp-42) , in renal cell carcinoma. Carcinogenesis, 2006, 27, 499-507.	1.3	26
1633	The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer and Prostatic Diseases, 2006, 9, 147-152.	2.0	148
1634	Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 2738-2744.	3.2	42
1635	A Phase II Trial of Vinorelbine in Patients with Advanced Gastroesophageal Adenocarcinoma. Cancer Investigation, 2006, 24, 346-350.	0.6	14
1636	Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis, 2006, 27, 1902-1908.	1.3	57
1637	A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (SU5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma. Japanese Journal of Clinical Oncology, 2006, 36, 100-103.	0.6	32
1638	Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo. Cancer Research, 2006, 66, 7983-7990.	0.4	132
1639	Interactions of Sequence Variants in Interleukin-1 Receptor–Associated Kinase4 and the Toll-Like Receptor 6-1-10 Gene Cluster Increase Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 480-485.	1.1	57
1640	Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 373-380.	1.1	17
1641	Complement Activated by Chimeric Anti–Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. Cancer Research, 2006, 66, 3876-3883.	0.4	36
1642	Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncology, 2006, 2, 705-716.	1.1	17
1643	Human PIRH2 Enhances Androgen Receptor Signaling through Inhibition of Histone Deacetylase 1 and Is Overexpressed in Prostate Cancer. Molecular and Cellular Biology, 2006, 26, 6502-6510.	1.1	83
1644	Identification of Novel Target Genes by an Epigenetic Reactivation Screen of Renal Cancer. Cancer Research, 2006, 66, 5021-5028.	0.4	141
1645	Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Molecular Cancer Therapeutics, 2006, 5, 2503-2511.	1.9	17
1646	Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Molecular Cancer Therapeutics, 2006, 5, 2484-2493.	1.9	55
1647	Mouse Models of Lung Cancer. Clinical Cancer Research, 2006, 12, 4396s-4402s.	3.2	41
1648	Physiological and Functional Interactions between Tcf4 and Daxx in Colon Cancer Cells. Journal of Biological Chemistry, 2006, 281, 15405-15411.	1.6	34
1649	The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes and Development, 2006, 20, 3049-3053.	2.7	26

#	Article	IF	CITATIONS
1650	Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1188-1199.	1.3	86
1651	Ventricular Tachycardia Indicating Cardiac Involvement in Metastatic Leiomyosarcoma. Journal of Clinical Oncology, 2006, 24, 3502-3504.	0.8	4
1652	Expanding the Therapeutic Index of Radiation Therapy by CombiningIn SituGene Therapy in the Treatment of Prostate Cancer. Technology in Cancer Research and Treatment, 2006, 5, 23-36.	0.8	9
1653	A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer. Clinical Cancer Research, 2006, 12, 4545-4552.	3.2	76
1654	A Cascade of Modules of a Network Defines Cancer Progression. Cancer Research, 2006, 66, 7379-7385.	0.4	27
1655	The clinical value of autofluorescence bronchoscopy for the diagnosis of lung cancer. European Respiratory Journal, 2006, 28, 915-919.	3.1	55
1656	Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment. Journal of Clinical Oncology, 2006, 24, 3081-3088.	0.8	52
1657	Impact of a Scientific Presentation on Community Treatment Patterns for Primary Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 382-388.	3.0	39
1658	The Effect of Medicare Health Care Delivery Systems on Survival for Patients with Breast and Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 769-773.	1.1	20
1659	Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Molecular Cancer Therapeutics, 2006, 5, 483-493.	1.9	294
1660	Interplay between Two Hormone-Independent Activation Domains in the Androgen Receptor. Cancer Research, 2006, 66, 543-553.	0.4	94
1661	Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates. Cancer Research, 2006, 66, 2328-2337.	0.4	143
1662	Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Annals of Oncology, 2006, 17, 473-483.	0.6	259
1663	Fertility Preservation in Young Women Undergoing Breast Cancer Therapy. Oncologist, 2006, 11, 422-434.	1.9	221
1664	Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-l±2b in metastatic melanoma. Annals of Oncology, 2006, 17, 571-577.	0.6	101
1665	A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Annals of Oncology, 2006, 17, 1399-1403.	0.6	120
1666	A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American merican men with a positive family history. Journal of Medical Genetics, 2006, 43, 507-511.	1.5	65
1667	A Role for the WWOX Gene in Prostate Cancer. Cancer Research, 2006, 66, 6477-6481.	0.4	92

#	Article	IF	CITATIONS
1668	Prostate Cancer: Local Staging at 3-T Endorectal MR Imaging—Early Experience. Radiology, 2006, 238, 184-191.	3.6	159
1669	Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2006, 24, 2337-2342.	0.8	141
1670	Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells. Molecular Cancer Therapeutics, 2006, 5, 1676-1682.	1.9	91
1671	Detection of Colon Wall Outer Boundary and Segmentation of the Colon Wall Based on Level Set Methods. , 2006, 2006, 3017-20.		11
1672	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. Clinical Cancer Research, 2006, 12, 4232-4236.	3.2	38
1673	Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients. Journal of the National Cancer Institute, 2006, 98, 172-180.	3.0	363
1674	Physical and Functional Interactions between Cas and c-Src Induce Tamoxifen Resistance of Breast Cancer Cells through Pathways Involving Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 5b. Cancer Research, 2006, 66, 7007-7015.	0.4	90
1675	Little patients, losing patience: pediatric cancer drug development. Molecular Cancer Therapeutics, 2006, 5, 1905-1908.	1.9	46
1676	Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas. Clinical Cancer Research, 2006, 12, 4163-4170.	3.2	64
1677	Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut, 2006, 55, 68-73.	6.1	62
1678	Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 2006, 24, 4738-4745.	0.8	587
1679	Higher Methylation Levels in Gastric Mucosae Significantly Correlate with Higher Risk of Gastric Cancers. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2317-2321.	1.1	159
1680	A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19472-19477.	3.3	99
1681	Human Papillomavirus Type 16 Integration in Cervical Carcinoma In Situ and in Invasive Cervical Cancer. Journal of Clinical Microbiology, 2006, 44, 1755-1762.	1.8	198
1682	Low-coherence enhanced backscattering: review of principles and applications for colon cancer screening. Journal of Biomedical Optics, 2006, 11, 041125.	1.4	35
1683	Common and Uncommon Histologic Subtypes of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation. Radiographics, 2006, 26, 1795-1806.	1.4	278
1684	The kallikrein world: an update on the human tissue kallikreins. Biological Chemistry, 2006, 387, 643-52.	1.2	60
1685	Diagnostic Accuracy of Colorectal Cancer Staging With Whole-Body PET/CT Colonography. JAMA - Journal of the American Medical Association, 2006, 296, 2590.	3.8	101

#	Article	IF	CITATIONS
1686	Tumor Epithelial Cell Matrix Metalloproteinase 9 Is a Target for Antimetastatic Therapy in Colorectal Cancer. Clinical Cancer Research, 2006, 12, 1876-1882.	3.2	60
1687	Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145. Carcinogenesis, 2006, 27, 1454-1464.	1.3	107
1688	Altered Expression and Localization of Creatine Kinase B, Heterogeneous Nuclear Ribonucleoprotein F, and High Mobility Group Box 1 Protein in the Nuclear Matrix Associated with Colon Cancer. Cancer Research, 2006, 66, 763-769.	0.4	79
1689	Epigenetic Events of Disease Progression in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2006, 132, 668.	1.5	81
1690	Cancer Anorexia and Cachexia. , 2006, , 645-659.		0
1691	Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2006, 24, 3831-3837.	0.8	292
1692	Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma. Cancer Research, 2006, 66, 7216-7224.	0.4	109
1693	Colon Cancer Metastatic to the Lung and the Thyroid Gland. Archives of Surgery, 2006, 141, 93.	2.3	29
1694	Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2006, 24, 36-44.	0.8	839
1696	The Concept of Suffering in Children and Adolescents With Cancer. Journal of Pediatric Oncology Nursing, 2006, 23, 92-102.	1.5	28
1697	Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action. Carcinogenesis, 2006, 27, 693-707.	1.3	14
1698	A Multicenter Randomized Controlled Trial to Evaluate the Effect of Adjuvant Cisplatin and 5-Fluorouracil Therapy after Curative Resection in Cases of Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 159-165.	0.6	109
1699	Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics. Expert Review of Anticancer Therapy, 2006, 6, 775-784.	1.1	16
1700	New Approaches to the Adjuvant Therapy of Colon Cancer. Oncologist, 2006, 11, 973-980.	1.9	43
1701	Prostate Cancer Screening Decision Making Under Controversy: Implications for Health Promotion Practice, 2006, 7, 134-146.	0.9	18
1702	Patterns of Care in Early-Stage Breast Cancer Survivors in the First Year After Cessation of Active Treatment. Journal of Clinical Oncology, 2006, 24, 77-84.	0.8	63
1703	Sentinel Lymph Node Sampling and Analysis in Colon Cancer: What Is the Question?. Journal of Clinical Oncology, 2006, 24, 3712-3713.	0.8	10
1706	Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncology, 2006, 2, 655-665.	1.1	20

#	Article	IF	CITATIONS
1707	Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKCÎ <sup>1</sup> as a Biomarker and Potential Oncogene in Ovarian Carcinoma. Cancer Research, 2006, 66, 4627-4635.	0.4	118
1708	Associations of Ki-ras Proto-oncogene Mutation and p53 Gene Overexpression in Sporadic Colorectal Adenomas with Demographic and Clinicopathologic Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1443-1450.	1.1	46
1709	Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. Clinical Cancer Research, 2006, 12, 1897-1905.	3.2	85
1710	Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Molecular Cancer Therapeutics, 2006, 5, 787-796.	1.9	83
1711	Effect of area poverty rate on cancer screening across US communities. Journal of Epidemiology and Community Health, 2006, 60, 202-207.	2.0	95
1712	Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes and Development, 2006, 20, 1331-1342.	2.7	181
1713	17β-Estradiol, Genistein, and 4-Hydroxytamoxifen Induce the Proliferation of Thyroid Cancer Cells through the G Protein-Coupled Receptor GPR30. Molecular Pharmacology, 2006, 70, 1414-1423.	1.0	269
1714	Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of Oncology, 2006, 17, 1096-1102.	0.6	84
1715	Long-term Survival of a Patient With Widespread Metastases From Epithelial Ovarian Carcinoma Receiving Mind-Body Therapies: Case Report and Review of the Literature. Integrative Cancer Therapies, 2006, 5, 395-399.	0.8	5
1716	Expanded Treatment Options in the Adjuvant Therapy of Colon Cancer: Implications for Oncology Nurses. Oncology Nursing Forum, 2006, 33, 81-90.	0.5	2
1717	Prognostic Markers of Local Relapse in Rectal Cancer: Are We Any Further Forward?. Journal of Clinical Oncology, 2006, 24, 4049-4050.	0.8	23
1718	Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut, 2006, 55, 519-528.	6.1	123
1719	FV peptide induces apoptosis in HEp 2 and HeLa cells: an insight into the mechanism of induction. Journal of Carcinogenesis, 2006, 5, 27.	2.5	15
1720	Treatment of prostate cancer. Annals of Oncology, 2006, 17, x207-x210.	0.6	1
1721	Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis. Carcinogenesis, 2006, 27, 1627-1635.	1.3	108
1722	Design of a Rotating Facility for Extracorporal Treatment of an Explanted Liver with Disseminated Metastases by Boron Neutron Capture Therapy with an Epithermal Neutron Beam. Radiation Research, 2006, 166, 81-88.	0.7	17
1723	Use of Rasâ€Transformed Human Ovarian Surface Epithelial Cells as a Model for Studying Ovarian Cancer. Methods in Enzymology, 2006, 407, 660-676.	0.4	15
1724	Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Molecular Cancer Therapeutics, 2006, 5, 296-308.	1.9	309

ARTICLE IF CITATIONS PET and PET/CT in Kidney Cancer. Medical Radiology, 2006, , 89-101. 1725 0.0 1 Lifestyle and Clinical Health Behaviors and PSA Tests. American Journal of Health Education, 2006, 37, 0.3 289-295. Second Prize: Elastographic Measurements of in-Vivo Radiofrequency Ablation Lesions of the Kidney. 1727 1.1 31 Journal of Endourology, 2006, 20, 959-964. Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung 54 Cancer. Cancer Investigation, 2006, 24, 492-496. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Current 1729 1.1 79 Opinion in Oncology, 2006, 18, 173-179. Automatic Correction of Level Set Based Subvoxel Accurate Centerlines for Virtual Colonoscopy., 0,, Novel lung IMRT planning algorithms with nonuniform dose delivery strategy to account for 1731 1.6 12 respiratory motion. Medical Physics, 2006, 33, 3390-3398. Influence of Genistein Isoflavone on Matrix Metalloproteinase-2 Expression in Prostate Cancer Cells. 0.8 36 Journal of Medicinal Food, 2006, 9, 491-497. Laparoscopic Resection of Colon Cancer and Synchronous Liver Metastasis. Journal of 1733 0.5 23 Laparoendoscopic and Advanced Surgical Techniques - Part A, 2006, 16, 51-53. 1734 Design of a Robot for Transperineal Prostate Needle Placement in MRI Scanner., 2006, , . PS-341 (Bortezomib) Induces Lysosomal Cathepsin B Release and a Caspase-2-dependent Mitochondrial Permeabilization and Apoptosis in Human Pancreatic Cancer Cells. Journal of Biological Chemistry, 1735 70 1.6 2006, 281, 11923-11932. Detection of Wilms' Tumor Antigenâ€"Specific CTL in Tumor-Draining Lymph Nodes of Patients with 3.2 36 Early Breast Cancer. Clinical Cancer Research, 2006, 12, 34-42. Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer. Clinical Cancer 1737 3.2 176 Research, 2006, 12, 7347-7352. Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer. Molecular 1.5 34 Cancer Research, 2006, 4, 971-981. Case 37-2006. New England Journal of Medicine, 2006, 355, 2349-2357. 1739 13.9 14 Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and 1740 58 Clinical Implications. Clinical Cancer Research, 2006, 12, 5040-5046. Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal 1741 0.8 236 Cancer: Radiation Therapy Oncology Group Trial 0012. Journal of Clinical Oncology, 2006, 24, 650-655. Management of prostate cancer. Part 2: localized and locally advanced disease. Expert Review of 1742 1.1 Anticancer Therapy, 2006, 6, 595-603.

#	Article	IF	CITATIONS
1743	Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. British Journal of Cancer, 2006, 94, 1402-1406.	2.9	26
1744	Noncardia Gastric Adenocarcinoma Remains an Important and Deadly Cancer in the United States: Secular Trends in Incidence and Survival. American Journal of Gastroenterology, 2006, 101, 2485-2492.	0.2	63
1745	Extracolonic Cancers Associated with Hereditary Nonpolyposis Colorectal Cancer in the Utah Population Database. American Journal of Gastroenterology, 2006, 101, 1591-1596.	0.2	29
1746	Can ovarian function be protected in young women receiving chemotherapy?. Nature Clinical Practice Oncology, 2006, 3, 532-533.	4.3	1
1747	Bystander Effect Contributes to the Antitumor Efficacy of CaSm Antisense Gene Therapy in a Preclinical Model of Advanced Pancreatic Cancer. Molecular Therapy, 2006, 13, 357-365.	3.7	13
1748	Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. British Journal of Cancer, 2006, 95, 1648-1652.	2.9	18
1749	The relationship between cigarette smoking and perceived dental treatment needs in the United States, 1988–1994. Journal of the American Dental Association, 2006, 137, 224-234.	0.7	26
1750	Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Molecular Cancer Therapeutics, 2006, 5, 2043-2050.	1.9	45
1751	Enhancement of UVB radiation–mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes. Molecular Cancer Therapeutics, 2006, 5, 418-429.	1.9	61
1752	Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Resistant Bladder Tumor Cells. Cancer Research, 2006, 66, 499-507.	0.4	80
1753	Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB Journal, 2006, 20, 1982-1991.	0.2	88
1754	Sulindac independently modulates extracellular signal–regulated kinase 1/2 and cyclic GMP–dependent protein kinase signaling pathways. Molecular Cancer Therapeutics, 2006, 5, 746-754.	1.9	19
1755	Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver. Human Gene Therapy, 2006, 17, 1214-1224.	1.4	163
1756	Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients. Journal of Clinical Oncology, 2006, 24, 1178-1187.	0.8	257
1757	Elastography: New Developments in Ultrasound for Predicting Malignancy in Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2917-2922.	1.8	510
1758	Genetics and pharmacogenetics of estrogen response. Expert Review of Endocrinology and Metabolism, 2007, 2, 503-516.	1.2	3
1759	Colon and Rectal Cancer: Laparoscopic or Open?. Clinical Cancer Research, 2007, 13, 6894s-6896s.	3.2	28
1760	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Molecular Cancer Therapeutics, 2007, 6, 1718-1727.	1.9	154

#	Article	IF	CITATIONS
1761	Papillary Thyroid Cancer and Polymorphic Variants in TSHR- and RET-Related Genes: a Nested Case-Control Study within a Cohort of U.S. Radiologic Technologists. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 174-177.	1.1	28
1762	Degradation of Lung Adenoma Susceptibility 1, a Major Candidate Mouse Lung Tumor Modifier, Is Required for Cell Cycle Progression. Cancer Research, 2007, 67, 10207-10213.	0.4	3
1763	Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 2696-2701.	0.8	174
1764	The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7570-7575.	3.3	126
1765	Experimental Immunotherapy of Colorectal Carcinoma by Monoclonal Antibody ND4. Hybridoma, 2007, 26, 10-16.	0.5	0
1766	NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Review of Proteomics, 2007, 4, 389-400.	1.3	55
1767	Death from Renal Failure Eighty Years On: How Far Have We Come?. Journal of Palliative Medicine, 2007, 10, 1236-1238.	0.6	9
1768	Preoperative Evaluation of Thyroid Pathology in Patients with Primary Hyperparathyroidism. Thyroid, 2007, 17, 59-62.	2.4	35
1769	Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca2+accumulation in colonocytes. American Journal of Physiology - Renal Physiology, 2007, 293, G935-G943.	1.6	47
1770	Identification of Tumor Antigens in Human Lung Squamous Carcinoma by Serological Proteome Analysis. Journal of Proteome Research, 2007, 6, 751-758.	1.8	79
1771	Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Annals of Oncology, 2007, 18, 1828-1833.	0.6	59
1772	Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncológica, 2007, 46, 1012-1018.	0.8	57
1773	Rrp1b, a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis. PLoS Genetics, 2007, 3, e214.	1.5	80
1774	Chemopreventive effects of lupulone, a hop β-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis, 2007, 28, 1575-1581.	1.3	56
1775	Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Annals of Oncology, 2007, 18, 1995-1999.	0.6	60
1776	Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results. Radiology, 2007, 242, 698-715.	3.6	324
1777	Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population. Gut, 2007, 56, 1079-1085.	6.1	61
1778	Low-gradient aortic stenosis: impact of prosthesis-patient mismatch on survival. European Heart Journal, 2007, 28, 2620-2626.	1.0	59

#	Article	IF	CITATIONS
1779	Ethnic differences in cancer incidence and mortality: the Birmingham Factory Screening Project. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 423-431.	0.2	6
1780	CXCL12 G801A Polymorphism Is a Risk Factor for Sporadic Prostate Cancer Susceptibility. Clinical Cancer Research, 2007, 13, 5056-5062.	3.2	83
1781	Adjuvant Treatment of Colon Cancer: Past, Present and Future. Journal of Chemotherapy, 2007, 19, 115-122.	0.7	25
1782	Irinotecan plus Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer: A Phase II Study. Oncology, 2007, 72, 279-284.	0.9	6
1783	Phase II Study of a 3-Week Schedule of Irinotecan Combined with Cisplatin in Previously Untreated Extensive-Stage Small-Cell Lung Cancer. Oncology, 2007, 73, 76-80.	0.9	6
1784	Retinoid Receptor Alpha and Beta Expression in Serous Ovarian Tumors. Oncology, 2007, 73, 81-89.	0.9	1
1785	Feature Extraction by Foley-Sammon Transform with Kernels. , 2007, , .		1
1786	Red American Ginseng: Ginsenoside Constituents and Antiproliferative Activities of Heat-Processed <i>Panax quinquefolius</i> Roots. Planta Medica, 2007, 73, 669-674.	0.7	167
1787	Mammographic Breast Density and Race. American Journal of Roentgenology, 2007, 188, 1147-1150.	1.0	141
1788	Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth. Molecular Endocrinology, 2007, 21, 343-358.	3.7	76
1789	FDC-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. British Journal of Radiology, 2007, 80, 508-515.	1.0	54
1790	Diagnostic Value of the Thin-Layer, Liquid-Based Pap Test in Endometrial Cancer. Acta Cytologica, 2007, 51, 735-741.	0.7	15
1791	Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomarkers in Medicine, 2007, 1, 187-202.	0.6	10
1792	Dynamic MRI of Solitary Pulmonary Nodules: Comparison of Enhancement Patterns of Malignant and Benign Small Peripheral Lung Lesions. American Journal of Roentgenology, 2007, 188, 26-36.	1.0	117
1793	Population and patient-specific target margins for 4D adaptive radiotherapy to account for intra- and inter-fraction variation in lung tumour position. Physics in Medicine and Biology, 2007, 52, 257-274.	1.6	90
1794	Impact of Clinician Gender on Examination Anxiety among Female Veterans with Sexual Trauma: A Pilot Study. Journal of Women's Health, 2007, 16, 1291-1299.	1.5	22
1795	Dielectric properties of human normal, malignant and cirrhotic liver tissue: <i>in vivo</i> and <i>ex vivo</i> measurements from 0.5 to 20 GHz using a precision open-ended coaxial probe. Physics in Medicine and Biology, 2007, 52, 4707-4719.	1.6	254
1796	Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1113-1118.	1.3	44

#	Article	IF	CITATIONS
1797	Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Annals of Oncology, 2007, 18, 1064-1070.	0.6	49
1798	Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification. Cancer Research, 2007, 67, 4425-4433.	0.4	51
1799	Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. European Respiratory Journal, 2007, 29, 757-760.	3.1	71
1800	Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Molecular Cancer Therapeutics, 2007, 6, 2188-2197.	1.9	47
1801	Change in Body Size and the Risk of Colorectal Adenomas. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 526-531.	1.1	77
1802	Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. European Respiratory Journal, 2007, 30, 598-599.	3.1	2
1803	Prevention of Gastric Cancer: A Miss. Journal of the National Cancer Institute, 2007, 99, 101-103.	3.0	29
1804	Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival. Cancer Research, 2007, 67, 2800-2808.	0.4	225
1805	Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines. Molecular and Cellular Proteomics, 2007, 6, 1997-2011.	2.5	179
1806	Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Molecular Cancer Therapeutics, 2007, 6, 967-978.	1.9	86
1807	Automatic Correction of Level Set Based Subvoxel Precise Centerlines for Virtual Colonoscopy Using the Colon Outer Wall. IEEE Transactions on Medical Imaging, 2007, 26, 1069-1078.	5.4	39
1808	Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncology, 2007, 3, 381-392.	1.1	27
1809	Optimized autofluorescence bronchoscopy using additional backscattered red light. Journal of Biomedical Optics, 2007, 12, 064016.	1.4	18
1810	Small-Bowel Tumors. Archives of Surgery, 2007, 142, 229.	2.3	194
1811	Sperm-Associated Antigen 9, a Novel Cancer Testis Antigen, Is a Potential Target for Immunotherapy in Epithelial Ovarian Cancer. Clinical Cancer Research, 2007, 13, 1421-1428.	3.2	66
1812	Integrative Genomic Analysis of Phosphatidylinositol 3′-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer. Clinical Cancer Research, 2007, 13, 5314-5321.	3.2	111
1813	Systematic Urokinase-Activated Anthrax Toxin Therapy Produces Regressions of Subcutaneous Human Non–Small Cell Lung Tumor in Athymic Nude Mice. Cancer Research, 2007, 67, 3329-3336.	0.4	31
1814	Psychological Disorders Among Children and the Parents of Children Undergoing Cancer Workup. Journal of Psychosocial Oncology, 2007, 25, 1-18.	0.6	24

#	Article	IF	CITATIONS
1815	Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis. , 2007, , 335-352.		0
1816	Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer. Cancer Research, 2007, 67, 930-939.	0.4	76
1817	Ultrasound-Enhanced Chemotherapy and Gene Delivery for Glioma Cells. Technology in Cancer Research and Treatment, 2007, 6, 433-442.	0.8	12
1818	Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10. Journal of Clinical Oncology, 2007, 25, 1553-1561.	0.8	216
1819	Prostate Cancer Screening with Prostate-Specific Antigen in Hemodialysis Patients. Urologia Internationalis, 2007, 78, 334-337.	0.6	8
1820	Lymphadenectomy in Bladder Cancer: A Review. Urologia Internationalis, 2007, 79, 191-199.	0.6	47
1821	CT Colonography (Virtual Colonoscopy): Technique, Indications and Performance. Digestion, 2007, 76, 34-41.	1.2	27
1822	A Review of the Use of Stents for Palliation of Esophageal and Lung Cancer. Current Cancer Therapy Reviews, 2007, 3, 45-60.	0.2	0
1823	Angiotensin-(1-7) Inhibits Growth of Human Lung Adenocarcinoma Xenografts in Nude Mice through a Reduction in Cyclooxygenase-2. Cancer Research, 2007, 67, 2809-2815.	0.4	123
1824	Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals of Oncology, 2007, 18, 709-715.	0.6	21
1825	Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology, 2007, 18, 2009-2014.	0.6	285
1826	Ovarian Volume Measurements in Mice With High-Resolution Ultrasonography. Journal of Ultrasound in Medicine, 2007, 26, 1419-1425.	0.8	6
1827	Gender Differences: Implications for Clinical Trials and Practice. Journal of Thoracic Oncology, 2007, 2, S15-S18.	0.5	18
1828	Biological Roles of Estrogen and Progesterone in Human Endometrial Carcinoma - New developments in potential endocrine therapy for endometrial cancer Endocrine Journal, 2007, 54, 667-679.	0.7	108
1830	What's next in translational medicine?. Clinical Science, 2007, 112, 217-227.	1.8	112
1831	Why older adults make more immediate treatment decisions about cancer than younger adults Psychology and Aging, 2007, 22, 505-524.	1.4	49
1832	Orthotopic Model of Human Pancreatic Ductal Adenocarcinoma and Cancer Cachexia in Nude Mice. Current Protocols in Pharmacology, 2007, 37, Unit 14.3.	4.0	8
1833	Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2007, 146, 376.	2.0	284

#	ARTICLE Orthotopic Models of Human Gastric Carcinoma in Nude Mice: Applications for Study of Tumor	IF	CITATIONS
1834 1835	Growth and Progression. Current Protocols in Pharmacology, 2007, 37, Unit 14.4. SEM Analysis of Oral Lichen Planus before and after Treatment with 13 Cis-Retinoic Acid. International Journal of Immunopathology and Pharmacology, 2007, 20, 75-79.	4.0	7
1836	Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer?. Journal of Thoracic Oncology, 2007, 2, 273-281.	0.5	51
1837	Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 39-43.	0.5	43
1838	Kinetic model of progression of cutaneous melanoma population. Melanoma Research, 2007, 17, 354-359.	0.6	3
1839	Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. European Journal of Cancer Prevention, 2007, 16, 184-191.	0.6	87
1840	Prostate-derived Ets Factor Is Overexpressed in Serous Epithelial Ovarian Tumors. International Journal of Gynecological Pathology, 2007, 26, 10-15.	0.9	22
1841	Challenges of Research on Women Veterans with Traumatic Stress Disorders. Journal of Empirical Research on Human Research Ethics, 2007, 2, 54-57.	0.6	1
1842	Inhibition of five xenografted human cancers and two murine cancers by the tripeptide tyroservatide. Anti-Cancer Drugs, 2007, 18, 467-470.	0.7	3
1843	Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy, 2007, 30, 655-662.	1.2	49
1844	National Survey of Perspectives of Palliative Radiation Therapy: Role, Barriers, and Needs. Cancer Journal (Sudbury, Mass ), 2007, 13, 130-137.	1.0	59
1845	PC cell-derived growth factor overexpression promotes proliferation and survival of laryngeal carcinoma. Anti-Cancer Drugs, 2007, 18, 29-40.	0.7	13
1846	Treatment of Cancer Metastatic to the Diaphysis of Long Bones. Techniques in Orthopaedics, 2007, 22, 127-133.	0.1	0
1847	Low-coherence enhanced backscattering of light: characteristics and applications for colon cancer screening. , 2007, , .		0
1848	Treatment for Microcarcinoma of the Thyroid—Clinical Experience. Clinical Nuclear Medicine, 2007, 32, 279-281.	0.7	60
1849	Research on Detecting Method of Submarine Oil Pipelines Corrosion Degree Based on Chaos Genetic Algorithm Neural Network. , 2007, , .		1
1850	Update on multi-center clinical trials in the United States. Transfusion and Apheresis Science, 2007, 36, 5-12.	0.5	1
1851	Strong association of interleukin-4 (â^'590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2007, 104, 796-802.	1.6	22

#	Article	IF	CITATIONS
1852	Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer. Urology, 2007, 69, 347-351.	0.5	14
1853	Active surveillance for favorable risk prostate cancer: Rationale, risks, and results. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 505-509.	0.8	29
1854	Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell, 2007, 1, 313-323.	5.2	2,534
1855	The Role of FDC-PET/CT Imaging in Head and Neck Malignant Conditions: Impact on Diagnostic Accuracy and Patient Care. Otolaryngology - Head and Neck Surgery, 2007, 137, 130-137.	1.1	71
1856	Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer. American Journal of Surgery, 2007, 193, 614-617.	0.9	15
1857	Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Annals of Diagnostic Pathology, 2007, 11, 89-96.	0.6	114
1858	Polymorphisms of DNA repair genes are risk factors for prostate cancer. European Journal of Cancer, 2007, 43, 231-237.	1.3	64
1859	Recurrent endometrial cancer: A retrospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 130, 114-120.	0.5	5
1860	Proline prodrug of melphalan, prophalan-l, demonstrates high therapeutic index in a murine melanoma model. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 752-758.	2.0	9
1861	Contrast-enhanced ultrasonography depicts small tumor vessels for the evaluation of pancreatic tumors. European Journal of Radiology, 2007, 61, 163-169.	1.2	16
1862	Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. Biochemical and Biophysical Research Communications, 2007, 353, 829-834.	1.0	91
1863	GSTT1 and GSTM1 allelic polymorphisms in head and neck cancer patients from Italian Lazio Region. Clinica Chimica Acta, 2007, 376, 174-178.	0.5	14
1864	Signal characteristic and enhancement patterns of pancreatic adenocarcinoma: evaluation with dynamic gadolinium enhanced MRI. Clinical Radiology, 2007, 62, 876-883.	0.5	17
1865	3D MR spectroscopic imaging in the evaluation of prostate cancer. Clinical Radiology, 2007, 62, 921-929.	0.5	23
1866	Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: Increased expression of AKT in advanced ovarian cancer. Cancer Letters, 2007, 246, 190-200.	3.2	49
1867	Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Letters, 2007, 250, 329-338.	3.2	21
1868	Human tissue kallikreins: The cancer biomarker family. Cancer Letters, 2007, 249, 61-79.	3.2	157
1869	FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Letters, 2007, 254, 288-297.	3.2	47

ARTICLE IF CITATIONS Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in 1870 3.2 18 LNCaP prostate cancer cells. Cancer Letters, 2007, 255, 127-134. Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer and Prostatic 1871 Diseases, 2007, 10, 224-236. Sun protection and Vitamin D: Three dimensions of obfuscation. Journal of Steroid Biochemistry and 1872 1.2 59 Molecular Biology, 2007, 103, 655-663. Enhanced Cytotoxicity of RIPTK Gene Therapy of Pancreatic Cancer via PDX-1 Co-Delivery. Journal of 0.8 Surgical Research, 2007, 137, 1-9. Effective Ablation of Pancreatic Cancer Cells in SCID Mice Using Systemic Adenoviral RIP-TK/GCV Gene 1874 0.8 11 Therapy. Journal of Surgical Research, 2007, 141, 45-52. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-Î<sup>o</sup>B in human prostate cell lines. Molecular and Cellular Endocrinology, 2007, 270, 8-16. 1.6 Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head 1876 0.7 27 and neck cancer. International Journal of Oral and Maxillofacial Surgery, 2007, 36, 632-639. β-Catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer. Medical Hypotheses, 2007, 69, 816-820. 1877 0.8 38 The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian 1878 1.1 16 carcinoma. Human Pathology, 2007, 38, 140-146. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence 1879 1.1 and survival. Human Pathology, 2007, 38, 1547-1552. Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the 1880 1.0 25 endometrium. International Journal of Gynecology and Obstetrics, 2007, 98, 39-43. Stromal Fibroblasts in Colorectal Liver Metastases Originate From Resident Fibroblasts and Generate 1881 158 an Inflammatory Microenvironment. American Journal of Pathology, 2007, 171, 1608-1618. Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia. 1882 1.9 183 American Journal of Pathology, 2007, 171, 263-273. Homeostatic Control of the Crypt-Villus Axis by the Bacterial Enterotoxin Receptor Guanylyl Cyclase C Restricts the Proliferating Compartment in Intestine. American Journal of Pathology, 2007, 171, 99 1847-1858. A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Nonâ€"Small Cell Lung Cancer. 1884 3.2 79 Clinical Cancer Research, 2007, 13, 1794-1800. Sarcoma de partes blandas: una patologÃa infrecuente con clÃnica habitual. Semergen, 2007, 33, 383-385. 1885 Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery. Molecular and Cellular 1886 2.5135 Proteomics, 2007, 6, 1115-1122. 1887 Paradigms in chemoradiotherapy. European Journal of Cancer, Supplement, 2007, 5, 277-285. 2.2

# 1888	ARTICLE T-regulatory cells are relatively deficient in squamous carcinomas undergoing regression in mice immunized with a squamous carcinoma vaccine enriched for immunotherapeutic cells. Cancer Gene Therapy, 2007, 14, 573-582.	IF 2.2	CITATIONS 2
1889	Laparoscopic Extraperitoneal Radical Prostatectomy in Complex Surgical Cases. Journal of Urology, 2007, 177, 1765-1770.	0.2	14
1890	Metastasis of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2007, , .	0.1	4
1891	Evaluation of the Antiproliferative Effects of Essiacâ,,¢ on In Vitro and In Vivo Models of Prostate Cancer Compared to Paclitaxel. Nutrition and Cancer, 2007, 58, 188-196.	0.9	8
1892	Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 2007, 25, 1539-1544.	0.8	2,159
1893	Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis. Cancer Research, 2007, 67, 8504-8510.	0.4	251
1894	Symptom Concerns and Resource Utilization in Patients with Lung Cancer. Journal of Palliative Medicine, 2007, 10, 899-903.	0.6	35
1895	Rapid and Simple Determination of Plasma and Erythrocyte MDA Levels in Prostate Cancer Patients by a Validated HPLC Method. Journal of Liquid Chromatography and Related Technologies, 2007, 30, 2435-2444.	0.5	3
1896	Robot-assisted needle placement in open MRI: System architecture, integration and validation. Computer Aided Surgery, 2007, 12, 15-24.	1.8	75
1897	Cancer Prevention and Screening Behaviors in Lesbians. Women and Health, 2007, 44, 15-39.	0.4	22
1898	Invasive Ability of Human Renal Cell Carcinoma Cell Line Caki-2 Is Accelerated by Gamma-Aminobutyric Acid, via Sustained Activation of ERK1/2 Inducible Matrix Metalloproteinases. Cancer Investigation, 2007, 25, 574-583.	0.6	28
1899	Men's perception of fatigue when newly diagnosed with localized prostate cancer. Scandinavian Journal of Urology and Nephrology, 2007, 41, 20-25.	1.4	3
1900	Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology, 2007, 25, 1545-1552.	0.8	852
1901	A Familial Component to Human Rectal Cancer, Independent of Colon Cancer Risk. Clinical Gastroenterology and Hepatology, 2007, 5, 1080-1084.	2.4	10
1902	Sulindac Induces Apoptosis and Inhibits Tumor Growth In Vivo in Head and Neck Squamous Cell Carcinoma. Neoplasia, 2007, 9, 192-199.	2.3	39
1903	Longitudinal Studies of Angiogenesis in Hormone-Dependent Shionogi Tumors. Neoplasia, 2007, 9, 563-568.	2.3	22
1904	Oral Cancer. Mayo Clinic Proceedings, 2007, 82, 878-887.	1.4	294
1905	The Role of Chemotherapy in the Curative Treatment of Patients with Liver Metastases from Colorectal Cancer. Surgical Oncology Clinics of North America, 2007, 16, 537-556.	0.6	11

#	Article	IF	CITATIONS
1906	Use and Awareness of Prostate Specific Antigen Tests and Race/Ethnicity. Journal of Urology, 2007, 177, 1475-1480.	0.2	18
1907	Predicting Bacillus Calmette-Guerin Immunotherapy Effectiveness. Journal of Urology, 2007, 178, 2247-2248.	0.2	Ο
1908	Differential Expression of TRAIL and its Receptors in Benign and Malignant Prostate Tissues. Journal of Urology, 2007, 177, 359-364.	0.2	32
1909	National and Local Trends in CT Colonography Reimbursement: Past, Present, and Future. Journal of the American College of Radiology, 2007, 4, 776-799.	0.9	21
1910	Tumor Microenvironment and the Immune Response. Surgical Oncology Clinics of North America, 2007, 16, 737-753.	0.6	7
1911	Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer, 2007, 55, 205-213.	0.9	222
1912	Sleep and quality of life in long-term lung cancer survivors. Lung Cancer, 2007, 58, 403-410.	0.9	73
1913	The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutrition Journal, 2007, 6, 20.	1.5	29
1914	Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro. Reproductive Biology and Endocrinology, 2007, 5, 38.	1.4	20
1915	The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. Journal of Translational Medicine, 2007, 5, 49.	1.8	71
1916	Elevated Vascular Endothelial Growth Factor Pretreatment Levels Are Correlated with the Tumor Burden in Hodgkin Lymphoma and Continue to Be Elevated in Prolonged Complete Remission. Clinical Lymphoma and Myeloma, 2007, 7, 400-405.	1.4	16
1917	When cecal intubation is a "must― Gastrointestinal Endoscopy, 2007, 65, 854-856.	0.5	0
1918	Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey. Gastrointestinal Endoscopy, 2007, 65, 1015-1022.	0.5	130
1919	Stenting of the proximal colon in patients with malignant large bowel obstruction: techniques and outcomes. Gastrointestinal Endoscopy, 2007, 66, 940-944.	0.5	127
1920	Designer stents: are we there yet?. Gastrointestinal Endoscopy, 2007, 66, 804-808.	0.5	10
1921	Regional differences in EpiPen prescriptions in the United States: The potential role of vitamin D. Journal of Allergy and Clinical Immunology, 2007, 120, 131-136.	1.5	212
1922	Transactivation of the EGFR by AP-1 Is Induced by Helicobacter pylori in Gastric Cancer. American Journal of Gastroenterology, 2007, 102, 2135-2146.	0.2	29
1923	Carcinogenicity of Agricultural Pesticides in Adults and Children. Journal of Agromedicine, 2007, 12, 39-56.	0.9	25

#	Article	IF	Citations
1924	Male Breast Cancer: A Different Disease than Female Breast Cancer?. Southern Medical Journal, 2007, 100, 197.	0.3	7
1925	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. Core Evidence, 2007, Volume 2, 0-0.	4.7	3
1926	Cell Cycle and Related Protein. Disease Markers, 2007, 23, 433-443.	0.6	2
1927	Claudin-7 is Highly Expressed in Chromophobe Renal Cell Carcinoma and Renal Oncocytoma. Journal of Korean Medical Science, 2007, 22, 305.	1.1	34
1928	African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: An epidemiologic review. Cancer Biomarkers, 2007, 3, 301-313.	0.8	131
1929	Indoor tanning: an emerging public-health concern. Expert Review of Dermatology, 2007, 2, 685-688.	0.3	0
1930	Bone health: the effect of androgen deprivation therapy in prostate cancer patients. International Journal of Urological Nursing, 2007, 1, 18-26.	0.1	3
1931	Induction Therapy with Paclitaxel and Carboplatin Followed by Hyperfractionated Radiotherapy plus Weekly Concurrent Chemotherapy and Subsequent Consolidation Therapy in Unresectable Locallyadvanced Non-Small-Cell Lung Cancer. Tumori, 2007, 93, 133-137.	0.6	1
1932	Prognostic factors of retroperitoneal soft tissue sarcomas: analysis of 132 cases. Chinese Medical Journal, 2007, 120, 1047-1050.	0.9	15
1934	Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. International Journal of Cancer, 2007, 120, 160-169.	2.3	29
1935	Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. International Journal of Cancer, 2007, 120, 278-284.	2.3	26
1936	Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. International Journal of Cancer, 2007, 120, 2687-2695.	2.3	27
1937	Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. International Journal of Cancer, 2007, 121, 66-75.	2.3	41
1938	Pesticide use and colorectal cancer risk in the agricultural health study. International Journal of Cancer, 2007, 121, 339-346.	2.3	112
1939	Folate receptor overexpression is associated with poor outcome in breast cancer. International Journal of Cancer, 2007, 121, 938-942.	2.3	224
1940	Serum soluble Fas levels and prediction of response to platinumâ€based chemotherapy in epithelial ovarian cancer. International Journal of Cancer, 2008, 122, 1716-1721.	2.3	11
1941	Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. Journal of Cellular Biochemistry, 2007, 101, 950-968.	1.2	83
1942	Features that determine telomere homolog oligonucleotide-induced therapeutic DNA damage-like responses in cancer cells. Journal of Cellular Physiology, 2007, 210, 582-595.	2.0	25

#	Article	IF	CITATIONS
1943	Salivary glutathione and uric acid levels in patients with head and neck squamous cell carcinoma. Head and Neck, 2007, 29, 648-654.	0.9	56
1944	Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer, 2007, 109, 2142-2153.	2.0	39
1945	Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. Cancer, 2007, 110, 876-884.	2.0	480
1946	Mass spectrometryâ€based "omics―technologies in cancer diagnostics. Mass Spectrometry Reviews, 2007, 26, 403-431.	2.8	98
1947	Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers in Surgery and Medicine, 2007, 39, 386-393.	1.1	180
1948	Study on the effects of laminarin, a polysaccharide from seaweed, on gut characteristics. Journal of the Science of Food and Agriculture, 2007, 87, 1717-1725.	1.7	146
1949	Clear cell sarcoma of soft tissues. Journal of Surgical Oncology, 2007, 95, 519-522.	0.8	58
1950	Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4113-4117.	1.0	66
1951	The Transcription Factor Nuclear Factor-kappa B and Cancer. Clinical Oncology, 2007, 19, 154-161.	0.6	198
1952	Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 995-1001.	0.4	11
1953	Spot Scanning Proton Therapy in the Curative Treatment of Adult Patients With Sarcoma: The Paul Scherrer Institute Experience. International Journal of Radiation Oncology Biology Physics, 2007, 69, 865-871.	0.4	30
1954	The effect of telephone versus print tailoring for mammography adherence. Patient Education and Counseling, 2007, 65, 416-423.	1.0	61
1955	Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 849, 43-52.	1.2	77
1956	A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Statistics in Medicine, 2007, 26, 98-109.	0.8	37
1957	Inhibition of SULT2B1b expression alters effects of 3βâ€hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate, 2007, 67, 1318-1329.	1.2	29
1958	Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene, 2007, 26, 5229-5237.	2.6	87
1959	An Analysis of Surgical Complications, Morbidity, and Cost Calculation in Patients Undergoing Multimodal Treatment for Operable Oropharyngeal Carcinoma. Laryngoscope, 2007, 117, 101-105.	1.1	20
1960	The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Therapy, 2007, 14, 431-439.	2.2	18

#	Article	IF	CITATIONS
1961	Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen. Clinical Pharmacology and Therapeutics, 2007, 82, 734-739.	2.3	28
1962	Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia, 2007, 21, 2519-2526.	3.3	24
1963	Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. British Journal of Cancer, 2007, 97, 543-549.	2.9	84
1964	Effects of Ultraviolet B Exposure on the Expression of Proliferating Cell Nuclear Antigen in Murine Skin <sup>¶</sup> . Photochemistry and Photobiology, 2004, 80, 587-595.	1.3	1
1965	Ultravioletâ€B Radiation Causes an Upregulation of Survivin in Human Keratinocytes and Mouse Skin <sup>¶</sup> . Photochemistry and Photobiology, 2004, 80, 602-608.	1.3	7
1966	Computer-Aided Diagnosis of Prostate Cancer with Emphasis on Ultrasound-Based Approaches: A Review. Ultrasound in Medicine and Biology, 2007, 33, 1010-1028.	0.7	54
1967	Recommendations for the surveillance of young women at increased risk for breast cancer. Journal of Medical Imaging and Radiation Oncology, 2007, 51, 1-11.	0.6	3
1968	Percutaneous radiofrequency ablation of renal tumours: Case series of 11 tumours and review of published work. Journal of Medical Imaging and Radiation Oncology, 2007, 51, 412-419.	0.6	9
1969	The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU International, 2007, 99, 296-300.	1.3	86
1970	Robotic radical prostatectomy: outcomes of 500 cases. BJU International, 2007, 99, 1109-1112.	1.3	250
1971	Laparoscopic partial nephrectomy. BJU International, 2007, 99, 1258-1263.	1.3	20
1972	Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. BJU International, 2007, 100, 770-774.	1.3	15
1973	CURRENT CLINICAL APPLICATIONS OF ENDOSCOPIC ULTRASOUND. ANZ Journal of Surgery, 2007, 77, 101-111.	0.3	7
1974	Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology, 2007, 50, 648-658.	1.6	120
1975	Tollâ€like receptor 2 –196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Science, 2007, 98, 1790-1794.	1.7	124
1976	Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background nonâ€cancerous gastric mucosae. Cancer Science, 2007, 98, 1853-1861.	1.7	60
1977	Upper gastrointestinal bleeding and the changing use of COXâ€2 nonâ€steroidal antiâ€inflammatory drugs and lowâ€dose aspirin. Alimentary Pharmacology and Therapeutics, 2007, 26, 1171-1178.	1.9	34
1978	Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. International Journal of Gynecological Cancer, 2007, 17, 1003-1010.	1.2	41

#	Article	IF	CITATIONS
1979	Improving Survival for Patients with Breast Cancer Compared with Intramural and Extramural Benchmarks. Clinical Breast Cancer, 2007, 7, 480-485.	1.1	3
1980	Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study. BMC Cancer, 2007, 7, 189.	1.1	18
1981	Adjuvant treatment of elderly breast cancer patients. Breast, 2007, 16, 159-165.	0.9	21
1982	Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2007, 173, 23-30.	1.0	6
1983	Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Experimental Hematology, 2007, 35, 75.e1-75.e11.	0.2	36
1984	Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. European Urology, 2007, 51, 366-374.	0.9	27
1985	Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecologic Oncology, 2007, 104, 70-76.	0.6	24
1986	Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—An analysis of 376 women. Gynecologic Oncology, 2007, 104, 396-400.	0.6	155
1987	Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecologic Oncology, 2007, 104, 540-546.	0.6	35
1988	Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecologic Oncology, 2007, 104, 707-713.	0.6	24
1989	Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecologic Oncology, 2007, 105, 17-22.	0.6	153
1990	High levels of serum prostate-specific antigen due to PSA producing follicular non-Hodgkin?s lymphoma. European Journal of Haematology, 2007, 79, 155-158.	1.1	9
1991	Outcome of multimodal treatment for oropharyngeal carcinoma: A single institution experience. Oral Oncology, 2007, 43, 402-407.	0.8	28
1992	An evaluation of evidence for the carcinogenic activity of bisphenol A. Reproductive Toxicology, 2007, 24, 240-252.	1.3	249
1993	Considerations in Treatment Planning for Esophageal Cancer. Seminars in Radiation Oncology, 2007, 17, 53-61.	1.0	26
1994	Health differences between European countries. Social Science and Medicine, 2007, 64, 1665-1678.	1.8	130
1995	Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter study. Surgery, 2007, 141, 67-75.	1.0	246
1996	Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. Toxicology and Applied Pharmacology, 2007, 220, 197-210.	1.3	35

	CITATION RE	PORT	
#	Article	IF	Citations
1997	S414: Update on Management of Oral Cancer. Journal of Oral and Maxillofacial Surgery, 2007, 65, 103.	0.5	0
1998	Mongolia: Establishing a National Palliative Care Program. Journal of Pain and Symptom Management, 2007, 33, 568-572.	0.6	24
1999	Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 104-110.e2.	0.4	177
2000	Cancer Immunomics: From Serological Proteome Analysis to Multiple Affinity Protein Profiling. Annals of the New York Academy of Sciences, 2007, 1107, 223-230.	1.8	43
2001	Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance. Advances in Experimental Medicine and Biology, 2007, 608, 23-30.	0.8	82
2002	Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?. European Radiology, 2007, 17, 873-887.	2.3	112
2003	Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?. European Radiology, 2007, 17, 1498-1509.	2.3	152
2004	Gender Difference as a Prognostic Factor in Patients Undergoing Resection of Non-Small Cell Lung Cancer. Surgery Today, 2007, 37, 546-551.	0.7	24
2005	The Hippo Pathway in Human Upper Gastrointestinal Dysplasia and Carcinoma: A Novel Oncogenic Pathway. International Journal of Gastrointestinal Cancer, 2007, 37, 103-9.	0.4	66
2006	Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome. American Journal of Obstetrics and Gynecology, 2007, 196, 546.e1-546.e7.	0.7	26
2007	Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. American Journal of Obstetrics and Gynecology, 2007, 197, 141.e1-141.e6.	0.7	81
2008	Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagnostic Cytopathology, 2007, 35, 143-147.	0.5	26
2009	ThinPrep Pap tests in patients with endometrial cancer: A histo-cytological correlation. Diagnostic Cytopathology, 2007, 35, 448-453.	0.5	13
2010	The Role of NMR-based Metabolomics in Cancerâ€fâ€fNote: We thank Kate Jordan for editorial assistance. L.L.C. is partially supported by grants: PHS/NIH CA095624 and DOD W81XWH-04–1-0190 , 2007, , 345-374.		9
2011	Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer. Annals of Surgical Oncology, 2007, 14, 885-892.	0.7	29
2012	Histological Features of Melanoma Sentinel Lymph Node Metastases Associated with Status of the Completion Lymphadenectomy and Rate of Subsequent Relapse. Annals of Surgical Oncology, 2007, 14, 906-912.	0.7	95
2013	Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Annals of Surgical Oncology, 2007, 14, 1136-1142.	0.7	82
2014	Update of Carcinoembryonic Antigen Radioimmunotherapy with 1311-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group. Annals of Surgical Oncology, 2007, 14, 2577-2590.	0.7	74

#	Article	IF	CITATIONS
2015	The Impact of Postoperative Complications on Long-Term Outcomes Following Curative Resection for Colorectal Cancer. Annals of Surgical Oncology, 2007, 14, 2559-2566.	0.7	211
2016	Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells. Annals of Surgical Oncology, 2007, 14, 3629-3637.	0.7	396
2017	Blue-Violet Excited Autofluorescence Spectroscopy and Imaging of Normal and Cancerous Human Bronchial Tissue after Formalin Fixation. Photochemistry and Photobiology, 2007, 83, 450-459.	1.3	23
2018	Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. IUBMB Life, 2007, 59, 394-401.	1.5	5
2019	Jacaranone: A cytotoxic constituent fromsenecio ambiguus subsp.ambiguus (Biv.) DC. Against renal adenocarcinoma achn and prostate carcinoma LNCaP cells. Archives of Pharmacal Research, 2007, 30, 701-707.	2.7	45
2020	Pattern and Outcome of admission to a medical oncology inpatient service. Journal of Cancer Education, 2007, 22, 80-85.	0.6	5
2021	High Expression of Plasminogen Activator Inhibitor-2 (PAI-2) is a Predictor of Improved Survival in Patients with Pancreatic Adenocarcinoma. World Journal of Surgery, 2007, 31, 493-502.	0.8	38
2022	Management of Renal Tumors by Image-Guided Radiofrequency Ablation: Experience in 105 Tumors. CardioVascular and Interventional Radiology, 2007, 30, 936-942.	0.9	121
2023	Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemotherapy and Pharmacology, 2007, 59, 613-620.	1.1	23
2024	Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemotherapy and Pharmacology, 2007, 60, 69-79.	1.1	91
2025	Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 53-61.	1.1	4
2026	A highly polar xanthophyll of 9′-cis-neoxanthin induces apoptosis in HCT116 human colon cancer cells through mitochondrial dysfunction. Molecular and Cellular Biochemistry, 2007, 300, 227-237.	1.4	18
2027	Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. International Urology and Nephrology, 2007, 39, 381-387.	0.6	13
2028	A Polymorphism of microRNA 27a Genome Region Is Associated With the Development of Gastric Mucosal Atrophy in Japanese Male Subjects. Digestive Diseases and Sciences, 2007, 52, 1691-1697.	1.1	39
2029	Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Investigational New Drugs, 2007, 25, 471-477.	1.2	126
2030	A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Investigational New Drugs, 2007, 25, 553-558.	1.2	75
2031	Colorectal Cancer Screening Among Midwestern Community-Based Residents: Indicators Of Success. Journal of Community Health, 2007, 32, 103-120.	1.9	11
2032	Increased abdominal girth in a 29-year-old breast cancer patient with extensive liver metastasis and presumed chemotherapy induced amenorrhea. A case report and review of the literature. Breast Cancer Research and Treatment, 2007, 106, 305-306.	1.1	1

#	Article	IF	CITATIONS
2033	Renal cell carcinoma bone metastasis—elucidating the molecular targets. Cancer and Metastasis Reviews, 2007, 26, 691-704.	2.7	31
2034	Surgeons' knowledge of quality indicators for gastric cancer surgery. Gastric Cancer, 2007, 10, 205-214.	2.7	20
2035	Rectal bleeding and previous anticoagulant treatment in patients with colorectal cancer do not predict outcome. Techniques in Coloproctology, 2007, 11, 121-127.	0.8	1
2036	Positive expression and correlation of chemokine receptor CXCR4 with nodal metastasis and prognosis in colorectal cancer. Chinese-German Journal of Clinical Oncology, 2007, 6, 552-556.	0.1	3
2037	DNA Stool Test for Colorectal Cancer: Hypermethylation of the Secreted Frizzled-Related Protein-1 Gene. Diseases of the Colon and Rectum, 2007, 50, 1618-1627.	0.7	53
2038	DNA Ploidy Status and Prognosis in Colorectal Cancer: A Meta-Analysis of Published Data. Diseases of the Colon and Rectum, 2007, 50, 1800-1810.	0.7	57
2039	Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 549-560.	2.2	73
2041	Laparoscopic lymphatic mapping and sentinel lymph node detection in colon cancer: technical aspects and preliminary results. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 1567-1571.	1.3	29
2042	Perioperative outcome in sarcoma surgery. Langenbeck's Archives of Surgery, 2007, 392, 83-93.	0.8	5
2043	Spontaneous regression of colorectal cancer: a review of cases from 1900 to 2005. International Journal of Colorectal Disease, 2007, 22, 727-736.	1.0	49
2044	Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. International Journal of Colorectal Disease, 2007, 22, 887-895.	1.0	37
2045	Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. International Journal of Colorectal Disease, 2007, 22, 1269-1276.	1.0	139
2046	Indications and Efficacy of the Human Papillomavirus Vaccine. Current Treatment Options in Oncology, 2007, 8, 393-401.	1.3	9
2047	State-of-the-art CT colonography: Update on technique and performance. Current Colorectal Cancer Reports, 2007, 3, 49-54.	1.0	3
2048	Pancreatoscopy: Present and future role. Current Gastroenterology Reports, 2007, 9, 136-143.	1.1	7
2049	Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?. Current Urology Reports, 2007, 8, 341-344.	1.0	4
2050	The Impact of High-dose Sodium Selenite Therapy on Bcl-2 Expression in Adult Non-Hodgkin's Lymphoma Patients: Correlation with Response and Survival. Biological Trace Element Research, 2007, 120, 1-10.	1.9	28
2051	Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunologic Research, 2007, 39, 79-93.	1.3	39

	CHAHON	CITATION REPORT	
#	Article	IF	Citations
2052	Management of gastric adenocarcinoma. Clinical and Translational Oncology, 2007, 9, 438-442.	1.2	18
2053	Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. Journal of Biomedical Science, 2007, 14, 797-807.	2.6	25
2054	Targeted therapies in head and neck cancer. Targeted Oncology, 2007, 2, 73-88.	1.7	15
2055	Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2007, 11, 961-969.	0.9	77
2056	Gene expression profiling in sarcomas. Critical Reviews in Oncology/Hematology, 2007, 63, 111-124.	2.0	67
2057	Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Research and Treatment, 2008, 109, 515-526.	1.1	64
2059	Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. International Urology and Nephrology, 2008, 40, 97-104.	0.6	37
2060	Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies. Digestive Diseases and Sciences, 2008, 53, 2090-2100.	1.1	5
2061	A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunology, Immunotherapy, 2008, 57, 43-52.	2.0	74
2062	A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemotherapy and Pharmacology, 2008, 61, 395-405.	1.1	64
2063	Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2008, 62, 647-653.	1.1	20
2064	A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemotherapy and Pharmacology, 2008, 62, 1103-1109.	1.1	19
2065	The Evaluation of Esophageal Adenocarcinoma Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Gastrointestinal Surgery, 2008, 12, 166-175.	0.9	35
2066	Relapsed acute lymphoblastic leukemia: Current status and future opportunities. Current Oncology Reports, 2008, 10, 453-458.	1.8	29
2067	Screening and chemoprevention in lung cancer. Clinical and Translational Oncology, 2008, 10, 274-280.	1.2	1
2068	Cellular binding partners of the human papillomavirus E6 protein. Archives of Virology, 2008, 153, 397-408.	0.9	74
2069	A pilot study of weekly docetaxel chemotherapy combined with regional hyperthermia for pretreated stage III non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 35-39.	0.1	0
2070	AG825 increases radiosensitivity of breast cancer cell. Chinese-German Journal of Clinical Oncology, 2008, 7, 587-589.	0.1	0

#	Article	IF	CITATIONS
2071	Esophageal cancer: adenocarcinoma in populations dominated by squamous cell histology. Esophagus, 2008, 5, 1-4.	1.0	1
2072	Cervicovaginal cytology and diagnosis of ovarian or peritoneal cancer: case report and literature review. Archives of Gynecology and Obstetrics, 2008, 277, 171-174.	0.8	8
2073	Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women – baseline data of a phase III vaccine trial. Wiener Klinische Wochenschrift, 2008, 120, 666-671.	1.0	4
2074	Metachronous bilateral soft tissue sarcoma of the extremities. Langenbeck's Archives of Surgery, 2008, 393, 207-212.	0.8	7
2075	Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations. Journal of Cancer Research and Clinical Oncology, 2008, 134, 609-615.	1.2	23
2076	Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1037-1042.	1.2	89
2077	Polymorphisms of selected Xenobiotic Genes contribute to the development of Papillary Thyroid Cancer susceptibility in Middle Eastern population. BMC Medical Genetics, 2008, 9, 61.	2.1	43
2078	Towards a comprehensive proteome of normal and malignant human colon tissue by 2â€D‣Câ€ESIâ€MS and 2â€DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics - Clinical Applications, 2008, 2, 11-22.	0.8	32
2079	The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics - Clinical Applications, 2008, 2, 1386-1402.	0.8	182
2080	Transgenerational effects of the endocrine disruptor vinclozolin on the prostate transcriptome and adult onset disease. Prostate, 2008, 68, 517-529.	1.2	114
2081	A third evaluation of tertiary cytoreduction. Journal of Surgical Oncology, 2008, 98, 530-534.	0.8	23
2082	Clinical significance of low expression of <i>Prostasin</i> mRNA in human gastric cancer. Journal of Surgical Oncology, 2008, 98, 559-564.	0.8	29
2083	Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer, 2008, 113, 286-292.	2.0	70
2084	Methylated <i>TMS1</i> and <i>DAPK</i> genes predict prognosis and response to chemotherapy in gastric cancer. International Journal of Cancer, 2008, 122, 603-608.	2.3	62
2085	Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. International Journal of Cancer, 2008, 123, 2337-2342.	2.3	31
2086	Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signalâ€transduction pathways. International Journal of Cancer, 2008, 123, 2543-2556.	2.3	121
2087	Oncogériatrie pratique. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 542-545.	0.0	1
2088	Cyclooxygenase (COX)-2 as a potent molecular target for prevention and therapy of oral cancer. Japanese Dental Science Review, 2008, 44, 57-65.	2.0	24

			2
#		IF	CITATIONS
2089	Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2008, 4, 57-69.	1.7	81
2090	Dosimetric Advantages of Four-Dimensional Adaptive Image-Guided Radiotherapy for Lung Tumors Using Online Cone-Beam Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2008, 70, 582-589.	0.4	60
2091	Hippocampal Neuron Number Is Unchanged 1 Year After Fractionated Whole-Brain Irradiation at Middle Age. International Journal of Radiation Oncology Biology Physics, 2008, 71, 526-532.	0.4	41
2092	Epidermal Growth Factor Receptor-Targeted Gelatin-Based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells. AAPS Journal, 2008, 10, 565-76.	2.2	69
2093	Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 2293-2300.	0.7	36
2094	Prognostic Relevance of Tensin4 Expression in Human Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 2606-2613.	0.7	39
2095	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.9	20
2096	Rectovaginal examinations and human papillomavirus: can we decrease the risk of colorectal infection?. American Journal of Obstetrics and Gynecology, 2008, 198, 260.e1-260.e2.	0.7	4
2097	Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. American Journal of Obstetrics and Gynecology, 2008, 198, 418.e1-418.e7.	0.7	19
2098	Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. American Journal of Obstetrics and Gynecology, 2008, 199, 533.e1-533.e8.	0.7	15
2099	Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Modern Pathology, 2008, 21, 1130-1138.	2.9	47
2100	NM23 as a prognostic biomarker in ovarian serous carcinoma. Modern Pathology, 2008, 21, 885-892.	2.9	20
2101	Anthropometric Risk Factors for Colorectal Polyps in Africanâ€American Women. Obesity, 2008, 16, 859-868.	1.5	44
2102	Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer, 2008, 18, 460-464.	1.2	10
2103	Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. International Journal of Gynecological Cancer, 2008, 18, 1202-1209.	1.2	70
2104	Alteration of cell-cycle regulation in epithelial ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 1169-1182.	1.2	57
2105	Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery. International Journal of Gynecological Cancer, 2008, 18, 1294-1299.	1.2	36
2106	Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: Proton pump inhibitor combination for prevention of postâ€stent reflux in patients with esophageal carcinoma involving the esophagoâ€gastric junction. Journal of Gastroenterology and Hepatology (Australia), 2008. 23. 723-728.	1.4	49

#	Article	IF	Citations
2107	A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Ecological Management and Restoration, 2008, 21, 430-436.	0.2	27
2108	Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 418-423.	1.4	228
2109	Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. BJU International, 2008, 101, 691-697.	1.3	20
2110	The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation, 2008, 76, 193-205.	1.0	45
2111	Targeting Slit–Roundabout signaling inhibits tumor angiogenesis in chemicalâ€ <del>i</del> nduced squamous cell carcinogenesis. Cancer Science, 2008, 99, 510-517.	1.7	81
2112	Expression of vasohibin as a novel endotheliumâ€derived angiogenesis inhibitor in endometrial cancer. Cancer Science, 2008, 99, 914-919.	1.7	55
2113	Metformin suppresses intestinal polyp growth in <i>Apc</i> <sup>Min/+</sup> mice. Cancer Science, 2008, 99, 2136-2141.	1.7	166
2114	<i>In vivo</i> antiâ€myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. British Journal of Haematology, 2008, 143, 520-531.	1.2	59
2115	Multiple-Instance Learning Algorithms for Computer-Aided Detection. IEEE Transactions on Biomedical Engineering, 2008, 55, 1015-1021.	2.5	33
2116	Current role and future potential of computed tomographic colonography for colorectal polyp detection and colon cancer screening—incidental findings. Clinical Imaging, 2008, 32, 280-286.	0.8	10
2117	Nephron-Sparing Surgery versus Radical Nephrectomy in the Treatment of Intracapsular Renal Cell Carcinoma up to 7cm. European Urology, 2008, 53, 803-809.	0.9	107
2118	Overexpression of Matrix Metalloproteinase 9 in Tumor Epithelial Cells Correlates with Colorectal Cancer Metastasis. Clinical and Translational Science, 2008, 1, 136-141.	1.5	14
2119	Prevalence and Significance of Human Papillomavirus in Oral Tongue Cancer: The Mayo Clinic Experience. Journal of Oral and Maxillofacial Surgery, 2008, 66, 1875-1880.	0.5	97
2120	Active Surveillance for Favorable Risk Prostate Cancer: What Are the Results, and How Safe Is It?. Seminars in Radiation Oncology, 2008, 18, 2-6.	1.0	25
2121	Chromosomal imbalances in oral squamous cell carcinoma: Examination of 31 cell lines and review of the literature. Oral Oncology, 2008, 44, 369-382.	0.8	78
2122	Expression of cyclooxygenase-2 and DNA topoisomerase II $\hat{I}\pm$ in precancerous and cancerous lesions of the oral mucosa. Oral Oncology, 2008, 44, 664-671.	0.8	18
2123	CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma – A pilot study. Oral Oncology, 2008, 44, 941-948.	0.8	33
2124	Pregnancy and Assisted Reproduction Techniques in Men and Women after Cancer Treatment. Placenta, 2008, 29, 152-159.	0.7	35

#	Article	IF	CITATIONS
2125	Bone marrow micrometastases in different solid tumors: Pathogenesis and importance. Surgical Oncology, 2008, 17, 153-164.	0.8	2
2126	A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer. Lung Cancer, 2008, 59, 76-80.	0.9	3
2127	Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. Lung Cancer, 2008, 62, 23-34.	0.9	75
2128	Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer, 2008, 62, 344-350.	0.9	9
2129	Improvement of the specificity of cancer detection by autofluorescence imaging in the tracheo-bronchial tree using backscattered violet light. Photodiagnosis and Photodynamic Therapy, 2008, 5, 2-9.	1.3	11
2130	Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin. American Journal of Clinical Dermatology, 2008, 9, 15-31.	3.3	114
2131	Chemotherapy for Breast Cancer. , 2008, , 319-325.		0
2132	Raman microspectroscopy for skin cancer detection in vitro. Journal of Biomedical Optics, 2008, 13, 024013.	1.4	116
2134	Soft Tissue Sarcoma: Can a Rescue Procedure be Performed when the First Surgery was Unsuccessful?. Revista Española De CirugÃa Ortopédica Y TraumatologÃa, 2008, 52, 21-26.	0.1	1
2135	Androgen biosynthetic pathways in the human prostate. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 207-221.	2.2	147
2136	Distinct TPEF/HPP1 gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis. Digestive and Liver Disease, 2008, 40, 920-926.	0.4	13
2137	Proteomic Profiling of Endothelial Cells in Human Lung Cancer. Journal of Proteome Research, 2008, 7, 1138-1150.	1.8	50
2139	Prostate growth and inflammation. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 254-260.	1.2	133
2140	Proinflammatory Cytokines Increase Hepatocellular Carcinoma Cells Thermotolerance: Evidence of How Local Inflammation May Negatively Impact Radiofrequency Ablation Local Control Rates. Journal of Surgical Research, 2008, 150, 118-124.	0.8	3
2141	Epithelioid sarcoma: the University of Washington experience. American Journal of Surgery, 2008, 196, 407-412.	0.9	50
2142	Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium. Annals of Diagnostic Pathology, 2008, 12, 112-117.	0.6	8
2143	Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 158-165.	0.8	33
2144	Ethnicity and its significance in the pathobiology of prostatic carcinoma in Southern Israel. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 31-36.	0.8	2

#	Article	IF	CITATIONS
2145	Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 47-52.	0.8	44
2146	Role of neutrophils in BCG immunotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 341-345.	0.8	100
2147	What is the best approach for screen-detected low volume cancers?—The case for observation. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 495-499.	0.8	11
2148	The Role of Infectious Agents in the Etiology of Ocular Adnexal Neoplasia. Survey of Ophthalmology, 2008, 53, 312-331.	1.7	113
2149	Ferruginol suppresses survival signaling pathways in androgen-independent human prostate cancer cells. Biochimie, 2008, 90, 843-854.	1.3	50
2151	Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: Implications for management. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 269-274.	0.5	28
2152	A tyrosine kinase inhibitor, β-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 41-50.	1.8	24
2153	Detection of lung cancer using weighted digital analysis of breath biomarkers. Clinica Chimica Acta, 2008, 393, 76-84.	0.5	206
2154	Malignant Biliary Obstruction: Distal. , 2008, , 287-298.		0
2155	Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin. Clinical Cancer Research, 2008, 14, 4981-4988.	3.2	65
2156	Radiofrequency Ablation in Bone Metastases. , 2008, , 207-214.		0
2157	Comparative Analysis of Survivin Expression in Untreated and Relapsed Canine Lymphoma. Journal of Veterinary Internal Medicine, 2008, 22, 989-995.	0.6	30
2158	Ultrasound Guided Percutaneous Microwave Ablation for Small Renal Cancer: Initial Experience. Journal of Urology, 2008, 180, 844-848.	0.2	124
2159	Integrin $\hat{I}\pm\hat{G}^2$ 4 Promotes Migration, Invasion through Tiam1 Upregulation, and Subsequent Rac Activation. Neoplasia, 2008, 10, 408-IN1.	2.3	65
2160	Laryngeal Cancer: Diagnosis and Preoperative Work-up. Otolaryngologic Clinics of North America, 2008, 41, 673-695.	0.5	215
2161	Risks of Neoadjuvant Chemotherapy and Radiation Therapy. Thoracic Surgery Clinics, 2008, 18, 71-80.	0.4	22
2162	Higher Than Expected Association of Clinical Prostate and Bladder Cancers. Journal of Urology, 2008, 179, S2-5.	0.2	19
2165	Neoadjuvant Therapy for Gastric Cancer. Advances in Surgery, 2008, 42, 151-168.	0.6	9

#	Article	IF	CITATIONS
2166	Oxygen Toxicity During One-Lung Ventilation: Is It Time to Re-Evaluate Our Practice?. Anesthesiology Clinics, 2008, 26, 273-280.	0.6	11
2167	Pediatric Cancer Deaths: Curative or Palliative?. Journal of Palliative Medicine, 2008, 11, 1301-1303.	0.6	9
2168	Impact of Interventional Bronchoscopy on Quality of Life in Malignant Airway Obstruction. Respiration, 2008, 76, 421-428.	1.2	77
2169	Lung Cancer Screening with CT. Clinics in Chest Medicine, 2008, 29, 1-14.	0.8	33
2170	Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Annals of Oncology, 2008, 19, 1650-1654.	0.6	44
2171	What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men. Health Education Research, 2008, 24, 280-291.	1.0	24
2172	Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Annals of Oncology, 2008, 19, 1271-1277.	0.6	25
2173	Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy. Clinical Cancer Research, 2008, 14, 7790-7797.	3.2	51
2174	Primary Breast Cancer. , 2008, , 423-433.		0
2175	Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis, 2008, 29, 1601-1607.	1.3	25
2176	Accuracy of <sup>18</sup> F-FDG PET/CT in Detecting Pelvic and Paraaortic Lymph Node Metastasis in Patients with Endometrial Cancer. American Journal of Roentgenology, 2008, 190, 1652-1658.	1.0	156
2177	Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. Journal of Clinical Oncology, 2008, 26, 1956-1964.	0.8	130
2178	A Novel Lung Cancer Signature Mediates Metastatic Bone Colonization by a Dual Mechanism. Cancer Research, 2008, 68, 2275-2285.	0.4	89
2179	Integrated system for planning peripheral bronchoscopic procedures. Proceedings of SPIE, 2008, , .	0.8	4
2180	Performance of a Previously Validated CT Colonography Computer-Aided Detection System in a New Patient Population. American Journal of Roentgenology, 2008, 191, 168-174.	1.0	45
2181	Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer. Journal of Chemotherapy, 2008, 20, 632-639.	0.7	59
2182	Effect of CKBM on Prostate Cancer Cell Growth <i>In Vitro</i> and <i>In Vivo</i> . Journal of Chemotherapy, 2008, 20, 246-252.	0.7	1
2183	Impact of Previous Tracheotomy as a Prognostic Factor in Patients with Locally Advanced Squamous Cell Carcinoma of the Larynx Submitted to Concomitant Chemotherapy and Radiation. Orl, 2008, 70, 381-388.	0.6	16

#	Article	IF	CITATIONS
2184	Recommendations on the Use of <sup>18</sup> F-FDG PET in Oncology. Journal of Nuclear Medicine, 2008, 49, 480-508.	2.8	978
2185	Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction. Endocrine Reviews, 2008, 29, 193-216.	8.9	100
2186	Computed tomographic colonography. Expert Review of Gastroenterology and Hepatology, 2008, 2, 371-384.	1.4	1
2187	Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Review of Molecular Diagnostics, 2008, 8, 277-288.	1.5	58
2188	Laryngeal Carcinoma in Nonsmoking Patients. Annals of Otology, Rhinology and Laryngology, 2008, 117, 564-568.	0.6	14
2189	Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 5995-6004.	3.2	460
2190	The Retinoblastoma Family Member pRb2/p130 Is an Independent Predictor of Survival in Human Soft Tissue Sarcomas. Clinical Cancer Research, 2008, 14, 4775-4779.	3.2	9
2191	Barriers to Enrollment of Elderly Adults in Early-Phase Cancer Clinical Trials. Journal of Oncology Practice, 2008, 4, 162-168.	2.5	56
2192	Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2008, 39, 81-85.	0.6	12
2193	Correlating EGFR Expression with Receptor-Binding Properties and Internalization of <sup>64</sup> Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines. Journal of Nuclear Medicine, 2008, 49, 1472-1479.	2.8	87
2194	Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database. Prostate Cancer and Prostatic Diseases, 2008, 11, 280-287.	2.0	14
2195	Stromal Transforming Growth Factor-Î <sup>2</sup> Signaling Mediates Prostatic Response to Androgen Ablation by Paracrine Wnt Activity. Cancer Research, 2008, 68, 4709-4718.	0.4	104
2196	Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Molecular Cancer Therapeutics, 2008, 7, 704-711.	1.9	35
2197	Surgery alone for squamous cell carcinoma of the oral cavity: survival rates, recurrence patterns, and salvage treatment. Acta Oto-Laryngologica, 2008, 128, 1132-1137.	0.3	25
2198	Association of TSC1/Hamartin, 14-3-3σ, and p27 Expression With Tumor Outcomes in Patients With pTa/pT1 Urothelial Bladder Carcinoma. American Journal of Clinical Pathology, 2008, 129, 918-923.	0.4	8
2200	Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry. Molecular and Cellular Proteomics, 2008, 7, 1162-1173.	2.5	191
2201	Activation of Signal Transducer and Activator of Transcription 3 through a Phosphomimetic Serine 727 Promotes Prostate Tumorigenesis Independent of Tyrosine 705 Phosphorylation. Cancer Research, 2008, 68, 7736-7741.	0.4	116
2202	Diagnostic Role of Circulating Free Plasma DNA Detection in Patients With Localized Prostate Cancer. American Journal of Clinical Pathology, 2008, 129, 756-762.	0.4	90

#	Article	IF	CITATIONS
2203	Partial Cancer Prevalence in Japan up to 2020: Estimates Based on Incidence and Survival Data from Population-based Cancer Registries. Japanese Journal of Clinical Oncology, 2008, 38, 146-157.	0.6	15
2204	High-Intensity Focused Ultrasound: Current Potential and Oncologic Applications. American Journal of Roentgenology, 2008, 190, 191-199.	1.0	317
2205	Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nature Reviews Urology, 2008, 5, 2-3.	1.4	25
2206	Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opinion on Pharmacotherapy, 2008, 9, 1609-1618.	0.9	50
2207	Computed Tomography Screening and Lung Cancer Outcomes. Yearbook of Medicine, 2008, 2008, 178-179.	0.1	0
2208	Computed Tomography Screening and Lung Cancer Outcomes. Yearbook of Oncology, 2008, 2008, 152-153.	0.1	0
2209	Survival of Patients with Stage I Lung Cancer Detected on CT Screening. Yearbook of Oncology, 2008, 2008, 149-151.	0.1	0
2210	Perineural Spread of Melanoma Demonstrated by F-18 FDG PET With MRI and Pathologic Correlation. Clinical Nuclear Medicine, 2008, 33, 106-108.	0.7	19
2211	Systematic pelvic floor training for lower urinary tract symptoms postâ€prostatectomy: a randomized clinical trial. International Journal of Urological Nursing, 2008, 2, 3-13.	0.1	13
2212	Influence of Subclinical Tumor Spreading on Survival After Curative Surgery for Colorectal Cancer. Archives of Surgery, 2008, 143, 122.	2.3	26
2213	Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. International Journal of Oncology, 0, , .	1.4	26
2214	Survival of Patients with Stage I Lung Cancer Detected on CT Screening. Yearbook of Medicine, 2008, 2008, 175-177.	0.1	1
2215	Detection of Papillary Thyroid Carcinoma With Serum Protein Profile Analysis. JAMA Otolaryngology, 2008, 134, 198.	1.5	12
2216	Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas. Cancer Control, 2008, 15, 47-54.	0.7	26
2217	Application of Gold Nanoparticles for Targeted Therapy in Cancer. Journal of Biomedical Nanotechnology, 2008, 4, 99-132.	0.5	68
2218	Lycopene in Cancer Prevention and Treatment. American Journal of Therapeutics, 2008, 15, 66-81.	0.5	80
2219	hCAP-D3 Expression Marks a Prostate Cancer Subtype With Favorable Clinical Behavior and Androgen Signaling Signature. American Journal of Surgical Pathology, 2008, 32, 205-209.	2.1	25
2220	Identification of Lung Cancer Patients by Serum Protein Profiling Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 133-139.	0.6	60

#	Article	IF	CITATIONS
2221	PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer. Pancreas, 2008, 37, 210-220.	0.5	54
2222	Recent developments in the clinical application of thyroid cancer biomarkers. Current Opinion in Oncology, 2008, 20, 13-18.	1.1	53
2223	Excision Repair Cross Complementing-1 and Topoisomerase IIα Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective Study. Journal of Thoracic Oncology, 2008, 3, 583-589.	0.5	41
2224	Renal Epithelial Neoplasms: Diagnostic Applications of Gene Expression Profiling. Advances in Anatomic Pathology, 2008, 15, 28-38.	2.4	22
2225	Systemic Therapy for Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass ), 2008, 14, 123-127.	1.0	35
2227	Small-Cell Lung Cancer: An Unusual Therapeutic Approach with More than 10-year Overall Survival. Case Report and Review of the Literature. Tumori, 2008, 94, 612-616.	0.6	1
2228	Surgery for renal carcinoma metastases. Urologia, 2008, 75, 1-3.	0.3	2
2229	Breast and Cervical Cancer Screening Among Low-income Women in Nebraska: Findings from the Every Woman Matters Program, 1993–2004. Journal of Health Care for the Poor and Underserved, 2008, 19, 797-813.	0.4	4
2230	Treating refractory leukemias in childhood, role of clofarabine. Therapeutics and Clinical Risk Management, 2008, Volume 4, 327-336.	0.9	13
2231	Sun exposure and vitamin D sufficiency. American Journal of Clinical Nutrition, 2008, 88, 570S-577S.	2.2	101
2232	Cancer Health Disparities: What We Have Done. American Journal of the Medical Sciences, 2008, 335, 254-259.	0.4	23
2233	Epidemiologic Characteristics of Prostate Cancer Detection. Korean Journal of Urology, 2009, 50, 1054.	1.2	3
2234	Clinicopathologic Findings of Micropapillary Carcinomas, according to Tumor Size. [Chapchi] Journal Taehan Oekwa Hakhoe, 2009, 76, 348.	1.1	2
2235	Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells. Journal of Veterinary Science, 2009, 10, 23.	0.5	52
2236	Epithelial Neoplasms of the Stomach. , 2009, , 563-579.		7
2237	Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2009, 66, 93.	0.7	18
2238	The Use of Endoscopic Ultrasonography and Other Imaging Modalities in the Preoperative Staging of Rectal Villous Tumours: A Case of Overstaging by Magnetic Resonance Imaging. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 639-641.	1.8	1
2239	Optimization of magnetic beads for maldi-TOF MS analysis. Frontiers in Bioscience - Landmark, 2009, Volume, 3712.	3.0	26

	CHATION	<b>KLFOKI</b>	
# 2240	ARTICLE Linear measurement of polyps in CT colonography using level sets on 3D surfaces. , 2009, 2009, 3617-20.	IF	CITATIONS
2241	Anti-Smoking Communication to Preadolescents With and Without a Cancer Diagnosis: Parents and Health Care Providers as Important Communicators. Children's Health Care, 2009, 38, 283-300.	0.5	2
2242	Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial. Journal of Clinical Oncology, 2009, 27, 4268-4273.	0.8	38
2243	A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Annals of Oncology, 2009, 20, 674-680.	0.6	189
2244	The Metastasis Efficiency Modifier Ribosomal RNA Processing 1 Homolog B (RRP1B) Is a Chromatin-associated Factor. Journal of Biological Chemistry, 2009, 284, 28660-28673.	1.6	30
2245	Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Review of Endocrinology and Metabolism, 2009, 4, 25-43.	1.2	44
2246	Insulin Receptor Substrate-2 Mediated Insulin-like Growth Factor-I Receptor Overexpression in Pancreatic Adenocarcinoma through Protein Kinase Cl̃. Cancer Research, 2009, 69, 1350-1357.	0.4	31
2247	"Staging the Aging―When Considering Androgen Deprivation Therapy for Older Men With Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 3420-3422.	0.8	28
2248	The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15855-15860.	3.3	31
2249	Nonreferral of Possible Soft Tissue Sarcomas in Adults: A Dangerous Omission in Policy. Sarcoma, 2009, 2009, 1-7.	0.7	28
2250	MicroRNA Profiling and Head and Neck Cancer. Comparative and Functional Genomics, 2009, 2009, 1-11.	2.0	116
2251	Management of Upper Tract Urothelial Carcinoma. Advances in Urology, 2009, 2009, 1-1.	0.6	3
2252	The Scandinavian Sarcoma Group. Monthly Notices of the Royal Astronomical Society: Letters, 2009, 80, 1-104.	1.2	16
2253	The Oncopathic Potency of <i>Clostridium perfringens</i> Is Independent of Its α-Toxin Gene. Human Gene Therapy, 2009, 20, 751-758.	1.4	3
2254	PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Annals of Oncology, 2009, 20, 1230-1235.	0.6	41
2255	Quercetin Is Able to Demethylate the p16INK4a Gene Promoter. Chemotherapy, 2009, 55, 6-10.	0.8	84
2256	Preoperative Prediction of Lymph Node Status in Gastric Cancer Patients with the Help of Computer Analysis. Digestive Surgery, 2009, 26, 256-261.	0.6	2
2257	A surgeon's case volume of oesophagectomy for cancer does not influence patient outcome in a high volume hospital. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 66-69.	0.5	14

#	Article	IF	CITATIONS
2258	Protein Expression in Human Non-Small Cell Lung Cancer: A Systematic Database. Pathobiology, 2009, 76, 277-285.	1.9	33
2259	A critical review of Vitamin D and cancer: A report of the IARC Working Group on vitamin D. Dermato-Endocrinology, 2009, 1, 25-33.	1.9	51
2260	A <sup>99m</sup> Tc-Labeled Triphenylphosphonium Derivative for the Early Detection of Breast Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 579-587.	0.7	19
2261	Antiangiogenic Gene Therapy With Soluble VEGFR-1, -2, and -3 Reduces the Growth of Solid Human Ovarian Carcinoma in Mice. Molecular Therapy, 2009, 17, 278-284.	3.7	47
2262	Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era. Expert Review of Anticancer Therapy, 2009, 9, 1783-1792.	1.1	7
2263	The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer. Endocrine Reviews, 2009, 30, 178-195.	8.9	116
2264	Comparative Serum Proteome Analysis of Human Lymph Node Negative/Positive Invasive Ductal Carcinoma of the Breast and Benign Breast Disease Controls via Label-Free Semiquantitative Shotgun Technology. OMICS A Journal of Integrative Biology, 2009, 13, 291-300.	1.0	30
2265	Arsenic Activates EGFR Pathway Signaling in the Lung. Toxicological Sciences, 2009, 109, 350-357.	1.4	63
2266	Prostatakarzinom. , 2009, , 485-635.		0
2267	Laparoscopic Nephroureterectomy: The Distal Ureteral Dilemma. Advances in Urology, 2009, 2009, 1-9.	0.6	21
2268	A murine model of myeloma that allows genetic manipulation of the host microenvironment. DMM Disease Models and Mechanisms, 2009, 2, 604-611.	1.2	39
2269	Emerging drugs for prostate cancer. Expert Opinion on Emerging Drugs, 2009, 14, 455-470.	1.0	7
2270	Guanylyl Cyclase C Prevents Colon Cancer Metastasis by Regulating Tumor Epithelial Cell Matrix Metalloproteinase-9. Cancer Research, 2009, 69, 3529-3536.	0.4	36
2271	State of the Art of Sentinel Lymph Node Biopsy in Vulvar Carcinoma. Women's Health, 2009, 5, 555-563.	0.7	3
2272	Kaempferol Inhibits Angiogenesis and VEGF Expression Through Both HIF Dependent and Independent Pathways in Human Ovarian Cancer Cells. Nutrition and Cancer, 2009, 61, 554-563.	0.9	174
2273	Galectin-3 Overexpression in Invasive Laryngeal Carcinoma, Assessed by Computer-assisted Analysis. Journal of Histochemistry and Cytochemistry, 2009, 57, 665-673.	1.3	23
2274	Giant retroperitoneal liposarcoma extending into the scrotum: a case report. Scottish Medical Journal, 2009, 54, 58-58.	0.7	0

#	Article	IF	CITATIONS
2276	Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Seminars in Cancer Biology, 2009, 19, 123-134.	4.3	29
2277	Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysis. BMC Cancer, 2009, 9, 227.	1.1	35
2278	Malignant transformation of oral potentially malignant disorders in males: a retrospective cohort study. BMC Cancer, 2009, 9, 260.	1.1	103
2279	Prognostic role of global DNAâ€methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. Journal of Cellular and Molecular Medicine, 2009, 13, 2115-2121.	1.6	42
2281	Role of intratumoral lymphatic vessels in the lymph node dissemination of laryngopharyngeal squamous cell carcinoma. Head and Neck, 2010, 32, 757-762.	0.9	1
2282	Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: Biomarkers of progression. International Journal of Cancer, 2009, 124, 2813-2828.	2.3	31
2283	Major 30â€day complications after radical radiotherapy. Cancer, 2009, 115, 293-302.	2.0	18
2284	Cystic fibrosis transmembrane conductance regulator ( <i>CFTR</i> ) gene mutations and risk for pancreatic adenocarcinoma. Cancer, 2010, 116, 203-209.	2.0	80
2285	Effect of polymorphisms in the 3′ untranslated region (3′â€UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Molecular Carcinogenesis, 2009, 48, 1030-1037.	1.3	35
2286	International epidemiology of prostate cancer: Geographical distribution and secular trends. Molecular Nutrition and Food Research, 2009, 53, 171-184.	1.5	350
2287	Monodemethylated polymethoxyflavones from sweet orange ( <i>Citrus sinensis</i> ) peel Inhibit growth of human lung cancer cells by apoptosis. Molecular Nutrition and Food Research, 2009, 53, 398-406.	1.5	141
2288	Hedgehog signaling is involved in differentiation of normal colonic tissue rather than in tumor proliferation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 369-379.	1.4	39
2289	Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer, 2009, 12, 69-78.	2.7	94
2290	Young-age onset of colorectal cancer in Israel. Techniques in Coloproctology, 2009, 13, 201-204.	0.8	16
2291	The Feasibility of Irreversible Electroporation for the Treatment of Breast Cancer and Other Heterogeneous Systems. Annals of Biomedical Engineering, 2009, 37, 2615-25.	1.3	83
2292	Prevalence, trend, and sociodemographic association of five modifiable lifestyle risk factors for cancer in Alberta and Canada. Cancer Causes and Control, 2009, 20, 395-407.	0.8	17
2293	Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes and Control, 2009, 20, 625-633.	0.8	105
2294	Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Familial Cancer, 2009, 8, 231-239.	0.9	52

#	Article	IF	CITATIONS
2295	The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Molecular Imaging and Biology, 2009, 11, 446-454.	1.3	143
2296	Being â€~at-risk' for developing cancer: cognitive representations and psychological outcomes. Journal of Behavioral Medicine, 2009, 32, 197-208.	1.1	27
2297	High-Dose Sodium Selenite Can Induce Apoptosis of Lymphoma Cells in Adult Patients with Non-Hodgkin's Lymphoma. Biological Trace Element Research, 2009, 127, 200-210.	1.9	38
2298	SELDI-TOF MS Proteomics in Breast Cancer. Clinical Proteomics, 2009, 5, 133-147.	1.1	4
2299	Prostate-specific antigen in the cerebrospinal fluid: A marker of local disease. Medical Oncology, 2009, 26, 143-146.	1.2	9
2300	Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clinical and Translational Oncology, 2009, 11, 526-533.	1.2	32
2301	Worldwide Impact of the Human Papillomavirus Vaccine. Current Treatment Options in Oncology, 2009, 10, 44-53.	1.3	25
2302	Novel therapies for relapsed acute lymphoblastic leukemia. Current Hematologic Malignancy Reports, 2009, 4, 148-156.	1.2	18
2303	Clinical characteristics of prostate cancer in advanced stage and its treatment by Chinese and Western medicine. Chinese Journal of Integrative Medicine, 2009, 15, 163-165.	0.7	0
2304	The incidence of soft tissue sarcoma in Dakshina Kannada: study in a District Government Hospital. Indian Journal of Surgery, 2009, 71, 10-14.	0.2	5
2306	Profiling of 95ÂMicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Realâ€īme PCR Analysis. World Journal of Surgery, 2009, 33, 698-709.	0.8	288
2307	Developing a Tissue Resource to Characterize the Genome of Pancreatic Cancer. World Journal of Surgery, 2009, 33, 723-731.	0.8	9
2308	Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemotherapy and Pharmacology, 2009, 63, 381-389.	1.1	26
2309	A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1083-1090.	1.1	13
2310	Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. Journal of Pathology, 2009, 218, 380-390.	2.1	62
2311	Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for <i>Helicobacter pylori</i> infection. Journal of Pathology, 2009, 219, 410-416.	2.1	109
2312	Antiproliferative effects of different plant parts of <i>Panax notoginseng</i> on SW480 human colorectal cancer cells. Phytotherapy Research, 2009, 23, 6-13.	2.8	59
2313	Inhibitory effects of the aqueous extract of <i>Magnolia officinalis</i> on the responses of human urinary bladder cancer 5637 cells <i>in vitro</i> and mouse urinary bladder tumors induced by <i>N</i> â€Butylâ€ <i>N</i> â€{4â€hydroxybutyl) nitrosamine <i>in vivo</i> . Phytotherapy Research, 2009, 23, 20-27	2.8	12

#	Article	IF	CITATIONS
2314	Novel multiâ€peptide vaccination in Hlaâ€A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927.	1.2	97
2315	Liposomal gemcitabine (GemLip)—efficient drug against hormoneâ€refractory Du145 and PCâ€3 prostate cancer xenografts. Prostate, 2009, 69, 1151-1163.	1.2	27
2316	PSA surge/flareâ€up in patients with castrationâ€refractory prostate cancer during the initial phase of chemotherapy. Prostate, 2009, 69, 1802-1807.	1.2	45
2317	Aspects of Bâ€Cell Nonâ€Hodgkin's Lymphoma Development: A Transition from Immuneâ€Reactivity to Malignancy. Scandinavian Journal of Immunology, 2009, 69, 387-400.	1.3	22
2318	Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1–cyclinâ€dependent kinase 4–p21 pathway. Cancer Science, 2009, 100, 1585-1590.	1.7	43
2319	Synergistic antiproliferative effect of mTOR inhibitors in combination with 5â€fluorouracil in scirrhous gastric cancer. Cancer Science, 2009, 100, 2402-2410.	1.7	39
2320	Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacologica Sinica, 2009, 30, 1537-1542.	2.8	60
2321	Combined inhibition of PAK7, MAP3K7 and CK2α kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts. Cancer Gene Therapy, 2009, 16, 731-740.	2.2	22
2322	Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene, 2009, 28, 3513-3525.	2.6	237
2323	Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. British Journal of Cancer, 2009, 100, 1032-1036.	2.9	86
2324	The Role of Fâ€18 Choline PET and PET/CT in Prostate Cancer. Imaging Decisions (Berlin, Germany), 2009, 13, 97-103.	0.2	0
2325	Expression of retinoic acid receptor β in dermatofibrosarcoma protuberans. Journal of Cutaneous Pathology, 2009, 36, 1141-1145.	0.7	3
2326	Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial–mesenchymal transition in nonâ€small cell lung cancer. Respirology, 2009, 14, 371-376.	1.3	17
2327	Prostate cancer: a serious disease suitable for prevention. BJU International, 2009, 103, 864-870.	1.3	38
2328	Responding to the challenge of cancer in Europe. Australian and New Zealand Journal of Public Health, 2009, 33, 298.	0.8	12
2329	Predictors of Toxicity and Toxicity Profile of Adjuvant Chemotherapy in Elderly Breast Cancer Patients. Breast Journal, 2009, 15, 404-408.	0.4	37
2330	Antioxidative and antiproliferative effects of astaxanthin during the initiation stages of 1,2â€dimethyl hydrazineâ€induced experimental colon carcinogenesis. Fundamental and Clinical Pharmacology, 2009, 23, 225-234.	1.0	53
2331	High mobility group box associated with cell proliferation appears to play an important role in hepatocellular carcinogenesis in rats and humans. Toxicology, 2009, 255, 160-170.	2.0	12

#	Article	IF	Citations
2332	X-Radiation Induces Non-Small-Cell Lung Cancer Apoptosis by Upregulation of Axin Expression. International Journal of Radiation Oncology Biology Physics, 2009, 75, 518-526.	0.4	21
2333	Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2154-2157.	1.0	63
2334	Dextrinâ^'Phospholipase A <sub>2</sub> : Synthesis and Evaluation as a Bioresponsive Anticancer Conjugate. Biomacromolecules, 2009, 10, 1358-1364.	2.6	78
2335	The footprints of cancer development: Cancer biomarkers. Cancer Treatment Reviews, 2009, 35, 193-200.	3.4	112
2336	De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. International Journal of Biochemistry and Cell Biology, 2009, 41, 1165-1172.	1.2	48
2337	Production of apoptosis-inducing substances from soybean protein by Clostridium butyricum: Characterization of their toxic effects on human colon carcinoma cells. Cancer Letters, 2009, 277, 190-198.	3.2	9
2338	Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Letters, 2009, 283, 84-91.	3.2	46
2339	Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 1447-1454.	2.0	35
2340	Otolaryngologists may not be doing enough to diagnose pediatric eosinophilic esophagitis. International Journal of Pediatric Otorhinolaryngology, 2009, 73, 1554-1557.	0.4	27
2341	Anti-metastatic potential of Punarnavine, an alkaloid from Boerhaavia diffusa Linn Immunobiology, 2009, 214, 245-255.	0.8	36
2342	Apoptosis-Inducing Factor and Colon Cancer. Journal of Surgical Research, 2009, 151, 163-170.	0.8	62
2343	Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line. Human Immunology, 2009, 70, 1010-1015.	1.2	18
2344	Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Human Pathology, 2009, 40, 1790-1797.	1.1	48
2345	Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases. Medical Hypotheses, 2009, 73, 387-388.	0.8	3
2346	"Collision―metastasis from unknown primary squamous cell carcinoma and papillary microcarcinoma of thyroid presenting as lateral cervical cystic mass. Auris Nasus Larynx, 2009, 36, 372-375.	0.5	7
2347	Chloroquine Inhibits Colon Cancer Cell Growth <i>In Vitro</i> and Tumor Growth <i>In Vivo</i> via Induction of Apoptosis. Cancer Investigation, 2009, 27, 286-292.	0.6	83
2348	DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Review of Molecular Diagnostics, 2009, 9, 243-257.	1.5	61
2349	Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointestinal Endoscopy, 2009, 70, 290-296.	0.5	72

#	Article	IF	CITATIONS
2350	Comparing Eccentric Resistance Exercise in Prostate Cancer Survivors On and Off Hormone Therapy: A Pilot Study. PM and R, 2009, 1, 1019-1024.	0.9	46
2351	Maintenance of white matter integrity in a rat model of radiation-induced cognitive impairment. Journal of the Neurological Sciences, 2009, 285, 178-184.	0.3	39
2352	TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer, 2009, 63, 98-105.	0.9	19
2353	Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer. Lung Cancer, 2009, 63, 360-367.	0.9	50
2354	A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer, 2009, 65, 187-191.	0.9	32
2355	PIK3CA alterations in Middle Eastern ovarian cancers. Molecular Cancer, 2009, 8, 51.	7.9	36
2357	Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 551-579.	9.6	110
2358	Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC). Cancer Investigation, 2009, 27, 877-884.	0.6	41
2359	Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Hematology/Oncology Clinics of North America, 2009, 23, 1121-1135.	0.9	35
2360	Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening. Journal of Chemical Information and Modeling, 2009, 49, 1420-1427.	2.5	15
2361	A min-max framework of cascaded classifier with multiple instance learning for computer aided diagnosis. , 2009, , .		2
2362	Dosimetric Evaluation of Heterogeneity Corrections for RTOG 0236: Stereotactic Body Radiotherapy of Inoperable Stage I-II Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1235-1242.	0.4	162
2363	Hormonoterapia como primer tratamiento en pacientes no subsidiarias de cirugÃa en cáncer de mama. Progresos En Obstetricia Y Ginecologia, 2009, 52, 14-24.	0.0	0
2364	Clinicopathological significance of cyclin A, p27 and Skp2 in ovarian epithelial tumors. Basic and Applied Pathology, 2009, 2, 53-58.	0.2	0
2365	Computer-aided Diagnosis of Soft Tissue Tumors on High-resolution Ultrasonography with Geometrical and Morphological Features. Academic Radiology, 2009, 16, 618-626.	1.3	11
2366	RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease. Neoplasia, 2009, 11, 956-963.	2.3	76
2367	An Overview of the Cancer Burden for Primary Care Physicians. Primary Care - Clinics in Office Practice, 2009, 36, 439-454.	0.7	9
2368	Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scandinavian Journal of Gastroenterology, 2009, 44, 782-786.	0.6	113

#	Article	IF	CITATIONS
2369	High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients. Pancreas, 2009, 38, 154-160.	0.5	30
2370	Antimetastatic Effects of Liposomal Gemcitabine and Empty Liposomes in an Orthotopic Mouse Model of Pancreatic Cancer. Pancreas, 2009, 38, 330-337.	0.5	51
2371	Preoperative Serum Placenta Growth Factor Level Is a Prognostic Biomarker in Colorectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 1630-1636.	0.7	32
2372	A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2009, 31, 936-941.	0.3	84
2373	Eyelid and Periorbital Cutaneous Malignant Melanoma. International Ophthalmology Clinics, 2009, 49, 25-43.	0.3	18
2374	RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma. Blood, 2009, 114, 619-629.	0.6	103
2375	Long-term outcome of adult acute lymphoblastic leukemia in Lebanon. Hematology/ Oncology and Stem Cell Therapy, 2009, 2, 333-339.	0.6	8
2376	Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 913-920.	0.6	40
2377	Diagnostic and Therapeutic Applications of Video-Assisted Mediastinoscopy. Clinical Pulmonary Medicine, 2010, 17, 177-183.	0.3	0
2378	Preoperative Local Staging of Esophageal Carcinoma Using Dual-Phase Contrast-Enhanced Imaging With Multi-Detector Row Computed Tomography. Journal of Computer Assisted Tomography, 2010, 34, 406-412.	0.5	8
2379	Automated Telephone Calls Improved Completion of Fecal Occult Blood Testing. Medical Care, 2010, 48, 604-610.	1.1	66
2380	Is there a link between dementia and cancer?. Aging Health, 2010, 6, 361-364.	0.3	1
2381	Chronomodulated chemotherapy versus conventional chemotherapy for Advanced and /or Metastatic Colorectal Cancer. The Cochrane Library, 0, , .	1.5	0
2382	Perceptions of Race/Ethnic Discrimination in Relation to Mortality Among Black Women. Archives of Internal Medicine, 2010, 170, 896.	4.3	48
2383	Association of Intravesical Tumor Location With Metastases to the Pelvic Lymph Nodes in Transitional Cell Cancer of the Bladder. American Journal of the Medical Sciences, 2010, 339, 341-344.	0.4	12
2384	Dose-response efficacy of caraway (Carum carvi L.) on tissue lipid peroxidation and antioxidant profile in rat colon carcinogenesis. Journal of Pharmacy and Pharmacology, 2010, 58, 1121-1130.	1.2	23
2385	Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews, 2010, 62, 346-361.	6.6	376
2386	Small (â‰ <b>¤</b> Âcm) cortical renal tumors: characterization with multidetector CT. Abdominal Imaging, 2010, 35, 488-493.	2.0	36

#	Article	IF	CITATIONS
2387	Shortâ€Term and Longâ€Term Outcomes After Simultaneous Resection of Colorectal Malignancies and Synchronous Liver Metastases. World Journal of Surgery, 2010, 34, 2133-2140.	0.8	39
2388	Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. Cancer Chemotherapy and Pharmacology, 2010, 65, 825-831.	1.1	15
2389	Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemotherapy and Pharmacology, 2010, 66, 209-218.	1.1	23
2390	Medullary thyroid cancer: RET testing of an archival material. European Archives of Oto-Rhino-Laryngology, 2010, 267, 613-617.	0.8	8
2391	XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Journal of Cancer Research and Clinical Oncology, 2010, 136, 779-786.	1.2	22
2392	Epidemiology, molecular changes, histopathology and diagnosis of colorectal cancer. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 252-259.	0.3	2
2393	Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift, 2010, 122, 368-379.	1.0	7
2394	Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. Journal of Gastroenterology, 2010, 45, 37-44.	2.3	114
2395	Management of liver metastases from colorectal cancer. Clinical Journal of Gastroenterology, 2010, 3, 128-135.	0.4	2
2396	Gastric Carcinoma—A Big Challenge in a Poor Economy. Journal of Gastrointestinal Cancer, 2010, 41, 101-106.	0.6	8
2397	Survival Benefit of Non-curative Gastrectomy for Gastric Cancer Patients with Synchronous Distant Metastasis. Journal of Gastrointestinal Surgery, 2010, 14, 282-288.	0.9	33
2398	Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Research and Treatment, 2010, 120, 245-251.	1.1	53
2399	Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Clinical and Experimental Metastasis, 2010, 27, 19-23.	1.7	22
2400	Characterization of a new renal cell carcinoma bone metastasis mouse model. Clinical and Experimental Metastasis, 2010, 27, 319-330.	1.7	27
2401	17β-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells. Molecular and Cellular Biochemistry, 2010, 342, 63-70.	1.4	24
2402	Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics, 2010, 6, 156-163.	1.4	77
2403	Recent Trends for Colorectal Cancer Screening in HIV-Infected Patients. Digestive Diseases and Sciences, 2010, 55, 761-766.	1.1	20
2404	Predicting factors of adjustment in Iranian children with cancer. Procedia, Social and Behavioral Sciences, 2010, 5, 859-864.	0.5	2

#	Article	IF	CITATIONS
2405	Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer. Seminars in Radiation Oncology, 2010, 20, 186-191.	1.0	23
2406	Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?. BMC Cancer, 2010, 10, 224.	1.1	18
2407	Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer, 2010, 10, 281.	1.1	32
2408	Relationship between tumor size and disease stage in non-small cell lung cancer. BMC Cancer, 2010, 10, 474.	1.1	29
2409	Intraabdominal and retroperitoneal soft-tissue sarcomas - outcome of surgical treatment in primary and recurrent tumors. World Journal of Surgical Oncology, 2010, 8, 81.	0.8	14
2410	Pro-apoptotic activity of ergosterol peroxide and (22E)-ergosta-7,22-dien-5α-hydroxy-3,6-dione in human prostate cancer cells. Chemico-Biological Interactions, 2010, 184, 352-358.	1.7	38
2411	The effects of ganoderma alcohols isolated from Ganoderma lucidum on the androgen receptor binding and the growth of LNCaP cells. Fìtoterapìâ, 2010, 81, 1067-1072.	1.1	16
2412	The effects of paclitaxel, dose density, and trastuzumab on treatmentâ€related amenorrhea in premenopausal women with breast cancer. Cancer, 2010, 116, 791-798.	2.0	131
2413	Central nervous system prophylaxis in adults with acute lymphoblastic leukemia. Cancer, 2010, 116, 2290-2300.	2.0	77
2414	Overexpressed epidermal growth factor receptor (EGFR)â€induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogenâ€activated protein kinase signaling pathway. Cancer, 2010, 116, 3603-3613.	2.0	27
2415	Inhibition of cytosolic chaperonin CCTζâ€1 expression depletes proliferation of colorectal carcinoma in vitro. Journal of Surgical Oncology, 2010, 102, 419-423.	0.8	27
2416	A dosimetric analysis of 6MV versus 15MV photon energy plans for intensity modulated radiation therapy (IMRT) of carcinoma of cervix. Reports of Practical Oncology and Radiotherapy, 2010, 15, 125-131.	0.3	17
2417	Investigation on supraphysiological thermal injury in two well-differentiated human hepatoma cell lines, HepG2 and Hep3B. Journal of Thermal Biology, 2010, 35, 411-416.	1.1	2
2418	Synthesis, in vitro structure–activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorganic and Medicinal Chemistry, 2010, 18, 477-495.	1.4	35
2419	Review role of topotecan in gynaecological cancers: Current indications and perspectives. Critical Reviews in Oncology/Hematology, 2010, 74, 163-174.	2.0	53
2420	Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell International, 2010, 10, 16.	1.8	106
2421	MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Medical Genomics, 2010, 3, 16.	0.7	55
2422	Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. Journal of Ovarian Research, 2010, 3, 9.	1.3	6

#	Article	IF	CITATIONS
2423	Development of decisionâ€support intervention for Black women with breast cancer. Psycho-Oncology, 2010, 19, 62-70.	1.0	48
2424	Characterization of a novel novobiocin analogue as a putative Câ€ŧerminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate, 2010, 70, 27-36.	1.2	42
2425	Chemomodulation of the antioxidative enzymes and peroxidative damage in the colon of 1,2â€dimethyl hydrazineâ€induced rats by ellagicacid. Phytotherapy Research, 2010, 24, S114-9.	2.8	21
2426	End of life in children with cancer: Experience at the Pediatric Oncology Department of the Istituto Nazionale Tumori in Milan. Pediatric Blood and Cancer, 2010, 54, 88-91.	0.8	25
2427	The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG: an International Journal of Obstetrics and Gynaecology, 2010, 117, 1451-1458.	1.1	55
2428	Activation of câ€Jun Nâ€terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells. British Journal of Pharmacology, 2010, 160, 1171-1184.	2.7	55
2429	Effects of Chronic Lymphocytic Leukemia on the Development and Progression of Malignant Melanoma. Dermatologic Surgery, 2010, 36, 368-376.	0.4	24
2430	Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene, 2010, 29, 4449-4459.	2.6	71
2431	Endoscopic resection of ampullary adenomas: Novel technique to reduce post procedure pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1338-1339.	1.4	1
2432	Diseases of the Breast. , 2010, , 458-461.		0
2433	MicroRNA as a Novel Modulator in Head and Neck Squamous Carcinoma. Journal of Oncology, 2010, 2010, 2010, 1-15.	0.6	20
2434	High cadmium / zinc ratio in cigarette smokers: potential implications as a biomarker of risk of prostate cancer Tropical Freshwater Biology, 2010, 23, 41-9.	0.1	18
2435	Laparoscopic Radicai Prostatectomy without Ligation of the Santorini's VenousPlexus. Urologia, 2010, 77, 57-62.	0.3	2
2436	Peritoneal carcinosis of ovarian origin. World Journal of Gastrointestinal Oncology, 2010, 2, 102.	0.8	37
2437	Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in Immunochemical Fecal Occult Blood Test–Positive Individuals. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2647-2654.	1.1	24
2438	Increased Number of CpG Island Hypermethylation in Tumor Suppressor Genes of Non-Neoplastic Gastric Mucosa Correlates with Higher Risk of Gastric Cancer. Digestion, 2010, 82, 27-36.	1.2	22
2439	Infantile Intracranial Neoplasms: Characteristics and Surgical Outcomes of a Contemporary Series of 21 Cases in an Egyptian Referral Center. Pediatric Neurosurgery, 2010, 46, 272-282.	0.4	14
2440	Pattern of Presentation and Survival of Breast Cancer in a Teaching Hospital in North Western Nigeria. Oman Medical Journal, 2010, 25, 104-107.	0.3	40

#	Article	IF	CITATIONS
2441	Soft tissue sarcoma of the thigh: Need for angiography in the developing countries. Annals of African Medicine, 2010, 9, 39.	0.2	3
2442	A New Access for Implantation of a Malleable Penile Prosthesis During Perineal Radical Prostatectomy. UroToday International Journal, 2010, 03, .	0.1	0
2443	Immunomodulatory Effects of <i>Withania Somnifera</i> on Azoxymethane Induced Experimental Colon Cancer in Mice. Immunological Investigations, 2010, 39, 688-698.	1.0	40
2444	Hematologic and Molecular Responses to Generic Imatinib in Patients With Chronic Myeloid Leukemia. Laboratory Medicine, 2010, 41, 547-550.	0.8	14
2445	Role of Pelvic Lymph Node Dissection in Lymph Node-Negative Patients with Invasive Bladder Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 247-251.	0.6	17
2446	CyberKnife Stereotactic Radiotherapy as Monotherapy for Low- to Intermediate-Stage Prostate Cancer: Early Experience, Feasibility, and Tolerance. Journal of Endourology, 2010, 24, 865-869.	1.1	48
2447	Endoscopic stenting for palliation of malignant biliary obstruction. Expert Review of Medical Devices, 2010, 7, 681-691.	1.4	21
2448	Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opinion on Emerging Drugs, 2010, 15, 1-11.	1.0	11
2449	Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors. Journal of Epidemiology and Community Health, 2010, 64, 117-123.	2.0	106
2450	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131.	0.3	15
2450 2451		0.3 3.0	15 15
	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131. Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free		
2451	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131. Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma	3.0	15
2451 2452	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131. Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biology and Therapy, 2010, 9, 423-429. Applying Community-Based Participatory Research Principles and Approaches in Clinical Trials: Forging a New Model for Cancer Clinical Research. Progress in Community Health Partnerships: Research,	3.0 1.5	15 30
2451 2452 2453	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131. Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biology and Therapy, 2010, 9, 423-429. Applying Community-Based Participatory Research Principles and Approaches in Clinical Trials: Forging a New Model for Cancer Clinical Research. Progress in Community Health Partnerships: Research, Education, and Action, 2010, 4, 37-46. The presence of JC virus in gastric carcinomas correlates with patient's age, intestinal histological	3.0 1.5 0.2	15 30 37
2451 2452 2453 2454	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131. Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biology and Therapy, 2010, 9, 423-429. Applying Community-Based Participatory Research Principles and Approaches in Clinical Trials: Forging a New Model for Cancer Clinical Research. Progress in Community Health Partnerships: Research, Education, and Action, 2010, 4, 37-46. The presence of JC virus in gastric carcinomas correlates with patient's age, intestinal histological type and aberrant methylation of tumor suppressor genes. Modern Pathology, 2010, 23, 522-530.	3.0 1.5 0.2 2.9	15 30 37 24
2451 2452 2453 2454 2455	Lung cancer in the Kashmir valley. Lung India, 2010, 27, 131. Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biology and Therapy, 2010, 9, 423-429. Applying Community-Based Participatory Research Principles and Approaches in Clinical Trials: Forging a New Model for Cancer Clinical Research. Progress in Community Health Partnerships: Research, Education, and Action, 2010, 4, 37-46. The presence of JC virus in gastric carcinomas correlates with patient's age, Intestinal histological type and aberrant methylation of tumor suppressor genes. Modern Pathology, 2010, 23, 522-530. Gene Therapy for Prostate Cancer. Postgraduate Medicine, 2010, 122, 166-180. Studies on the Mechanism of Action of Dextrinâ <sup>o</sup> Phospholipase A <sub>2</sub> and Its Suitability for	3.0 1.5 0.2 2.9 0.9	15 30 37 24 13

		CITATION R	EPORT	
#	Article		IF	CITATIONS
2459	Complications of Laparoscopic and Robotic-Assisted Radical Cystectomy. , 2010, , 233	-245.		2
2460	Recognition and characterization of small colonic neoplasia with high-definition colonc i-Scan is as precise as chromoendoscopy. Digestive and Liver Disease, 2010, 42, 45-50.		0.4	101
2461	Ethnic issues in endoscopy. Gastrointestinal Endoscopy, 2010, 71, 1108-1112.		0.5	23
2462	A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretrowith non-small cell lung cancer. Lung Cancer, 2010, 70, 71-76.	eated patients	0.9	16
2463	Pancreatic cancer stem cells $\hat{a} {\in} ``$ update and future perspectives. Molecular Oncology,	2010, 4, 431-442.	2.1	74
2464	<i>Ipomoea obscura </i> ameliorates cyclophosphamide-induced toxicity by modulating system and levels of proinflammatory cytokine and GSH. Canadian Journal of Physiolog Pharmacology, 2010, 88, 1042-1053.	g the immune yy and	0.7	14
2465	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therap Renal Cell Carcinoma. Journal of Translational Medicine, 2010, 8, 8.	y in metastatic	1.8	29
2466	Efficacy and Toxicity of Chemoradiation in the Treatment of HIV-Associated Anal Cance Colorectal Cancer, 2010, 9, 238-242.	er. Clinical	1.0	14
2467	The Impact of Age on the Treatment and Survival of Ovarian Cancer Patients. Clinical C Other Gynecologic Malignancies, 2010, 3, 122-125.	Ivarian Cancer &	0.2	1
2469	Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. Nat Urology, 2010, 7, 84-93.	ure Reviews	1.9	30
2470	Chronic Myelogenous Leukemia. , 2010, , 193-211.			0
2471	Expression of the vitamin D receptor, 25-hydroxylases, 1α-hydroxylase and 24-hydroxy kidney and renal clear cell cancer. Journal of Steroid Biochemistry and Molecular Biolog 376-382.		1.2	69
2472	Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer I 296, 74-87.	_etters, 2010,	3.2	9
2473	Having progress with upfront chemotherapy in ovarian cancer. Is it still a possible goal Journal of Cancer, 2010, 46, 2140-2142.	?. European	1.3	1
2474	Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hy European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 150, 80-8		0.5	30
2475	Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading carcinoma: Initial results. European Journal of Radiology, 2010, 74, e176-e180.	g of renal cell	1.2	27
2476	Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochen Biophysical Research Communications, 2010, 392, 373-379.	nical and	1.0	218
2477	Antileukemic action of (â^)-epicatechin in the spleen of rats with acute myeloid leuken Chemical Toxicology, 2010, 48, 3391-3397.	nia. Food and	1.8	16

#	Article	IF	CITATIONS
2478	Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 290-295.	0.8	2
2479	Secretomic and Proteomic Analysis of Potential Breast Cancer Markers by Two-Dimensional Differential Gel Electrophoresis. Journal of Proteome Research, 2010, 9, 1302-1322.	1.8	82
2480	The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Molecular Imaging and Biology, 2010, 12, 98-107.	1.3	97
2481	Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reproductive BioMedicine Online, 2010, 21, 566-571.	1.1	88
2482	Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine, 2010, 5, 1435-1445.	1.7	38
2483	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncology, The, 2010, 11, 561-570.	5.1	576
2484	Recombinant Human Interleukin-24 Suppresses Gastric Carcinoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> . Cancer Investigation, 2010, 28, 85-93.	0.6	23
2485	Promoter Methylation Status of Multidrug Resistance 1 (MDR1) Gene in Noncancerous Gastric Mucosa Correlates With <i>Helicobacter Pylori</i> Infection and Gastric Cancer Occurrence. Cancer Investigation, 2010, 28, 711-716.	0.6	7
2486	Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. Journal of Experimental and Clinical Cancer Research, 2010, 29, 108.	3.5	67
2487	Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2010, 29, 28.	3.5	37
2488	First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Review of Anticancer Therapy, 2010, 10, 47-60.	1.1	84
2489	Modulating effect of <i>Withania somnifera</i> on TCA cycle enzymes and electron transport chain in azoxymethane-induced colon cancer in mice. Immunopharmacology and Immunotoxicology, 2010, 32, 523-527.	1.1	16
2490	Automatic detection of abnormalities in lung radiographs caused by planocellular lung cancer. , 2011, , ,		1
2491	Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer. International Reviews of Immunology, 2011, 30, 127-137.	1.5	58
2492	Andrographolide Inhibits Oral Squamous Cell Carcinogenesis through NF-κB Inactivation. Journal of Dental Research, 2011, 90, 1246-1252.	2.5	47
2493	Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. British Journal of Cancer, 2011, 105, 640-648.	2.9	71
2494	7149 POSTER Sequential Use of Targeted Therapies (TT) in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience. European Journal of Cancer, 2011, 47, S520.	1.3	0
2495	Proportion of Flat- and Depressed-Type and Laterally Spreading Tumor Among Advanced Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2011, 9, 503-508.	2.4	63

#	Article	IF	CITATIONS
2496	Pancreatic Cancer: The Role of Pancreatic Stellate Cells in Tumor Progression. Pancreatology, 2011, 10, 673-681.	0.5	104
2497	Lung Cancer in Women: a Comparison with Men and an Analysis of Cases Diagnosed in Ourense (Spain) 1999–2006. Archivos De Bronconeumologia, 2011, 47, 61-65.	0.4	5
2498	Modern Transurethral Resection in the Management of Superficial Bladder Tumours. British Journal of Medical and Surgical Urology, 2011, 4, 91-100.	0.2	5
2499	The Current Role of Partial Surgery As a Strategy for Functional Preservation in Laryngeal Carcinoma. Acta Otorrinolaringologica (English Edition), 2011, 62, 231-238.	0.1	11
2500	Use of Tamoxifen With Postsurgical Irradiation May Improve Survival in Estrogen and Progesterone Receptor–Positive Male Breast Cancer. Clinical Breast Cancer, 2011, 11, 39-45.	1.1	48
2501	Dural Metastases from Disseminated Prostate Cancer Clinically Mimicking a Benign Reactive Condition of the Dura: Case Report and Review of the Literature. Urologia Internationalis, 2011, 86, 239-241.	0.6	5
2502	Pictorial Essay: The Value of Rectal Water in the Assessment of Rectosigmoid Pathology. Canadian Association of Radiologists Journal, 2011, 62, 110-121.	1.1	0
2503	Melanoma. Methods in Molecular Biology, 2011, 727, 123-139.	0.4	4
2504	Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature. Cancer Treatment Reviews, 2011, 37, 444-455.	3.4	37
2505	miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomedicine and Pharmacotherapy, 2011, 65, 436-442.	2.5	40
2506	Tumor–host cell interactions in the bone disease of myeloma. Bone, 2011, 48, 121-128.	1.4	49
2507	Glucocorticoid receptor signaling and prostate cancer. Cancer Letters, 2011, 302, 1-10.	3.2	53
2508	Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Letters, 2011, 303, 47-55.	3.2	192
2509	The soluble EP2 receptor FuEP2/Ex2 suppresses endometrial cancer cell growth in an orthotopic xenograft model in nude mice. Cancer Letters, 2011, 306, 67-75.	3.2	8
2510	Atypical squamous cells of undetermined significance in postmenopausal women: a comparative retrospective analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 159, 418-421.	0.5	9
2511	Assessment of symptom control in patients with cancer in Northwestern Turkey. European Journal of Oncology Nursing, 2011, 15, 137-144.	0.9	25
2512	Adult pancreatic rhabdomyosarcoma: One rear case and review of the literature. European Journal of Radiology Extra, 2011, 79, e21-e22.	0.1	1
2513	Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells. Biochemical and Biophysical Research Communications, 2011, 405, 168-172.	1.0	33

		CITATION R	EPORT	
#	Article		IF	CITATIONS
2514	Inhibition of estrogen actions in human gynecological malignancies: New aspects of er therapy for endometrial cancer and ovarian cancer. Molecular and Cellular Endocrinolo 161-167.	ıdocrine gy, 2011, 340,	1.6	31
2515	Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-E in vivo study of treating androgen-independent intraosseous prostate cancer. Urologic Seminars and Original Investigations, 2011, 29, 624-633.		0.8	5
2516	A retrospective study of pemetrexed combined with oxaliplatin as secondâ€line treatm nonâ€smallâ€cell lung cancer: Comparable toxicity, better outcome. Thoracic Cancer,		0.8	0
2517	Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of s ovarian cancer in mice. Cancer Gene Therapy, 2011, 18, 100-109.	olid human	2.2	14
2518	The Role of the Immune System in Hematologic Malignancies that Affect Bone. , 2011,	, 391-409.		0
2519	Phase II Trial of Oxaliplatin and Capecitabine After Progression to First-Line Chemother Androgen-Independent Prostate Cancer Patients. American Journal of Clinical Oncolog Clinical Trials, 2011, 34, 155-159.		0.6	18
2520	Proteomic Analysis of Potential Breast Cancer Biomarkers. , 2011, , .			1
2521	Prostate Cancer: Essential Diagnostic and Therapeutic Considerations. , 0, , .			0
2522	Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with co and 150 healthy blood donors Annals of Cancer Research and Therapy, 2011, 19, 15-	plorectal cancer 19.	0.1	3
2523	Surgical Treatment of Pulmonary Metastases from Melanoma: Emerging Options. , 202	11,,.		0
2524	The Value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer Journal of Medical Sciences, 2011, 8, 148-155.	. International	1.1	14
2525	Prognostic Significance of Preoperative C-Reactive Protein Elevation and Thrombocyto with Non-Metastatic Renal Cell Carcinoma. Korean Journal of Urology, 2011, 52, 104.	sis in Patients	1.2	20
2526	Prognostic Factors for Gastric Cancer Patients with Synchronous Metastasis. [Chapchi Taehan Oekwa Hakhoe, 2011, 80, 16.	] Journal	1.1	0
2527	Solitary and Multiple Pulmonary Nodules. , 2011, , 451-459.			0
2528	The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma. Internatio Surgical Oncology, 2011, 2011, 1-14.	nal Journal of	0.3	33
2529	Holoclone Forming Cells from Pancreatic Cancer Cells Enrich Tumor Initiating Cells and Novel Model for Study of Cancer Stem Cells. PLoS ONE, 2011, 6, e23383.	Represent a	1.1	43
2530	Do DNA-Methylation and Histone Acetylation Play a Role in Clear Cell Renal Carcinoma Radical Nephrectomy Specimens in a Long-Term Follow-up. International Journal of Imr and Pharmacology, 2011, 24, 149-158.	? Analysis of nunopathology	1.0	8
2531	Vaccines for Colorectal Cancer and Renal Cell Carcinoma. Cancer Journal (Sudbury, Ma 283-293.	ss ), 2011, 17,	1.0	6

	CITATION N	LEPUKI	
# 2532	ARTICLE Unexpected Findings on Gallium-67 Scintigraphy. Clinical Nuclear Medicine, 2011, 36, 132-133.	IF 0.7	Citations
2533	Influence of CXCR4/SDF-1 axis on E-cadherin/β-catenin complex expression in HT29 colon cancer cells. World Journal of Gastroenterology, 2011, 17, 625.	1.4	22
2534	Radioprotectors and Chemoprotectors in the Management of Lung Cancer. Medical Radiology, 2011, , 223-245.	0.0	0
2535	Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system. BJU International, 2011, 107, 1216-1222.	1.3	28
2536	Prognostic models for renal cell carcinoma recurrence: External validation in a Japanese population. International Journal of Urology, 2011, 18, 667-671.	0.5	10
2537	Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Science, 2011, 102, 622-629.	1.7	15
2538	Declined Guideline Adherence in Older Breast Cancer Patients: A Population-Based Study in The Netherlands. Breast Journal, 2011, 17, 239-245.	0.4	32
2539	Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS Journal, 2011, 278, 16-27.	2.2	1,305
2540	Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene, 2011, 30, 201-211.	2.6	78
2541	Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia, 2011, 25, 1314-1323.	3.3	63
2543	Clinicopathologic Considerations: How Can We Fine Tune Our Approach to Sarcoma?. Seminars in Oncology, 2011, 38, S3-S18.	0.8	50
2544	Tos crónica como presentación de un cáncer de pulmón. FMC Formacion Medica Continuada En Atencion Primaria, 2011, 18, 673-674.	0.0	0
2545	ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. BMC Cancer, 2011, 11, 229.	1.1	52
2546	Exploring the uncertainties of early detection results: model-based interpretation of mayo lung project. BMC Cancer, 2011, 11, 92.	1.1	3
2547	Nuclear beta-catenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer. Diagnostic Pathology, 2011, 6, 109.	0.9	19
2548	Estrogen receptor beta expression in prostate adenocarcinoma. Diagnostic Pathology, 2011, 6, 61.	0.9	23
2549	An unusual case of persistent groin pain after total hip arthroplasty: a case report. Journal of Medical Case Reports, 2011, 5, 67.	0.4	4
2550	A novel method for color correction in epiluminescence microscopy. Computerized Medical Imaging and Graphics, 2011, 35, 646-652.	3.5	31

			_
#	Article	IF	CITATIONS
2551	Cáncer de pulmón en mujeres, comparativo con hombres: análisis de los casos diagnosticados en el Complexo Hospitalario de Ourense entre 1999 y 2006. Archivos De Bronconeumologia, 2011, 47, 61-65.	0.4	9
2552	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radical Biology and Medicine, 2011, 50, 313-322.	1.3	49
2553	LHRH-conjugated lytic peptides directly target prostate cancer cells. Biochemical Pharmacology, 2011, 81, 104-110.	2.0	29
2554	Multi-target drug discovery in anti-cancer therapy: Fragment-based approach toward the design of potent and versatile anti-prostate cancer agents. Bioorganic and Medicinal Chemistry, 2011, 19, 6239-6244.	1.4	60
2555	Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Molecular BioSystems, 2011, 7, 2997.	2.9	31
2556	Predictors of Inpatient Death and Complications among Postoperative Elderly Patients with Metastatic Brain Tumors. Annals of Surgical Oncology, 2011, 18, 521-528.	0.7	46
2557	Prognostic Value of Nuclear β-catenin Overexpression at Invasive Front in Colorectal Cancer for Synchronous Liver Metastasis. Annals of Surgical Oncology, 2011, 18, 1553-1559.	0.7	21
2558	Breast Cancer in Hong Kong, Southern China: The First Population-Based Analysis of Epidemiological Characteristics, Stage-Specific, Cancer-Specific, and Disease-Free Survival in Breast Cancer Patients: 1997–2001. Annals of Surgical Oncology, 2011, 18, 3072-3078.	0.7	44
2559	Tumor–stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clinical and Experimental Metastasis, 2011, 28, 779-791.	1.7	17
2560	MUTYH Tyr165Cys, OGG1 Ser326Cys and XPD Lys751Gln polymorphisms and head neck cancer susceptibility: a case control study. Molecular Biology Reports, 2011, 38, 1251-1261.	1.0	25
2561	Association between age and synchronous liver metastasis in female colorectal cancer patients. Journal of Cancer Research and Clinical Oncology, 2011, 137, 959-964.	1.2	1
2562	Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1371-1377.	1.2	17
2563	Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1435-1444.	1.2	8
2564	A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. International Journal of Colorectal Disease, 2011, 26, 583-592.	1.0	20
2565	Effect of preoperative neutrophil–lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. International Journal of Colorectal Disease, 2011, 26, 1059-1065.	1.0	118
2566	Current topics in colorectal liver metastasis. International Journal of Clinical Oncology, 2011, 16, 451-451.	1.0	1
2567	Early postoperative discharge following radical vulvectomy and bilateral inguinal lymphadenectomy for vulvar carcinoma. Gynecological Surgery, 2011, 8, 89-91.	0.9	3
2570	Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdominal Imaging, 2011, 36, 38-45.	2.0	37

#	Article	IF	CITATIONS
2571	Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2011, 60, 1497-1502.	2.0	80
2572	CEA is an Independent Prognostic Indicator that is Associated with Reduced Survival and Liver Metastases in SCLC. Cell Biochemistry and Biophysics, 2011, 59, 113-119.	0.9	23
2573	GUCY2C-targeted cancer immunotherapy: past, present and future. Immunologic Research, 2011, 51, 161-169.	1.3	10
2574	Effects of a Weight Loss Intervention on Body Mass, Fitness, and Inflammatory Biomarkers in Overweight or Obese Breast Cancer Survivors. International Journal of Behavioral Medicine, 2011, 18, 333-341.	0.8	85
2575	Collecting duct carcinoma of the kidney. Hellenike Cheirourgike Acta Chirurgica Hellenica, 2011, 83, 225-229.	0.1	0
2576	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer, 2011, 11, 31.	1.1	86
2577	A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. BMC Cancer, 2011, 11, 510.	1.1	12
2578	The HOPE fixation technique - a promising alternative to common prostate cancer biobanking approaches. BMC Cancer, 2011, 11, 511.	1.1	27
2579	Spatial-temporal analysis of non-Hodgkin lymphoma in the NCI-SEER NHL case-control study. Environmental Health, 2011, 10, 63.	1.7	27
2580	In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer. BMC Systems Biology, 2011, 5, 144.	3.0	12
2581	JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells. Journal of Biomedical Science, 2011, 18, 61.	2.6	24
2582	Shortâ€ŧerm cancer mortality projections: A comparative study of prediction methods. Statistics in Medicine, 2011, 30, 3387-3402.	0.8	20
2583	Imageâ€Guided Prostate Cancer Therapy Using Aptamerâ€Functionalized Thermally Crossâ€Linked Superparamagnetic Iron Oxide Nanoparticles. Small, 2011, 7, 2241-2249.	5.2	205
2584	Highâ€risk stage II colon cancer after curative resection. Journal of Surgical Oncology, 2011, 104, 45-52.	0.8	37
2585	Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer?. Journal of Magnetic Resonance Imaging, 2011, 33, 167-172.	1.9	105
2586	Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptori± and i². Journal of Cellular Physiology, 2011, 226, 1334-1339.	2.0	40
2587	A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic cancer. Electrophoresis, 2011, 32, 2028-2035.	1.3	27
2588	Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina. Patient Education and Counseling, 2011, 83, 256-260.	1.0	9

ARTICLE IF CITATIONS Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with 2589 0.6 41 Phosphoinositide 3-Kinase. Genes and Cancer, 2011, 2, 753-762. Prevalence of Small Solid Pseudo papillary Tumors. American Journal of Roentgenology, 2011, 197, 2590 1.0 W964-W964. Molecular Mechanism of Silymarin-Induced Apoptosis in a Highly Metastatic Lung Cancer Cell Line 2591 0.7 12 Anip973. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 317-324. Regulatory Role of Zinc on the Biokinetics and Biodistribution of 65Zn During the Initiation of 2592 0.9 Experimentally Induced Colon Cancer. Nutrition and Cancer, 2011, 63, 212-217. Coalition Building and the Intervention Wheel to Address Breast Cancer Screening in Hmong Women. 2593 0.4 3 Clinical Medicine and Research, 2011, 9, 1-6. A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated 2594 0.6 Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 63-68. Demethylation of <i>TMS1 </i>Gene Sensitizes Thyroid Cancer Cells to TRAIL-Induced Apoptosis. Journal 2595 1.8 19 of Clinical Endocrinology and Metabolism, 2011, 96, E215-E224. A Narrative Review Summarizing the State of the Evidence on the Health-Related Quality of Life Among 2596 1.5 Childhood Cancer Survivors. Journal of Pediatric Oncology Nursing, 2011, 28, 75-82. Airways colonizations in patients undergoing lung cancer surgerya<sup>-†</sup>. European Journal of 2597 0.6 19 Cardió-thoracic Surgery, 2011, 40, 309-19. Regulation of p21, MMP-1, and MDR-1 Expression in Human Colon Carcinoma HT29 Cells by Tian Xian 2598 0.8 Liquid, a Chinese Medicinal Formula, In Vitro and In Vivo. Integrative Cancer Therapies, 2011, 10, 58-69. Does Racism Affect Health? Evidence from the United States and the United Kingdom. Journal of Health 2599 0.9 10 Politics, Policy and Law, 2011, 36, 187-214. A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior. Clinical Cancer Research, 2011, 17, 2385-2394. 3.2 2601 A new view of radiation-induced cancer. Radiation Protection Dosimetry, 2011, 143, 358-364. 0.4 26 Virtual cystoscopy: the evaluation of bladder lesions with computed tomographic virtual cystoscopy. 0.3 Canadian Urological Association Journal, 2011, 5, 34-37. Mycobacterial Strains That Stimulate the Immune System Most Efficiently as Candidates for the 2603 1.0 22 Treatment of Bladder Cancer. Journal of Molecular Microbiology and Biotechnology, 2011, 20, 24-28. CTLA-4 +49A> G Polymorphism Is Associated with Advanced Non-Small Cell Lung Cancer Prognosis. 2604 1.2 Respiration, 2011, 82, 439-444. mRNA Expression of Bone Morphogenetic Proteins and Their Receptors in Human Renal Cell 2605 0.6 11 Carcinoma. Urologia Internationalis, 2011, 87, 353-358. Evaluation of CXCR4 chemokine receptor as a prognostic marker in colorectal carcinoma. Egyptian Journal of Pathology, 2011, 31, 19-24

#	Article	IF	Citations
2607	Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biology and Therapy, 2011, 11, 50-57.	1.5	44
2608	Roles for Rat Hepatocyte Malignant Transforming Factor (HMTF) in Late Stage of Hepatocarcinogenesis. Toxicologic Pathology, 2011, 39, 1084-1090.	0.9	1
2609	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Review of Anticancer Therapy, 2011, 11, 1631-1640.	1.1	17
2610	A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer, 2011, 105, 346-352.	2.9	108
2611	Incidence and Outcome of Male Breast Cancer: An International Population-Based Study. Journal of Clinical Oncology, 2011, 29, 4381-4386.	0.8	175
2612	Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine. International Journal of Molecular Sciences, 2011, 12, 1595-1604.	1.8	65
2613	Red Mold Rice Mitigates Oral Carcinogenesis in 7,12-Dimethyl-1,2-Benz[a]anthracene-Induced Oral Carcinogenesis in Hamster. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	0.5	13
2614	Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. Clinical Cancer Research, 2011, 17, 560-568.	3.2	40
2615	MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-ÂB signals in gastric cancer cells. Carcinogenesis, 2011, 32, 175-181.	1.3	31
2616	Regulatory T Cells in Colorectal Cancer: From Biology to Prognostic Relevance. Cancers, 2011, 3, 1708-1731.	1.7	18
2617	Apoptotic Cell Death and Inhibition of Wnt/ <i>β</i> -Catenin Signaling Pathway in Human Colon Cancer Cells by an Active Fraction (HS7) from <i>Taiwanofungus camphoratus</i> . Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-13.	0.5	27
2618	Six Novel Susceptibility Loci for Early-Onset Androgenetic Alopecia and Their Unexpected Association with Common Diseases. PLoS Genetics, 2012, 8, e1002746.	1.5	92
2619	Hepatitis B and C Virus Infection and Cholangiocarcinoma: A Case-Control Study in Turkey. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2012, 22, 187-191.	0.1	1
2620	Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma. Cancer Research, 2012, 72, 4504-4514.	0.4	40
2621	Wait Times in Diagnostic Evaluation and Treatment for Patients With Stage III Non-Small Cell Lung Cancer in British Columbia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 373-377.	0.6	11
2622	Angiogenic Activity of Hepatitis B and C Viruses. Antiviral Chemistry and Chemotherapy, 2012, 22, 159-170.	0.3	31
2623	Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle, 2012, 11, 1468-1476.	1.3	18
2624	Spatial-Temporal Analysis of Cancer Risk in Epidemiologic Studies with Residential Histories. Annals of the American Association of Geographers, 2012, 102, 1049-1057.	3.0	15

#	Article	IF	CITATIONS
2625	Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer. Journal of Biological Chemistry, 2012, 287, 29261-29272.	1.6	82
2626	Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Annals of Oncology, 2012, 23, 1795-1802.	0.6	60
2627	Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. British Journal of Cancer, 2012, 106, 107-115.	2.9	55
2628	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death and Disease, 2012, 3, e436-e436.	2.7	137
2629	Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. British Journal of Cancer, 2012, 106, 53-60.	2.9	15
2630	Prostate Anatomy and Prostate Cancer Screening, Diagnosis, Staging, and Prevention. , 2012, , 29-40.		0
2631	Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene, 2012, 31, 2512-2520.	2.6	69
2632	Difficult Differential Diagnoses in Testicular Pathology. Archives of Pathology and Laboratory Medicine, 2012, 136, 435-446.	1.2	67
2633	Primary Care Colorectal Cancer Screening Recommendation Patterns. Medical Decision Making, 2012, 32, 198-208.	1.2	10
2634	Nonpalliative Surgical Resection for Gastric Cancer Patients with Distant Metastasis. Journal of Investigative Surgery, 2012, 25, 100-106.	0.6	10
2635	Effect ofAerva lanataon cell-mediated immune responses and cytotoxic T-lymphocyte generation in normal and tumor-bearing mice. Journal of Immunotoxicology, 2012, 9, 25-33.	0.9	8
2636	The Role of Progesterone and Its Receptor on Cyclin G1 Expression in Endometrial Carcinoma Cells. Reproductive Sciences, 2012, 19, 1205-1210.	1.1	4
2637	Tumor Size as a Prognostic Factor in Gastric Cancer Patient. Journal of Gastric Cancer, 2012, 12, 164.	0.9	28
2638	Role of Nitrative and Oxidative DNA Damage in Inflammation-Related Carcinogenesis. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-11.	3.0	149
2639	Modulatory effects of Crataeva nurvala bark against testosterone and N-methyl-N-nitrosourea-induced oxidative damage in prostate of male albino rats. Pharmacognosy Magazine, 2012, 8, 285.	0.3	6
2640	Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1032-1040.	0.5	28
2641	Mitochondrial Copy Number is Associated with Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1574-1581.	1.1	78
2642	An overview of treatment strategies for cancer pain with a focus on interventional strategies and techniques. Pain Management, 2012, 2, 569-580.	0.7	7

#	Article	IF	CITATIONS
2643	Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Experimental and Therapeutic Medicine, 2012, 3, 555-559.	0.8	42
2644	Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nuclear Medicine Communications, 2012, 33, 613-620.	0.5	75
2645	A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro. Oncology Reports, 2012, 27, 1104-1110.	1.2	12
2646	Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats. Oncology Reports, 2012, 28, 2177-2187.	1.2	18
2647	Transforming growth factor β-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line. Oncology Letters, 2012, 3, 229-233.	0.8	27
2648	<i>Chapter 1</i> : The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality, 1975–2000: An Introduction to the Problem. Risk Analysis, 2012, 32, S6-S13.	1.5	15
2649	Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows <i>In Vivo</i> Antitumor Activity. Clinical Cancer Research, 2012, 18, 5934-5948.	3.2	49
2650	Promoter Methylation in Head and Neck Tumorigenesis. Methods in Molecular Biology, 2012, 863, 187-206.	0.4	9
2651	The Controversies of Statin Therapy. Journal of the American College of Cardiology, 2012, 60, 875-881.	1.2	140
2652	Descriptive epidemiology of gastric adenocarcinoma in the State of Texas by ethnicity: Hispanic versus White non-Hispanic. Gastric Cancer, 2012, 15, 405-413.	2.7	11
2653	Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. International Journal of Clinical Oncology, 2012, 17, 604-609.	1.0	25
2654	Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Research and Treatment, 2012, 136, 495-502.	1.1	52
2655	Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population. Molecular and Cellular Biochemistry, 2012, 368, 119-126.	1.4	12
2656	ls sampling transitional zone in patients who had prior negative prostate biopsy necessary?. International Urology and Nephrology, 2012, 44, 1071-1075.	0.6	2
2657	Optimizing Health Care Resource Utilization in the Surgical Management of Patients With Suspected Lung Cancer. Annals of Thoracic Surgery, 2012, 94, 1667-1672.	0.7	7
2658	Mechanisms of natural brassinosteroid-induced apoptosis of prostate cancer cells. Food and Chemical Toxicology, 2012, 50, 4068-4076.	1.8	45
2659	Followup of Neutrophil-to-Lymphocyte Ratio and Recurrence of Clear Cell Renal Cell Carcinoma. Journal of Urology, 2012, 187, 411-417.	0.2	114
2660	Prostate Specific Antigen Levels and Prostate Cancer Detection Rates in Patients With End Stage Renal Disease. Journal of Urology, 2012, 187, 2061-2067.	0.2	13

#	Article	IF	CITATIONS
2661	NADiA ProsVue Prostate-specific Antigen Slope Is an Independent Prognostic Marker for Identifying Men at Reduced Risk of Clinical Recurrence of Prostate Cancer After Radical Prostatectomy. Urology, 2012, 80, 1319-1327.	0.5	14
2662	Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 169-175.	0.6	21
2663	Expression and association of HER2 with prognosis in early-stage (T1–T2N0M0) non-small cell lung cancer. Tumor Biology, 2012, 33, 1719-1725.	0.8	9
2664	Simultaneous transurethral resection of a bladder tumor and benign prostatic hyperplasia: Four case reports and literature review. Urological Science, 2012, 23, 31-33.	0.2	0
2665	Sentinel Lymph Node in Lung Cancer Surgery. Thoracic Surgery Clinics, 2012, 22, 205-214.	0.4	7
2666	Esperanza y Vida: A Culturally and Linguistically Customized Breast and Cervical Education Program for Diverse Latinas at Three Different United States Sites. Journal of Health Communication, 2012, 17, 160-176.	1.2	50
2667	Upper Tract Urothelial Carcinoma: Current Treatment and Outcomes. Urology, 2012, 79, 749-756.	0.5	49
2668	TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Therapy, 2012, 19, 652-658.	2.2	65
2669	Breast cancer metastasising to the pelvis and abdomen: what the gynaecologist needs to know. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 788-794.	1.1	9
2670	The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of patients with resectable colorectal liver metastases: a meta-analysis. American Journal of Surgery, 2012, 204, 84-92.	0.9	20
2671	Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition. Human Pathology, 2012, 43, 708-719.	1.1	54
2672	Combination of epithelial-mesenchymal transition and cancer stem cell–like phenotypes has independent prognostic value in gastric cancer. Human Pathology, 2012, 43, 520-528.	1.1	97
2673	Silencing of homeobox B9 is associated with down-regulation of CD56 and extrathyroidal extension of tumor in papillary thyroid carcinoma. Human Pathology, 2012, 43, 1221-1228.	1.1	15
2674	Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene, 2012, 499, 303-308.	1.0	11
2675	Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer, 2012, 12, 510.	1.1	55
2676	Diaryl ether derivatives as anticancer agents – a review. MedChemComm, 2012, 3, 1356.	3.5	59
2677	Validation of Dermoscopy as a Real-time Noninvasive Diagnostic Imaging Technique for Actinic Keratosis. Archives of Dermatology, 2012, 148, 1159.	1.7	60
2678	A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells. Cancer Letters, 2012, 326, 199-205.	3.2	20

#	Article	IF	CITATIONS
2679	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2012, 48, 887-892.	0.8	42
2680	Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer, 2012, 75, 38-44.	0.9	65
2681	The Pathology of Melanoma. Dermatologic Clinics, 2012, 30, 445-468.	1.0	22
2682	Expression of MSP58 in human colorectal cancer and its correlation with prognosis. Medical Oncology, 2012, 29, 3136-3142.	1.2	11
2684	Clinical study of a noninvasive multimodal sono-contrast induced spectroscopy system for breast cancer diagnosis. Medical Physics, 2012, 39, 1571-1578.	1.6	4
2685	X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer. Radiation Oncology, 2012, 7, 183.	1.2	19
2686	Association of GSTP1 Ile105Val Polymorphism and Risk of Head and Neck Cancers: A Meta-Analysis of 28 Case-Control Studies. PLoS ONE, 2012, 7, e48132.	1.1	16
2687	Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in Mice. PLoS ONE, 2012, 7, e51848.	1.1	118
2689	Metastatic brain tumors. , 2012, , 864-892.		16
2690	Defective Expression and DNA Variants of TGFBR2 in Chinese Small Cell Lung Carcinoma. , 0, , .		0
2691	Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT). Medicina Oral, Patologia Oral Y Cirugia Bucal, 2012, 17, e94-e101.	0.7	13
2692	AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma. Oncology Letters, 2012, 3, 865-870.	0.8	25
2693	Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. Journal of Gynecologic Oncology, 2012, 23, 175.	1.0	17
2694	p38α MAPK mediates 17βâ€estradiol inhibition of MMPâ€2 and â€9 expression and cell migration in human lovo colon cancer cells. Journal of Cellular Physiology, 2012, 227, 3648-3660.	2.0	32
2695	Fibronectin attachment protein from bacillus Calmetteâ€Guerin as targeting agent for bladder tumor cells. International Journal of Cancer, 2012, 131, 591-600.	2.3	15
2696	Arctigenin Antiâ€Tumor Activity in Bladder Cancer T24 Cell Line Through Induction of Cellâ€Cycle Arrest and Apoptosis. Anatomical Record, 2012, 295, 1260-1266.	0.8	27
2697	Integrating New Therapies in the Treatment of Advanced Melanoma. Current Treatment Options in Oncology, 2012, 13, 327-339.	1.3	8
2698	Long-term adaptation of the human lung tumor cell line A549 to increasing concentrations of hydrogen peroxide. Tumor Biology, 2012, 33, 739-748.	0.8	8

		CITATION RE	PORT	
#	Article		IF	CITATIONS
2699	Hereditary medullary thyroid carcinoma: the management dilemma. Familial Cancer, 20	12, 11, 157-165.	0.9	7
2700	Ovarian tissue cryopreservation for fertility preservation in cancer patients: Successful establishment and feasibility of a multidisciplinary collaboration. Journal of Assisted Rep and Genetics, 2012, 29, 495-502.	roduction	1.2	53
2701	Cervical Cancer Screening, Diagnosis and Treatment Interventions for Racial and Ethnic Systematic Review. Journal of General Internal Medicine, 2012, 27, 1016-1032.	Minorities: A	1.3	77
2703	Possible implication of Mdm2 as a prognostic marker in invasive laryngeal carcinoma. En Archives of Oto-Rhino-Laryngology, 2012, 269, 1795-1804.	uropean	0.8	12
2704	Non-curative gastric resection for patients with stage 4 gastric cancer—a single cente and current review of literature. Langenbeck's Archives of Surgery, 2012, 397, 745-753	r experience	0.8	45
2705	Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 c review of literature. Gastric Cancer, 2012, 15, 131-136.	ases and	2.7	40
2706	Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: Role of H Chemico-Biological Interactions, 2012, 195, 1-10.	sp70 protein.	1.7	48
2707	Expression and Clinical Significance of Ezrin in Non–Small-Cell Lung Cancer. Clinical L 2012, 13, 196-204.	ung Cancer,	1.1	26
2708	Local breast cancer recurrence after mastectomy and immediate breast reconstruction cancer: A meta-analysis. Breast, 2012, 21, 230-236.	for invasive	0.9	106
2709	Nonâ€conventional radiotherapy versus conventional radiotherapy for inoperable nonâ cancer: A metaâ€analysis of randomized clinical trials. Thoracic Cancer, 2012, 3, 269-27	€smallâ€cell lung '9.	0.8	7
2710	Saliva: A potential media for disease diagnostics and monitoring. Oral Oncology, 2012,	48, 569-577.	0.8	219
2711	Proteomic analysis of differentially expressed serum proteins in lung cancer. Open Life 5 7, 343-353.	iciences, 2012,	0.6	2
2712	Application of surface-enhanced Raman in skin cancer by plasma. Laser Physics, 2012, 2	2, 996-1001.	0.6	3
2713	Modulation of angiogenesis by dietary phytoconstituents in the prevention and interve cancer. Molecular Nutrition and Food Research, 2012, 56, 14-29.	ntion of breast	1.5	55
2714	Monascus purpureus-fermented products and oral cancer: a review. Applied Microbiolog Biotechnology, 2012, 93, 1831-1842.	gy and	1.7	34
2715	Impact of Clinical and Pathohistological Characteristics on the Incidence of Recurrence in Elderly Patients with Gastric Cancer. World Journal of Surgery, 2012, 36, 338-345.	and Survival	0.8	14
2716	Case–control study of smoking and non-melanoma skin cancer. Cancer Causes and C 245-254.	ontrol, 2012, 23,	0.8	28
2717	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of serous ovarian carcinoma. Clinical and Experimental Metastasis, 2012, 29, 239-252.	high grade	1.7	50

#	Article	IF	CITATIONS
2718	Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients. Molecular Biology Reports, 2012, 39, 1895-1901.	1.0	22
2719	Preliminary evaluation of the reliability and validity of the Shame and Stigma Scale in head and neck cancer. Head and Neck, 2013, 35, 172-183.	0.9	73
2720	Surgical approaches to gastric cancer. Journal of Surgical Oncology, 2013, 107, 250-258.	0.8	20
2721	Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma. Tumor Biology, 2013, 34, 4089-4100.	0.8	38
2722	Genetic Susceptibility to Head and Neck Cancer. , 2013, , 977-1002.		0
2723	Mass Spectrometric Profiling of Low-Molecular-Weight Proteins. Methods in Molecular Biology, 2013, 1023, 83-95.	0.4	3
2724	Functional CYP1A1 genetic variants, alone and in combination with smoking, contribute to development of head and neck cancers. European Journal of Cancer, 2013, 49, 2143-2151.	1.3	27
2725	Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. Journal of Biomedical Science, 2013, 20, 39.	2.6	28
2726	Elevated Preoperative Carcinoembryonic Antigen (CEA) and Ki67 Is Predictor of Decreased Survival in IIA Stage Colon Cancer. World Journal of Surgery, 2013, 37, 208-213.	0.8	38
2727	Combination of three cytotoxic agents in small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 413-418.	1.1	4
2728	F-18 FDG PET/CT in the assessment of patients with unexplained CEA rise after surgical curative resection for colorectal cancer. International Journal of Colorectal Disease, 2013, 28, 1699-1705.	1.0	9
2730	AXL Mediates TRAIL Resistance in Esophageal Adenocarcinoma. Neoplasia, 2013, 15, 296-IN34.	2.3	18
2731	Women and Lung Cancer: What is New?. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 87-94.	0.4	75
2732	Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed?. Hepatology, 2013, 57, 2346-2357.	3.6	102
2733	Poorer Survival of Male Breast Cancer Compared with Female Breast Cancer Patients May Be Due to Biological Differences. Japanese Journal of Clinical Oncology, 2013, 43, 954-963.	0.6	36
2734	Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2013, 72, 1055-1061.	1.1	1
2735	A case of rectal tumor in which the shape altered with regression in short period. BMC Gastroenterology, 2013, 13, 146.	0.8	4
2736	Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region. International Journal of Clinical Oncology, 2014, 19, 744-52.	1.0	32

#	Article	IF	CITATIONS
2737	Potential therapeutic role of Tridham in human hepatocellular carcinoma cell line through induction of p53 independent apoptosis. BMC Complementary and Alternative Medicine, 2013, 13, 323.	3.7	12
2738	MiRNA-199a-3p in Plasma as a Potential Diagnostic Biomarker for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 397-405.	0.7	53
2739	Effects of Milk and Milk Products Consumption on Cancer: A Review. Comprehensive Reviews in Food Science and Food Safety, 2013, 12, 249-264.	5.9	108
2740	Metaâ€analysis of simultaneous versus staged resection for synchronous colorectal liver metastases. Hepatology Research, 2013, 43, 72-83.	1.8	21
2741	Inhibition of Lung Adenocarcinoma Transfected with Interleukin 28A Recombinant Adenovirus (Ad-mIFN-λ <sub>2</sub> ) <i>In Vivo</i> . Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 124-130.	0.7	14
2742	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell, 2013, 23, 186-199.	7.7	340
2743	Citation classics: Top 50 cited articles in â€~respiratory system'. Respirology, 2013, 18, 71-81.	1.3	45
2744	Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. Tumor Biology, 2013, 34, 1503-1510.	0.8	9
2745	Evaluation of the efficacy of Virtual Colonoscopy in assessment of colorectal lesions using conventional Optical Colonoscopy as the gold standard. Egyptian Journal of Radiology and Nuclear Medicine, 2013, 44, 433-440.	0.3	0
2746	Bone metastases in endometrial cancer: Report on 19 patients and review of the medical literature. Gynecologic Oncology, 2013, 130, 474-482.	0.6	53
2747	An improved method of automatic colon segmentation for virtual colon unfolding. Computer Methods and Programs in Biomedicine, 2013, 109, 1-12.	2.6	16
2748	Downregulation of signalling molecules involved in angiogenesis of prostate cancer cell line (PC-3) by kombucha (lyophilized). Biomedicine and Preventive Nutrition, 2013, 3, 53-58.	0.9	33
2749	InÂvitro maturation of human immature oocytes for fertility preservation. Fertility and Sterility, 2013, 99, 1173-1181.	0.5	141
2750	Miscellaneous Syndromes and Their Management. Surgical Clinics of North America, 2013, 93, 519-531.	0.5	1
2751	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2013, , 1027-1047.		0
2752	Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. British Journal of Cancer, 2013, 108, 1566-1570.	2.9	36
2753	Percutaneous Renal Surgery for Renal Pelvic Tumors: Overcoming the Difficulties. , 2013, , 107-114.		0
2754	Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. European Urology, 2013, 64, 530-539.	0.9	101

#	Article	IF	CITATIONS
2755	Concise Review: The Relevance of Human Stem Cell-Derived Organoid Models for Epithelial Translational Medicine. Stem Cells, 2013, 31, 417-422.	1.4	111
2756	Natural Killer Cell Immunoglobulin-like Receptor (KIR) genotypes in Follicular Lymphoma patients: Results of a pilot study. Gene, 2013, 525, 136-140.	1.0	5
2757	MiRNAâ€199aâ€3p: A potential circulating diagnostic biomarker for early gastric cancer. Journal of Surgical Oncology, 2013, 108, 89-92.	0.8	73
2758	The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene, 2013, 32, 2900-2906.	2.6	40
2759	Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report. World Journal of Surgical Oncology, 2013, 11, 305.	0.8	13
2760	ATL: A Meta-analysis. International Journal of Gynecological Cancer, 2013, 23, 422-430.	1.2	19
2761	Genetic and expressional variations of APEX1 are associated with increased risk of head and neck cancer. Mutagenesis, 2013, 28, 213-218.	1.0	27
2762	Primary mediastinal sarcoma: surgical outcomes of 21 cases. Interactive Cardiovascular and Thoracic Surgery, 2013, 17, 982-986.	0.5	14
2763	Incidental Gall Bladder Carcinoma in Laparoscopic Cholecystectomy: A Report of 6 Cases and a Review of the Literature. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 85-8.	0.8	16
2764	Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma. Disease Markers, 2013, 35, 317-325.	0.6	20
2765	Prognostic significance of immunoglobulin M overexpression in laryngeal squamous cell carcinoma. Acta Oto-Laryngologica, 2013, 133, 1080-1087.	0.3	6
2766	Impact of Unplanned Excision on Prognosis of Patients with Extremity Soft Tissue Sarcoma. Sarcoma, 2013, 2013, 1-5.	0.7	41
2767	The relationship between HLA-G levels and oxidative stress parameters in patients with breast cancer. Turkish Journal of Medical Sciences, 2013, 43, 870-877.	0.4	1
2768	Overall Survival Should Be the Primary Endpoint in Clinical Trials for Advanced Non-Small-Cell Lung Cancer. Current Oncology, 2013, 20, 150-160.	0.9	36
2769	Inhibitory Effect of Baicalin and Baicalein on Ovarian Cancer Cells. International Journal of Molecular Sciences, 2013, 14, 6012-6025.	1.8	89
2770	Dose reduction in oncological staging multidetector CT: effect of iterative reconstruction. British Journal of Radiology, 2013, 86, 20120224-20120224.	1.0	30
2771	Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer. Oncology Reports, 2013, 30, 1832-1840.	1.2	35
2772	Dachshund Binds p53 to Block the Growth of Lung Adenocarcinoma Cells. Cancer Research, 2013, 73, 3262-3274.	0.4	55

ARTICLE IF CITATIONS The Prognostic Value of the Apoptosis Pathway in Colorectal Cancer: A Review of the Literature on 2773 3.6 62 Biomarkers Identified by Immunohistochemistry. Biomarkers in Cancer, 2013, 5, BIC.S11475. Hematopoietic Tumors., 2013,, 608-678. 2774 The Evaluation of Factors Believed to Contribute to Obesity in Acute Lymphocytic Leukemia Survivors. 2775 0.2 1 ICAN: Infant, Child, & Adolescent Nutrition, 2013, 5, 51-55. Optimal strategy for penile rehabilitation after robotâ€assisted radical prostatectomy based on 2776 preoperative erectile function. BJU International, 2013, 111, 658-665. Overview of the use of OncotypeDX®as an additional treatment decision tool in early breast cancer. 2777 1.1 31 Expert Review of Anticancer Therapy, 2013, 13, 179-194. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells. Cell Biology International, 2013, 37, 464-470. 2778 1.4 Applicability of 3T Body <scp>MRI</scp> in Assessment of Nonfocal Bone Marrow Involvement of 2779 0.6 6 Hematopoietic Neoplasia in Dogs. Journal of Veterinary Internal Medicine, 2013, 27, 1165-1171. Salvage stereotactic radiosurgery for brain metastases. Expert Review of Neurotherapeutics, 2013, 13, 2780 1.4 1285-1295. A randomised, waitâ€list controlled trial: evaluation of a cognitive–behavioural group intervention on 2781 1.0 38 psychoâ€sexual adjustment for men with localised prostate cancer. Psycho-Oncology, 2013, 22, 2186-2192. Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced 2782 ovarian cancers. Biomarkers, 2013, 18, 532-541. Loss of COP1 expression determines poor prognosis in patients with gastric cancer. Oncology 2783 19 1.2 Reports, 2013, 30, 1971-1975. The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces 2784 1.4 apoptosis in acute lymphoblastic leukaemia cells. International Journal of Oncology, 2013, 42, 239-246. Surgery plus adjuvant radiotherapy versus surgery alone for stage II endometrial cancer. The 2785 1.5 0 Cochrane Library, 2013, , . Can the R.E.N.A.L Nephrometry Score Preoperatively Predict Postoperative Clinical Outcomes in Patients Undergoing Open and Laparoscopic Partial Nephrectomy?. Current Urology, 2013, 7, 90-97. 2786 0.4 Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate 2787 2.33 Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 911-915. Prognostic Significance of the Extent of Lymph Node Involvement in Stage II-N1 Non-small Cell Lung 2788 Cancer. Chest, 2013, 144, 1253-1260. Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines. 2789 1.2 26 Oncology Reports, 2013, 30, 2316-2322. 2790 microRNA and gene networks in human pancreatic cancer. Oncology Letters, 2013, 6, 1133-1139. 19

#	Article	IF	CITATIONS
2791	Medical Mistrust Influences Black Women's Level of Engagement in BRCA1/2 Genetic Counseling and Testing. Journal of the National Medical Association, 2013, 105, 17-22.	0.6	101
2792	Identifying Serum Biomarkers for Ovarian Cancer by Screening With Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry and the Artificial Neural Network. International Journal of Gynecological Cancer, 2013, 23, 667-672.	1.2	1
2793	miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncology Reports, 2013, 30, 701-706.	1.2	62
2794	CHD8 is an independent prognostic indicator that regulates Wnt/β-catenin signaling and the cell cycle in gastric cancer. Oncology Reports, 2013, 30, 1137-1142.	1.2	39
2795	Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis. Oncology Reports, 2013, 30, 1920-1928.	1.2	20
2796	Crude alkaloid extract of Rhazya stricta inhibits cell growth and sensitizes human lung cancer cells to cisplatin through induction of apoptosis. Genetics and Molecular Biology, 2013, 36, 12-21.	0.6	35
2797	Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma. OncoTargets and Therapy, 2013, 6, 621.	1.0	6
2798	Preoperative N Staging of Gastric Cancer by Stomach Protocol Computed Tomography. Journal of Gastric Cancer, 2013, 13, 149.	0.9	23
2799	Fistulation as a complication of intra-abdominal soft-tissue sarcomas; a case series. Journal of Radiology Case Reports, 2013, 7, 15-21.	0.2	16
2800	Patients from the Oral Oncology Center, UNESP, Araçatuba with an indication for prosthesis. Molecular and Clinical Oncology, 2013, 1, 733-736.	0.4	2
2801	Oropharyngeal Squamous Cell Carcinoma Metastatic to Lower-Extremity Soft Tissues: A Case Report and Literature Review. Ear, Nose and Throat Journal, 2013, 92, E38-E41.	0.4	2
2802	Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition. PLoS ONE, 2013, 8, e77400.	1.1	26
2803	Incidence, Predictive Factors, and Clinical Outcomes of Acute Kidney Injury after Gastric Surgery for Gastric Cancer. PLoS ONE, 2013, 8, e82289.	1.1	55
2804	Expression and significance of 90K/Mac-2BP in prostate cancer. Experimental and Therapeutic Medicine, 2013, 5, 181-184.	0.8	22
2805	Resistin -420C>G Promoter Variant and Colorectal Cancer Risk. International Journal of Biological Markers, 2014, 29, 233-238.	0.7	20
2806	PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer. PLoS ONE, 2014, 9, e89350.	1.1	169
2807	Chinese Herbal Medicine Suppresses Invasion-Promoting Capacity of Cancer-Associated Fibroblasts in Pancreatic Cancer. PLoS ONE, 2014, 9, e96177.	1.1	22
2808	Overexpression of MEOX2 and TWIST1 Is Associated with H3K27me3 Levels and Determines Lung Cancer Chemoresistance and Prognosis. PLoS ONE, 2014, 9, e114104.	1.1	35

ARTICLE IF CITATIONS Site Specific Effect of Tobacco Addiction in Upper Aerodigestive Tract Tumors: A Retrospective 2809 0.8 7 Clinicopathological Study. Scientific World Journal, The, 2014, 2014, 1-4. Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: analysis in 1.0 Japanese women. Journal of Gynecologic Oncology, 2014, 25, 118 Extraintestinal Helminth Infection Reduces the Development of Colitis-Associated Tumorigenesis. 2811 2.6 25 International Journal of Biological Sciences, 2014, 10, 948-956. Who Will Benefit from Noncurative Resection in Patients with Gastric Cancer with Single Peritoneal 0.4 Metastasis?. American Surgeon, 2014, 80, 124-130. Imaging Integrin  $\hat{I} \pm v \hat{I}^2 \hat{J}$  and NRP-1 Positive Gliomas with a Novel Fluorine-18 Labeled RGD-ATWLPPR 2813 1.341 Heterodimeric Peptide Probe. Molecular Imaging and Biology, 2014, 16, 781-792. Prognostic impact of genomic instability in colorectal cancer. British Journal of Cancer, 2014, 110, 2159-2164. The feasibility of radical cystectomy in elderly patients. Turk Uroloji Dergisi, 2014, 40, 9-14. 2815 0.4 3 Design and analysis of finite element based sensors for diagnosis of liver disorders using 2816 0.5 biocompatible metals. Technology and Health Care, 2014, 22, 867-875. miR-335 Represents an Independent Prognostic Marker in Epithelial Ovarian Cancer. American Journal 2817 0.4 46 of Clinical Pathology, 2014, 141, 437-442. High Nuclear Expression of HDGF Correlates with Disease Progression and Poor Prognosis in Human Endometrial Carcinoma. Disease Markers, 2014, 2014, 1-7. Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in 2819 1.8 16 Pancreatic Adenocarcinoma. International Journal of Molecular Sciences, 2014, 15, 4104-4125. Neurogenin  $3\hat{\epsilon}^{\oplus}$  Directed Cre Deletion of Tsc1 Gene Causes Pancreatic Acinar Carcinoma. Neoplasia, 2014, 2.3 16,909-917. Low-Dose Computer Tomography as a Screening Tool for Lung Cancer in a High Risk Population. 2821 0.8 5 Advances in Experimental Medicine and Biology, 2014, 852, 31-37. A Community-Based Intervention to Promote Breast Cancer Awareness and Screening among Asian 0.4 American Women. International Quarterly of Community Health Education, 2014, 34, 171-185. Undervalued Criteria in the Evaluation of Multimodal Trials for Upper GI Cancers. Cancer 2823 2 0.6 Investigation, 2014, 32, 497-506. p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression. American Journal of Clinical Pathology, 2824 46 2014, 141, 593-604. Development of the pediatric advanced care quality of life scale (PAC-QoL): Evaluating comprehension 2825 0.8 10 of items and response options. Pediatric Blood and Cancer, 2014, 61, 1835-1839. <scp>HBP</scp>1 promoter methylation augments the oncogenic l<sup>2</sup>â€catenin to correlate with prognosis in <scp>NSCLC</scp>. Journal of Cellular and Molecular Medicine, 2014, 18, 1752-1761.

		CITATION REP	ORT	
#	Article		IF	CITATIONS
2827	Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulinâ€like growth factor and hypoxia. Cancer Science, 2014, 105, 553-559.	5	1.7	11
2828	Dental pulp therapy for primary teeth in children undergoing cancer therapy. Pediatric Blood and Cancer, 2014, 61, 2297-2301.		0.8	7
2829	A case–control study on serum antioxidants status ( <scp>S</scp> e, <scp>Z</scp> n, and) Tj ETQ4 Hematology, 2014, 36, e34-6.	ט 0 0 rgBT /Ov	verlock 10 0.7	) Tf 50 667 0
2830	Predicting Novel Antitumor Agents: 3Dâ€Pharmacophore Mapping of βâ€ <i>N</i> â€biaryl Ether Sulfonamideâ€Based Hydroxamates as Potentially MMPâ€2 Inhibitors. Molecular Informatics, 2014, 573-587.	33,	1.4	7
2831	The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Therapy, 2014, 21, 12-23.		2.2	30
2832	Cytochrome P450-isoenzyme 1A1 in susceptibility to tobacco-related lung cancer. Asian Cardiovasc and Thoracic Annals, 2014, 22, 315-318.	ular	0.2	9
2833	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncology, 2014, 10, 79-90.		1.1	23
2834	Analysis of MicroRNAs in Sputum to Improve Computed Tomography for Lung Cancer Diagnosis. Journal of Thoracic Oncology, 2014, 9, 33-40.		0.5	91
2835	Eradication of Growth of HER2-Positive Ovarian Cancer With Trastuzumab-DM1, an Antibody-Cytoto Drug Conjugate in Mouse Xenograft Model. International Journal of Gynecological Cancer, 2014, 24 1158-1164.		1.2	27
2836	Immunolocalization of Corticotropin-Releasing Hormone (CRH) and Its Receptors (CRHR1 and CRHI in Human Endometrial Carcinoma. International Journal of Gynecological Cancer, 2014, 24, 1549-15		1.2	13
2837	Interlude of cGMP and cGMP/Protein Kinase G Type 1 in Pancreatic Adenocarcinoma Cells. Pancreas 2014, 43, 784-794.	,	0.5	36
2838	Management of Neglected Periorbital Squamous Cell Carcinoma Requiring Orbital Exenteration. Journal of Craniofacial Surgery, 2014, 25, 729-734.		0.3	18
2839	The Influences of Immigration on Health Information Seeking Behaviors Among Korean Americans a Native Koreans. Health Education and Behavior, 2014, 41, 173-185.	nd	1.3	35
2840	Role of dysregulated expression of leptin and leptin receptors in colorectal carcinogenesis. Tumor Biology, 2014, 35, 871-879.		0.8	17
2841	Radiofrequency ablation ( <scp>RFA</scp> ) of renal cell carcinoma ( <scp>RCC</scp> ): experience ir tumours. BJU International, 2014, 113, 416-428.	ı 200	1.3	178
2842	Matched Comparison of Robotic vs Laparoscopic Nephroureterectomy: An InitialÂExperience. Urolo 2014, 83, 345-349.	gy,	0.5	30
2843	Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells. Bioorganic and Medicinal Chemistry, 2014, 22, 1809-1820.		1.4	47
2844	Clinical characteristics of ischemic colitis after surgery for colorectal cancer. Surgery Today, 2014, 44, 1090-1096.		0.7	5

#	Article	IF	CITATIONS
2845	Loss of SS18-SSX1 Inhibits Viability and Induces Apoptosis in Synovial Sarcoma. Clinical Orthopaedics and Related Research, 2014, 472, 874-882.	0.7	28
2846	Quality of Life, Anxiety and Depression in Soft Tissue Sarcomas as Compared to More Common Tumours: An Observational Study. Applied Research in Quality of Life, 2014, 9, 123-131.	1.4	16
2847	Cytotoxicity and antimicrobial activities of green synthesized silver nanoparticles. European Journal of Medicinal Chemistry, 2014, 76, 256-263.	2.6	110
2848	Korean American Women's Perceptions about Physical Examinations and Cancer Screening Services Offered in Korea: The Influences of Medical Tourism on Korean Americans. Journal of Community Health, 2014, 39, 221-229.	1.9	27
2849	p28GANK is a novel marker for prognosis and therapeutic target in gastric cancer. Molecular Biology, 2014, 48, 84-90.	0.4	5
2850	Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumor Biology, 2014, 35, 1357-1363.	0.8	40
2851	Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumor Biology, 2014, 35, 1565-1574.	0.8	22
2852	Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology. Nuclear Medicine and Molecular Imaging, 2014, 48, 1-15.	0.6	86
2853	Jak-2 Positive Myeloproliferative Neoplasms. Current Treatment Options in Oncology, 2014, 15, 147-156.	1.3	9
2854	Cáncer de páncreas, diagnóstico y tratamiento paliativo con terapia homeopática. Revista Médica De HomeopatÃa, 2014, 7, 17-23.	0.1	0
2855	Non-neoplastic Soft Tissue Masses That Mimic Sarcoma. Orthopedic Clinics of North America, 2014, 45, 245-255.	0.5	7
2856	The Clinical Use of PET/CT in the Evaluation of Melanoma. Methods in Molecular Biology, 2014, 1102, 553-580.	0.4	9
2857	The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 1-17.	0.6	83
2858	18 F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients. European Journal of Radiology, 2014, 83, 2224-2230.	1.2	8
2859	Virtual colon flattening method based on colonic outer surface. Computer Methods and Programs in Biomedicine, 2014, 117, 473-481.	2.6	2
2860	In vitro apoptotic effect of cassaine-type diterpene amides from Erythrophleum fordii on PC-3 prostate cancer cells. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4989-4994.	1.0	11
2861	Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation inÂPatients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 270-277.	0.4	35
2862	Liposarcoma: a soft tissue tumor with many presentations. Musculoskeletal Surgery, 2014, 98, 171-177.	0.7	8

ARTICLE IF CITATIONS Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. 2863 1.2 51 Medical Oncology, 2014, 31, 164. Comparison of the effects of pulmonary rehabilitation with chest physical therapy on the levels of fibrinogen and albumin in patients with lung cancer awaiting lung resection: a randomized clinical 2864 0.8 trial. BMC Pulmonary Medicine, 2014, 14, 121. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous periphéral blood stem cell transplants in patients with multiple myeloma: a 2865 1.0 14 phase II study. Supportive Care in Cancer, 2014, 22, 2911-2916. Free radical quenching effect of Shemamruthaaâ€"a Siddha drug in 7,12-dimethylbenz(a)anthracene-induced experimental breast cancer rats. Comparative Clinical Pathology, 2014, 23, 1703-1713. 2866 0.3 Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in 2867 0.8 40 endometrial cancer. Tumor Biology, 2014, 35, 5805-5814. Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A. Tumor Biology, 2014, 35, 6373-6381. 2868 0.8 Mother–Daughter Dyad Recruitment and Cancer Intervention Challenges in an African American 2869 1.8 1 Sample. Journal of Racial and Ethnic Health Disparities, 2014, 1, 120-129. Experience of Interstitial Permanent I125 Brachytherapy for Extremity Soft Tissue Sarcomas. Clinical 2870 0.6 Oncology, 2014, 26, 230-235. The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer. 2872 1.3 36 European Journal of Cancer, 2014, 50, 1291-1300. Cytotoxic and apoptotic activities of Amorphophallus campanulatus (Roxb.) Bl. tuber extracts against 1.8 human colon carcinoma cell line HCT-15. Saudi Journal of Biological Sciences, 2014, 21, 524-531. Diagnostic Accuracy of Sonoelastography in Detecting Malignant Thyroid Nodules: A Systematic 2874 1.0 48 Review and Meta-Analysis. American Journal of Roentgenology, 2014, 202, W379-W389. Leptin Promotes Metastasis by Inducing an Epithelialâ€Mesenchymal Transition in A549 Lung Cancer 0.6 44 Cells. Oncology Research, 2014, 21, 165-171. Competition in Colon Cancer Screening? What is the Role of Colonoscopy?. Viszeralmedizin, 2014, 30, 2876 0.0 5 6-6. Time trends in T3 to T4 laryngeal cancer: A populationâ€based longâ€term analysis. Head and Neck, 2014, 36, 2877 0.9 1727-1731. Deregulation of p53 and RB Transcriptional Control Leads to Overexpression of DNA 2878 0.2 10 Methyltransferases in Lung Cancer. Journal of Cancer Research and Practice, 2014, 1, 14-27. Clinicopathologic Profile and Outcome of Extranodal Diffuse Large B-Cell NHL: Egyptian National 2879 0.1 Cancer Institute Experience. Forum of Clinical Oncology, 2015, 6, 8-12. Ureteral Involvement and Diabetes Increase the Risk of Subsequent Bladder Recurrence after 2880 Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. Urological Science, 2015, 26, 0.2 0 S14-S15. Male Breast Cancer in India: Series from a Cancer Research Centre. Indian Journal of Surgical 2881 Oncology, 2015, 6, 384-386.

#	Article	IF	CITATIONS
2882	Accuracy of hysteroscopic biopsy, compared to dilation and curettage, as a predictor of final pathology in patients with endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 757-760.	0.5	15
2883	Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Cancer Biomarkers, 2015, 15, 317-323.	0.8	17
2884	Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro. Molecular Medicine Reports, 2015, 11, 317-326.	1.1	11
2885	Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model. Oncology Letters, 2015, 10, 3067-3072.	0.8	9
2886	Microarray technology to investigate genes associated with papillary thyroid carcinoma. Molecular Medicine Reports, 2015, 11, 3729-3733.	1.1	17
2887	Treatment of Adult Soft Tissue Sarcomas: An Overview. Rare Cancers and Therapy, 2015, 3, 69-87.	0.2	19
2888	ls revisional surgery mandatory when an unexpected sarcoma diagnosis is made following primary surgery?. World Journal of Surgical Oncology, 2015, 13, 306.	0.8	42
2889	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Journal of Translational Medicine, 2015, 13, 247.	1.8	57
2890	Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer. SpringerPlus, 2015, 4, 688.	1.2	37
2891	Frequency of <scp>C</scp> lass <scp>I</scp> and <scp>II HLA</scp> alleles in patients with lung cancer according to chemotherapy response and 5â€year survival. Clinical Respiratory Journal, 2015, 9, 297-304.	0.6	12
2892	Survivorship. Journal of Surgical Oncology, 2015, 111, 648-655.	0.8	7
2893	Anti-Cancer Drugs Reactivate Tumor Suppressor miR-375 Expression in Tongue Cancer Cells. Journal of Cellular Biochemistry, 2015, 116, 836-843.	1.2	20
2894	Role of RUNX2 in Breast Carcinogenesis. International Journal of Molecular Sciences, 2015, 16, 20969-20993.	1.8	47
2895	Ureteral Involvement and Diabetes Increase the Risk of Subsequent Bladder Recurrence after Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. BioMed Research International, 2015, 2015, 1-8.	0.9	6
2896	MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways. Wspolczesna Onkologia, 2015, 3, 201-206.	0.7	13
2897	Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells. Oncology Letters, 2015, 9, 2211-2217.	0.8	3
2898	Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphisms and the Risk of Head and Neck Cancer. PLoS ONE, 2015, 10, e0123347.	1.1	3
2899	Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?. Advances in Urology, 2015, 2015, 1-6.	0.6	6

#	Article	IF	CITATIONS
2900	Impact of Procyanidins from Different Berries on Caspase 8 Activation in Colon Cancer. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-13.	1.9	30
2901	Association of Pre-miR-146a rs2910164 Polymorphism with Papillary Thyroid Cancer. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	9
2902	Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study. International Journal of Gynecological Cancer, 2015, 25, 4-11.	1.2	9
2903	Serum markers in prostate cancer detection. Current Opinion in Urology, 2015, 25, 59-64.	0.9	14
2904	Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists. Future Oncology, 2015, 11, 1181-1189.	1.1	0
2905	Gut bacteria and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 86-90.	3.3	39
2906	Numerical modeling and optimization of the cryosurgery operations. Journal of Computational and Applied Mathematics, 2015, 290, 259-267.	1.1	13
2907	The role of social support and social networks in health information–seeking behavior among Korean Americans: a qualitative study. International Journal for Equity in Health, 2015, 14, 40.	1.5	89
2908	Burden of soft-tissue and bone sarcoma in routine care. Cancer Epidemiology, 2015, 39, 440-446.	0.8	46
2909	The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway. International Journal of Oncology, 2015, 46, 2629-2638.	1.4	71
2910	Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells. Oncology Reports, 2015, 33, 2023-2030.	1.2	9
2911	Fine Needle Aspiration Cytology of Lobular Breast Carcinoma and Its Variants. Acta Cytologica, 2015, 59, 37-42.	0.7	6
2912	p21â€activated kinase 1 predicts recurrence and survival in patients with nonâ€metastatic clear cell renal cell carcinoma. International Journal of Urology, 2015, 22, 447-453.	0.5	7
2913	A randomized controlled trial of two interventions to increase colorectal cancer screening among Hispanics on the Texas–Mexico border. Cancer Causes and Control, 2015, 26, 1-10.	0.8	27
2914	Oncologic and Functional Outcomes of Surgical and Nonsurgical Treatment of Advanced Squamous Cell Carcinoma of the Supraglottic Larynx. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1111.	1.2	22
2915	Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal <scp>ROS</scp> levels. BioFactors, 2015, 41, 52-57.	2.6	24
2916	TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer. Oncology Letters, 2015, 9, 1059-1064.	0.8	0
2917	Inflammation and Lung Cancer: The Link to Angiogenesis. , 2015, , 137-159.		0

#	Article	IF	Citations
2918	Detection of In Vivo DNA Damage Induced by Very Low Doses of Mainstream and Sidestream Smoke Extracts Using a Novel Assay. American Journal of Preventive Medicine, 2015, 48, S102-S110.	1.6	15
2919	Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia. Gynecologic Oncology, 2015, 136, 549-553.	0.6	11
2920	XPD, APE1, and MUTYH polymorphisms increase head and neck cancer risk: effect of gene-gene and gene-environment interactions. Tumor Biology, 2015, 36, 7569-7579.	0.8	15
2921	Lyophilized strawberries prevent 7,12-dimethylbenz[α]anthracene (DMBA)-induced oral squamous cell carcinogenesis in hamsters. Journal of Functional Foods, 2015, 15, 476-486.	1.6	9
2922	Diagnostic performance of bone scintigraphy and 11C-choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 155-161.	0.1	9
2923	Predictive factors for survival and recurrence rate in patients with node-negative gastric cancer—a European single-centre experience. Langenbeck's Archives of Surgery, 2015, 400, 27-35.	0.8	20
2924	In Vivo Antineoplastic Effects of the NSAID Sulindac in an Oral Carcinogenesis Model. Cancer Prevention Research, 2015, 8, 642-649.	0.7	7
2925	C-type natriuretic peptide and its precursor: potential markers in human prostate cancer. Biomarkers in Medicine, 2015, 9, 319-326.	0.6	4
2926	Treatment, comorbidity and survival in stage III laryngeal cancer. Head and Neck, 2015, 37, 698-706.	0.9	10
2927	Antiangiogenesis as the novel mechanism for justicidin A in the anticancer effect on human bladder cancer. Anti-Cancer Drugs, 2015, 26, 428-436.	0.7	9
2928	Health-Related Quality of Life in Advanced Prostate Cancer and Its Treatments: Biochemical Failure and Metastatic Disease Populations. Clinical Genitourinary Cancer, 2015, 13, 101-112.	0.9	29
2929	Unplanned Excision of Soft-Tissue Sarcomas. Journal of Bone and Joint Surgery - Series A, 2015, 97, 597-603.	1.4	87
2930	BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35, 591-599.	1.0	18
2931	Numerical simulation of cryosurgeries and optimization of probe placement. Computational Mathematics and Mathematical Physics, 2015, 55, 1579-1589.	0.2	2
2932	Operative technique and early experience for robotic-assisted laparoscopic nephroureterectomy (RALNU) using da Vinci Xi. SpringerPlus, 2015, 4, 298.	1.2	25
2933	Cohort Profile: The Shanghai Men's Health Study. International Journal of Epidemiology, 2015, 44, 810-818.	0.9	111
2934	Surveillance After Treatment for Upper Tract Transitional Cell Carcinoma. , 2015, , 61-68.		0
2935	Intensive surveillance following curative treatment of colorectal cancer allows effective treatment of recurrence even if limited to 4Âyears. International Journal of Colorectal Disease, 2015, 30, 1677-1684.	1.0	7

		CITATION REPORT		
#	Article		IF	Citations
2936	Race and ethnicity considerations in GI endoscopy. Gastrointestinal Endoscopy, 2015,	82, 593-599.	0.5	20
2939	Case study: Transforming cancer care at a community oncology practice. Healthcare, 2	2015, 3, 160-168.	0.6	6
2940	18F-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography in the Thyroid and in Head and Neck Squamous Cell Carcinoma. PET Clinics, 2015, 10, 75	Malignancies of 5-88.	1.5	5
2941	Reduced retinoids and retinoid receptors' expression in pancreatic cancer: A link to pa Molecular Carcinogenesis, 2015, 54, 870-879.	tient survival.	1.3	37
2942	Increased DNA methyltransferase 1 protein expression correlates significantly with intension histological type and gender in gastric carcinomas. Advances in Medical Sciences, 201	estinal 5, 60, 50-57.	0.9	9
2943	Survival trends in Hypopharyngeal cancer: A population-based review. Laryngoscope, 2	.015, 125, 624-629.	1.1	177
2944	Prevalence of head and neck tumours in Calabar, South Eastern Nigeria. Asian Journal of Sciences, 2016, 7, 123-126.	of Medical	0.0	5
2945	Relationship between Preoperative 18F-Fluorodeoxyglucose Uptake and Epidermal Gro Receptor Status in Primary Colorectal Cancer. Yonsei Medical Journal, 2016, 57, 232.	owth Factor	0.9	2
2946	Is there any association between National Institute of Health category IV prostatitis ar prostate-specific antigen levels in patients with low-risk localized prostate cancer?. Int Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 346-350.	ıd ernational	0.7	3
2947	The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endo Journal of Cancer, 2016, 7, 538-545.	metrial Cancer.	1.2	39
2948	Effect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation. Medical Science, 2016, 6, 1337-1347.	Archives of	0.4	6
2949	AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelia OncoTargets and Therapy, 2016, 9, 2385.	l ovarian cancer.	1.0	13
2950	The Relevance of Women's Diseases, Jun Activation-domain Binding Protein 1 (JAB1) a p27 <sup>kip1</sup> . Journal of Menopausal Medicine, 2016, 22, 6.	nd	0.3	6
2951	Gastrointestinal lymphoma in Western Algeria: pattern of distribution and histological (retrospective study). Journal of Gastrointestinal Oncology, 2016, 6, 1011-1016.	subtypes	0.6	5
2952	Mutations in the Mitochondrial ND1 Gene Are Associated with Postoperative Prognosi Renal Cell Carcinoma. International Journal of Molecular Sciences, 2016, 17, 2049.	s of Localized	1.8	25
2953	Increase of Incidence and Mortality of Ovarian Cancer during 2003–2012 in Jiangsu Frontiers in Public Health, 2016, 4, 146.	Province, China.	1.3	23
2954	Soft Tissue Sarcomas of the Arm – Oncosurgical and Reconstructive Principles withi Interdisciplinary Setting. Frontiers in Surgery, 2016, 3, 12.	n a Multimodal,	0.6	25
2956	Retzius Space Preservation Technique for Robotic-Assisted Laparoscopic Radical Prost Kidney Transplant Patient: First Case in Thailand and Our First Experience. Transplanta Proceedings, 2016, 48, 3130-3133.		0.3	11

#	Article	IF	CITATIONS
2957	SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis. Oncology Reports, 2016, 35, 1796-1806.	1.2	24
2958	Prevalencia mutacional de los genes BRCA1 y BRCA2 en pacientes con cáncer de mama y ovario atendidos en el Ãrea de Salud de La Ribera (Comunidad Valenciana, España). Revista Espanola De Patologia, 2016, 49, 214-218.	0.6	2
2959	Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells. International Journal of Pharmaceutics, 2016, 513, 648-658.	2.6	72
2960	Reversal effect of ouabain on multidrug resistance in esophageal carcinoma EC109/CDDP cells by inhibiting the translocation of Wnt/β-catenin into the nucleus. Tumor Biology, 2016, 37, 15937-15947.	0.8	5
2961	Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells. Molecular and Cellular Endocrinology, 2016, 436, 240-249.	1.6	33
2962	Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway. Stem Cells, 2016, 34, 2799-2813.	1.4	65
2963	The cancer genetics and pathology of male breast cancer. Histopathology, 2016, 68, 110-118.	1.6	51
2964	Trends in incidence and survival for upper tract urothelial cancer ( <scp>UTUC</scp> ) in the state of Victoria – Australia. BJU International, 2016, 117, 45-49.	1.3	16
2965	Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with nonâ€smallâ€cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 349-358.	0.7	3
2966	Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings, 2016, 91, 1645-1666.	1.4	158
2967	Cancer-specific incidence rates of tuberculosis. Medicine (United States), 2016, 95, e4919.	0.4	27
2968	Constructing and Validating 3D-pharmacophore Models to a Set of MMP-9 Inhibitors for Designing Novel Anti-melanoma Agents. Molecular Informatics, 2016, 35, 238-252.	1.4	9
2969	Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial. Trials, 2016, 17, 8.	0.7	2
2970	Epigenetic impact of infection on carcinogenesis: mechanisms and applications. Genome Medicine, 2016, 8, 10.	3.6	112
2971	Mucosal alphaâ€papillomaviruses are not associated with esophageal squamous cell carcinomas: Lack of mechanistic evidence from <scp>S</scp> outh <scp>A</scp> frica, <scp>C</scp> hina and <scp>I</scp> ran and from a worldâ€wide metaâ€analysis. International Journal of Cancer, 2016, 139, 85-98.	2.3	36
2972	Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. Biomaterials, 2016, 76, 273-281.	5.7	105
2973	Long noncoding RNAs as potential biomarkers in gastric cancer: Opportunities and challenges. Cancer Letters, 2016, 371, 62-70.	3.2	55
2974	Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology, 2016, 141, 57-64.	0.6	33

#	Article	IF	CITATIONS
2975	Male Breast: Clinical and Imaging Evaluations of Benign and Malignant Entities with Histologic Correlation. American Journal of Medicine, 2016, 129, 776-791.	0.6	39
2976	Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network. Annals of Surgical Oncology, 2016, 23, 1279-1286.	0.7	18
2977	The Microenvironment of Lung Cancer and Therapeutic Implications. Advances in Experimental Medicine and Biology, 2016, 890, 75-110.	0.8	96
2978	Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers. Oral and Maxillofacial Surgery Clinics of North America, 2016, 28, 115-126.	0.4	3
2979	Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer. Tumor Biology, 2016, 37, 2299-2304.	0.8	30
2980	Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. Archives of Gynecology and Obstetrics, 2016, 293, 239-246.	0.8	50
2981	Elevated incidence of fractures in women with invasive breast cancer. Osteoporosis International, 2016, 27, 499-507.	1.3	19
2982	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). International Journal of Clinical Oncology, 2016, 21, 110-117.	1.0	3
2983	Mapping intermolecular interactions and active site conformations: from human MMP-1 crystal structure to molecular dynamics free energy calculations. Journal of Biomolecular Structure and Dynamics, 2017, 35, 564-573.	2.0	15
2984	Male Breast Cancer Has Limited Effect on Survivor's Perceptions of Their Own Masculinity. American Journal of Men's Health, 2017, 11, 246-252.	0.7	13
2985	Timing and Utility of Relapse Surveillance after Allogeneic Hematopoietic Cell Transplantation in Children with Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 696-700.	2.0	3
2986	Establishment and characterization of a new human acinar cell carcinoma cell line, Faraz-ICR, from pancreas. Pancreatology, 2017, 17, 303-309.	0.5	6
2987	Inhibition effects of chlorogenic acid on benign prostatic hyperplasia in mice. European Journal of Pharmacology, 2017, 809, 191-195.	1.7	22
2988	Targeting and Internalization of Liposomes by Bladder Tumor Cells Using a Fibronectin Attachment Protein-Derived Peptide–Lipopolymer Conjugate. Bioconjugate Chemistry, 2017, 28, 1481-1490.	1.8	14
2989	Polyphenolic compounds from Korean Lonicera japonica Thunb. induces apoptosis via AKT and caspase cascade activation in A549 cells. Oncology Letters, 2017, 13, 2521-2530.	0.8	15
2990	Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 1530-1538.	1.9	37
2991	National Utilization of Partial Nephrectomy Pre- and Post- AUA Guidelines: Is This as Good as It Gets?. Clinical Genitourinary Cancer, 2017, 15, 591-597.e1.	0.9	9
2992	Image-guided ablation of renal cell carcinoma. Clinical Radiology, 2017, 72, 636-644.	0.5	28

ARTICLE IF CITATIONS FOXR2 Promotes the Proliferation, Invasion, and Epithelialâ€Mesenchymal Transition in Human 2993 0.6 17 Colorectal Cancer Cells. Oncology Research, 2017, 25, 681-689. Mass spectrometry as a tool for biomarkers searching in gynecological oncology. Biomedicine and 2994 2.5 Pharmacotherapy, 2017, 92, 836-842. Recurrent bladder tumors after transurethral resection: Diagnostic yield of MDCT-virtual 2995 0.3 0 cystoscopy. Egyptian Journal of Radiology and Nuclear Medicine, 2017, 48, 509-517. IncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. Biomedicine and 2996 2.5 Pharmacotherapy, 2017, 89, 1269-1276. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against 2997 Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells. Journal of Medicinal 2.9 27 Chemistry, 2017, 60, 8441-8455. Ultrasound-guided percutaneous radiofrequency ablation for treating small renal masses. Actas Urol $\tilde{A}^3$ gicas Espa $\tilde{A}$ ±olas (English Edition), 2017, 41, 497-503. 2998 0.2 Radiofrecuencia percutÃ; nea guiada por ecografÃa en el tratamiento de masas renales pequeñas. Actas 2999 0.3 3 UrolÃ<sup>3</sup>gicas Españolas, 2017, 41, 497-503. Laparoscopic vs robotic nephroureterectomy: Is it time to re-establish the standard? Evidence from a 3000 systematic review. Arab Journal of Urology Árab Association of Urology, 2017, 15, 177-186. PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer. Oncology Letters, 3002 0.8 27 2017, 14, 5871-5875. Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth. Scientific Reports, 2017, 7, 1.6 15060. Overexpression of WDFY2 inhibits prostate cancer cell growth and migration via inactivation of Akt 3004 12 0.8 pathway. Tumor Biology, 2017, 39, 101042831770482. Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews. BMC Health Services Research, 2017, 17, 413. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial 3006 1.1 7 ovarian cancer. Human Pathology, 2017, 60, 114-120. Aging-Associated Nonmelanoma Skin Cancer: A Role for the Dermis., 2017, 913-930. DNA methylation-based variation between human populations. Molecular Genetics and Genomics, 2017, 3008 1.0 76 292, 5-35. The Role of Cyclooxygenase-2 in Colorectal Carcinogenesis. Clinical Colorectal Cancer, 2017, 16, 3009 165-172. Aqueous extract of Cordyceps sinensis potentiates the antitumor effect of DDP and attenuates 3010 therapy-associated toxicity in non-small cell lung cancer via ll<sup>o</sup>Bl<sup>±</sup>/NFl<sup>o</sup>B and AKT/MMP2/MMP9 pathways. 1.7 10 RSC Ádvances, 2017, 7, 37743-37754. Optimal three-dimensional reconstruction for lung cancer tissues. Technology and Health Care, 2017, 25, 423-434.

#	Article	IF	CITATIONS
3012	Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation. World Journal of Gastroenterology, 2017, 23, 1171.	1.4	55
3013	Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 1132.	1.8	47
3014	Rehabilitation after Total Laryngectomy—A Tribute to the Pioneers of Voice Restoration in the Last Two Centuries. Frontiers in Medicine, 2017, 4, 81.	1.2	36
3015	Metastatic Renal Cell Carcinoma Presenting as a Paranasal Sinus Mass: The Importance of Differential Diagnosis. Case Reports in Otolaryngology, 2017, 2017, 1-5.	0.1	10
3016	The need for endodontic treatment and systemic characteristics of hematopoietic stem cell transplantation patients. Brazilian Oral Research, 2017, 31, e50.	0.6	3
3017	Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Veterinaria Scandinavica, 2017, 59, 71.	0.5	192
3018	Molecular Testing in Chronic Myelogenous Leukemia. , 2017, , 413-418.		0
3019	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 4657-4664.	1.0	3
3020	Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer. Oncology Reports, 2017, 38, 1733-1741.	1.2	20
3022	Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). Inflammation Research, 2018, 67, 617-626.	1.6	20
3023	A service evaluation of on-line image-guided radiotherapy to lower extremity sarcoma: Investigating the workload implications of a 3Âmm action level for image assessment and correction prior to delivery. Radiography, 2018, 24, 142-145.	1.1	0
3024	Systemic therapy for brain metastases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 137-153.	1.0	23
3025	The use of polysulfated polysaccharides heparin like compounds, glycosaminoglycans and Vitamin B17 as a possible treatment for prostate cancer. Medical Hypotheses, 2018, 112, 1-3.	0.8	3
3026	Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma. European Journal of Radiology, 2018, 99, 88-93.	1.2	5
3027	Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status. American Journal of Neuroradiology, 2018, 39, 273-279.	1.2	31
3028	An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression. Cell Research, 2018, 28, 556-571.	5.7	24
3029	Isolation of circulating tumor cells in pancreatic cancer patients by immunocytochemical assay. Journal of Clinical Laboratory Analysis, 2018, 32, .	0.9	4
3030	Biogenic synthesis of copper oxide nanoparticles using <i>olea europaea</i> leaf extract and evaluation of their toxicity activities: An <i>in vivo</i> and <i>in vitro</i> study. Biotechnology Progress, 2018, 34, 218-230.	1.3	97

#	Article	IF	CITATIONS
3031	MRI findings associated with microscopic residual tumor following unplanned excision of soft tissue sarcomas in the extremities. Skeletal Radiology, 2018, 47, 181-190.	1.2	16
3032	Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. International Journal of Hematology, 2018, 107, 185-193.	0.7	72
3033	Efficacy of endoscopic self-expandable metal stent placement versus surgical bypass for inoperable pancreatic cancer-related malignant biliary obstruction: a propensity score-matched analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 971-976.	1.3	4
3034	Effect of erythrinaline alkaloids from Erythrina lysistemon on human recombinant caspase-3. African Journal of Pharmacy and Pharmacology, 2018, 12, 183-187.	0.2	9
3035	Cysts mark the early stage of metastatic tumor development in non-small cell lung cancer. Oncotarget, 2018, 9, 6518-6535.	0.8	5
3036	Effects of mdig on proliferation and apoptosis of lung cancer cells. Oncology Letters, 2018, 16, 7146-7151.	0.8	0
3037	In vitro and in vivo anti-leukemic effects of cladoloside C2 are mediated by activation of Fas/ceramide synthase 6/p38 kinase/c-Jun NH2-terminal kinase/caspase-8. Oncotarget, 2018, 9, 495-511.	0.8	9
3038	ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & amp; Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). Journal of Contemporary Brachytherapy. 2018. 10. 260-266.	0.4	44
3039	Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. International Journal of Nanomedicine, 2018, Volume 13, 6961-6986.	3.3	50
3040	Obstructive Jaundice due to Pancreatic Involvement as an Initial Presentation of Adult Acute Lymphoblastic Leukemia. Case Reports in Hematology, 2018, 2018, 1-3.	0.3	1
3041	Primary breast lymphoma: A mimic of inflammatory breast cancer. International Journal of Surgery Case Reports, 2018, 53, 410-413.	0.2	5
3042	The Final Diagnosis: Colorectal Carcinoma, In the Context of Attenuated Familial Adenomatous Polyposis, Mimicking Pulmonary Carcinoma. Cureus, 2018, 10, e2867.	0.2	0
3043	Prevention of pancreatic acinar cell carcinoma by Roux-en-Y Gastric Bypass Surgery. Nature Communications, 2018, 9, 4183.	5.8	15
3044	Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study. Chemotherapy, 2018, 63, 207-213.	0.8	11
3045	Adult soft tissue sarcoma and time to treatment initiation: An analysis of the National Cancer Database. Journal of Surgical Oncology, 2018, 117, 1776-1785.	0.8	17
3046	Soft tissue sarcoma affecting the right shoulder of a man with paraplegia from a remote traumatic spinal cord injury: a case report. Spinal Cord Series and Cases, 2018, 4, 55.	0.3	0
3047	A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Management and Research, 2018, Volume 10, 1089-1114.	0.9	94
3048	Synchronous colorectal cancer using CT colonography vs. other means: a systematic review and meta-analysis. Abdominal Radiology, 2018, 43, 3241-3249.	1.0	13

#	Article	IF	CITATIONS
3049	No Evidence for an Association between JC Polyomavirus Infection and Gastroduodenal Diseases. Gastrointestinal Tumors, 2018, 5, 47-53.	0.3	4
3050	<i>In Vivo</i> Study of the Effects of ER <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"&gt;<mml:mrow><mml:mi>î²</mml:mi></mml:mrow> on Apoptosis and Proliferation of Hormone-Independent Prostate Cancer Cell Lines PC-3M. BioMed Research International. 2018. 2018. 1-10.</mml:math 	0.9	4
3051	Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers, 2018, 10, 195.	1.7	6
3052	In vitro antineoplastic effects of auranofin in canine lymphoma cells. BMC Cancer, 2018, 18, 522.	1.1	5
3053	Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1. Cell and Bioscience, 2018, 8, 9.	2.1	34
3054	Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer. Journal of Clinical Laboratory Analysis, 2018, 32, e22565.	0.9	21
3056	Advanced Larynx Cancer. , 2018, , 818-829.		0
3057	Oxaliplatin effects on the DNA molecule studied by force spectroscopy. Biomedical Physics and Engineering Express, 2019, 5, 055009.	0.6	2
3058	An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific Reports, 2019, 9, 12070.	1.6	58
3059	Effect of KNL1 on the proliferation and apoptosis of colorectal cancer cells. Technology in Cancer Research and Treatment, 2019, 18, 153303381985866.	0.8	24
3060	Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. Frontiers in Oncology, 2019, 9, 986.	1.3	7
3061	Time to treatment initiation and survival in adult localized, highâ€grade soft tissue sarcoma. Journal of Surgical Oncology, 2019, 120, 1241-1251.	0.8	29
3062	Pinocembrin inhibits the proliferation and migration and promotes the apoptosis of ovarian cancer cells through down-regulating the mRNA levels of N-cadherin and GABAB receptor. Biomedicine and Pharmacotherapy, 2019, 120, 109505.	2.5	27
3063	Primary hepatic neuroendocrine carcinoma with massive hepatomegaly in a youngâ€old woman. Liver International, 2019, 39, 2205-2206.	1.9	1
3064	Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells. Biomolecules, 2019, 9, 437.	1.8	10
3065	Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. Journal of Ovarian Research, 2019, 12, 6.	1.3	63
3066	Comparing Diagnostic Evaluations for Rectal Bleeding and Breast Lumps in Primary Care: a Retrospective Cohort Study. Journal of General Internal Medicine, 2019, 34, 1146-1153.	1.3	2
3067	Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c. Experimental Cell Research, 2019, 382, 111462.	1.2	22

#	Article	IF	CITATIONS
3068	Combined spatial frequency spectroscopy analysis with visible resonance Raman for optical biopsy of human brain metastases of lung cancers. Journal of Innovative Optical Health Sciences, 2019, 12, .	0.5	15
3069	Clinicopathologic Characterization of Bilateral Testicular Germ Cell Tumors With Immunohistochemical Evaluation of Mismatch Repair and <i>BRAF</i> (V600E) Genes Mutations. International Journal of Surgical Pathology, 2019, 27, 619-623.	0.4	5
3070	Hospitalization Burden of Biliary Strictures and Cholangitis After Pancreaticoduodenectomy. Journal of Surgical Research, 2019, 241, 95-102.	0.8	5
3071	Imaging of theÂEsophagus. , 2019, , 295-324.		2
3072	Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review. Clinical Oral Investigations, 2019, 23, 4371-4382.	1.4	10
3073	Superficially invasive stage IA vulvar squamous cell carcinoma—therapy and prognosis. International Journal of Gynecological Cancer, 2019, 29, 466-473.	1.2	8
3074	Lung cancer imaging methods in China from 2005 to 2014: A national, multicenter study. Thoracic Cancer, 2019, 10, 708-714.	0.8	4
3075	Targeting anaplastic lymphoma kinase in neuroblastoma. Apmis, 2019, 127, 288-302.	0.9	53
3076	Gold Nanoparticle-Incorporated Molecularly Imprinted Microgels as Radiation Sensitizers in Pancreatic Cancer. ACS Applied Bio Materials, 2019, 2, 1177-1183.	2.3	27
3077	Hematopoietic Tumors. , 2019, , 688-772.		19
3078	A systematic review and meta-analysis approach on diagnostic value of MLH1 promoter methylation for head and neck squamous cell carcinoma. Medicine (United States), 2019, 98, e17651.	0.4	3
3079	Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer. Nuclear Medicine Communications, 2019, 40, 63-72.	0.5	7
3080	Patterns of Care and Survival in Elderly Patients With Locally Advanced Soft Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 749-754.	0.6	9
3082	The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neuro-Oncology Practice, 2019, 6, 274-282.	1.0	9
3083	Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review. Clinical Breast Cancer, 2019, 19, e48-e65.	1.1	34
3084	Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?. Journal of Oncology Pharmacy Practice, 2020, 26, 781-786.	0.5	0
3085	Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses. American Journal of Roentgenology, 2020, 214, 122-128.	1.0	2
3086	A different perspective: Can urine pH be important in the diagnosis of prostate cancer?. Urologia, 2020, 87, 19-22.	0.3	3

#	Article	IF	CITATIONS
3087	Small-world networks of prognostic genes associated with lung adenocarcinoma development. Genomics, 2020, 112, 4078-4088.	1.3	7
3088	Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN). Journal of Clinical Medicine, 2020, 9, 2427.	1.0	10
3089	Effects of activating GABAB1 receptor on proliferation, migration, invasion and epithelial-mesenchymal transition of ovarian cancer cells. Journal of Ovarian Research, 2020, 13, 126.	1.3	3
3090	DNA Framework-Supported Electrochemical Analysis of DNA Methylation for Prostate Cancers. Nano Letters, 2020, 20, 7028-7035.	4.5	31
3091	The potential role of dietary plant ingredients against mammary cancer: a comprehensive review. Critical Reviews in Food Science and Nutrition, 2022, 62, 2580-2605.	5.4	11
3092	The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials. Journal of Ovarian Research, 2020, 13, 56.	1.3	3
3093	The Value of CEUS in Distinguishing Cancerous Lymph Nodes From the Primary Lymphoma of the Head and Neck. Frontiers in Oncology, 2020, 10, 473.	1.3	17
3094	Time to Treatment Initiation and Survival in Adult Localized High-Grade Bone Sarcoma. Sarcoma, 2020, 2020, 1-9.	0.7	7
3095	Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. Nuclear Medicine and Biology, 2020, 86-87, 9-19.	0.3	5
3096	Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma. BMC Veterinary Research, 2020, 16, 97.	0.7	1
3097	Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer. British Journal of Cancer, 2020, 123, 973-981.	2.9	12
3098	State of the Art in Fertility Preservation for Female Patients Prior to Oncologic Therapies. Medicina (Lithuania), 2020, 56, 89.	0.8	4
3099	Rural–urban disparities in colorectal cancer survival and risk among men in Utah: a statewide population-based study. Cancer Causes and Control, 2020, 31, 241-253.	0.8	24
3100	Pattern of recurrence in patients with endometrial cancer: A retrospective study. European Journal of Surgical Oncology, 2020, 46, 1697-1702.	0.5	15
3101	Optimal treatment strategy with nilotinib for patients with newly diagnosed chronicâ€phase chronic myeloid leukemia based on early achievement of deep molecular response (MR <sup>4.5</sup> ): The phase 2, multicenter Nâ€Road study. Cancer Medicine, 2020, 9, 3742-3751.	1.3	4
3102	Soft tissue pathology for the radiologist: a tumor board primer with 2020 WHO classification update. Skeletal Radiology, 2021, 50, 29-42.	1.2	8
3103	Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer. Breast Cancer Research and Treatment, 2021, 186, 237-245.	1.1	6
3104	COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario. Cancer Treatment and Research Communications, 2021, 28, 100425.	0.7	1

#	Article	IF	CITATIONS
3105	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. Annals of Surgical Oncology, 2021, 28, 4706-4717.	0.7	16
3106	Candidate Identification Technique for Lung Cancer. International Journal of Reliable and Quality E-Healthcare, 2021, 10, 1-13.	1.0	0
3107	The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Translational Oncology, 2021, 14, 100973.	1.7	8
3108	<i>In vivo</i> diagnosis of skin cancer with a portable Raman spectroscopic device. Experimental Dermatology, 2021, 30, 652-663.	1.4	30
3109	Resection of a kidney tumor with superselective targeted balloon-occluded chemoembolization. Onkourologiya, 2021, 16, 49-58.	0.1	0
3110	Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway. Infection, Genetics and Evolution, 2021, 88, 104669.	1.0	9
3111	Potential Therapeutic Targets of Quercetin, a Plant Flavonol, and Its Role in the Therapy of Various Types of Cancer through the Modulation of Various Cell Signaling Pathways. Molecules, 2021, 26, 1315.	1.7	73
3112	Assessment of Tumor Response in Mice with Ovarian Peritoneal Carcinomatosis using Doppler Ultrasound of the Superior Mesenteric Artery and Celiac Trunk. Ultrasound in Medicine and Biology, 2021, 47, 759-768.	0.7	1
3113	Evaluation of Rare Types of Breast Cancer among Indian Patients – a Retrospective Study from a Regional Cancer Center. Indian Journal of Surgical Oncology, 2021, 12, 286-289.	0.3	0
3114	Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report. Journal of International Medical Research, 2021, 49, 030006052110097.	0.4	3
3115	Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by ZHER2-Idarubicin Conjugate: An in vitro Study. Iranian Journal of Pathology, 2021, 16, 109-118.	0.2	1
3116	Onâ€Water and Efficient Ullmannâ€Type Oâ€Arylation Cross Coupling Reaction of Phenols and Aryl Tosylates in the Presence of Fe <sub>3</sub> 0 <sub>4</sub> @Starchâ€Au as Nanocatalyst. ChemistrySelect, 2021, 6, 3941-3951.	0.7	12
3117	Prognostic value of Balkan endemic nephropathy and gender on upper tract urothelial carcinoma outcomes after radical nephroureterectomy: A cohort study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 786.e9-786.e16.	0.8	5
3118	Comparison between male and female breast cancer survival using propensity score matching analysis. Scientific Reports, 2021, 11, 11639.	1.6	9
3119	To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer?. European Journal of Surgical Oncology, 2021, 47, 1398-1405.	0.5	6
3120	Pancreatic cancer: A review of epidemiology, trend, and risk factors. World Journal of Gastroenterology, 2021, 27, 4298-4321.	1.4	180
3121	Oncological and prognostic analysis of soft tissue sarcoma of the elbow: report using the bone and soft tissue tumor registry in Japan. Japanese Journal of Clinical Oncology, 2021, 51, 1608-1614.	0.6	3
3122	Blood Flow and Shear Stress Allow Monitoring of Progression and Prognosis of Tumor Diseases. Frontiers in Physiology, 2021, 12, 693052.	1.3	5

#	Article	IF	CITATIONS
3123	LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis. Cancer Cell International, 2021, 21, 425.	1.8	15
3124	Clinicopathological study of urothelial neoplasms in urinary bladder with special reference to expression of Her2/neu and Ki-67 in malignant lesions. Indian Journal of Pathology and Oncology, 2021, 8, 378-385.	0.1	1
3125	Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. , 2021, 38, 287-295.		6
3126	Chemopreventive activity of hydroethanolic Murraya koenigii leaves extract (HEMKLE) against chemically induced skin carcinogenesis in mice. International Journal for Vitamin and Nutrition Research, 2021, 91, 396-410.	0.6	1
3127	EVALUATION OF THE ROLE OF GEMCITABINE AND ERLOTINIB IN STAGE IIIB AND STAGE IV NSCLC ADENOCARCINOMA OF LUNG AS A FIRST LINE CHEMOTHERAPY REGIMEN AND ASSESSING THE ACUTE TOXICITY, OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL RESPECTIVELY , 2021, , 36-39.		0
3128	Gray lesions of the breast and its diagnostic significance: A retrospective study from rural India. Journal of Microscopy and Ultrastructure, 2021, 9, 119.	0.1	0
3129	Can Current Treatments for Advanced Non–Small-Cell Lung Cancer Be Improved?. JAMA - Journal of the American Medical Association, 2004, 292, 499.	3.8	15
3130	Treatment of Rare Ovarian Malignancies. , 2006, , 207-225.		1
3131	Principles of Screening for Cancer. , 2006, , 161-176.		2
3132	Cervix, Vulva, and Vagina. , 2006, , 881-898.		1
3133	Bone Stromal Cells As Therapeutic Targets In Osseous Metastasis. , 2005, , 369-386.		1
3134	CpG Island Hypermethylation Changes during Prostate Cancer Progression and Metastasis. , 2005, , 45-79.		1
3135	Living with Advanced Cancer. , 2007, , 429-446.		7
3136	Radioguided Biopsy of the Sentinel Lymph Node in Patients with Non-Small Cell Lung Cancer. , 2008, , 166-171.		6
3137	Androgen Receptor Coregulators and Their Role in Prostate Cancer. , 2009, , 341-374.		1
3138	Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis. , 2008, , 259-270.		1
3139	Common Non-Small-Cell Carcinomas and Their Variants. , 2008, , 216-307.		8
3140	Insulin-Like Growth Factors and Breast Cancer Therapy. Advances in Experimental Medicine and Biology, 2007, 608, 101-112.	0.8	25

# 3141	ARTICLE The Oral Disease Burden Faced by Older Adults. , 0, , 15-40.	IF	CITATIONS 2
3142	Epidemiology of Hormone-Associated Cancers as a Reflection of Age. Advances in Experimental Medicine and Biology, 2008, 630, 57-71.	0.8	10
3143	Genes, Environment, and Cancer Disparities. , 2009, , 49-82.		2
3144	The Natural History of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2008, , 5-19.	0.1	1
3145	Cancer Prevention in Populations High At-Risk for the Development of Oral Cancer: Clinical Trials with Black Raspberries. , 2011, , 259-280.		2
3146	Obesity, Diabetes, and Risk of Cancer. , 2006, , 233-254.		2
3147	Potassium Channels, Cell Cycle, and Tumorigenesis in the Central Nervous System. , 2006, , 177-191.		2
3148	Hereditary Factors in Endometrial Cancer. , 2007, , 195-216.		1
3149	Clinical Significance of Enzymes in Disease and Diagnosis. , 2019, , 213-231.		4
3150	Oral Cancer: Epidemiology and Infections (Bacterial and Fungal) Global Incidence. , 2017, , 95-113.		1
3151	Pathology of Pancreatic Cancer. , 2008, , 497-511.		1
3152	Cutaneous Melanoma. Recent Results in Cancer Research, 2008, 170, 151-157.	1.8	4
3153	Reality-Based Estimation of Needle and Soft-Tissue Interaction for Accurate Haptic Feedback in Prostate Brachytherapy Simulation. , 2007, , 34-48.		21
3154	Fertility Issues and Options in Young Women with Cancer. , 2008, 178, 203-224.		10
3155	Aging-associated Non-melanoma Skin Cancer: A Role for the Dermis. , 2010, , 587-599.		2
3156	Liver Cancer. , 2011, , 225-249.		1
3157	Angiogenesis Modulation by Arachidonic Acid-derived Lipids: Positive and Negative Regulators of Angiogenesis. , 2013, , 19-28.		2
3158	Non-Hodgkin's Lymphoma. , 2008, , 2371-2404.		3

#	Article	IF	CITATIONS
3159	MRI of the Female Pelvis. , 2005, , 269-342.		4
3160	MRI of the Male Pelvis and the Bladder. , 2005, , 371-424.		2
3161	Central Nervous System Tumors. , 2010, , 421-445.		8
3162	Urothelial Tumors of the Upper Urinary Tract and Ureter. , 2012, , 1516-1553.e7.		10
3163	Systemic therapy for gynecological neoplasms: Ovary, cervix, and endometrium. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 515-544.	0.5	11
3164	Decision counseling in cancer prevention and control Health Psychology, 2005, 24, S71-S77.	1.3	69
3165	Children With Cancer , 2006, , 41-55.		3
3167	Biliary Tract Cancer. , 2006, , 787-800.		47
3169	Globalization and Tobacco. , 2006, , 39-67.		7
3170	Phase Ia/Ib Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 434-440.	0.5	31
3171	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 582-587.	0.5	12
3172	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 787-795.	0.5	34
3173	Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival. Journal of Thoracic Oncology, 2006, 1, 960-964.	0.5	18
3174	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis and Haemostasis, 2009, 101, 541-546.	1.8	19
3175	Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia Blood, 2004, 104, 479-479.	0.6	5
3176	Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. CytoJournal, 2006, 3, 10.	0.8	80
3177	Filipino American Women's Perceptions and Experiences With Breast Cancer Screening. Oncology Nursing Forum, 2006, 33, E71-E78.	0.5	24
3178	Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?. Medical Science Monitor, 2014, 20, 428-433.	0.5	4

#	Article	IF	CITATIONS
3179	Serum Calcium and Risk of Nonmedullary Thyroid Cancer in Patients with Primary Hyperparathyroidism. Medical Science Monitor, 2016, 22, 4482-4489.	0.5	9
3180	Clinical Characteristics of Non-Melanoma Skin Cancers Recurring within 5 years after Mohs Micrographic Surgery: Single Institution Retrospective Chart Review. Journal of Clinical and Investigative Dermatology, 2017, 5, 01-04.	0.1	1
3181	Repressive Effects of Resveratrol on Androgen Receptor Transcriptional Activity. PLoS ONE, 2009, 4, e7398.	1.1	38
3182	Crystal Structure of Crataeva tapia Bark Protein (CrataBL) and Its Effect in Human Prostate Cancer Cell Lines. PLoS ONE, 2013, 8, e64426.	1.1	19
3183	DNA Repair Gene XRCC1 Polymorphisms and Head and Neck Cancer Risk: An Updated Meta-Analysis Including 16344 Subjects. PLoS ONE, 2013, 8, e74059.	1.1	11
3184	Digitoflavone Inhibits lκBα Kinase and Enhances Apoptosis Induced by TNFα through Downregulation of Expression of Nuclear Factor κB-Regulated Gene Products in Human Pancreatic Cancer Cells. PLoS ONE, 2013, 8, e77126.	1.1	17
3185	Metastasis-Associated in Colon Cancer 1 Is a Novel Survival-Related Biomarker for Human Patients with Renal Pelvis Carcinoma. PLoS ONE, 2014, 9, e100161.	1.1	17
3186	Inhibition of IGF-1-Mediated Cellular Migration and Invasion by Migracin A in Ovarian Clear Cell Carcinoma Cells. PLoS ONE, 2015, 10, e0137663.	1.1	8
3187	Impact of stage, management and recurrence on survival rates in laryngeal cancer. PLoS ONE, 2017, 12, e0179371.	1.1	41
3188	New aspects on the role of lipoxygenases in cancer progression. Histology and Histopathology, 2005, 20, 969-75.	0.5	50
3189	Multiple Metachronous Malignant Fibrous Histiocytomas of the Upper Limbs – a Case Report. Klinicka Onkologie, 2014, 27, 438-441.	0.1	2
3190	Radiotherapy in lung cancer: Current and future role. Sisli Etfal Hastanesi Tip Bulteni, 2019, 53, 353-360.	0.1	6
3191	Extracto etanólico de Baccharis genistelloides (carqueja) sobre el cáncer de colon inducido con 1,2-dimetilhidrazina en ratas*. Anales De La Facultad De Medicina, 2011, 71, 88.	0.0	3
3192	Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. Journal of King Abdulaziz University, Islamic Economics, 2018, 39, 733-735.	0.5	6
3193	Alanine to Serine Variant at Position 986 of Calcium Sensing Receptor and Colorectal Cancer Risk. Iranian Journal of Cancer Prevention, 2016, 9, e8098.	0.7	3
3194	HMGCS2 enhances invasion and metastasis via direct interaction with PPARα to activate Src signaling in colorectal cancer and oral cancer. Oncotarget, 2017, 8, 22460-22476.	0.8	55
3195	Targeting invadopodia to block breast cancer metastasis. Oncotarget, 2011, 2, 562-568.	0.8	66
3196	Growth-arrest-specific 7C protein inhibits tumor metastasis via the N-WASP/FAK/F-actin and hnRNP U/β-TrCP/β-catenin pathways in lung cancer. Oncotarget, 2015, 6, 44207-44221.	0.8	20

#	Article	IF	CITATIONS
3197	Genome-Wide Analysis of Low Dose Bisphenol-A (BPA) Exposure in Human Prostate Cells. Current Genomics, 2019, 20, 260-274.	0.7	12
3198	Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. Cancer Genomics and Proteomics, 2018, 15, 185-191.	1.0	5
3199	Statistically based survival rate estimation in patients with soft tissue tumors. Romanian Journal of Orthopaedic Surgery and Traumatology, 2018, 1, 84-89.	0.1	1
3200	The expression of GST isoenzymes and p53 in non-small cell lung cancer Folia Histochemica Et Cytobiologica, 2010, 48, 122-7.	0.6	10
3201	Growth factors involved in prostate carcinogenesis. Frontiers in Bioscience - Landmark, 2005, 10, 1355.	3.0	29
3202	Current research on the use of hormonal therapy in the treatment of advanced or recurrent endometrial cancer. Women's Oncology Review, 2004, 4, 175-181.	0.0	1
3204	Prognostic Impact of the Metastatic Lymph Node Ratio on Survival in Rectal Cancer. Annals of Coloproctology, 2013, 29, 100.	0.5	16
3205	Research on Liver Tumor Proliferation and Angiogenesis Based on Multi-Modality Molecular Imaging. Sheng Wu Wu Li Hsueh Bao, 2011, 27, 355-364.	0.1	7
3206	Molecular mechanisms of denbinobin-induced anti-tumorigenesis effect in colon cancer cells. World Journal of Gastroenterology, 2005, 11, 3040.	1.4	30
3207	Vitamin D receptor geneTru9I polymorphism and risk for incidental sporadic colorectal adenomas. World Journal of Gastroenterology, 2005, 11, 4794.	1.4	24
3208	Complex pattern of colon cancer recurrence including a kidney metastasis: A case report. World Journal of Gastroenterology, 2005, 11, 5571.	1.4	7
3209	Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World Journal of Gastroenterology, 2005, 11, 5644.	1.4	91
3210	Multiple von Meyenburg complexes mimicking diffuse liver metastases from esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2006, 12, 4250.	1.4	20
3211	Current status and prospects of clinical proteomics studies on detection of colorectal cancer: Hopes and fears. World Journal of Gastroenterology, 2006, 12, 6594.	1.4	36
3212	Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World Journal of Gastroenterology, 2007, 13, 761.	1.4	19
3213	Alterations of tumor-related genes do not exactly match the histopathological grade in gastric adenocarcinomas. World Journal of Gastroenterology, 2010, 16, 1129.	1.4	10
3214	Intraprocedural bowel cleansing with the JetPrep cleansing system improves adenoma detection. World Journal of Gastroenterology, 2015, 21, 8184.	1.4	9
3215	Contactin 1: A potential therapeutic target and biomarker in gastric cancer. World Journal of Gastroenterology, 2015, 21, 9707.	1.4	17

#	Article	IF	CITATIONS
3217	MicroRNA‑409 may function as a tumor suppressor in endometrial carcinoma cells by targeting Smad2. Molecular Medicine Reports, 2019, 19, 622-628.	1.1	15
3218	Primary Adenosquamous Cell Carcinoma of the Pancreas: A Case Report with a Review of the Korean Literature. Korean Journal of Internal Medicine, 2011, 26, 348.	0.7	13
3219	A cohort study on the association of MDM2 SNP309 with lung cancer risk in Bangladeshi population. Korean Journal of Internal Medicine, 2020, 35, 672-681.	0.7	6
3220	Expression of maspin in testis tumors with germ cells andits relation with angiogenesis factors. Turkish Journal of Medical Sciences, 2016, 46, 1197-1202.	0.4	2
3221	Age Related Prostate-Specific Antigen Reference Range among Men in South-East Caspian Sea. Pakistan Journal of Biological Sciences, 2007, 10, 1496-1500.	0.2	2
3222	Fecal-based DNA assays: a new, noninvasive approach to colorectal cancer screening Cleveland Clinic Journal of Medicine, 2004, 71, 497-503.	0.6	12
3223	Prostate-specific antigen: how to advise patients as the screening debate continues Cleveland Clinic Journal of Medicine, 2005, 72, 521-527.	0.6	5
3224	Phase II Study of Induction Irinotecan + Cisplatin Chemotherapy Followed by Concurrent Irinotecan + Cisplatin Plus Twice-Daily Thoracic Radiotherapy. Tuberculosis and Respiratory Diseases, 2007, 63, 154.	0.7	2
3225	Significant Association of XPD Asp312Asn Polymorphism with Breast Cancer in Taiwanese Patients. Chinese Journal of Physiology, 2010, 53, 130-135.	0.4	12
3226	Potential Role of CCND1 G870A Genotype as a Predictor for Urothelial Carcinoma Susceptibility and Muscle-Invasiveness in Taiwan. Chinese Journal of Physiology, 2011, 54, 196-202.	0.4	14
3227	Transitional cell cancer of ureter misdiagnosed as pelviureteric junction obstruction: Pitfalls of standard diagnostic tools. Indian Journal of Cancer, 2008, 45, 184.	0.2	2
3228	Multiple primary cancers of the colon, rectum, and the thyroid gland. Saudi Journal of Gastroenterology, 2008, 14, 202.	0.5	4
3229	Cytotoxic effect of methanolic extract, alkaloid and terpenoid fractions of Stachys pilifera against HT-29 cell line. Research in Pharmaceutical Sciences, 2018, 13, 404.	0.6	28
3230	Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial. AYU: an International Quarterly Journal of Research in Ayurveda, 2019, 40, 34.	0.3	4
3231	Three Cases of Synchronous Solid Tumor and Multiple Myeloma. Cancer Research and Treatment, 2004, 36, 338.	1.3	11
3232	EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor. Neoplasma, 2011, 58, 27-34.	0.7	14
3233	Do Cancer Stem Cells have an Immunomodulatory Role Different from the Bulk of Tumor Cells?. Journal of Carcinogenesis & Mutagenesis, 2013, S14, .	0.3	5
3234	Tumor-Dependent and -Independent Serum/Plasma Biomarkers for Early Diagnosis of Lung Cancer. Translational Medicine (Sunnyvale, Calif ), 2016, 06, .	0.4	5

#	Article	IF	CITATIONS
3235	Breast and Cervical Cancer Screening Behaviors of African American Sexual Minority Women. Journal of General Practice (Los Angeles, Calif ), 2013, 01, .	0.1	10
3236	Evaluation of cancer records from 2000-2004 in Denizli, Turkey. Genetics and Molecular Research, 2009, 8, 64-75.	0.3	2
3237	Pneumo-CT assessing response to neoadjuvant therapy in esophageal cancer: Imaging-pathological correlation. World Journal of Gastrointestinal Oncology, 2013, 5, 222.	0.8	10
3238	Hyoscine for polyp detection during colonoscopy: A meta-analysis and systematic review. World Journal of Gastrointestinal Endoscopy, 2014, 6, 549.	0.4	18
3239	Squamous Cell Carcinoma of the Oral Tissues: A Comprehensive Review for Oral Healthcare Providers. Journal of Contemporary Dental Practice, 2005, 6, 1-16.	0.2	59
3240	The Role of 3D Ultrasound and 3D Power Doppler Imaging in the Diagnosis and Evaluation of Ovarian Cancer: New Perspectives. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2007, 1, 38-41.	0.1	2
3241	Complete Resection of Pulmonary Metastatic Melanoma. Korean Journal of Thoracic and Cardiovascular Surgery, 2011, 44, 165-168.	0.6	2
3242	Lung Cancer. Annals of Saudi Medicine, 2005, 25, 1-12.	0.5	28
3243	The sensitivity of MR colonography using dark lumen technique for detection of colonic lesions. Turkish Journal of Gastroenterology, 2020, 25, 271-278.	0.4	4
3244	Incidental gallbladder cancers: Our clinical experience and review of the literature. Turkish Journal of Surgery, 2016, 32, 107-110.	1.0	3
3245	Identification of differentially expressed genes in prostatic epithelium in relation to androgen receptor CAG repeat length. International Journal of Biological Markers, 2006, 21, 96-105.	0.7	7
3246	Soft-tissue Sarcoma. Journal of the American Academy of Orthopaedic Surgeons, The, 2009, 17, 40-47.	1.1	88
3247	Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer. Canadian Urological Association Journal, 2010, 4, 257-262.	0.3	20
3248	Acute Lymphoblastic Leukemia: What Have We Learned About the Effects of This Disease and Its Treatment on the Nervous System?. , 0, , .		1
3249	Dual-Track Pathway of Bladder Carcinogenesis: Practical Implications. Archives of Pathology and Laboratory Medicine, 2006, 130, 844-852.	1.2	50
3250	Comparison between preoperative biopsy and post-excision histology results in sarcoma: Experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. South African Journal of Surgery, 2014, 52, 45.	0.1	5
3251	Primary Extra Nodal Non Hodgkin Lymphoma: A 5 Year Retrospective Analysis. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4889-4895.	0.5	38
3252	Identification of a Cancer Stem-like Population in the Lewis Lung Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2012, 13, 761-766.	0.5	9

#	Article	IF	CITATIONS
3253	Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2273-2276.	0.5	5
3254	Environmental Radioactivity and High Incidence Rates of Stomach and Esophagus Cancer in the Van Lake Region: A Causal Relationship?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 375-380.	0.5	10
3255	Lack of Associations between Vitamin D Metabolism-Related Gene Variants and Risk of Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 957-961.	0.5	16
3256	Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20. Asian Pacific Journal of Cancer Prevention, 2016, 17, 255-259.	0.5	3
3257	Commonest Cancers in Pakistan - Findings and Histopathological Perspective from a Premier Surgical Pathology Center in Pakistan. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1061-1075.	0.5	14
3258	G protein pathway suppressor 2 suppresses gastric cancer by destabilizing epidermal growth factor receptor. Cancer Science, 2021, 112, 4867-4882.	1.7	7
3259	Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 565-584.	0.5	4
3260	CANCER IN THE ELDERLY PART 1 OF 2. The Consultant Pharmacist, 2004, 19, 676-695.	0.4	1
3261	Three-Dimensional Conformal Radiation Therapy. , 2004, , 171-203.		0
3262	Breast Cancer. Obstetrics and Gynecology, 2004, 104, 4.	1.2	2
3267	Bone Metastases in Advanced Prostate Cancer. Oncology & Hematology Review, 2005, 00, 1.	0.2	0
3268	Renal MRI. , 2005, , 149-183.		0
3269	Salvage of suboptimal prostate seed implantation: re-implantation of an underdosed region of the prostate base. , 2005, , 602-610.		0
3271	Trends in the Treatment of Colorectal Cancer. Oncology & Hematology Review, 2005, 00, 1.	0.2	0
3272	Initial experience with the FIRST system in Utrecht. , 2005, , 438-452.		0
3273	MRI of the Breast. , 2005, , 425-479.		0
3274	MRI of the Bile Ducts, Gallbladder, and Pancreas. , 2005, , 63-127.		0
3275	Systemic therapy for renal cell carcinoma. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 263-272.	0.5	1

		CITATION REPORT	
# 3276	ARTICLE Fertility options in women with gynecologic malignancies. Women's Oncology Review, 2005, 5, 185-191.	IF 0.0	CITATIONS
3277	Future challenges in clinical and translational research for endometrial cancer. International Journal of Gynecological Cancer, 2005, 15, 398-399.	1.2	0
3278	Recent insights into myeloma bone disease. BoneKEy Osteovision, 2005, 2, 17-25.	0.6	0
3279	New Methods for Visualizing the Airways. , 2005, , 413-424.		0
3281	Cancer Prevention Among Rural Youth: Building a "Bridge" to Better Health With Genealogy. Journal of Cancer Education, 2005, 20, 103-107.	0.6	2
3282	Perioperative Care of Patients with Musculoskeletal Neoplasms. , 2005, , 465-483.		Ο
3283	Câncer de mama, menopausa e qualidade de vida. Revista Brasileira De Ginecologia E Obstetricia, 2005, 27, .	0.3	0
3284	Nutritional Management in the Patient with an Upper Gastrointestinal Cancer. , 2005, , .		0
3285	Clinical Diagnosis of Asbestos-Related Disease. , 2005, , 309-380.		0
3286	Omega-3 Fatty Acids and Cancer Prevention. Nutrition and Disease Prevention, 2005, , .	0.1	0
3289	Cancer, sexuality and sexual expression. , 2005, , 636-643.		4
3290	Cytoreductive surgery: pelvis. , 2005, , 139-182.		0
3291	Fighting Breast Cancer: A Call for a New Paradigm. , 2005, 9, 73-6.		0
3292	General tumor factors. , 2005, , 127-137.		0
3293	CT Colonography. , 2006, , 84-89.		0
3294	AnatomÃa patolÃ <sup>3</sup> gica del melanomaNuevos conceptos. , 2006, , 243-263.		0
3295	EpidemiologÃa del cáncer de piel. , 2006, , 47-60.		6
3297	IMRT Lung. , 2006, , 359-369.		0

#	Article	IF	CITATIONS
3298	IMRT for Malignancies of the Upper Abdomen and Retroperitoneum. , 2006, , 383-390.		0
3299	Physical and Psychosocial Issues in Lung Cancer Survivors. , 2006, , 1881-1900.		0
3300	Intravesical therapy for bladder cancer: now and future. Drug Delivery System, 2006, 21, 46-51.	0.0	0
3301	Nódulos pulmonares solitarios y múltiples. , 2006, , 555-567.		0
3302	De effecten van aerobe training voor en tijdens chemotherapie bij een patiënt met borstkanker: een casusbespreking. , 2006, , 943-946.		0
3303	Histopathological Classification. Medical Radiology, 2006, , 1-14.	0.0	0
3304	Batch Classification with Applications in Computer Aided Diagnosis. Lecture Notes in Computer Science, 2006, , 449-460.	1.0	7
3306	La importancia de la detección precoz del melanoma, exploración médica y autoexploración. , 2006, , 175-187.		0
3307	Tratamiento del cáncer de piel en receptores de órganos. , 2006, , 631-640.		1
3308	CirugÃa de los ganglios linfáticos regionales en el melanoma maligno. , 2006, , 561-571.		0
3310	Radical Prostatectomy and Other Pelvic Surgeries. , 2006, , 135-154.		3
3312	Active Surveillance with Selective Delayed Intervention for Favorable Risk Prostate Cancer. Seminars in Preventive and Alternative Medicine, 2006, 2, 15-21.	0.1	2
3315	Promoting Small and Large Bowel Health. , 2006, , .		0
3316	LAPAROSCOPIC PARTIAL NEPHRECTOMY: CURRENT STATUS â–. , 2006, , 553-576.		2
3317	Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver. Human Gene Therapy, 2006, .	1.4	0
3318	Gene Expression Analysis for the Identification of Genes Involved in Early Tumour Development. , 2007, , 62-68.		0
3319	Periampullary and Pancreatic Tumors. , 2007, , 849-866.		0
3321	Le cancer du sein métastatique chez la femme âgée : revue synthétique de l'ensemble des options thérapeutiques. , 2007, , 197-203.		Ο

#	Article	IF	CITATIONS
3323	Role of Transforming Growth Factor-β in the Pathogenesis of Human Head and Neck Squamous Cell Carcinoma. , 2008, , 21-32.		0
3325	Targeted Downregulation of TGF-β2 with AP 12009 in Tumor Therapy. , 2008, , 635-651.		0
3326	Head and Neck Malignancies: Chemotherapy and Radiation Perspective. , 2008, , 425-430.		0
3328	Exploratory Identification of Image-Based Biomarkers for Solid Mass Pulmonary Tumors. Lecture Notes in Computer Science, 2008, 11, 612-619.	1.0	2
3329	Pineal Tumors: Fractionated Radiation Therapy Perspective. , 2008, , 371-376.		0
3331	Current status of lung cancer screening. , 2008, , 69-76.		0
3333	Pulmonary Neoplasia. Archives of Pathology and Laboratory Medicine, 2008, 132, 1053-1054.	1.2	0
3334	Cancer care in Australia. Biomedical Imaging and Intervention Journal, 2008, 4, e30.	0.5	2
3335	Liver-Directed Therapy for Metastatic Melanoma to the Liver. , 2009, , 1-14.		0
3336	Molecular Genetic Etiology of Prostate Cancer. The Open Genomics Journal, 2008, 1, 13-21.	0.5	1
3337	Soft tissue sarcomas in Mosul: a pathologic evaluation. Annals of the College of Medicine Mosul, 2008, 34, 152-160.	0.0	0
3338	Technique of Sentinel Lymph Node Biopsy and Lymphatic Mapping During Laparoscopic Colon Resection for Cancer. Ecancermedicalscience, 2009, 1, 60.	0.6	2
3340	Fluorescence Cytoscopy. , 2009, , 19-24.		0
3342	Wolf in lamb′s skin: Vulval carcinoma mimicking bartholin gland abscess. Indian Journal of Sexually Transmitted Diseases and AIDS, 2009, 30, 46.	0.6	1
3343	Changes in Prostate Cancer Pattern according to Prostate-Specific Antigen Screening Test. Korean Journal of Urology, 2009, 50, 439.	1.2	4
3344	Lycopene and Its Potential Role in Prostate Cancer Prevention. , 2009, , 329-351.		0
3347	Antimetastatic Therapy in Colorectal Cancer: Role of Tumor Cell Matrix Metalloproteinase 9 (Methodology). , 2009, , 137-153.		0
3348	Colorectal cancer surveillance after colon cancer resection and post-polypectomy. , 2009, , 157-175.		0

		CITATION REPC	DRT	
#	Article	I	F	Citations
3351	Hybrid Imaging of Head and Neck Malignancies. , 2010, , 137-170.			0
3352	PET in uterine malignancies. Health, 2010, 02, 652-660.	C	).1	0
3354	Lasers in Laparoscopic Surgery. , 2010, , 79-89.			0
3355	Perioperative fatal embolic cerebrovascular accident after radical prostatectomy. , 2010	, 1, 26.		0
3356	P53- The Molecular Guardian Crashes in Gastric Adenocarcinomas - A Study in an Ethnic Population. Journal of Carcinogenesis & Mutagenesis, 2010, 01, .	Kashmiri c	).3	3
3357	Office Assessment of Patient with Head and Neck Cancer. Otorhinolaryngology Clinics,	2010, 2, 1-5. c	).1	0
3358	Blood–Brain Barrier, Blood Flow, Neoplasms and Epilespy. , 2010, , 21-34.			0
3359	Implementation and Clinical Trials in the United States. , 2011, , 65-73.			0
3360	PET-CT in Colorectal Carcinoma. , 2011, , 245-264.			0
3362	MicroRNA, circulating microRNA and tumor. Academic Journal of Second Military Medica 2010, 30, 1128-1132.	al University, G	).0	0
3363	Myeloproliferative Neoplasms. , 2011, , 698-732.			2
3364	9 Imaging in the Evaluation of Patients with Prostate Cancer. , 2011, , 147-163.			0
3365	7 Imaging-Based Screening for Colorectal Cancer. , 2011, , 109-126.			0
3366	Robot-Assisted Radical Nephroureterectomy. , 2011, , 257-268.			0
3367	Erkrankungen von Mund, Speiseröhre und Magen. , 2011, , 273-357.			0
3368	Is there any relationship between PSA and increased peripheral CD4+CD25highFOX3+ T cancer patients?. Journal of Health Sciences, 2011, 1, 75-82.	reg in prostate	).5	0
3370	Surgical Management of Cerebral Metastases. , 2012, , 178-191.			0
3371	Warfarin Use During Fecal Occult Blood Testing: A Meta-Analysis. Gastroenterology Res 45-51.	earch, 2012, 5,	).4	2

#	Article	IF	CITATIONS
3372	NEW STRATEGIES IN LIVER SURGERY FOR IV STAGE METASTATIC COLORECTAL CANCER Journal of IMAB, 2012, 18, 1, 231-238.	0.1	0
3373	IMPROVING CANCER SURVIVORSHIPS: TARGETING PHYSICAL ACTIVITY AND INACTIVITY AT TEACHABLE MOMENTS. Journal of the University of Malaya Medical Centre, 2012, 15, 5-10.	0.0	0
3376	Molecular Imaging Techniques in Clinical Practice of Tumors. Advanced Topics in Science and Technology in China, 2013, , 603-632.	0.0	0
3377	A Novel Learning Formulation in a unified Min-Max Framework for Computer Aided Diagnosis. IOSR Journal of Computer Engineering, 2013, 13, 44-52.	0.1	0
3378	The Role of MicroRNA in Head and Neck Cancer. , 2013, , 1019-1048.		0
3379	Surgical Management for Transitional Cell Carcinoma of the Upper Tract. , 2013, , 359-372.		0
3380	Long-Term Lung Cancer Survival in a Province of Spain. Journal of Pulmonary & Respiratory Medicine, 0, , .	0.1	1
3381	Compuestos fenólicos de la fracción metanólica de Bidens pilosa, sobre la neoplasia gástrica, inducida en ratas. Anales De La Facultad De Medicina, 2013, 68, 105.	0.0	0
3382	Resection of liver metastases from ocular melanoma remains discussional: an experience with 5 cases. Academic Journal of Second Military Medical University, 2013, 32, 1035-1036.	0.0	0
3384	Estrogen like agents as anticancer drugs : Theory , synthesis and analysis. International Journal of Scientific and Engineering Research, 0, , .	0.1	Ο
3385	Profile of Secondary Bone Cancer in Lomé (Togo). Open Journal of Rheumatology and Autoimmune Diseases, 2014, 04, 192-197.	0.1	1
3386	Comparison of cervical cytological screening results between postmenopausal and elderly women. Turk Patoloji Dergisi, 2014, 30, 38.	0.1	4
3387	Prostatakarzinom. , 2014, , 513-676.		0
3388	Radical prostatectomy specimens - a voice against focal therapy. Central European Journal of Urology, 2014, 67, 235-41.	0.2	1
3390	Orthotopic bladder replacement in women. , 1995, , 361-377.		0
3391	Underwriting Younger Ages: Pediatric Mortality Risk Evaluation. , 1998, , 133-144.		0
3392	Underwriting Younger Ages: Pediatric Mortality Risk Evaluation. , 1998, , 133-144.		0
3393	Male Breast Cancer: 9 Year Experience and Review in Mid-Western Ireland. Open Breast Cancer Journal, 2014, 4, 38-41.	0.2	0

#	Article	IF	CITATIONS
3394	Study of the epidemiology and management of laryngeal cancer in Kasr Al-Aini Hospital. The Egyptian Journal of Otolaryngology, 2014, 30, 208-214.	0.1	3
3395	Occurrence of Different Types of Endometrial Carcinoma in Hysterectomy Specimens from Different Hospitals in Karachi, Pakistan. American Journal of Life Sciences, 2015, 3, 143.	0.3	0
3396	Aging-Associated Nonmelanoma Skin Cancer: A Role for the Dermis. , 2015, , 1-19.		0
3397	Karzinome des Magens und ösophagogastralen Übergangs. , 2015, , 1-11.		0
3398	Comparison of Prostate Specific Antigen and Prostate Specific Antigen Density for Predicting the Degree of Gleason Score of Prostate Cancer. Journal of Analytical Oncology, 2015, 4, 39-43.	0.1	0
3399	Value of Dual Assessment of Carcinoembryonic Antigen and Fluorine-18-Fluoro-Deoxyglucose Positron Emission Tomography in Colorectal Cancer Recurrence. European Journal of Basic Medical Sciences, 2015, 5, 25-30.	0.2	0
3400	Usefulness of determining CA 125 and HE4 serum concentration in diagnosis of ovarian cancer. Annales Academiae Medicae Silesiensis, 2015, 69, 138-149.	0.1	0
3401	Profile of Malignant Bone Tumors among Rheumatology Inpatients in Lome (Togo). Open Journal of Rheumatology and Autoimmune Diseases, 2016, 06, 51-56.	0.1	1
3402	Histopathology of Oral Cavity Cancer and Potentially Malignant Disorders. , 2017, , 155-279.		0
3403	Mammographic parenchymal patterns in asymptomatic women. Saudi Journal of Medicine and Medical Sciences, 2017, 5, 232.	0.3	2
3404	Multiple Primary Synchronous Renal Cancer and Thyroid Gland Cancer at Patient with Doubling Inferior Vena Cava and Renal Veins on Both Sides (Clinical Case). Medical Visualization, 2017, , 36-43.	0.1	0
3405	HORMONE RECEPTOR STATUS OF BREAST CANCER IN NORTHERN REGION OF INDIA- A STUDY. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 2362-2365.	0.1	0
3406	Multiple Primary Synchronous-Methacronous Cancer of Kidneys and Prostate Gland (Clinical Case). Medical Visualization, 2017, , 62-72.	0.1	1
3407	Gastrointestinal Lymphoma in Tertiary Gastroenterology Center: Epidemiological, Clinical and Endoscopic Features. Makedonski Medicinski Pregled Revue Medicale Macedonienne, 2017, 71, 105-112.	0.0	0
3408	A Common Promoter Polymorphism (-23Hphl) in Insulin Gene and Susceptibility to Colorectal Cancer. International Journal of Cancer Management, 2017, 10, .	0.2	0
3409	Hysteroscopy Classification for Endometrial Cancer. , 2018, , 269-280.		0
3410	Pancreatoduodenectomy with Simultaneous Venous Resection for Advanced Ductal Pancreatic Head Cancer: A Case Control Study. Surgical Science, 2018, 09, 381-398.	0.1	0
3411	Screening for Ovarian Cancer by Different Modes of Transvaginal Sonography. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2018, 12, 186-196.	0.1	0

~		<u> </u>	
		REP	<b>NDT</b>
$\sim$	IIAI	IVE FV	

#	Article	IF	CITATIONS
3412	Stauffer's syndrome: A rare paraneoplastic syndrome with renal cell carcinoma. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 546.	0.1	0
3413	Primary Malignant Bones Cancers in Cote d'lvoire: Epidemiological and Histopathological Aspects. Open Journal of Pathology, 2018, 08, 51-59.	0.0	0
3414	Evaluation of Concordance between Gleason Scores of Tansrectal Ultrasound Guided Biopsy and Radical Prostatectomy Samples in Prostate Cancer. Journal of Analytical Oncology, 2018, 7, 8-13.	0.1	0
3415	Incidental gallbladder cancer: Review of 3856 cholecystectomies. Journal of Surgery and Medicine, 0, ,	0.0	1
3416	Statistically Based Survival Rate Estimation in Patients with Soft Tissue Tumors. Romanian Journal of Orthopaedic Surgery and Traumatology, 2018, 1, 7-7.	0.1	0
3417	Oxidative stress and anti-oxidants in pre and post operative cases of breast carcinoma. Turkish Journal of Pharmaceutical Sciences, 2018, 15, 354-359.	0.6	3
3418	SURGICAL MINI-FLANK APPROACH TO THE KIDNEY WITH LOCALIZED RENAL CELL CARCINOMA. Siberian Journal of Oncology, 2018, 17, 28-33.	0.1	0
3419	Modern ideas about the methods of surgical organ-preserving treatment of kidney cancer. Vestnik of Russian Military Medical Academy, 2018, 20, 249-253.	0.1	Ο
3420	Targeted Agents and Immunotherapy. , 2019, , 381-388.		0
3421	Clinical risk profile associated with ovarian cancer. Obstetrica Si Ginecologie, 2019, 1, 22.	0.0	0
3421 3422	Clinical risk profile associated with ovarian cancer. Obstetrica Si Ginecologie, 2019, 1, 22. Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, , 12-17.	0.0	0
	Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, ,		
3422	Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, , 12-17. Long-Term Survival of Rectal Cancer With Lung Metastasis–A Case Report of Possible Metronomic	0.1	0
3422 3423	Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, , 12-17. Long-Term Survival of Rectal Cancer With Lung Metastasis–A Case Report of Possible Metronomic Effect of Tegafur-Uracil. International Surgery, 2019, 104, 494-498.	0.1	0
3422 3423 3424	Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, , 12-17.         Long-Term Survival of Rectal Cancer With Lung Metastasis–A Case Report of Possible Metronomic Effect of Tegafur-Uracil. International Surgery, 2019, 104, 494-498.         Surgical Management for Transitional Cell Carcinoma of theÂUpper Tract. , 2020, , 325-343.	0.1	0 0 0
3422 3423 3424 3425	Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, , 12-17.         Long-Term Survival of Rectal Cancer With Lung Metastasis–A Case Report of Possible Metronomic Effect of Tegafur-Uracil. International Surgery, 2019, 104, 494-498.         Surgical Management for Transitional Cell Carcinoma of theÂUpper Tract. , 2020, , 325-343.         Epidermal Growth Factor Receptor: Promising Targets for Non-Small-Cell Lung Cancer. , 2020, , 465-471.	0.1	0 0 0 2
3422 3423 3424 3425 3426	Potential Effects of EGFR Exon 21 L858R Mutations in Lung Cancer. Medical Science and Discovery, 0, , 12-17.         Long-Term Survival of Rectal Cancer With Lung Metastasis–A Case Report of Possible Metronomic Effect of Tegafur-Uracil. International Surgery, 2019, 104, 494-498.         Surgical Management for Transitional Cell Carcinoma of theÂUpper Tract. , 2020, , 325-343.         Epidermal Growth Factor Receptor: Promising Targets for Non-Small-Cell Lung Cancer. , 2020, , 465-471.         Mediastinal soft tissue sarcoma: dark sides and future lights. Mediastinum, 2020, 4, 9-9.         Demonstration of Deoxyribonucleic Acid in Colorectal Cancer Using Feulgen reaction. Annals of	0.1	0 0 0 2 1

	CITATION RI	CITATION REPORT	
# 3431	ARTICLE Fertility options in women with gynecologic malignancies. Women's Oncology Review, 2005, 5, 185-191.	IF 0.0	CITATIONS
3443	Treatment Options in Superficial (pTA/pT1/CIS) Bladder Cancer. , 2005, , 131-144.		0
3444	PET and PET/CT Imaging in Colorectal Cancer. , 2006, , 147-164.		0
3445	PET and PET/CT Imaging in Esophageal and Gastric Cancers. , 2006, , 165-180.		0
3446	PET Imaging in Brain Tumors. , 2006, , 79-87.		0
3451	Contrast-Enhanced Ultrasound of the Prostate. , 2005, , 359-364.		Ο
3452	Renal Tumors. , 2006, 167, 123-133.		1
3455	Small Pulmonary Nodules: Detection Using Multidetector-Row Computed Tomography. , 2008, , 247-260.		0
3456	Secondary Primary Cancer Following Chemoradiation for Non-Small-Cell Lung Cancer. , 2008, , 261-267.		0
3457	Role of Brachytherapy in Treatment of Head and Neck Malignancy. , 2005, , 93-113.		0
3458	Diet, Exercise, and Behavioral Treatment of Obesity. , 2006, , 445-455.		0
3459	Molecular Profiling in Breast Cancer. , 2006, , 559-576.		0
3461	Robotic Transperitoneal Four Arm Laparoscopic Radical Prostatectomy: Points of Technique. , 2008, , 49-69.		0
3465	Cytokine Gene Therapy for Genitourinary Cancer. , 2007, , 223-241.		1
3469	Hereditary Issues In Ovarian Cancer. , 2007, , 169-193.		0
3471	Treatment Options in Superficial (pTa/pT1/CIS) Bladder Cancer. , 2007, , 75-101.		0
3472	Robot-Assisted Radical Cystectomy and Urinary Diversion. , 2007, , 161-168.		7
3473	Prostate Carcinoma: Introduction. , 2009, , 211-219.		0

#	Article	IF	CITATIONS
3474	Prostate Carcinoma: Conventional Imaging Techniques – Gray-Scale, Color, and Power Doppler Ultrasound. , 2009, , 221-228.		1
3475	Les cancers du sein de la femme âgée de plus de 70 ans Le point en France. , 2007, , 335-347.		1
3476	Carcinome invasif de la vulve. , 2007, , 425-431.		0
3477	Radiofrequency Ablation (RFA). , 2008, , 167-177.		0
3478	Prostatakarzinom. , 2014, , 513-676.		0
3479	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568.	2.0	0
3480	Anthocyanins: Promising Natural Compounds for Prevention and Treatment of Oral Squamous Cell Carcinoma. Middle East Journal of Rehabilitation and Health Studies, 2020, 7, .	0.1	0
3481	The cytotoxic and apoptotic effects of <i>Ferulago</i> W. Koch extracts on various cancer cell lines. Turkish Journal of Biochemistry, 2021, 46, 281-291.	0.3	3
3482	New Mexico's capacity for increasing the prevalence of colorectal cancer screening with screening colonoscopies. Preventing Chronic Disease, 2005, 2, A07.	1.7	6
3483	The evolving definition of advanced prostate cancer. Reviews in Urology, 2004, 6 Suppl 8, S10-7.	0.9	16
3484	The future in advanced prostate cancer: take your partners or is the last dance for me?. Reviews in Urology, 2004, 6 Suppl 10, S29-44.	0.9	1
3485	Optimal surgical management of the obese man with prostate cancer: laparoscopic or perineal radical prostatectomy. Reviews in Urology, 2005, 7, 46-7.	0.9	0
3486	Prostatic intraepithelial neoplasia: an overview. Reviews in Urology, 2005, 7 Suppl 3, S11-8.	0.9	22
3488	Women's views on chemoprevention of breast cancer: qualitative study. Canadian Family Physician, 2006, 52, 624-5.	0.1	41
3489	Salvage cryosurgery of the prostate after radiation failure. Reviews in Urology, 2004, 6 Suppl 4, S27-36.	0.9	3
3490	Molecular Basis of Steroid Action in the Prostate. Cellscience, 2005, 1, 27-55.	0.3	15
3491	Management of oxaliplatin-induced peripheral neuropathy. Therapeutics and Clinical Risk Management, 2005, 1, 249-58.	0.9	96
3492	Chronic diarrhea due to metastatic breast cancer. MedGenMed: Medscape General Medicine, 2005, 7, 17.	0.2	0

ARTICLE IF CITATIONS Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a 3493 0.5 45 systematic review and meta-analysis. Canadian Journal of Surgery, 2007, 50, 459-66. Current aproach to cancer pain management: Availability and implications of different treatment options. Therapeutics and Clinical Risk Management, 2007, 3, 381-400. 3494 Southern community cohort study: establishing a cohort to investigate health disparities. Journal of 3495 0.6 160 the National Medical Association, 2005, 97, 972-9. Soft-tissue sarcoma in black Africans: pattern, distribution and management dilemma. Journal of the 3496 National Medical Association, 2007, 99, 88-93. Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening. Journal of the 3497 0.6 11 National Medical Association, 2006, 98, 51-7. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 20-7. 3498 0.8 Screening techniques for prevention and early detection of colorectal cancer in the average-risk 3499 0.8 4 population. Gastrointestinal Cancer Research: GCR, 2007, 1, 98-106. Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human 3501 1.4 26 colorectal cancer cells. International Journal of Oncology, 2007, 31, 1149-56. Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human 3502 1.4 38 colorectal cancer cells. International Journal of Oncology, 2008, 32, 975-83. Monophasic synovial sarcoma presenting as mitral valve obstruction. Texas Heart Institute Journal, 0.1 2010, 37, 472-5. Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. 3504 4.73 Core Evidence, 2007, 2, 31-49. Gallbladder cancer: adenoma-carcinoma or dysplasia-carcinoma sequence?. Gastroenterology and Hepatology, 2008, 4, 735-7. MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Ethnicity and 3506 1.0 30 Disease, 2010, 20, S1-96-100. Applicabillity of noninvasive biomarkers in prostate cancer diagnosis. MÃ l dica, 2010, 5, 41-4. 0.4 Molecular genetics of testicular germ cell tumors. American Journal of Cancer Research, 2012, 2, 3509 1.4 31 153-67. Parenchymal signal intensity in 3-T body MRI of dogs with hematopoietic neoplasia. Comparative 0.4 Mediciné, 2013, 63, 174-82. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor 3511 0.5 26 outcome. Anticancer Research, 2010, 30, 1279-85. More comprehensive discussion of CRC screening associated with higher screening. American Journal of Managed Care, 2013, 19, 265-71.

#	Article	IF	CITATIONS
3513	Radiosensitivity and repair kinetics of gamma-irradiated leukocytes from sporadic prostate cancer patients and healthy individuals assessed by alkaline comet assay. Iranian Biomedical Journal, 2010, 14, 67-75.	0.4	8
3514	Clinical, epidemiological and histopathological prognostic factors in oral squamous carcinoma. Current Health Sciences Journal, 2010, 36, 201-5.	0.2	0
3515	Stereological Evaluation of Tumor Regression Rates in Lung Cancer Using CT Via the Cavalieri Method. Eurasian Journal of Medicine, 2008, 40, 109-14.	0.2	1
3516	MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 2710-8.	0.5	9
3517	Role of plasma osteopontin as a biomarker in locally advanced breast cancer. American Journal of Translational Research (discontinued), 2015, 7, 723-32.	0.0	21
3518	Somatic mutation in synchronous primary adenocarcinomas of the left lung: a case report. International Journal of Clinical and Experimental Pathology, 2015, 8, 8579-84.	0.5	Ο
3519	Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance. International Journal of Clinical and Experimental Pathology, 2015, 8, 14034-9.	0.5	14
3520	CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS. BIOforum Europe: Trends and Techniques in Life Science Research, 2009, 3, 14-16.	0.0	1
3521	The role and expression of miR-100 and miR-203 profile as prognostic markers in epithelial ovarian cancer. American Journal of Translational Research (discontinued), 2016, 8, 2403-10.	0.0	11
3522	Anticancer Effect of PeÅŸmen (Apiaceae) on Cancer Cell Proliferation. Iranian Journal of Pharmaceutical Research, 2016, 15, 501-504.	0.3	4
3526	Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Research, 2009, 29, 1143-50.	0.5	15
3527	Reconstruction of Brachial Artery with Great Saphenous Vein Graft in A Case of Residual Soft Tissue Sarcoma Arm. World Journal of Plastic Surgery, 2020, 9, 88-91.	0.2	Ο
3528	Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. American Journal of Translational Research (discontinued), 2020, 12, 923-939.	0.0	5
3529	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. Annals of Surgical Oncology, 2022, 29, 3274-3286.	0.7	5
3530	Basics of immunotherapy for epithelial ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102283.	0.6	4
3531	Non-Surgical Management of Metastatic Breast Cancer and Palliative Care. , 2022, , 497-517.		2
3534	Utility of Keratins as Biomarkers for Human Oral Precancer and Cancer. Life, 2022, 12, 343.	1.1	12
3535	A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. Journal of Cancer Research and Clinical Oncology 2022, 148, 1955-1963	1.2	8

#	Article	IF	CITATIONS
3536	Study on the Quality of Life among Cancer Survivors Attending a Tertiary Care Cancer Center in Malaysia. Journal of Public Health Research, 2021, 10, jphr.2021.2919.	0.5	2
3537	Cytotoxic cobalt (III) Schiff base complexes: in vitro anti-proliferative, oxidative stress and gene expression studies in human breast and lung cancer cells. BioMetals, 2022, 35, 67-85.	1.8	16
3538	E-Cadherin Phosphorylation by Protein Kinase D1/Protein Kinase Cμ is Associated with Altered Cellular Aggregation and Motility in Prostate Cancer. Cancer Research, 2005, 65, 483-492.	0.4	97
3539	Diabetes Mellitus and Subsite-Specific Colorectal Cancer Risks in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 133-137.	1.1	117
3540	Radiofrequency Ablation (RFA). , 2008, , 167-177.		0
3541	Radiofrequency Ablation in Bone Metastases. , 2008, , 207-214.		1
3542	Colorectal Cancer Prevention. , 2008, , 291-312.		0
3545	Advances in molecular classification of renal neoplasms. Histology and Histopathology, 2006, 21, 325-39.	0.5	20
3549	Computer-aided detection and second reading utility and implementation in a high-volume breast clinic. , 0, , 8-15.		1
3550	A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2005, 11, 284-289.	3.2	23
3551	A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway. Molecular Cancer Therapeutics, 2004, 3, 885-893.	1.9	188
3552	Improving locoregional outcome in high-intermediate-risk and high-risk stage I endometrial cancer with surgical staging followed by brachytherapy. Radiation Oncology Journal, 2022, 40, 103-110.	0.7	1
3553	Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. Heliyon, 2022, 8, e09474.	1.4	1
3555	World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates. Cancer Research Communications, 2022, 2, 518-532.	0.7	0
3556	Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness. Cancer Research, 2005, 65, 727-731.	0.4	83
3557	Synthesis and development of seven-membered constrained cyclic urea based PSMA inhibitors <i>via</i> RCM. New Journal of Chemistry, 0, , .	1.4	0
3558	Prognostic Significance of Metastasis-Associated Protein S100A4 (Mts1) in Prostate Cancer Progression and Chemoprevention Regimens in an Autochthonous Mouse Model. Clinical Cancer Research, 2005, 11, 147-153.	3.2	54
3559	Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Molecular Cancer Therapeutics, 2004, 3, 641-646.	1.9	82

#	Article	IF	CITATIONS
3560	From Microarray to Bedside: Targeting NF-κB for Therapy of Lymphomas. Clinical Cancer Research, 2005, 11, 2-6.	3.2	381
3561	A Novel Assay to Assess Primary Human Cancer Infectibility by Replication-Selective Oncolytic Adenoviruses. Clinical Cancer Research, 2005, 11, 351-360.	3.2	24
3562	Testisin, a Glycosyl-Phosphatidylinositol–Linked Serine Protease, Promotes Malignant Transformation <i>In vitro</i> and <i>In vivo</i> . Cancer Research, 2005, 65, 868-878.	0.4	31
3563	Cyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2005, 11, 1160-1166.	3.2	52
3564	UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan. Clinical Cancer Research, 2005, 11, 1226-1236.	3.2	216
3565	Effects of Reduced Cigarette Smoking on Levels of 1-Hydroxypyrene in Urine. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 834-842.	1.1	27
3566	Measures for Ascertaining Use of Colorectal Cancer Screening in Behavioral, Health Services, and Epidemiologic Research. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 898-905.	1.1	91
3567	A Third-Generation Bisphosphonate, Minodronic Acid (YM529), Augments the Interferon αĴ²-Mediated Inhibition of Renal Cell Cancer Cell Growth Both <i>In vitro</i> and <i>In vivo</i> . Clinical Cancer Research, 2005, 11, 853-859.	3.2	21
3568	Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Molecular Cancer Therapeutics, 2004, 3, 933-940.	1.9	149
3570	Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 1434-1452.	1.3	8
3571	Xenoestrogen Action in Prostate Cancer: Pleiotropic Effects Dependent on Androgen Receptor Status. Cancer Research, 2005, 65, 54-65.	0.4	91
3572	Inhibitory Effect of Antagonists of Bombesin and Growth Hormone-Releasing Hormone on Orthotopic and Intraosseous Growth and Invasiveness of PC-3 Human Prostate Cancer in Nude Mice. Clinical Cancer Research, 2005, 11, 49-57.	3.2	38
3573	The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer. Clinical Cancer Research, 2005, 11, 795-805.	3.2	206
3574	Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice. Clinical Cancer Research, 2005, 11, 329-334.	3.2	45
3575	The Functions of EphA1 receptor tyrosine kinase in Several Tumors Current Medicinal Chemistry, 2022, 29, .	1.2	1
3576	Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with Chemoradiation. Clinical Cancer Research, 2005, 11, 600-605.	3.2	71
3577	Non-neoplastic pathologies mimicking sarcoma – Experience from a tertiary referral centre multidisciplinary team. European Journal of Radiology, 2022, 156, 110510.	1.2	0
3578	Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method. Frontiers in Oncology, 0, 12, .	1.3	5

#	Article	IF	CITATIONS
3579	Causes of Cancer in the World: Comparative Risk Assessment of Nine Behavioral and Environmental Risk Factors. Cureus, 2022, , .	0.2	6
3580	Early and isolated breast cancer metastasis to the pituitary: A case report and systematic review. , 0, 13, 462.		3
3581	One novel ACOT7–NPHP4 fusion gene identified in one patient with acute lymphoblastic leukemia: a case report. BMC Medical Genomics, 2022, 15, .	0.7	2
3582	Cancer and ovarian tissue cryopreservation. Turkish Journal of Medical Sciences, 0, , .	0.4	2
3583	Preliminary observational study of the implementation of hyperthermic intraperitoneal chemotherapy in ovarian cancer in the gynecological surgery department at the University Hospital of Strasbourg. Journal of Gynecology Obstetrics and Human Reproduction, 2023, 52, 102501.	0.6	0
3587	Natural products and their mechanisms in potential photoprotection of the skin. Journal of Biosciences, 2022, 47, .	0.5	2
3589	The Natural History and Prognosticative Factors of Adult Extremity Soft Tissue Sarcomas: An Asian Perspective. Annals of the Academy of Medicine, Singapore, 2010, 39, 771-777.	0.2	1
3590	ROC Curve Analysis of Serum Tumor Markers in the Diagnosis of Ovarian Malignant Tumors. Advances in Clinical Medicine, 2022, 12, 11534-11541.	0.0	0
3591	Colposcopy postmenopause: A challenge in cervical cancer elimination goal!. Journal of Mid-Life Health, 2022, 13, 263.	0.4	0
3592	Extraskeletal Ewing's sarcoma of the mediastinum: Case report. Frontiers in Oncology, 0, 13, .	1.3	4
3593	A Novel Bioinspired Algorithm for Mixed and Incomplete Breast Cancer Data Classification. International Journal of Environmental Research and Public Health, 2023, 20, 3240.	1.2	0
3594	Long-term outcomes of margin-controlled excision for eyelid melanoma. Eye, 2023, 37, 1009-1013.	1.1	1
3596	Relationship Between Pre-existing Cancer and Tuberculosis. Integrated Science, 2023, , 79-88.	0.1	0
3597	Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review. Frontiers in Oncology, 0, 13, .	1.3	0
3611	Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications. , 2023, , 1-19.		0
3612	Molecular testing in myeloproliferative neoplasms. , 2024, , 569-587.		1